CA2405912A1 - Albumin fusion proteins - Google Patents

Albumin fusion proteins Download PDF

Info

Publication number
CA2405912A1
CA2405912A1 CA002405912A CA2405912A CA2405912A1 CA 2405912 A1 CA2405912 A1 CA 2405912A1 CA 002405912 A CA002405912 A CA 002405912A CA 2405912 A CA2405912 A CA 2405912A CA 2405912 A1 CA2405912 A1 CA 2405912A1
Authority
CA
Canada
Prior art keywords
cancer
immune
albumin
fragment
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002405912A
Other languages
French (fr)
Inventor
Craig A. Rosen
William A. Haseltine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27394014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2405912(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2405912A1 publication Critical patent/CA2405912A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

Description

DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

~~ TTENANT LES PAGES 1 A 221 NOTE : Pour les tomes additionels, veuillez contacter 1e Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME
NOTE POUR LE TOME / VOLUME NOTE:

Albumin Fusion Proteins BACKGROUND OF THE INVENTION
- The invention relates generally to Therapeutic proteins (including, but, not limited to, a polypeptide, antibody, or peptide, or fragments and variants thereof]
fused to albumin or fragments or variants of albumin. The invention further relates to Therapeutic proteins (including, but not limited to, a polypeptide, antibody, or peptide, or fragments and variants thereof) fused to albumin or fragments or variants of albumin, that exhibit extended shelf life and/or extended or therapeutic activity in solution. These fusion proteins are herein collectively referred to as "albumin fusion proteins of the invention."
The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical. compositions, formulations and kits. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells.
The invention is also directed to methods of iri uitro stabilizing a Therapeutic protein via fusion or conjugation of the Therapeutic protein to albumin or fragments or variants of albumin.
Human serum albumin (HSA, or HA), a protein of 5~5 amino acids in its mature form (as shown in .Figure 15 or in SEQ ID N0:18), is responsible for a significant proportion of the osmotic pressure of serum and also functions as a carrier of endogenous and exogenous ligands. At present, HA for clinical use is' produced by extraction from human blood. The production of recombinant HA (rHA) in microorganisms has been disclosed in EP 330 451 and EP 361 991.
The role of albumin as a carrier molecule and its inert naturevare desirable ' properties for use as a Garner and transporter of polypeptides i~ vivo. The use of albumin as a component of an albumin fusion protein as a carrier for various proteins has been suggested in WO 93/15199, WO 93/15200, and EP 413 622. The use of N-terminal fragments of HA for fusions to polypeptides has also been proposed (EP 399 666). Fusion of albumin to the Therapeutic protein may be achieved by genetic manipulation, such that the DNA coding for HA, or a fragment thereof, is joined to the DNA coding for the Therapeutic protein. A suitable host is then transformed or transfected with the fused nucleotide sequences, so arranged on a suitable plasmid as to express a.fusion polypeptide.
The expression may be effected in vitro from, for example, prokaryotic or eukaryotic cells, or in vivo e.g. from a transgenic organism.
Therapeutic proteins in their native state or when recombinantly produced, such as interferons and growth hormones, are typically labile molecules exhibiting short shelf lives, particularly when formulated in aqueous solutions. The instability in these molecules when formulated for administration dictates that many of the molecules must be lyophilized and refrigerated at all times during storage, thereby rendering the molecules difficult to transport . and/or store. Storage problems are particularly acute when pharmaceutical formulations must be stored and dispensed outside of the hospital environment. Many. protein and peptide drugs also require the addition of high concentrations of other protein such as albumin to reduce or prevent loss of protein due to binding to the container. This is a major concern with respect to proteins such as 7FN. For this reason, many Therapeutic proteins are formulated in combination with large proportion of albumin Garner molecule (,100-1000 fold excess), though this is an undesirable and expensive feature of the formulation.
Few practical .solutions to the storage problems of labile protein molecules have been proposed. Accordingly, there is a need for stabilized, long lasting formulations of proteinaceous therapeutic molecules that axe easily dispensed, preferably with a simple formulation requiring minimal post-storage manipulation.
SUMMARY OF THE INVENTION
. The present invention is based, in part, on the discovery that Therapeutic proteins may be stabilized to extend the shelf life, and/or to retain the Therapeutic protein's activity for extended periods of time in solution, in vitro and/or in vivo, ~by genetically 'or chemically fusing or conjugating the Therapeutic protein to albumin or a fragment (portion) or variant of albumin, that is sufficient .to stabilize the protein and/or its activity.
In addition it has been determined that the use of albumin-fusion proteins or albumin conjugated proteins mayneduce the need to formulate protein solutions with Large excesses of carrier proteins (such as albumin, unfused) to prevent loss of Therapeutic proteins due to factors such as binding to the container. .
The present invention . encompasses albumin fusion proteins comprising a Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants thereof) fused to albumin or a fragrrient (portion) or variant of albumin. The present invention also encompasses albumin fusion proteins comprising a Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants thereof) fused to albumin or a fragment (portion) or variant of albumin, that is sufficient to prolong the shelf life of the Therapeutic protein, and/or stabilize the Therapeutic protein and/or its activity in solution (or in a pharmaceutical composition) in vitro and/or ifi vivo. Nucleic acid molecules encoding the - albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic ,acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells.
The invention also encompasses pharmaceutical formulations comprising an albumin fusion protein of the invention and a pharmaceutically acceptable diluent or carrier. Such formulations may be in a kit or container. Such kit or container may be packaged with instructions pertaining to the extended shelf life of the Therapeutic protein.
Such formulations may be used in methods of treating, preventing, ameliorating or diagnosing a disease or~ disease symptom in a patient, preferably a mammal, most preferably a human, comprising the step of administering the pharmaceutical formulation to the patient.
In other embodiments, the present invention encompasses methods of preventing .
treating, or ameliorating a disease or disorder. In preferred embodiments, the present invention encompasses a method of treating a disease or disorder listed in the "Preferred Indication Y" colmm of Table 1 comprising administering to a patient in which such treatment, prevex~tiori or amelioration is desired an albumin fusion protein of the invention that comprises a Therapeutic protein portion corresponding to a Therapeutic protein (or fragment or variant thereof) disclosed in the "Therapeutic Protein X" column of Table 1 (in the same. row as the disease or disorder to be treated is listed in the "Preferred Indication Y" column of Table 1) in an amount effective to treat prevent or ameliorate the disease or disorder.
In another embodiment, the invention includes a method of extending the shelf life of ~ a Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants thereof) comprising the step of fusing or conjugating the Therapeutic protein to albumin or a fragment (portion) or variant of albumin, that is sufficient to extend the shelf life of the Therapeutic protein. In a preferred embodiment, the Therapeutic protein used according to this method is fused to the albumin, or the fragment or variant of albumin. In a most preferred embodiment, the Therapeutic protein used according to this method is fused to albumin, or a fragment or variant of albumin, via recombinant DNA
technology or genetic engineering. , ' .
In another embodiment, the invention includes a method of stabilizing a Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants thereof) in solution, comprising the step of fusing or. conjugating the Therapeutic protein to albumin or a fragment (portion) or variant of albumin, that.is sufficient to stabilize the Therapeutic protein. In a preferred embodiment, the Therapeutic protein,used according to this method is fused to the albumin, or the fragment or variant of albumin. In a most preferred embodiment, the Therapeutic protein used according to this method is fused .to albumin, or a fragment or variant of albumin, via recombinant DNA technology or genetic engineering.
The present invention further includes transgenic organisms modified to contain the nucleic acid molecules of the invention, preferably 'modified to express the albLUnin 25. fusion proteins encoded by the nucleic acid molecules.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 depicts the extended shelf life of an ~HA fusion protein in terms of the biological activity (Nb2 cell proliferation) of HA-hGH remaining after incubation in cell culture media for up to 5 weeks at 37°C. Under these conditions, hGH
has no observed activity by week 2.
Figure 2 depicts the extended shelf life of an HA fusion protein in terms of the 4 .

stable biological activity (Nb2 cell proliferation) of HA-hGH remaining after incubation in cell culture media for up to 3 weeks at 4,'37, or 50°C. Data is normalized to the biological activity of hGH at time zero.
Figures 3A and 3B compare the biological activity of HA-hGH with hGH in the Nb2 cell proliferation assay. Figure- 3A shows proliferation after 24 hours of incubation with various concentrations of hGH or the albumin fusion protein, and Figure 3B shows proliferation after 4~ hours of incubation With various concentrations of hGH
or the albumin fusion protein.
Figure 4 shows a map of a plasmid (pPPC0005) that can be used ~as the base vector into which polynucleotides encoding the Therapeutic proteins (including polypeptide and -fragments and variants thereof) may be cloned to .form HA-fusions: ~Plasmid Map key:
PRBIp:~PRB1 S. cerevisicze promoter; FL,: Fusion leader sequence; rHA: cDNA
encoding HA; ADHlt: ADHI S. ce~evisicze terminator; T3: T3 sequencing primer site; T7:

sequencing primer site; Amp R: ~i-lactamase gene; ors: origin of replication.
Please note that in the provisional applications to which this application claims priority, the plasmid in Figure 4 was labeled pPPC0006, instead of pPPC0005. In addition the drawing of this plasmid did not show certain pertinent restriction sites in this vector. Thus in the present application, the drawing is labeled pPPC0005 and more restriction sites of the same vector are shown. -Figure 5 compares the , recovery of vial-stored HA-IFN solutions of various concentrations with a stock solution after 48 or 72 hours ~of storage.
Figure 6 compaxes the activity of an HA-a-IFN fusion protein after administration to monkeys via IV or SC:
Figure 7 describes the bioavailability arid stability of an HA-a-IFN fission protein.
~ Figure 8 is a map of an expression vector for the production of HA- -IFN.
Figure 9 shows the location of loops in HA.
Figure 10 is ari example of the modification of an HA loop. , Figure 11 is a representation of the HA loops.
Figure 12 shows.the HA loop IV.
Figure I3 shows-the tertiary structure of HA.
Figure 14 shows an example of a scFv-HA fusion .
Figure 15 shows the amino acid sequence of the mature form of human albumin (SEQ ID NO: I 8) and a polynucleotide encoding it (SEQ ID NO: I7).
DETAILED DESCRIPTION
As described above, the present invention is based, in part, on the discovery that a Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants thereof) may be stabilized to extend the shelf life and/or retain the Therapeutic protein's activity for extended periods of time in solution (or in a pharmaceutical composition) in vitro and/or in vivo, by genetically fusing or chemically conjugating the Therapeutic protein, polypeptide or peptide to all or a portion of albumin sufficient to stabilize the protein and its activity:
The present .invention relates generally to albumin fusion proteins and methods of treating, preventing, br ameliorating diseases or disorders. As used herein, "albumin fusion protein" refers to a protein formed by the fusion of at least one molecule of albumin (or a fragment or variant thereof) to at least one molecule of a Therapeutic protein (or fragment or variant thereo ). An albumin fusion proteinJof the invention comprises at least a fragment or variant of a Therapeutic protein and at least a fragment or variant of human serum albumin, which are associated with one another, preferably by genetic fusion (i.e., the -albumin fusion protein is generated by translation of a nucleic acid in which a polynucleotide encoding all or a portion of a Therapeutic protein is joined in-frame with a polynucleotide encoding all or a portion of albumin) or chemical conjugation to one another. ' The.~Therapeutic protein and albumin protein, once part of the albumin fusion protein, may be referred to as a "portion", "region" or "moiety" of the albumin fusion protein (e.g., a "Therapeutic protein portion" or an "albumin pxotein portion").
In one embodiment, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a Therapeutic protein (e.g., as described in Table 1) and a serum albumin protein. In other embodiments; the invention provides an albumin fusion protein comprising, or alternatively' consisting of, a biologically active and/or therapeutically active fragment of a Therapeutic protein and a serum albumin protein. In _ other embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a biologically active and/or therapeutically active variant of a Therapeutic protein and a serum albumin protein. In preferred embodiments, the serum albumin protein component of the albumin fusion protein is the mature portion of serum ' 6~
albumin.
In further embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a Therapeutic protein, and a biologically active and/or therapeutically active fragment of serum albumin. In further embodiments, the 5, invention provides an albumin fusion protein comprising, or alternatively consisting of, a Therapeutic protein and a biologically active and/or therapeutically active variant of serum albumin. In preferred embodiments, the Therapeutic protein portion of the albumin fusion protein is the mature portion of the Therapeutic protein: In a further preferred embodiment, the Therapeutic protein portion of the albumin fusion protein is the extracellular soluble domain of the Therapeutic protein. In an alternative embodiment, the Therapeutic protein portion of the albumin fusion protein is the active form of the Therapeutic protien. ' _ In further _embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a biologically active and/or therapeutically active fragment or variant of a Therapeutic protein and a biologically active and/or therapeutically active fragment or variant of serum albumin. In preferred embodiments, the:
invention provides an albumin fusion protein comprising, or alternatively consisting of, the mature portion of a Therapeutic protein and the mature portion of serum albumin.
Therapeutic proteins As stated above, an albumin fusion protein of the invention comprises at least 'a fragment or variant of a Therapeutic protein and at least a fragment or variant of human serum albumin, which are associated with one another, preferably by genetic fusion or chemical conjugation.
, As used herein, "Therapeutic protein" refers to proteins, polypeptides, antibodies, peptides or fragments or variants thereof, having one or more therapeutic and/or biological activities: Therapeutic proteins encompassed by the invention include but are not limited to, proteins; polypeptides, peptides, antibodies, and biologics. (The terms peptides, proteins, and polypeptides are used interchangeably herein.) It is specifically contemplated that the term "Therapeutic protein" encompasses antibodies and fragments and variants thereof. Thus an albumin fusion protein of the invention may contain at least a fragment or variant of a Therapeutic. protein, and/or at least a fragment or variant of an antibody.

Additionally, the term "Therapeutic protein" may refer to the endogenous or naturally occurring correlate of a Therapeutic protein.
By a polypeptide 1 displaying a "therapeutic .activity" or a protein that is "therapeutically active"-~is meant a polypeptide that possesses one or more known biological and/or therapeutic activities associated with a therapeutic protein such as one or more of the Therapeutic proteins described herein or otherwise known in the art. As a non-limiting example, a "Therapeutic protein" is a protein that is useful to treat, prevent or ameliorate a disease, condition or disorder. As a non-limiting example, a "Therapeutic protein" may be one that binds specifically to a particular cell type (normal (e.g., lymphocytes) or abnormal e.g., (cancer cells)) and therefore may be used to target a compound (drug, or cytotoxic agent) to that cell type specifically.
In another non-limiting example, a "Therapeutic protein" is a protein that has a biological activity, and in particular, a biological activity that is useful for treating preventing or ameliorating a disease. A non-inclusive list of biological activities that may I S be possessed by a Therapeutic protein includes, - enhancing the immune response, promoting angiogenesis, inhibiting angiogenesis, regulating hematopoietic functions, stimulating nerve growth, enhancing an immune response, inhibiting an immune response, or any one or more of the biological activities described in the' "Biological Activities" -section below. ' As used herein, "therapeutic activity" or "activity"may refer to an activity whose effect is consistent with a desirable therapeutic outcome in humans; or to desired effects in non-human mammals or in other species or organisms. Therapeutic activity 'may be measured in vivo or in. vitro. For example, a desirable effect may be assayed in cell culture. As an example, when hGH is the Therapeutic protein, the effects of hGH on cell proliferation as described in Example 1 may be used as the endpoint for which therapeutic activity is measured. Such in vitro or cell culture assays are commonly available for many Therapeutic proteins as described in the art. . Examples of assays include, but are not.
limited to. those described herein in the Examples section or in the "Exemplary Activity Assay" column of Table 1.
Therapeutic proteins corresponding to a Therapeutic protein portion of an albumin fusion .protein of the invention, such as cell surface , and secretory proteins, are often modified by the attachment of one or more oligosaccharide groups. The' modification, 8 . -referred to as glycosylation, can dramatically affect the physical properties of proteins and can be important in protein stability, secretion, and localization.
Glycosylation occurs at specific locations along the polypeptide backbone. There are usually two major types of glycosylation: glycosylation characterized by O-linked oligosaccharides, which are attached to serine or threonine residues; and glycosylation characterized by N-linked oligosaccharides, which are attached to asparagine residues in an Asn-X-Ser/Thr sequence, where X can be any amino acid except proline. N-acetylneuramic acid (also known as sialic acid) is usually the terminal residue of both N-linked and 0-linked oligosaccharides.
Variables such as protein structure and cell type influence the number and nature of the carbohydrate units within the chains at different glycosylation sites.
Glycosylation isomers are also common at the same site within a given cell type.
For example, several types of human interferon are glycosylated. Natural human interferon-a2 is O-glycosylated at threonine 106, and N-glycosylation occurs, at asparagine 72 in interferon-a14 (Adolf et czl., J. Biochem 276:511 (1991); Nyrizan TA et czl., J.
Biochem 329:295 (1998)). The oligosaccharides at asparagine 80 in natural.
interferon-(31 a may play an important factor in the solubility and stability of the protein, but may not . be essential for its biological activity. This permits the production of an unglycosylated analog (interferon-(31b) engineered with sequence modifications to enhance stability (Hosoi et ccl., J. Interferon Res. 8:375 (1988; Karpusas et al., Cell Mol Life Sci 54:1203 (I998); Knight, J. Interferon Res. 2:421 (I982); Runkel et czl., Pharrn Res 15:641 (I998);
Lin, Dev. Biol. Stand. 96:97 (1998))1. Interferon-y contains two N-linked oligosaccharide chains at positions 25 and 97, both important for the efficient formation of the bioactive recombinant protein, and having an influence on the pharmacokinetic properties of the _.
protein (Sareneva et al., Eur. J. Biochem 242:191 (1996); Saxeneva et czl,.
Biochem J.
' 303:831 (1994); Sareneva et cal., J. Interferon Res. 13:267 .(1993)). Mixed O-linked and N-linked glycosylation also .occurs, for example in human erythropoietin, N-linked glycosylation occurs at asparagine residues located at positions 24, 38 and 83 while O-linked glycosylation occurs at a serine residue located at position 126 (Lai et czl., J. Biol.
Chem. 261:31 I6 (1986); Broudy et al., Arch. Biochem. Biophys. 265:329 (1988)).
Therapeutic proteins corresponding to a Therapeutic protein portion of ari albumin fusion protein of the invention, as well as analogs and~variants thereof, may be modified so that glycosylation at one or more sites is altered as a result of manipulations) of their nucleic acid sequence, by the- host cell in which they are expressed, or due to other conditions of their expression. For example, glycosylation isomers may be produced by abolishing or introducing glycosylation sites,~e.g., by substitution or deletion of amino acid residues, such as substitution of glutamine for asparagine, or unglycosylated recombinant proteins may be produced by expressing the proteins in host cells that will not glycosylate them, e.g. in E. coli or glycosylation-deficient yeast. These approaches are described in more detail below and are known in the art.
Therapeutic proteins (particularly those disclosed in Table 1) and their nucleic acid sequences are well known in the art and available in public databases such as Chemical Y
Abstracts Services Databases (e.g., the CAS Registry), GenBank, and GenSeq as shown in Table 1. .
Additional Therapeutic proteins corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention include, but are not limited to, one or more of the Therapeutic proteins or peptides disclosed in the "Therapeutic Protein X"
column of Table 1., or fragment or variable thereof.
Table 1 provides a non-exhaustive list of Therapeutic proteins that correspond to a Therapeutic protein portion of an albumin fusion protein of the invention. The "Therapeutic Protein X" cohunn discloses Therapeutic protein molecules followed by parentheses containing scientific and brand names that comprise, or alternatively consist of, that Therapeutic protein molecule or a fragment or variant thereof.
"Therapeutic protein X" as used herein may refer either to~ an individual Therapeutic protein molecule (as defined by the amino acid sequence obtainable frorin the CAS and- Genbank accession numbers), or to the entire group of Therapeutic. proteins associated with a given Therapeutic protein molecule disclosed in this column. The "Exemplary Identifier"
. column provides Chemical Abstracts Services (CAS) Registry Numbers (published by the American Chemical Society) and/or Genbank Accession Numbers ((e.g., Locus ID, NP XXX~~~ (Reference Sequence Protein), and XP XXXXX (Model Protein) identifiers available through the national Center for Biotechnology Information (NCBI) webpage at www.ncbi.nlm.nih.gov) that correspond to~ entries in the CAS Registry or Genbank database which contain an amino acid sequence of the Therapeutic Protein Molecule or of a fragment or variant of the Therapeutic Protein Molecule. In addition GenSeq Accession numbers and/or journal publication citations are given to identify the exemplary amino acid sequence for some polypeptides. The summary pages associated with each of these CAS and Genbank and GenSeq Accession Numbers as well as the cited journal publications (e.g., PubMed ID number (PMID)) are each incorporated by reference in their entireties, particularly with respect to the amino acid sequences described therein. The "PCT/Patent Reference" column provides U.S. Patent numbers, or PCT
International Publication Numbers corresponding to patents and/or published patent applications that describe the Therapeutic protein molecule. Each of the patents and/or published patent applications cited in the "PCT/Patent Reference" column are herein incorporated by reference in their entireties. In particular, the amino acid sequences of the specified polypeptide set forth in the sequence listing of each cited "PCT/Paterit Reference", the variants of these amino acid sequences (mutations, fragments, etc.) set forth, for example, in the detailed description of each cited "PCT/Patent Reference", the .therapeutic indications set forth, for example, in the detailed description of each cited "PCT/Patent Reference", and the activity asssaysfor the specified polypeptide set forth in the detailed description, and more particularly, the examples of each cited "PCT/Patent Reference" are incorporated herein by reference. The "Biological activity" column describes Biological activities associated with he Therapeutic protein molecule. The "Exemplary.
Activity Assay" column provides references. that describe assays which may be used to test the therapeutic and/or biological activity of a Therapeutic protein or an albumin fusion.protein of the invention comprising a Therapeutic protein X portion. Each of the references cited in the "Exemplary Activity Assay" column are herein incorporated by reference in their entireties, particularly with respect to the description of the respective activity assay described in the reference (see Methods section, for example), for assaying the corresponding biological activity set forth in the "Biological Activity"
column of Table 1.
The "Preferred Indication Y" column describes~disease, disorders, and/or conditions that may be treated, prevented, diagnosed, or ameliorated by Therapeutic protein X
or an albumin fiision protein of the invention comprising a Therapeutic protein X
portion.
The recitation of "Cancer" in the "Preferred Indication Y" column indicates that corresponding Therapeutic protein, fusion protein containing the Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., leukemias, cancers, and/or as described below under "Hyperproliferative Disorders").
In specific embodiments, a Therapeutic protein having a "Cancer" recitation in the "Preferred Indication" column of Table l, an albumin fusion protein that comprises a Therapeutic protein portion corresponding to this Therapeutic protein,. and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate a neoplasm-located in, a tissue selected from the group consisting of: colon, abdomen, bone, breast, digestive system, liver, pancreas, prostate, peritoneum, lung, blood (e.g., leukemia), endocrine glands (adrenal, parathyroid, pituitary; testicles, ovary, thymus, thyroid), uterus, eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital..
In specif c embodiments, a Therapeutic protein having a "Cancer" recitation in the "Preferred Indication" column of Table l, an albumin fusion protein that comprises a Therapeutic, protein portion corresponding to this Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate a pre-neoplastic condition, selected from the group consisting of hyperplasia (e.g., endometrial hyperplasia and/or ~ as described in the section entitled "Hyperproliferative Disorders"), metaplasia (e.g., connective tissue metaplasia, atypical metaplasia, and/or as described in the section entitled "Hyperproliferative Disorders"), and/or dysplasia (e.g., cervical dysplasia, and bronchopulmonary dysplasia).
In another specific embodiment, a Therapeutic protein having a "Cancer"
recitation in the "Preferred Indication" column of Table 1, an albumin fusion protein that comprises a Therapeutic protein portion corresponding to this Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate a benign dysproliferatiVe disorder selected from the group consisting of: benign tumors, fibrocystic conditions, tissue hypertrophy, and/or as -described in the section entitled "Hyperproliferative Disorders":
The recitation of "Iminune/Hematopoietic" in.the "Preferred Indication Y"
column indicates that corresponding Therapeutic protein, fusion protein containing the Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperp~oliferative Disorders"), blood disorders (e.g., as described below under "hnmune Activity" "Cardiovascular Disorders"
and/or "Blood-Related Disorders"), and infections (e.g., as described below under "Infectious Disease").
In specific embodiments, a Therapeutic protein having a "Immune/Hematopoietic"
recitation in the "Preferred Indication" column of Table l, a fusion protein containing this a . Therapeutic protein, and fragments and variants thereof, may .be used for example, to diagnose,, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: anemia;°pancytopenia, leukopenia, thrombocytopenia, leukemias, Hodgkin's disease, non-Hodgkin's. lymphoma, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, asthma, AIDS, autoimmune disease, rheumatoid ' arthritis, granulomatous disease, immune deficiency, inflammatory bowel disease, sepsis,. neutropenia, neutrophilia, psoriasis, immune reactions ~ to transplanted organs and tissues, systemic lupus erythematosis, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, and allergies.
The recitation of "Reproductive" in the "Preferred Indication Y" column indicates that corresponding Therapeutic protein, fusion protein containing the Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to .neoplastic diseases (e.g., as .
described below under "Hyperproliferative Disorders"), and disorders of the reproductive system (e.g., as described below under "Reproductive System Disorders").
In specific embodiments, a Therapeutic protein having a "Reproductive"
recitation in the "Preferred Indication" ' column of ' Table l, a fission protein containing this Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cryptorchism, prostatitis, inguinal hernia, varicocele, leydig cell tumors, verrucous ~ carcinoma, prostatitis, malacoplakia, Peyronie's disease, penile carcinoma, squamous cell hyperplasia, dysmenorrhea, ovarian, adenocarcinoma, Turner's syndrome, mucopurulent cervicitis,~ Sertoli-leydig tumors, ovarian cancer, uterine cancer, pelvic inflammatory disease, -testicular cancer, prostate cancer, I~linefelter's syndrome, Young's syndrome, premature ejaculation, diabetes mellitus, cystic fibrosis, Kartagener's syndrome, testicular atrophy, testicular feminization, anorchia, ectopic testis, epididymitis, orchitis, gonorrhea, syphilis, testicular torsion, vasitis nodosa, germ cell tumors, stromal tumors, dysrnenorrhea, retroverted uterus, endometriosis, fibroids, adenomyosis, anovulatory bleeding, amenorrhea, Cushing's syndrome, hydatidiform moles, Asherman's syndrome, premature menopause, precocious puberty, uterine polyps, dysfunctional uterine bleeding, cervicitis, chronic cervicitis, mucopurulent cervicitis, cervical dysplasia, cervical polyps, Nabothian cysts, cervical erosion, cervical incompetence, -cervical neoplasms, pseudohermaphroditism, and premenstrual syndrome.
The recitation of "Musculoskeletal" in the "Preferred Indication Y" column indicates that corresponding Therapeutic protein, fusion protein containing the Therapeutic protein, and fragments and variants thereof, 'may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), and disorders of the immune system (e.g., as described below under "Immune Activity").
In specific embodiments, a Therapeutic protein having a "Musculoskeletal"
recitation in the "Preferred Indication" column of Table 1, a fusion protein containing this Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease. or disorder selected from the group .
consisting of bone cancers (e.g., osteochondromas, benign chondromas, chondroblastoma, chondromyxoid fibromas; osteoid osteomas, giant cell tumors, multiple myeloma, osteosarcomas), Paget's Disease, rheumatoid arthritis, systemic lupus erythematosus, osteomyelitis, Lyme Disease, gout, . bursitis, tendonitis, osteoporosis, .osteoarthritis, muscular dystrophy, mitochondrial myopathy, cachexia, and multiple sclerosis.
The recitation of "Cardiovascular" in the "Preferred Indication ~Y" column indicates that corresponding Therapeutic protein, fusion protein containing the Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic .diseases (e.g., as described below under "Hyperproliferative Disorders"), and disorders of the cardiovascular system (e.g., as described below under "Cardiovascular Disorders").
In specific embodiments, a Therapeutic protein having a "Cardiovascular"
recitation in the "Preferred 'Indication" column of Table 1,, a fusion protein containing this Therapeutic .protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate a~ disease or disorder selected from the group consisting of myxomas, fibromas, rhabdomyomas, cardiovascular abnormalities (e.g., . 14 congenital heart defects, cerebral arteriovenous malformations, septal defects), heart disease (e.g:, heart failure, congestive heart disease, arrhythmia, tachycardia, fibrillation, pericardial Disease, endocarditis), cardiac arrest, heart valve disease (e.g., stenosis, regurgitation, prolapse), vascular disease (e.g., hypertension, coronary artery disease, angina, ~ aneurysm, arteriosclerosis; peripheral vascular disease), hyponatremia, hypernatremia, hypokalemia, and hyperkalemia.
The recitation of "Mixed Fetal" in the "Preferred Indication Y" column indicates that corresponding Therapeutic protein, fusion protein containing the Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders").
In specific embodiments, a Therapeutic protein having a "Mixed Fetal"
recitation iri the "Preferred Indication" column of Table l, an albumin fusion protein that comprises a Therapeutic protein portion corresponding to this Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: spina bifida, hydranencephaly, neurofibromatosis, fetal alcohol syndrome, diabetes mellitus, PKU, Down's syndrome, Patau syndrome, Edwards syndrome, Turner syndrome, Apert syndrome, Carpenter syndrome, Conradi syndrome, Crouzon syndrome, cutis. laxa, Cornelia de Lange syndrome, Ellis-van Creveld syndrome; Holt-Grain syndrome, Kartagener syndrome, Meckel-Gruber syndrome, Noonan syndrome, Pallister-Hall syndrome, Rubinstein-Taybi syndrome, Scimitar syndrome, Smith-Lemli-Opitz ~ syndrome, thromocytopenia-absent radius (TAR) syndrome, Treacher Collins syndrome, Williams syndrome, Hirschsprung's disease, M,eckel's diverticulum, polycystic kidney disease, Turner's syndrome, and gonadal dysgenesis, Klippel-Feil syndrome, Ostogenesis imperfecta, muscular dystrophy, " Tay-Sachs disease, Wilm's tumor,,neuroblastoma, and retinoblastoma.
The recitation of "Excretory" in the "Preferred Indication Y" column indicates that corresponding Therapeutic protein, . fusion protein containing the Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate , diseases and/or .disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders") and renal disorders (e.g., as described below under "Renal Disorders"). , In specific embodiments, a Therapeutic protein having a "Excretory" recitation in the "Preferred Indication'.' column of Table l, an albumin fusion protein that comprises a Therapeutic protein portion corresponding to this Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: bladder cancer, prostate cancer, benign prostatic hyperplasia, bladder disorders (e.g., urinary incontinence;
urinary retention, urinary. obstruction, urinary tract Infections, interstitial cystitis, prostatitis, neurogenic bladder, hematuria), renal -disorders (e.g., hydronephrosis, proteinuria, renal failure, pyelonephritis, urolithiasis, reflux nephropathy, and unilateral obstructive uropathy). ~ .
The recitation of "Neural/Sensory" in the "Preferred. Indication Y" column indicates that corresponding Therapeutic protein, fusion protein containing the Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders") and diseases or disorders of the nervous system (e.g., as described below under "Neural Activity and Neurological Diseases").
In specific -embodiments, a Therapeutic protein having a "Neural/Sensory"
recitation in the "Preferred Indication" column of Table l, an albumin fusion protein that comprises a Therapeutic protein portion corresponding to this Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of:
brain cancer (e.g., brain stem glioma, brain tumors, central nervous system (Primary) lymphoma, central nervous system lymphoma, cerebellar astrocytoma, and cerebral astrocytoma, neurodegenerative disorders (e.g., ,Alzheimer's Disease, Creutzfeldt-Jakob Disease, Parkinson's Disease, and Idiopathic Presenile Dementia), . encephalomyelitis, cerebral malaria, meningitis, metabolic brain diseases (e.g., phenylketonuria and pyruvate carboxylase deficiency), cerebellar ataxia, ataxia telangiectasia, and AIDS
Dementia Complex, schizophrenia, attention deficit disorder, hyperactive attention deficit disorder, autism, and obsessive compulsive disorders. ' The recitation of "Respiratory" in the "Preferred Indication Y" column indicates that corresponding Therapeutic protein, fusion protein containing the Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders") and diseases ora disorders of the respiratory system (e.g., as described below under "Respiratory Disorders") In specific embodiments, a Therapeutic protein having a "Respiratory"
recitation in the "Preferred Indication" column of Table l, an albumin fusion protein that comprises a Therapeutic protein portion corresponding to this Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cancers of the respiratory system such as larynx cancer, pharynx cancer, trachea cancer, epiglottis cancer, lung cancer, squamous cell carcinomas, small cell (oat cell) carcinomas, large cell carcinomas, and adenocarcinomas.. Allergic reactions, cystic fibrosis, sarcoidosis, histiocytosis X, infiltrative lung diseases :(e.g., pulmonary fibrosis .and lymphoid interstitial pneumonia), obstructive airway diseases (e.g., asthma, emphysema, chronic or acute bronchitis), occupational lung diseases (e.g., silicosis and asbestosis), pneumonia, and pleurisy.
The recitation of "Endocrine" in the "Preferred Indication Y" column indicates that .
corresponding Therapeutic protein, fusion protein containing the Therapeutic protein, and fragments and variants thereof, may be used for example, to. diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders") and diseases or disorders of the respiratory system (e.g., ~ as described below under "Respiratory Disorders"), renal disorders (e.g., as described below under "Renal Disorders"), and disorders of the endocrine system (e.g., as described below under "Endocrine Disorders".
In specific embodiments, a Therapeutic protein having a "Endocrine" recitation in the "Preferred Indication" column of Table l, an albumin fusion protein that comprises a Therapeutic protein portion corresponding to this Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate a .
disease or disorder selected from the group consisting of cancers of endocrine tissues and organs (e:g., cancers of the hypothalamus, pituitary gland, thyroid gland, parathyroid glands, pancreas, adrenal glands, ovaries, and testes), diabetes (e.g., diabetes insipidus, type I and type II diabetes mellitus), obesity,-disorders related to pituitary glands (e.g., hyperpituitarism, hypopituitarisrn, and pituitary dwarfism), hypothyroidism, hyperthyroidism, goiter, reproductive disorders (e.g: male and female infertility), disorders related to adrenal glands (e.g., Addison's Disease, corticosteroid deficiency, and Cushing's Syndrome), kidney cancer (e.g., hypernephroma, transitional cell cancer, and Wilin's tumor), diabetic nephropathy, interstitial nephritis, polycystic kidney disease, glomerulonephritis (e.g., IgM mesangial proliferative glomerulonephritis and glomerulonephritis caused by autoimmune disorders; such as Goodpasture's syndrome), and nephrocalcinosis.
The recitation of "Digestive" in the "Preferred Indication Y." column indicates that corresponding Therapeutic protein, fusion protein containing the Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or .ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders") and diseases or disorders of the gastrointestinal system (e.g., as described below under "Gastrointestinal Disorders".
In specific embodiments, a Therapeutic protein having a "Digestive" recitation in the "Preferred Indication" column of Table 1, an albumin fusion protein that comprises'a Therapeutic protein portion corresponding to this Therapeutic protein, and fragments and ' variants thereof, may be used 'for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: ulcerative colitis, appendicitis, Crohn's disease, hepatitis, hepatic encephalopathy, portal hypertension, cholelithiasis, cancer of the digestive system (e.g., biliary tract cancer, stomach cancer, colon cancer, gastric cancer, pancreatic cancer, cancer of the bile duct, tumors of the colon (e.g:, polyps or cancers), and cirrhosis), pancreatitis, ulcerative disease, pyloric stenosis, gastroenteritis, ' gastritis, gastric atropy, benign tumors of the duodenum, distension, irritable bowel syndrome, malabsorption, congenital disorders of the small intestine, bacterial and parasitic infection, megacolon, Hirschsprung's disease, aganglionic megacolon, acquired megacolon, ~ colitis, anorectal 'disorders (e.g., anal fistulas, hemorrhoids), congenital disorders of the liver (e.g., Wilson's disease, hemochromatosis, cystic fibrosis, biliary atresia, and alphal-antitrypsin deficimcy), portal hypertension, cholelithiasis, and jaundice.
. The recitation of "Connective/Epithelial" in the "Preferred Indication Y"
column indicates that corresponding Therapeutic protein, fusion protein containing the Therapeutic protein, and fragments and ,variants thereof, may be used for-example,- o diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), cellular and genetic abnormalities (e.g., as described below under "Diseases at the Cellular Level "), angiogenesis (e.g., as described below under, "Anti-Angiogenesis Activity "), and or to promote or inhibit regeneration (e.g., as described belowunder "Regeneration "), and wound healing (e.g., as described below under "Wound Healing and Epithelial Cell Proliferation").
In specific embodiments, a Therapeutic protein having a "Connective/Epithelial"
recitation in the "Preferred Indication" column of Table 1, an albumin fusion protein that comprises a Therapeutic protein portion corresponding to this Therapeutic protein, and fragments and variants thereof, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from,the group consisting of:
connective tissue metaplasia, mixed connective tissue disease, focal epithelial hyperplasia, epithelial metaplasia, mucoepithelial dysplasia, graft v. host disease, polymyositis, cystic hyperplasia, cerebral dysplasia, tissue hypertrophy, Alzheimer's disease, lymphoproliferative disorder, Waldenstron's macroglobulinemia, Cz-ohn's disease, pernicious anemia, idiopathic Addison'.s disease, glomeiulonephritis, bullous pemphigoid, Sjogren's . syndrome, diabetes mellitus, cystic fibrosis, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, osteoporosis, osteocarthritis, periodontal disease, wound healing, relapsing polychondritis, vasculitis, polyarteritis nodosa, Wegener's .
granulomatosis, cellulitis, rheumatoid arthritis, psoriatic arthritis, discoid lupus erythematosus, systemic lupus erythematosus, scleroderma; CREST syndrome, Sjogren's ''syndrome, polymyositis, dermatomyositis, mixed connective tissue disease, relapsing ~polychondritis, vasculitis, Henoch-Schonlein syndrome, erythema nodosum, polyarteritis ' riodosa, temporal (giant cell) axteritis, Takayasu's arteritis, Wegener's granulomatosis, Reiter's , syndrome, Behcet's syndrome, ankylosing spondylitis, cellulitis, keloids, Ehler Danlos syndrome, Marfan syndrome, pseudoxantoma elasticum, osteogenese imperfecta, chondrodysplasias, epidermolysis bullosa, Alport syndrome, and cutis laxa., Therapeutic Exemplary PCT/Patent ReferencePreferred Indication . Identifier Y
Protein X

HETF052 B03768 US6066724-A Neural/Sensory, - Re roductive -HETEZ10 - B03769 US6066724-A Cancer HLICR58~ B08775 WO200052160-A1 Cancer HMCIS41 B08776 W0200052160-A1 Cancer HCESA34 B08891 W0200017222-A1 Cancer HCRMZ90 B08892 W0200017222-A1 Cancer HDPXQ54 B08893 WO200017222-A1 Immune/Hemato oietic HETCL11 B08894 ~ W0200017222-A1 Cancer HFXDN34 B08895 W0200017222-A1 Neural/Sensory HKAAV24 B08896 WO200017222-A1 Cancer HMTBE31 B08897 W0200017222-A1 Cancer HRADL70 B08898 W0200017222-A1 Excretory, ImmunelHemato oietic HTXGG31 B08899 W0200017222-A1 Cancer HWHHL34 B08900 W0200017222-A1 Cancer HYAAY40 . B08901 W0200017222-A1 Immune/Hemato . oietic . ' .

HPASA81 B08902 W0.200017222-A1 Digestive, Endocrine, ~ ' Re roductive HCNDA61 B08903 W0200017222-A1 Digestive, , Re roductive HTHCZ41 B08904 ~ W0200017222-A1 Cancer HKADJ17 B08905 W0200017222-A1 Connective/Epithelial, Immune/Hematopoietic, -Re roductive HMSII78 ' B08906 W0200017222-A1 Cancer HCFBL76 B08907 W0200017222-A1 Cancer HFVHR84 ' B08908 W0200017222-A1 Connective/Epithelial, Di estive HIBCB67 B08909 W0200017222-A1 Cancer HCELI29 B08910 W0200017222-A1 Cancer HAHDZ77 B08911 WO200017222-A1 Cardiovascular, . Mixed Fetal HDHMA45.- B08912 W0200017222-A1 Cardiovascular, . Neural/Sensory HELAW45 B08913 WO200017222-A1 Cardiovascular HFIAB31 B08914 W0200017222-A1 Cancer HLWBKOS B08915 ' W0200017222-A1 Cancer HLDBX13 B08916 W0200017222-A1 Di estive HMAGA15 B08917 W0200017222-A1 Cancer HMWFT53 B08918 W0200017222-A1 Immune/Hemato oietic HNFJD91 , B08919 ~ ~ WO200017222-A1 Cardiovascular, Cormective/Epithelial, Immune/Iiemato oietic HTGCM55~ B08920 W0200017222-A1 Cardiovascular, . Digestive, Immune/Hemato oietic HTTEX77 B08921 W0200017222-A1 Cancer ' .

HFXDN34 B08922 W0200017222-A1 Neural/Sensory HDPMI18 B08923 W0200017222-A1 Cancer HETGL41 B08924 W0200017222-A1 Cancer HPASA81 B08925 W0200017222-A1 Digestive, _ Endocrine, .

Re roductive HCNDA61 B08926 W0200017222-A1 Digestive, Re roductive HTTEX77 B08927 WO200017222-A1 Cancer HFXDN34 B08934 W0200017222-A1 Neural/Senso HETGL41 B08935 W0200017222-A1 Cancer HPASA81 B08936 W0200017222-A1 Digestive, Endocrine, Re roductive HCNDA61 B08940 W0200017222-A1 Digestive, . Re roductive HTTEX77 B08982 W0200017222-A1 Cancer HAOAB14 B12301 W0200029422-A1 Digestive, Musculoskeletal HHFBY53 B12302 W0200029422=A1 Cancer HE2FE69 B12303 W0200029422-A1 Cancer HNHFI33 B12305 ~ W0200029422-A1 Imrnune/Hemato oietic -HAMFE15 B12306 W0200029422-A1 Cancer HAMFE82 B12307 ~ ~ W0200029422-A1 Cancer HCWEM59 B12308 W0200029422-A1 Immune/Hemato oietic HDPGE10 B12309 W0200029422-A1 Immune/Hemato oietic HDPGP94 B12310 , WO200029422-Al Digestive, Immune/Hemato oietic HFPBY77 B12311 W0200029422-A1 Cancel HFXHK32 B12312 W0200029422-Al Neural/Sensory HMTAKOS B12313 W0200029422-A1 Cancer HMWDC93 B12314 WO200029422-A1 Immune/Hemato oietic HSPBY40 B12315 WO200029422-A1 Cancer HODDO08 B12316 W0200029422-A1 Cancer HCFNK47 B12317 W0200029422-A1 Cancer HE2FL70 B12318 W0200029422-A1 Immune/Hematopoietic, ' Mixed Fetal, Neural/Sensory H2MBY03 B12319 W0200029422-A1 Cancer HACBS38 B12320 W0206029422-A1 Cancer HAGFG51 B12321 W0200029422-A1 Neural/Sensory ' HBQAB44 B 12322 W0200029422-A1 Neural/Sensory, Reproductive, ' Res iratory, - HHEMA59 B12323 WO200029422-A1 Cancer HJBAV55 B12324 W0200029422-A1 Cancer HLHEY02 B1232.~ ~ W0200029422-A1 Endocrine, Res iratory HSAA094 B12326 W0200029422-A1 Cancer HTXKP61 ~ B12327 W0200029422-A1 Cancer HWABC21 ~ B12328 W0200029422-A1 Cancer HWBDI30 B12329 W0200029422-A1 Cancer HYBAR26 B12330 W0200029422-A1 Musculoskeletal HA3AF57 B12331 W0200029422-A1 Cancer HAMFE15 B12332 W0200029422-A1 Cancer HAMFE82 B12333 W0200029422-A1 Cancer-HAMFE15 B12338 W0200029422-A1 Cancer HAMFE82 B12339 W02000.29422-A1 Cancer HLDOK36 B15551 W0200056752-A2 Cancer ~

HDPBW68 B15552 ' W0200056752-A2 Cancer HHEF024 B15553 W0200056752-A2 Cardiovascular, Immune/Hematopoietic, Neural/Sensory HEGAL46 B15554 W0200056752-A2 Cancer HFOYC02 B15555 W0200056752-A2 Cancer HDABV82 B15556 W0200056752-A2 Cancer HCEMU42 B15557 W0200056752-A2 Cancer HSIF061 B15558 W0200056752-A2 Cancer HDPBW68 B15559 W0200056752-A2 Cancer HDPBW68 B15562 W0200056752-A2 Cancer HSIF061 B 15566 W0200056752-A2 Cancer HOEAL47 B'18715 W0200054651-A2 Cancer .

HE9SF68 B18755 ' W0200055204-A1 Cancer HLICQ90 B24437 W0200035937-A1 Cancer HNTSM04 B24438 W0200035937-A1 Cancer HMCAL59 B24439 . W0200035937-A1 Cancer ~

HMAC004 B24440 W0200035937-A1 Cancer HMAHY59 B24441 W0200035937-A1 Cancer HFXLL52 B24442 W0200035937-A1 Neural/Sensory HKABY55 B24443 W0200035937-A1 Cancer ~

HCQCF36 B24444 W0200035937-A1 Digestive, Immune/Hemato oietic HTAD022 B24445 W0200035937-A1 Immune/Hemato oietic _ HHFHD92 B24446 W0200035937-A1 Cancer HNGFW58 B24447 W0200035937-A1 Cancer HOEFV61 B24448 W0200035937-Al Cancer ~

HPIAQ68 B24449 ~ W0200035937-A1 Immune/Hematopoietic, Re reductive HNFFY60 B24450 W0200035937-A1 Cancer HCE3H20 B24451 W0200035937-A1 Cancer HE8EW79 B24452 W0200035937-A1 Cancer HTTDF41 B24453 W0200035937-A1 Cancer.

HSSGJ45 B24454 ~ W0200035937-A1 Cancer HLWBY76 B24455 W0200035937-Al Cancer HDPBN34 B24456 WO200035937-A1 Immune/Heri~ato oietic HMSHY73 B24457 WO200035937-A1 Cancer ' HPRBF19 B24458 W0200035937-A1 Cancer -HNFJE06 B24459 W0200035937-A1 Immune/Hematopoietic, Musculoskeletal HCTICF61 B24460 W0200035937-A1 Re reductive HBJLH40 . B24461 W0200035937-A1 Cancer HDPMV72 B24462 W0200035937-A1 Cancer HEMFA84 B24463 W0200035937-Al Cancer HTOHW95 ' B24464 W0200035937-Al Cancer HITNAH63 B24465 W0200035937-A1 Re reductive ~

HISBT59 B24466 W0200035937-A1 Cancer ' .

HNTAS52 B24467 W0200035937-A1 Cancer HRACM44 B24468 ~ W0200035937-A1 Excretory, , Immune/Hemato oietic HFPES77 B24469 W0200035937-A1 Cancer HUSXU29 B24470 W0200035937-A1 Cancer HOHBB49 B24471 W0200035937-A1 Musculoskeletal HRABX31 B24472 WO200035937-A1 Excretory, ' Immune/Hematopoietic, Musculoskeletal HROBD68 B24473 W0200035937-A1 Cancer HMHBE18 ~ B24474 ~ W0200035937-A1 Cancer HNHDY21 824475 W0200035937-A1 Immune/Hemato oietic HOEBZ89 B24476 W0200035937-A1 Cancer HYAAJ71 824477 W0200035937-A1 Immune/Hemato oietic HTEKS16 B24478 W0200035937-A1 Connective/Epithelial, Mixed Fetal, Re reductive HCUFX40 B24479 WO200035937-A1 Immune/Hemato oietic HCWDL7S B24480 W0200035937-A1 Cardiovascular, ' Immune/Hemato oietic HNHKJ57 B24481 ' WO200035937-A1 Immune/Hemato oietic HCMSS06 B24482 W0200035937-A1 Cancer HIBCE35 B24483 ~ W0200035937-A1 Cancer HE8EW79 B24484 W0200035937-AM Cancer HTTDF41 ~ B24485 W0200035937-A1 Cancer HSSGJ45 824486 W0200035937-A1 Cancer HCMSS06 B24487 W0200035937-A1 Cancer .
~

HCMSS06 B24597 W0200035937-AI Cancer ' HAOAB64 . B25576 W0200029435-A1 Musculoskeletal, , Re reductive HOHCH55 B25577 ' WOZ00029435-A1 Cancer .

HTLEW81 825578 ' W0200029435-A1 Cancer HARA044 B25579 W0200029435-A1 eural/Sensory N

HDPCL05 B25580 W0200029435-A1 Immune/Hemato oietic HDPUW68 B25581 ~ W0200029435-A1 Cancer HOHBY69 B25582 W0200029435-A1 Cancer HCDDP40 B25583, W0200029435-A1 Immune/Hematopoietic, Musculoskeletal HUSAQOS B25585 W0200029435-A1 Cancer HOUDJ81 B25586 W0200Q2943S-A1 Cancer .

HPWCM76 B25587 W0200029435-A1 Re reductive HOHCH55 B25588 W0200029435-A1 Cancer HDPCL05 B25589 W0200029435-A1 Immune/Hemato oietic HOHBY69 B25590 W0200029435-A1 Cancer HUSAQ05 B25592 W0200029435-A1 Cancer.

HOUDJ81 B25593 ~ W0200029435-A1 Cancer HUSA 05 B25618 W0200029435-A1 Cancer HE8NG02 _ B25665 , , W0200043495-A2 Mixed Fetal, ' ~ Re reductive HWBDM37 , B25666 W0200043495-A2 Digestive, , Immune/Hematopoietic, Re reductive HODFN71 B25668 W0200043495-A2 Mixed Fetal, Re reductive-HODGE68 B25669 W0200043495-A2 Re reductive HCECN54 B25670 W0200043495-A2 Excretory, Neural/Sensory HE8UB86 B25671 W0200043495-A2 Cancer.

HNHKY10 B25672 W0200043495-A2 ImmunelHemato oietic HNHLB93 B25673 W0200043495-A2 Immune/Hemato oietic HNHON23 B25674 , W0200043495-A2 ImmunelHematopoietic, ' Musculoskeletal HTEPG70 B25675 W0200043495-A2 Re reductive HNHOJ75 B25676 W0200043495-A2 Immune/Hemato oietic HDTIT10 B25677 W0200043495-A2 Cancer ~

HKAOS84 B25678 W0200043495-A2 Connective/E ithelial HAPUC89 B25679 W0200043495-A2 Cancer ~

HWAAD63 B25680 W0200043495-A2 Endocrine, ' Excretory, Immune/Hemato oietic HUCPD31 B25681 W0200043495-AZ Cancer HDQHD03 B25682 W0200043495-A2 Immune/Hematopoietic, Neural%Sensory HKAKK09 B25683 WO200043495-A2 Connective/Epithelial, ' Digestive, Mixed Fetal HOCNF19 B25684 W0200043495-A2 Di estive HTLIT32 B25685 W0200043495-A2 Re roductive HODEJ32 B25686 W0200043495-A2 Re roductive HNHMV54 B25687 W0200043495-A2 Immune/Hemato oietic HODEE95 B25688 ~ W0200043495-A2 Re roductive HLHAM10 . B25689 W0200043495-A2 Cancer -HNHOG73 B25690 W0200043495-A2 Immune/Hemato oietic HBGNM47 B25691 W0200043495-A2 Cancer HAUBA08 ~ B25692 W0200043495-A2 Cancer .

HYBBE75 B25693 ~ W0200043495-A2 Musculoskeletal HTLGY87 B25694 W0200043495-A2 Cancer HNHPD10 ~ B25695 W0200043495-A2~ Immune/Hemato oietic HODEI83 B25696' WO200043495-A2 Re roductive HMUAI20 B25697 W0200043495-A2 Cancer HE90W20 B25698. W0200043495-A2 Immune/Hematopoietic, Mixed Fetal, Neural/Sensory HDTIT10 B25699 W0200043495-A2 Cancer HWAAD63 B25700 WO200043495-A2 Endocrine, ' Excretory, - . ' Immune/Hemato oietic HWAAD63 B25701 W0200043495-A2 Endocrine, Excretory, Immune/Hemato oietic HEMCV19 B25703 W0200043495-A2 Cancer HEMCV19 B25704 W0200043495-A2 Cancer .

HEMCV19 ' B25705 W0200043495-A2 Cancer ' HAUBA08 B25706 W0200043495-A2 Cancer HEMCV19 B25707 W0200043495-A2 Cancer HE9OW20 ~B25715 W0200043495-A2 Immune/Hematopoietic, .
Mixed Fetal, Neural/Sensory HT4SB02 B27560 W0200055175-A1 Immune/Hemato oietic HCHAC68 B27562 W0200055175-A1 Cancer HCHCA79 B27_ 563 W0200055175-A1 Digestive, NeurallSensory, Re roductive HCHMY57 B27564 W0200055175-Al Cancer HCHOY52 B27566 WO200055175-A1 Cancer HCHQB93 B27567 W0200055175-A1 Cancer HCMSA37 - B27568 W0200055175-A1 Cardiovascular HCMSX51 B27570 W0200055175-A1 Cancer HCNAI74 B27571 W0200055175-A1 Di estive HCPAE41 B27578 W0200055175-A1 Cancer HCQAQ47 B27580 W0200055175-A1 Cancer HCQBH72 B27581 W0200055175-A1 Digestive, , - ~ ' Excretory, Immune/Hemato oietic HCQDD32 B27585 WO200055175-A1 Digestive, Immune/Hematopoietic, Re reductive HCQDT67 B27586 WO200055175-A1 Cancer HCRAY10 B27587. W0200055175-A1 Cancer HCRBI79 B27589 - W0200055175-A1 Cancer HNFAD50 B27591 W0200055175-A1 Cancer HCRNF78 B27592 ~ W0200055175-A1 Cancer HCUAF85 B27594 W0200055175-A1 Immune/Hemato oietic HCUBM41 B27598 W0200055175-A1 Immune/Hemato oietic HCUBN69 B27599 W0200055175-A1 Immune/Hemato oietic HCUDD64 B27602 W0200055175-A1 Cancer HCUEC55 B27604 W0200055175-A1 Immune/Hemato oietic HCUFC77 B27607 W0200055175-A1 Cancer HBJBR40 B27686 W0200055201-A1 Immune/Hemato oietic HBJCH46 B27687 W0200055201-A1 ImmunelHematopoietic, Musculoskeletal HBJFU30 .B27698 WO200055201-A1 Cancer -HBJAY14 B27704 W0200055201-A1 Immune/Hemato oietic HBJND04 B27708 W0200055201-A1 Cancer HBKEA94 B27711 W0200055201-A1 Cancer ~

HBJDS79 B27712 W0200055201-A1 Cancer HBKEI41 B27713 WO200055201-A1 Endocrine, Mixed Fetal, Re reductive HBJH083 B27720 W0200055201-A1 Immune/Hematopoietic, Re reductive HBMCT40 B27721 W0200055201-A1 Cancer HBMTX26 B27724 W0200055201-A1 Immune/Hemato oietic HBMTY48 B27725 WO200055201-A1 Immune/Hematopoietic, .
Re reductive HBMUD59 B27726 W0200055201-A1 Cancer HBMUI10 B27727 W0200055201-Al Cancer ' HCEEU18 B27794 W0200055199-A1 Cancer HCDCB03 B27795 W0200055199-A1 Cancer HCE1G78 B27797 W0200055199-A1 Cancer HCDEB19 B27799 W0200055199-A1 Cancer HCEDR26 B27801. ~ W0200055I99-A1 Digestive, ' Immime/Hematopoietic,.
Neural/Sensory HCDBW67 B27804 W0200055199-A1 Cancer HCDDX81 B27808 W0200055199-A1 Musculoskeletal HBZAI75 .B27809 WO200055199-A1 Digestive, ' Re reductive HCDEN46 B27810 W0200055199-A1 Cancer HCE1D45 ' B2781~1 W0200055199-A1 Cancer HCElY27 B27813 W0200055199-A1 Digestive, Neural/Sensory, Re reductive HCE2I23 . B27816 W0200055199-A1 Neural/Sensory HCE2P90 B27817 W0200055199-A1 Neural/Sensory HCE3A54 B27818 W0200055199-A1 Neural/Sensory HCE3D89 B27819 W0200055199-A1 Endocrine, Neural/Sensory IiCE3N23 B27820 W0200055199-A1 Cancer HCE4T64 B2782I _ WO200055i99-AI Cancer HCE5J64 B27823 W0200055199-AI Digestive, Neural/Sensory HGEC077 B27824 W0200055199-AI Cancer HCEDH42 B27825 W0200055199-A1 Neiiral/Senso HCEDJ05 B27826 W0200055199-A1 NeurallSensory HCEEE79 B27829 W0200055199-A1 Neural/Sensory HCEFH3I _B27837 W0200055199-A1 Cancer .

HCDDL48 B27838 W0200055199-A1 Musculoskeletal HFVIC33 B27908 W0200055171-A1 Cancer HEMAH05 B27909 W0200055171-A1 Cancer HHSBI65 B27911 W0200055171-Al Cancer HLEAA24 B27917 _W0200055171-Al Inimurie/Hemato oietic HPTTQ91 B27919 W0200055171-A1 Cancer _ HPMGY89 B27923 W0200Q55171-A1 Cancer H2LA003 B27933 W0200055171-A1 Cancer .

H2MBA76 B27937 W0200055171-AI Cancer H2MBF60 B27938 W0200055171-A1 Cancer H6BSF56 ~ _B27939 W0200055171-A1 Cancer H6BSM88 B27940 W0200055171-A1 Cancer H6EEU40 B27941 W0200055171-A1 Cancer HACAB68 B27943 W0200055171-A~l Connective/Epithelial, _ Immune/Hemato oietic HACBA04 B27945 W0200055171-A1 Cancer HACBJ1 I . B27946 W0200055171-A1 Cancer HACBS86 B27947 W0200055171-A1 Cancer HACBT91 B27948 W0200055171-A1 Cancer - HADAB60 B27951 W02000S517I-A1 Cancer HADDE7i B27956 W020005517i-AI Cancer HAGFU31 B28014 W0200055177-A2 Neural/Sensory HAPBR13 B280I7 W0200055177-A2 Cancer HAQBG57 B28020 W0200055177-A2 Cancer HARAE26 B28022 W0200055177-A2 Neural/Sensory HAHEM51 B28032 W0200055177-A2 Cardiovascular HAICL90 B28035 _ Digestive, WO200055177-A2 Immune/Hematopoietic, Re roductive HAMFC67 B2_8038 W0200055177-A2 Cancer HAPBU09 B28041 W0200055177-A2 Cancer HAPNL62 B28043 W0200055177-AZ Cancer HAPNY10 B28045 W0200055I77-A2 Cancer HAP U7i B28048 W0200055177-A2 Cancer HARAT69 B28054 W0200055177-A2 Cancer HAGEU26 828059 W0200055I77-A2 Neural/Senso HANGB24 828060 W0200055177-A2 Cancer HNGER85 B282~86 W0200058355-A1 Iznmune/Hemato oietic HNGET33 B28287 W0200058355-A1 Irnmune/Hematd oietic HNGFA25 B28292 W0200058355-A1 Immune/Hemato oietic HNGFG04 828297 W0200058355-Al ImmunelHemato oietic HNGFG74 B28298 W0200058355-A1 IrnmunelHemato oietic HNGFI21 828301 W0200058355-A1 Cancer HNGFM31 B28302 W0200058355-A1 Immune/Hemato oietic HCIJCK44 B28303 W0200058355-A1 Cancer HNGFQ18 B28304 W0200058355-A1 Immune/Hemato oietic .

HNGFR54 B28305 W0200058355-AI ImmunelHemato oietic ' HNGGF13 B28309 W0200058355-Al Immune/Hemato oietic HNGGL11 B28311 W0200058355-A1 Immune/Hemato oietic HNGGP65 B2$312 W0200'058355-A1 Immune/Hemato oietic HNGHM47 B28316 ' W0200058355-A1 Immune/Hemato oietic HNGIH40 B28318 WO200058355-A1 Immune/Hemato oietic HNGIM83 B28321 WO200058355-A1 Immune/Hemato oietic HNGIS27 B28322 . W0200058355-A1 Immune/Hemato oietic HADFB84 ~ 828707 W0200055198-A1 Cancer HADFDO1 B28708 W0200055198-Al Cancer HADFK11 B28709 W0200055198-A1 Connective/E ithelial HADFT44 B28710 W0200055198-A1 Connective/Epithelial, Mixed Fetal, Neural/Sensory HADGD93 B28714 W0200055198-A1' Cardiovascular, Connective/E ithelial HAFBB15 B28716 W0200055198-A1 Cancer HAGAB62 B28718 W0200055198-Al Cancer HAGAF75 . B28720 W0200055198-A1 Digestive, Neural/Sensory HAGAZ36 B28722 W0200055198-A1~ Neural/Sensory H2CBH91 B28725 W0200055198-A1 Cancer HAGBV29 B28730 W0200055198-A1 Immune/Hematopoietic, - NeurallSensory HAGCH67 B28732 W0200055198-A1 Neural/Senso HAGCI69 B28'733 W0200055198-A1. Neural/Sensory, Re reductive .

HAGCT33 ' B28734 W0200055198-A1 Immune/Hematopoietic, Mixed Fetal, - Neural/Sensory HAGDG84 B28737 W0200055198-A1 Immune/Hematopoietic, Neural/Sensory HAGD070 B28743 W0200055198-A1 Cancer HAGDW68 B28746 W0200055198-A1 Endocrine, Neural/Sensory HAGEG10 828748 W0200055198-A1 Cancer HAGEK37 B28750 W0200055198-A1 Cancer HTAD061 ' B29803 W0200061779-A1 Cancer HELDH39 B29805 W0200061779-A1 Cancer HSLCV16 B29806 W0200061779-A1 Cancer HTOJL95 B29807 W0200061779-A1 Cancer HOEBK60 B29810 W0200061779-A1 Cancer HSAWN53 B29813 W0200061779-A1 Immune/Hemato oietic HORBS82 B29814 W0200061779-A1 Cancer HORBV76 B29815 W0200061779-A1. .Cardiovascular, ImmtmelHematopoietic, ' Re reductive HTEHA56 B29822 W0200061779-A1 - Cancer HMWER46 B29828 W0200061779-A1 Cancer HPRAD30' B29829 W0200061779-A1 Cancer HTLDD89 B29832 W0200061779-A1 Re reductive HMCJC19 B29835 . W0200061779-A1 Immune/Hemato oietic HROBW46 B29841 . W0200061779-A1 Digestive, Immune/Hemato oietic HSOBB94 B29842 W0200061779-A1 Cancer HSOBP75 B29844 W0200061779-A1 Cancer HNHKS19 B29848 ' WO200061779-Al Immune/Hemato oietic, Re roductive HNHKV56 B29849 ' W0200061779-A1 Immune/Hemato oietic HWLIL31 B29850 W0200061779-A1 Cancer HMVBC31 B32002 W0200058350-A1 Cancer HMVBC84 B32003 W0200058350-Al Digestive, I mmune/Hematopoietic, Neural/Sensory HMWA082 B32006 W0200058350-A1 Immune/Hemato oietic HMWBK35 B32008 W0200058350-A1 Cancer HHENT16 B32010 W0200058350-A1 Cancer -HMWEF46 B32020 W0200058350-A1 Immune/Hemato oietic HMWEX02 B32022 W0200058350-Al Cancer HKGCK41 B32027 WO200058350-A1 Cancer HMWHR36 B32029 W0200058350-A1 Immune/Hemato oietic HMWIQ26 B32031 W0200058350-A1 Cancer HMWIU49 B32032 W0200058350-A1 Cancer HMWJJ64 . B32035 W0200058350-A1 Cancer HNEAK38 B32040 W0200058350-A1 Immune/Hemato oietic HNECD52 B32043 WO200058350-A1 Immune/Hematopoietic, Neural/Sensory HNECL75 B32045 W0200058350-A1 Cancer HNECW49 B32046 ' WO200058350-A1 Immune/Hemato oietic HNEDA05 B32048 W0200058350-A1 Immune/Hemato oietic HETKD92 B32371 W0200047602-A1 Cancer HNTSN12 B32372 W0200047602-A1 Cancer-HMQBV64 B32373 W0200047602-A1 Cancer HTELM16 B32374 . W0200047602-A1 Re roductive HSDFJ26 B32375 W0200047602-A1 Cancer HNGND37 B32376 W0200047602-A1 Cancer ' .

HWBDV80 B32377. W0200047602-A1 Cancer HDPOR60 B32378 W0200047602-A1 Cancer HWBFY57. B32379 W0200047602-A1 Digestive, ImmunelHemato oietic HNHOL24 B32380 W0200047602-A1 Immune/Hemafo oietic HWHIB26 B32381 W0200047602-A1 Cancer HHAAF20 B32382 WO200047602-A1 Cancer HNHNE04 B32383 W0200047602-A1 Immune/Hemato oietic HSAA065 B32384 W0200047602-A1 Cancer HTEN007 B32385 W0200047602-A1 Re roductive HTLHI35 B32386' W0200047602-A1 Immune/Hematopoietic, ' _ ~ Musculoskeletal, Re roductive -HTLHY14 B32387 W0200047602-A1 Imniune/Hematopoietic, ' , Neural/Sensory, Re roductive HTXKY63 B32388 W0200047602-A1 Immune/Hemato oietic ' HOUDC53 B32389 W0200047602-A1 Cancer HWLGV78 - B32390 W0200047602-A1 Cancer HCGLB30 B32391 W0200047602-A1 Cancer HTELP17 B32392 ' W0200047602-A1 Cancer HFXBS43 'B32393 W0200047602-A1 NeurallSenso HNGOM56 B32394 W0200047602-A1 Immune/Hemato oietic .

HTXON32 B32395 W0200047602-A1 Immune/Hemato oietic HDQH040 B32396 WO200047602-A1 Cancer HKBAB11 B32397 W0200047602-A1 Immune/Hemato oietic HRAAN56 B32398 W0200047602-A1 Excretory, Re roductive HFIDS78 B32399 W0200047602-A1 Connective/Epithelial, . _ Digestive, Musculoskeletal HSDIB20 B32400 W0200047602-A1 Cancer HHEPU04 B32401 W0200047602-Al Cancer HNGKN89 B32402 W0200047602-A1 Immune/Hemato oietic HE9TH18 B32403 W0200047602-A1 Cancer HHFHM89 B32404. W0200047602-A1 Cancer HASAV70 B32405 W0200047602-A1 Cancer -HSDFJ26 B32406 W0200047602-A1 Cancer HODAA16. B32407 WO200047602-A1 Cancer HODAA16 B32408 W0200047602-A1 Cancer HGBIB74 B32409 WO200047602-A1 Cancer HCRMU04 B32410 W0200047602-A1 Cancer HSAA065 B32411 ' WO200047602-A1 Cancer HSAA065 B32412 W0200047602-A1 Cancer HSMBB92 B32413 W0200047602-A1 Cancer -HHEPU04 B32414 W0200047602-A1 Cancer HLDNA86 B32415 W0200047602-A1 Cancer HE9TH18 B32416 W0200047602-A1' Cancer ~

HHFHM33 B32447 ' W0200047602-Al Cancer HUUAV63 B32481 W0200047602-A1 Cancer .

HE2CJ53 B33721 W0200056753-A1 Cancer HE2HF76 B33724 W0200056753-A1 Cancer HDTDE66 B33729 ~ W020b056753-A1 Cancer HDTKJ29 B33735 W0200056753-A1 Cancer HDTLM18 B33736 W0200056753-A1 Immune/Hemato oietic HE2AI94 B33740 WO200056753-A1 Cancer HE2BD72 B33741 W0200056753-A1 Cancer HE2CI-I58 B33744 WO200056753-A.1 Digestive, . Mixed Fetal HE2NW57 B33753 W0200056753-A1 Mixed Fetal HE2PJ56 B33755 WO200056753-A1 Cancer HE2P093 B33756 WO200056753-A1 Cancer HE6AU52 B33757 W0200056753-A1 Mixed Fetal .

HAEAV42 B33758 ' W0200056753-A1 Cancer HE2AT61 B33759 W0200056753-A1 Cancer HE2CK47. B33761 W0200056753-A1 Cancer ' HE2DJ84 B33763 W0200056753-A1 Cancer HE2CJ53 B33770 W0200056753-A1 Cancer HSHAS72 B33832 W0200056753-A1 Cancer HEMDR05 B33845 W0200056881-A1 Cardiovascular, Digestive, .
ImmunelHemato oietic HADXA10 B33846 W0200056881-A1 Cancer HEOMF59 B33847 W0200056881-A1 Immune/Hemato oietic HEONP08 B33854 W0200056881~A1 Immune/Hemato oietic HEPAD15 B33855 ~ W0200056881-A1 Endocrine, ' Re roductive HEIAC52 B33860 W0200056881-A1 Cancer .

HEQAP92 B33862 W0200056881-A1 Cancer HEQB1VI94 B33865 ~ W0200056881-A1 Cancer HETAA62 B33870 W0200056881-A1 Cancer HETEY67. ~B33873 W0200056881-A1 ConnectivelEpithelial, ~ Re roductive HETDP76 B33874 W0200056881-A1 Cancer .
~

HEQBF89 B33875 W0200056881-A1 Re roductive HETIN36 B3'3877 WO200056881-A1 Cancer HFAUA23 B33881 W0200056881-A1 Cancer HFCAG75 B33882 WO200056881-A1 Cancer HFCAQ17 B33883 W0200056881-A1 Cancer HFCDN13 B33887 W0200056881-A1 Cancer HFCDT67 B33888 W0200056881-A1 Cancer HFCEI04 B33891 W0200056881-A1 Neural/Sensory HTSGY89 B33946 W0200056881-Al Cancer HFCAQ17 B33947 W0200056881-A1 Cancer HGLAH86 B33965 W0200056765-A1 Immune/Hemato oietic HHEBP28 B33971 ' W0200056765-A1 Cancer HHEMC55 B33973 W0200056765-A1 Immune/Hemato oietic HHEMM20 ' B33974 W0200056765-A1 hnmune/Hemato oietic HHEMP35 B33976 W0200056765-A1 Cancer HHEMZ08. B33977 W0200056765-A1 Cancer HHENR74 B33980 W0200056765-Al ImmunelHemato oietic HHEOK77 B33983 W0200056765-A1 Cancer HHEQI04 B33986 W0200056765-A1 Connective/Epithelial, - Excretory, Immune/Hemato oietic HHFBA31 B33987 W0200056765-A1 Cancer HHFFF87 B33992 ~ W0200056765-A1 Cancer HHFFL34 B33993 W0200056765-A1 Cancer HHFFS40 B33994 W0200056765-A1 Cancer HHGBF91 B34005 W0200056765-A1 Cancer ' HE9NB82 B34092 W0200056755-A1 Cancer .HEAAC21 B34095 W0200056755-A1 Cancer _ HEAAM54 B34100 W0200056755-A1 Re roductive HEAAU28 B34102 W0200056755-A1 Re roductive HEBAT05. B34104 W0200056755-A1 Cancer HEBCN80 B34107 W0200056755-A1 Neural/Sensory HEBCY54 B34108 W0200056755-Al Cancer - , HEBDW31 ~ B34111 W0200056755-A1 Cancer HEBFL36 B34112 W0200056755-A1 NeurallSensory HEBGE07 B34114 WO200056755-A1 Neural/Senso HEBGE23 B34115 W0200056755-A1 Cancer HEGAI20 B34119 W0200056755-A1 Re roductive HEBCI18 B34121 W0200056755-A1 Digestive, Tmmune/Hematopoietic, Neural/Sensory HEBDF90 B34125 W0200056755-Al Cancer HELDK79 B34127 W0200056755-A1 Cardiovascular HELEL76 B34130 W0200056755-A1 Cancer HELF030 B34131 W0200056755-A1 Cancer _ HEMCJ80 B34138 W0200056755-Al Cancer HDPAR73 B34201 WO200056755-Al Cancer HDPAR73 B34202 W0200056755-A1 Cancer HATBI94 B34222 W0200055352-A2 .Cancer ' HATCB45 . B34224 W0200055352-A2 Endocrine, Immune/Hemato oietic HATDW05 ~ B34229 W0200055352-A2 Endocrine HATEH20 B34231 ~ W0200055352-A2 Cancer HAWBA65 B34233 W0200055352-A2 Cancer HBBBA42 B34236 W0200055352-A2 Cancer HBBBE83 B34238 W0200055352-A2 Cancer HBBMAll B34239 W0200055352-A2 Neural/Sensory HBCGE46 B34244 W0200055352-A2 Musculoskeletal HBGML95 B34249 ' W0200055352-A2 Re roductive HBHAA05 B34251 W0200055352-A2 Neural/Sensory HBHAA53 B34252 W0200055352-A2 Neural/Sensory HBIAA59 B34253 W0200055352-A2 Cancer HBICW51 B34262 , W0200055352-A2 Digestive, v Immune/Hematopoietic, Neural/Sensory HFCET43 B34299 W0200056883-A1 Cancer HFEAG55 B34302 W0200056883-A1 Cancer HFEAY59 B34304 WO200056883-A1 Connective/E ithelial HFFAV61 B34308 W0200056883-A1 NeurallSenso HFGAN63 B34312 W0200056883-A1 Cancer HFICH70 B34316 W0200056883-A1 Musculoskeletal HFIHQ57 B,3431'7 W0200056883-A1 Musculoskeletal, - Re roductive HFIHZ75 B34318 WO200056883-A1 Cancer HFIJA29 B34321 WO200056883-A1 Cancer HFIJD81 B34322 W0200056883-A1 Cancer HFIUK66 B34324 W0200056883-A1 Cancer HFIXC39 B34326 WO200056883-A1 Cancer HFIXC69 B34327 W0200056883-Al Cancer HLWAU42 B34329 W0200056883-A1 Cancer HFIZF51 B34331 W0200056883-Al Musculoskeletal HFKDX53 B34333 W0200056883-A1 Cancer HFKEG63 B34335 W0200056883-A1 Excretory HFKES05 B34336 W0200056883-A1 Cancer HFKES35 B34337 W0200056883-A1 Cancer HFKEU12 B34338 . W0200056883-A1 Excretory HFOYR54 B34344 W0200056883-A1 Cancer HFPBJ64 B34347 W0200056883-A1 Musculoskeletal, Neural/Sensory HFXBV67 , B34441 W0200056767-A1 Digestive, Neural/Senso HFXBY20. B34442 W0200056767-A1 Neural/Sensory HFXGT51 B34462 WO200056767-A1 Nemal/Sensory HFXGW04 B34463 WO200056767-A1 Cancer HFXHL83 B34466 W0200056767-A1 Neural/Sensory HFXJB21 B34468 W0200056767-A1 Neural/Sensory ~

HFXJN93. B34469 W0200056767-A1 Neural/Sensory HFXJT53 B34470 W0200056767-A1 Cancer HFXLK91 B34472 W0200056767-A1 Cancer HFXHM49 B34473 W0200056767-A1 Neural/Sensory HGBDV35 B34474 W0200056767-A1 Cancer -HEPCU48 B34476 W0200056767-A1 Cancer HGBGN34 B34478 W0200056767-A1 Connective/Epithelial, ' Digestive, Re roductive HGBGX31 B34479 W0200056767-A1 Cancer HGBHP91 B34482 W0200056767-A1 Di estive HCEFN51 B34580 W0200056751-A1 Cancer .

HCEFZ82 B34581 ~ W0200056751-A1~ Cancer HCEJL08 B34585 W0200056751-Al Cancer HCENN67 B34588 ' W0200056751-A1 Digestive, Endocrine, Neural/Sensory HCEPC90 B34592 W0200056751-A1 Neural/Sensory HCETL19 B34597 W0200056751-A1 Immune/Hematopoietic, Neural/Sensory, Re reductive HCFAT42 B34602 W0200056751-A1 Immune/Hemato oietic HCFAT66 B34603 W0200056751-A1 Immune/Hemato oietic HCFBM77 B34605 W0200056751-A1 Immune/Hemato oietic HCFLJ52 B34611 W0200056751-A1 Cancer HCFLP48 B34613 W0200056751-Al Immune/Hemato oietic HCFLQ12 B34614 W0200056751-A1 Cancer HCFMA39 B34617 W0200056751'-A1 Immune/Hemato oietic HCFML07 B34619 W0200056751-A1 Cancer HCFMX88 B34620 W0200056751-A1 Immune/Hematopoietic, Neural/Senso HCFNN16 B34623 W0200056751-A1 Cancer HCFNN75 ~ B34624 W0200056751-A1 Cancer HLYBI48 B34774 W0200058356-A,1 Immune/Hemato oietic .

HFKES35 B34777 WO200058356-A1 Cancer HLYBU15 B34781 W0200058356-A1 Immune/Hemato oietic HLYDXO1 B34789 W0200058356-A1 Cancer HLYEA60 B34790 ~ W0200058356-A1 Cancer HLYEU59 B34793 W0200058356-A1 Immune/Hemato oietic HLYGE16 B34794 W0200058356-A1 Cancer HLYGV19 B34795 WO200058356-A1 Cancer HLYGY91 B34796 W0200058356-A1 Cancer HMADJ14 B34797 W0200058356-A1 Connective/Epithelial, , Immune/Hematopoietic, Musculoskeletal HMAGFO1 B34798 W0200058356-A1 Cancer HMDAB44 B34806 W0200058356-A1 Neural/Senso HMDAE88 B34808 WO200058356-A1 Neural/Senso HMDAG62 B34809 W0200058356-Al Cancer HMDAK20 B34810 W0200058356-A1 Neural/Sensory HMECM77 B34815 W0200058356-A1 Cardiovascular HMECQ59 B34816 W0200058356-A1 Cancer HMEEZ07 B34821 W0200058356-A1 Cardiovascular, Re reductive HDPCV29 B34856 W0200056766-A1 Immune/Hemato oietic HDPCW16 B34857 ' W0200056766-A1 Cancer HDPFG13' B34859 W0200056766-A1 Cancer ~

HDPFU43 B34860 W0200056766-A1 Cancer HDPFZ05 B34861 ~ W0200056766-A1 Immune/Hematopoietic, - Neural/Senso HDPGA84 B34862 W0200056766-A1 Cancer HDPIH25 B34864 W0200056766-A1 Cancer HDPKC55 B34866 . W0200056766-A1 Cardiovascular, Immune/Hematopoietic, ' ~ Re reductive HDPNC21 B34868 ~ W0200056766-A1 Cancer HDPOL37 ' B34869 W0200056766-A1 Immune/Hematopoietic, ~ Re reductive HDPSZ07 B34871 W0200056766-A1 ImmunelHemato oietic HDP~N20 -- , B34872 W0200056766-Al Immune/Hemato oietic HDQGN08 B34874 W0200056766-A1 Immune/Hemato oietic HDPGE24 B34877 W0200056766-A1 Cancer HDPJV53 B34878 W0200056766-A1 Immune/Hemato oietic HDPOC24 ~ B34881 W0200056766-A1 Cancer HDPPC19 B34883 W0200056766-A1 Immune/Hemato oietic HBCA031 B34886 ~ W0200056766-A1 Cancer HDQGD06 B34889 W0200056766-A1 Cancer HDRAA17 ~ B34890 W0200056766-A1 Cancer HDRAC68 B34891 W0200056766-A1 Cancer HDSAH37 B34893 W0200056766-A1 Connective/E ithelial HDSAP15 B34896 W0200056766-A1 Cancer HDTAS57 B34897 WO200056766-A1 Cancer HDPFU43 B34916 W0200056766-A1 Cancer HDPKC55 B34932 W0200056766-A1 Cardiovascular, Immune/Hematopoietic, Re roductive HPRCB54 B36696 WO200071150-A1 Cancer HMQAT69 B37348 W0200058335-A1 Cancer - HMQBL90 B37349 ~ W0200058335-A1 Digestive, ImmunelHemato oietic HMQCX41 B37354 W0200058335-A1 Immune/Hemato oietic HMQDU07. B37356 W020005833-5-A1 Digestive;
I mmune/Hematopoietic, Musculoskeletal HMSDI67 B37365 WO200058335-AI Digestive, Immune/Hemato oietic HMSHC86 B37372 W0200058335-A1 Immune/Hemato oietic HMSII36 B37376 W0200058335-A1 Irnmune/Hemato oietic HMSIT42 B37377 WO200058335-A1 Digestive, .
ImmunelHematopoietic, Neural/Sensory HMSKQ91 B37381 W0200058335-A1 Immune/Hemato oietic HMTAT36 B37384 W0200058335-A1 Cancer HMUBK53 B37390 W0200058335-A1 Cancer HMUB015 B37392 W0200058335-A1 Cancer HMUBZ15 B37393 W0200058335-A1 Cancer HMSLF15 ' B37984 W0200055371-A1 Cancer HKAET41 B37985 ' W0200055.371-Al Connective/Epithelial, Digestive, Re roductive HE9RJ42 B37987 W0200055371-A1 Mixed Fetal HDPAS92 B37988 W0200055371-A1 Cancer HATDF29 B37989 W0200055371-A1 Cancer HWLHH15 B37990 W0200055371-A1 Di estive HBXFL29 B37991 W0200055371-A1 Cancer HKGBF67 B37992 W0200055371-A1 Cancer HWHGP7.1 B37993 W0200055371-A1 Connective/Epithelial, . Immune/Hematopoietic, Re roductive HLWCU38 B37994 W0200055371-A1 Cancer HMTAX46 ~ B37995 W0200055371-A1 Cancer ~

HIBEU15 B37996 W0200055371-A1 Excretory, Immune/Hematopoietic, Neural/Sensory HDPQV66 B37997 W0200055371-A1 Cancer HFXGW52 B37.998 W0200055371-A1 Neural/Sensory HHEQR55 837999 W0200055371-A1 Immune/Hemato oietic HNHNW84 B38000 W0200055371-A1 Immune/Hemato oietic HAJBX74 B38001 ~ W0200055371-A1 Cancer ~

~HCUGE72 B38002 W0200055371-A1 Cancer HTEQI22 B38003 WO200055371-A1 Cancer HDPYE41 B38004 W0200055371-A1 ImmunelHemato oietic HDTII23 B38005 W0200055371-A1 ImmunelHemato oietic HAMFL84 B38007 W0200055371-A1 Cancer HTELW37 B38008 WO200055371-A1 Re reductive HNGOU56 B38009 W0200055371-A1 Immune/Hemato oietic HOUHD63 B38010 W0200055371-A1 Cancer HPJCX13 B38011 W0200055371-A1 Cancer HNHCT15 B38012 W0200055371-Al Cancer HKGBF67 B38013 W0200055371-A1 Cancer HWHGP71 B38014 W0200055371-A1 Connective/Epithelial, ImmunelHematopoietic, .
Re reductive HTEQI22 B38016 W0200055371-A1 Cancer HJBCI01 B38017 W0200055371-A1 .Cancer HTSFV18 838018 ~ WO200055371-A1 Cancer HPJBF63 B38019 ~ W0200055371-A1 Cancer HWHGP71 B38044 WO200055371-A1 Connective/Epithelial, Immune/Hematopoietic, Re reductive HNEDU46 B38119 ' W0200058468-A2 Cancer 'HNFDY31 B38124 W0200058468-A2' Cancer ~

HNFEA17 B38125 W0200058468-A2 Cancer HNFET12 B38127 W0200058468-A2 Immune/Hematooietic HNFGR08 B38129 W0200058468-A2 Immune/Hemato oietic HNFGW37 B38130 W0200058468-A2 Immune/Hemato oietic .

HNFGW53 B38131 W0200058468-A2 Cancer HNFHA34 B38132 W0200058468-A2 Cancer HNFJE27 B38137 WO200058468-A2 Immune/Hemato oietic .

HNGAM58 B38143 W0200058468-A2 ImmunelHemato oietic HNGAT83 B38144 W0200058468-A2 ImmunelHemato oietic HNGBE63 B38148 W0200058468-A2 Immune/Hemato oietic HNGBH53 B38149 W0200058468-A2 ImmunelHemato oietic ' HNGBJ74 B38150 W0200058468-A2 Immune/Hemato oietic HNGBQ61 B38152 W0200058468-A2 Immune/Hemato oietic HNGBW25 B38154 W0200058468-A2 Immune/Hemato oietic HNGCF64 B38156 W0200058468-A2 Immune/Hemato oietic HNGDH22 B38158 W0200058468-A2 Immune/Hemato oietic HNGDQ38 B38161 W0200058468-A2 Immune/Hemato oietic HNGDR39 B38162 W0200058468-A2 Immune/Hemato~ oietic HNGEA34 ' B38165. W0200058468-A2 Digestive, Immune/Hemato oietic HTOJB02 B38205 W0200058469-A1 Immune/Hemato oietic HSDEA26 B38207 W0200058469-A1 Neural/Sensory HATCF80 838209 W0200058469-A1 Cancer HTOAI~03 B38215 W0200058469-A1 Cancer HSLAB11 B38216 W0200058469-A1 Cancer HSJAU93 B38218 W0200058469-A1 Cancer HSHBT15 B38221 W0200058469-A1 Cancer HSLCS31 B38234 WO200058469-A1 Cancer HSLCS34 B38235 W0200058469-A1 Cancer ~

HOBNF51 B38237 W0200058469-A1 Cancer HSFAM19 B38242 WO200058469-Al Cancer HNHEY29 B38245 W0200058469-A1 Immune/Hemato oietic HTHDB20 838248 W0200058469-A1 Immune/Hemato oietic HPMGM06., B38250 W0200058469-A1 Digestive, Neural/Sensory, Re reductive HDPMA04 B38321 W0200061623-A1 Immune/Hemato oietic HEMFQ46 B38322 W0200061623-A1 Cancer HI~AJK47 B38324 W0200061623-A1 Cancer HCGMF16~ B38325 W0200061623-A1 Cancer HMSGU01 B38326 W0200061623-A1 Cancer HNTCE26 B38327 W0200Q61623-A1 Cancer HPTTI70 B38328 WO200061623-A1 Cancer HNSAD53 B38329 W0200061623-A1 Digestive HTEBV72 B38330 W0200061623-A1 Re reductive HCE3Z61 B38331 WO200061623-A1 Cancer HSSGD52 B38332 W0200061623-Al Cancer HAPSA79 B38333 WO200061623-A1 Cancer -, HASAU84 B38334 W0200061623-A1 Cancer HLWEA51 B38335 W0200061623-A1 Cancer .

HNFIZ34 ' B38336 W0200061623-A1 Cancer HTELS08 B38337 W0200061623-A1 Re reductive HTLEJ24 B38338 W0200061623-A1 Cancer HCEHF62 B38339 W02000'61623-A1 Cancer HUFBY15 B38340 W0200061623-A1 Digestive, Musculoskeletal, Re reductive HELHD85 B38341 W0200061623-A1 Cancer HOFNY91 B38342 W0200061623-A1 Cancer' HEGAK44 B38343 WO200061623-A1 Cancer HETBA14 B38344 W0200061623-A1 Cancer HBAFV19 B38345 W0200061623-A1 Cancer HTXD017 B38346 W0200061623-Q1 Immune/Hematopoietic, Neural/Sensory, Res irate HE8DS15 B38347 W0200061623-A1 Cancer HLDOW79 B38348 W0200061623-A1 Cardiovascular, . Di estive HOFND85 B38349 W0200061623-A1 Cancer HBIBU30 B38350 W0200061623-A1 Cancer HODFG71 ~ B38351 W0200061623-A1 Re reductive HNHGE28 B38352 W0200061623-A1 Cancer HYASD09 B38355 W0200061623-A1 Cancer HDPCL63 B38356 W0200061623-A1 Cancer HBDAD07 B38357 ' W0200061623-A1 Immuiie/Hemato oietic HTOHG09 B38361 W0200061623-A1 Cancer HWBEX31 $38362 W0200061623-A1 Cancer HLHDP16 B38363 W0200061623-A1 Cancer HSDBC88 B38364 WO200061623-A1. Cancer HOVBX78 . B38365 WO200061623-A1 Cancer HWADJ89 B38367 W0200061623-Al Immune/Hemato oietic HYABE50 B38368 W0200061623-A1 Cancer ' HSJAQ17 B38369 W0200061623-A1 Cancer HCUGM86 B38370 W0200061623-A1 Immune/Hemato oietic HLDQC46 B38371 W0200061623-A1 Cancer HOFOA59 B38372 W0200061623-A1 Re reductive HFABG18 B38373 W0200061623-A1 Cancer HNHLY33 B38374 W0200061623-A1 Immune/Hemato oietic HFCFJ18 B38375 W0200061623-A1 Cancer HANGG89 B38376 W0200061623-A1 Cancer HNHOD46 B38377 W0200061623-Al Immune/Hemato oietic HLYBI58 _ B38379~. W0200061623-A1 Cancer HAJBG14 B38381 W0200061623-A1 Cancer HE9NN84 B38382 W0200061623-A1 Cancer HAPSA79 B38383 W0200061623-A1 Cancer HAPSA79 B38384 W0200061623-A1 Cancer HTLEJ24 B38385 W0200061623-A1 Cancer HEGAK44 B38386 WO200061623-A1 Cancer H'TXD017 B38387 W0200061623-A1 Irninune/Hematopoietic, Neural/Sensory, Res iratory HBIBB20 ~ B38388 W0200061623-A1 Cancer HSIDL71 B38389 W0200061623-Al Cancer HOVBX78 B38390 . W0200061623-A1 Cancer HYABE50 B38391 W020Q061623-A1 Cancer HFCFJ18 B38392 W0200061623-A1 Cancer HPRAL78 ~ B38394 w WO200061623-A1 Cancer HCE5F84 838395 W0~00061623-A1 Cancer -HAMHE82 B38396 W0200064623-A1 Cancer .

HACBZ59 B38472 WO200061623-A1 Cancer HACBZ59 B38475 W0200061623-A1 Cancer HWL U40 B38514 W0200061623-A1 Cancer HFKFI35 B38527 W0200056882-A1 Excretory HFPCZ55 B38529 W0200056882-A1 Cancer HFPDR39 B38533 ~ W0200056882-Al Cancer HFPDX08 B38536 W0200056882-A1 . Lancet HFRAB10 B38539 W0200056882-A1 Excretory, Immune/Hematopoietic, Neural/Sensory HFSBE94 B38541 W0200056882-A1 Immune/Hemato oietic HFTAR30 B38545 W0z00056882-A1 Cancer HFTBB50 B38546 W0200056882-A1 Cancer HFSAY91 B38551 W0200056882-A1 Cancer HFSBC10 B38552 - W0200056882-A1 Immune/Hematopoietic, Mixed Fetal HFTDK11 B38555 W0200056882-A1 Cancer HFVHW43 B38560 W0200056882-A1 Digestive HFXBI64 B38567 WO200056882-A1 Neural/Sensory HFXBL05 ~ B38568 W0200056882-A1 Mixed Fetal, Neural/Sensory HHGBV02 B38971 W0200056880-A1 Immune/Hematopoietic, Re reductive HHGBW55 B38972 WO200056880-A1 Immune/Hematopoietic, Re reductive HHGDI12 B38976 W0200056880-A1 Neural/Sensory HHPBG90 B38983 W0200056880-A1 Cancer HHPFP26 B38987 W0200056880-A1 Cancer HHPGU74 B38990 W0200056880-A1 Neural/Sensory HHPEB61 B38991 W0200056880-A1 Cancer -HHSBJ92 B39002 W0200056880-A1 Cancer HHPSE03 B39004 W0200056880-A1 Neural/Sensory HHSCQ67 B39005 W0200056880-A1 Cancer HHSDB43 B39007~ W0200056880-A1 Cancer HHTLH79 B39015 W0200056880-A1 Immune/Hematopoietic, Musculoskeletal, Neural/Sensory HIABC70 B39016 W0200056880-A1 Cancer HIBCR82 B39017 W0200056880-Al Mixed Fetal, Neural/Sensory HIBEC45 B39019 W0200056880-A1 Cancer HILCA24 B39020 WO200056880-A1 Digestive, Immune/Hematopoietic, Re roductive HLHBS54 B39093 W0200058513-A1 Cancer HLMCT95 B39098 ~ W0200058513-A1 Cancer HLDRU08 B39100 W0200058513-A1 Cancer HLDXF43 B39101 W0200058513~-A1 Cancer HLEAA10 B39102 W0200058513-A1 Immune/Hemato oietic HLHCB33 B39104 WO200058513-A1 Digestive, Reproductive, Res iratory HLHCF14 B39105 W0200058513-A1 Connective/Epithelial, Res iratory HLHCN51 B39107 ' W0200058513-A1 Digestive, Immune/Hematopoietic, Res iratory HLHDM38 B39109 W0200058513-A1 Cancer HLHEX62 B39111 W0200058513-A1 Excretory, I mmune/Hematopoietic, Res iratory HLHSG15 B39114 W0200058513-A1 Cancer HLIBD74 B39117 W0200058513-A1 Di estive HLICO10 B39120 W0200058513-A1 Cancer HLJBI22 B39121 W0200058513-A1 Cancer HLLAX95 B39123 WO200058513-A1 Immune/Hemato oietic .

HLMBZ14 B39127 WO200058513-A1 Immune/Hemato oietic HLMDHO1 B39129 W0200058513-A1 Immtme/Hemato oietic HLMDU23 B39130 W0200058513-A1 Immune/Hemato oietic HLMFU53 B39133 W0200058513-A1 Cancer HLMHG68 B39135 W0200058513-A1 Cancer HLMIM84 B39137 W0200058513-A1 Cancer HLMIQ83 B39139 W0200058513-A1 Immune/Fiemato oietic HLDRT09 B39140 W0200058513-A1 Cancer HE9EA10 B39181 WO200056754-A1 Cancer HE6CS65 B39182 WO200056754-A1 Cancer HE8BE20 B39190 W0200056754-A1 Cancer HE8BT58 B39193 W0200056754-A1 Cancer HE8CA13 B39195 W0200056754-A1 Cancer HE8FC10 B39201 W0200056754-A1 Immune/Hematopoietic, _ ~ Mixed Fetal, Re roductive HE8FG24 B39202 W0200056754-Al Cancer HE8FL24 B39203 W0200056754-A1 Mixed Fetal ~ ' HE8MA27 B39204 W0200056754-A1 Cancer HE8MG56 B39205 W0200056754-A1 Mixed Fetal HE8QU21 B39208 W0200056754-A1 Immune/Hematopoietic, Mixed Fetal HE8UX34 B39210 W0200056754-A1 Mixed Fetal HE9CY05 B39216 WO200056754-A1 Mixed Fetal HE9DG54 B3921.7 W0200056754-A1 Cancer HE9DZ47 - B39218 W0200056754-A1 Endocrine, ' Immune/Hematopoietic, Mixed Fetal HE8EX86 B39226 W0200056754-A1 Cancer HMEIH57 B39310 W0200057903-A2 Cardiovascular, ~ Immune/Hemato oietic HFEBA88 B39312 W0200057903-A2 Cancer .

HMEKW44 B39317 W0200057903-A2 Cardiovascular, Immune/Hematopoietic, Neural/Sensory HMELM75 B39318 W0200057903-A2 Cancer HMIAC52 B39322 W0200057903-A2 Cancer HMIAL39 B39325 W0200057903-A2 Cancer HMIBD93 B39329 W0200057903-A2 Cancer HMIBE9-5 B39330 ' W0200057903-A2 Neural/Sensory HMMAL32 B39344 W0200057903-A2 Immune/Hemato oietic -HMMBK55 B39348 W0200057903-A2 Immune/Hemato oietic HMMBR63 B39350 W0200057903-A2 Cancer HMMBS55 B39351 W0200057903-A2 Immune/Hematopoietic, Re roductive HMMBT47 B39352 W0200057903-A2 Immune/Hemato oietic HMMCD35 B39353 WO200057903-A2 Immune/Hemato oietic HFKCZ13 B39362 W0200057903-A2 Cancer HFKCZ13 B39363 W0200057903-A2 Cancer HOAAL10 B39402 W0200058340-A2 Musculoskeletal HTXCV44 B39406 W0200058340-A2 Immune/Hematopoietic, , NeurallSensory HTXDJ75 B39407 WO200058340=A2 Digestive, Immune/Hematopoietic, Mixed Fetal HSIDZ25 B39410 ~ W0200058340-A2 Cancer HTXEN33 B39413 W0200058340-A2 Immune/Hematopoietic, Re roductive -HJPDK61 B39419 W0200058340-A2 Cancer HNHBM16 B39420 W0200058340-A2 Immune/Hematopoietic, Neural/Sensory HNHDE58 B39422 W0200058340-A2 Cancer HTTDT67 B39425 ~ W0200058340-A2 Cancer HTLEP55 B39427 W0200058340-A2 Cancer HCUBA28 B39430 WO200058340-A2 Cancer HSNAT08 B39433 W0200058340-A2 Cancer HTOEVO1 B39437 , ~ W0200058340-A2 ImmunelHematopoietic, Re roductive HSQBF66 B39439 ~ W0200058340-A2 Cancer HSJBY32~ B39445 W0200058340-A2 Immune/Hematopoietic, Musculoskeletal, Neural/Sensory HPMCV30 B39447 W0200058340-A2 Cancer HPMDF45 B39448 W0200058340-A2 Excretory, Immune/Hematopoietic, Re roductive HPIBI40 B40153 W0200058496-A1 Cancer HRDBA20 B40154 ~ W0200058496-A1 Musculoskeletal HTJMA64 B40156 ~ W0200058496-A1 Cancer HTHDF86 B40157 W0200058496-Al Immune/Hemato oietic ~

HRDBA20 B40158 WO200058496-Al Musculoskeletal HSAAN03 B40161 W0200058496-A1 Cancer HRABZ80 B40162 W0200058496-A1 Excretory, Immune/Hematopoietic, Musculoskeletal HPDDQ28 B40163 W0200058496-A1 Endocrine, Musculoskeletal HOSBX14 B40166 W0200058496-A1 Immune/Hematopoietic, Musculoskeletal, Re roductive HCRAI29 B40168 W0200058496-A1 Neural/Sensory .

HSAXI10 B40171 W020005,8496-A1 Digestive, Immune/Hemato oietic HTSFV18 B40172 W0200058496-A1 Cancer HNHGK22 B40174 ' W0200058496-A1 Immune/Hemato oietic HPMFP48 B40176 WO200058496-Ai Cancer HUSGL67 B40177 ' W0200058496-A1 Cancer HOFM016 B40180 W0200058496-A1 Re roductive HPMAI31 B401.82 W0200058496-A1 Cancer HTTAP37 B40184 W0200058496-A1 Immune/Hematopoietic, Re roductive HSABA15 B40187 W0200058496-A1 Cancer HPEAA65 B40188 W0200058496-A1 Digestive, Immune/Hematopoietic, Re roductive HSSAN03 B40189 W0200058496-A1 Cancer HTTDG27 B40194 W0200058496-A1 Re roductive HTPDV75 B40195 W0200058496-A1 Digestive, , Re roductive HMJAC12 . B40197 W0200058496-A1 Neural/Sensory HTLEJ24 B40198 W0200058496-A1 Cancer ' HBAMC47 B434.15 WO200055350-A1 Excretory HBGDH11 B43571 W0200055350-A1 Cancer HCHAK72 B43572 W0200055350-A1 Cancer HSRAB84 B43594 W0200055350-A1 Cancer HMWBH91 B43612 WO200055350-A1 Cancer HUFFG07 B43619 W0200055350-A1 Cancer HMEIY69 ~ B43625 W0200055350-A1 Cancer HIBCN93 B43651 W0200055350-A1 Cancer HDPQE64 B43656. W0200055350-A1 Cancer HSYCY88 B43723 W0200055350-A1 Cancer HCMSD61 B43779 W0200055350-A1 Cancer H2CBK94 B43801 ~ W0200055350-A1 Digestive, . . Neural/Sensory, . Res iratory HE9NK60 B43812 W0200055350-A1 Cancer HTXDT74 B43844 W0200055350-A1 Cancer HTTKN45 B43848 W0200055350-A1~ Cancer HSSGC06 B43861 W0200055350-A1 Cancer HE8AM92 B43893 W0200055350-A1 Cancer HWLHZ28 B43,933 W0200055350-A1 Cancer HCEDM42 B43935 W0200055350-A1 Cancer HMWFM73 B43952 W0200055350-A1 Cancer HCHBQ27 B44Q28 W0200055350-A1 Re roductive HCHBQ27 B44029 W0200055350-A1 Re reductive HCEGS49 844338 W0200058358-A1 Connective/Epithelial, Neural/Sensory, Re reductive HTODH57 B44349 W0200058358-A1 Immune/Hemato oietic HRTAR24 B44351 W0200058358-A1 Digestive, Immune/Hemato oietic HSLAW59 B44355 W0200058358-A1 Immune/Hematopoietic, Musculoskeletal HODAG07 B44358 W0200058358-A1 Re reductive HODBA45 B44360 W0200058358-A1 Re reductive HODBD79 B44361 W0200058358-A1 , Immune/Hematopoietic, Re reductive HODDG72 B44363 W0200058358-A1 Cancer HSVAE42 B44367 - W0200058358-A1 Connective/Epithelial, Neural/Sensory HNHAG83 B44369 W0200058358-A1 Immune/Hematopoietic, Mixed Fetal, Musculoskeletal HSIDA39 B44374 W0200058358-A1 ~I7igestive HYBAW56 ' B44375 ' W0200058358-A1 Musculoskeletal ~

HSATI91 B44376 ~ W0200058358-A1 Immune/Hemato oietic HPWAO89 B44379 W0200058358-A1 Immune/Hematopoietic, Re reductive HOUCD12 B44380 W0200058358-A1 Connective/E ithelial HWTAM38 B44381 ~ W0200058358-A1 Digestive, ' . Immune/Hematopoietic, ' Re reductive HKGCE62. B44597 W0200058339-A2 Immune/Hemato oietic HKGAK45 B44601 W0200058339-A2 Musculoskeletal, ~ Re reductive HKGBC33 B44602 W0200058339-A2 Immune/Hemato oietic HKGBH54 B44606 W0200058339-A2 Cancer HKGCK41 B44608 W0200058339-A2 Cancer HKGCX05 B44610 ' W0200058339-A2 Cancer HKGDA95 B44611 W0200058339-A2 Cancer HKIME53 B44612 W0200058339-A2 Cancer -HKIXR91 B44616 W0200058339-A2 Cancer.

HKMLT89 B44625 W0200058339-A2 Excretory, Immune/Hematopoietic, ' Re reductive HKMMU76 B44629 W0200058339-A2 Cancer HL3AE69 B44635 W0200058339-A2 Cancer HLDBV54 B44638 W0200058339-A2 Cancer .

'HLDNF18 . B44639 . WO200058339-A2 Cancer HLDOL74 B44642 W0200058339-A2 Cancer HKIMG23 B44643 W0200058339-A2 Cancer HLDBV18 B44645 W0200058339-A2 Cancer HMQBU44 B44647 W0200058339=A2 Cancer HNHDM21 B44703 W0200058494-A1 Immune/Hemato oietic HNHDM43 B44704 WO200058494-A1 Immune/Hemato oietic HNHDX28 B44708 W0200058494-A1 hrlmune/Hemato oietic HNHEG30 B44713 W0200058494-A1 Immune/F3emato oietic ~

HNHEL22 B44715 W0200058494-A1 Immune/Hemato oietic . ' HNHFF60 B44720 W0200058494-A1 Immune/Hemato oietic HTHDH18 B.44723 W0200058494-A1 Immune/Hemato oietic HTHDP65 B44724 W0200058494-A1 Cancer HTHDT25 B44725 W0200058494-A1 Immune/Hemato oietic HTGAQ29 B44727 W0200058494=Al Immune/Hemato oietic HTGAS70 B44728 W0200058494-A1 Cancer HNHGD95 B44731 W0200058494-A1 Cardiovascular, Immune/Hemato oietic HNHGR82 B44733 W0200058494-A1 Immune/Hemato oietic HSAYL24 B44763 W0200058336-A1 Immune/Hemato oietic HTGDS92 B44764 WO200058336-A1 Cancer HTWDJ17 B44767 W0200058336-A1 Cancer HNGJL07 B44776 WO200058336-A1 Immune/Hematopoietic, Neural/Sensory HSSGS62 B44785 W0200058336-A1 Musculoskeletal, Re reductive HOVCC73 B44786 WO200058336-A1 Immune/Hematopoietic, Re reductive HSAY082 B44788 W0200058336-A1 Endocrine, Immune/Hemato oietic ~

HMACT74 B44791 W0200058336-Al Immune/Hemato oietic HMIAD75 B44792 W0200058336-Al Neural/Sensory HUFA092 B44795 WO200058336-A1. Digestive, Re reductive HTWFA21 B44799 W020005'8336=A1 Immune/Hemato oietic HSDKE82 B44802 W0200058336-A1 Neural/Sensory HMAJS26 B44803 WO200058336-A1 Cancer HKGAP57 ~ B44811 W0200058336-A1 Immune/Hemato oietic HCWUW24 B44831 W0200055176-A2 Immune/Hemato oietic HDPAE80 B44832 WO200055176-A2 Cancer HCUFE33 ~ B44833 W0200055176-A2 Immune/Hemato oietic HCUFJ09' B44834 W0200055176-A2 Cancer HCUGR26 B44840 W0200055176-A2 Immune/Hemato oietic HCUHM71 B44844 W0200055176-A2 Immune/Hematopoietic, Musculoskeletal HCWAK88 B44847 W0200055176-A2 Immune/Hemato oietic HCWFK03 B44855 W0200055176-A2 Cancer HCWHT52 B44858 W0200055176-A2 Immune/Hemato oietic HCWKO32 B44859 W0200055176-A2 ImmLme/Hemato oietic HCWUF93 B44861 ~ WO200055176-A2 Cancer HDACJ52 B44865 W0200055176-A2 Cancer.

HDFAB86 B44866 W0200055176-A2, Mixed Fetal, Neural/Sensory HDHAA55 B44870 W0200055176-A2 Immune/Hematopoietic, Neural/Sensory HDHEB12 B44871 W0200055176-A2 Immune/Hematopoietic, Neural/Sensory HDHIA16 B44874 ~ W0200055176-A2 Cancer HDHIA26 B44875 W0200055176-A2 Neural/Sensory ' HARNB17 B44909 ~ W0200055176-A2 Cancer HBKEE60 B44917 W0200055200-A1 Di estive HBMWJ92 B44920 W0200055200-A1 Cancer HBMXW83 B44924 W0200055200-A1 Cancer HCE3R01 B44926 W0200055200-A1 Cancer -HBNBJ76 B44930 W0200055200-A1 Cancer HBQAC72 B44935 W0200055200-Al Neural/Sensory ' HBSAJ63 B44937 W0200055200-A1 Cancer HATDE03 B44938 W0200055200-A1 Cancer HBSDD24 B44939 WO200055200-A1 Cancer HBWBD25 B44940 W0200055200-A1 Immune/Hematopoietic, Neural/Sensory HBXBM24 B44943 W0200055200-A1 Neural/Sensory HBXBM78 . B44944 W0200055200-A1 Cancer HBNAX40 B44947 W0200055200-A1 Cancer HBXCQ03 B44949 W0200055200-A1 Cancer HBXFI33 B44955 W0200055200-A1 Immune/Hematopoietic, Neural/Sensory HBXGE12 B44958 W0200055200-A1 Cancer HCDAA24 B44960 W0200055200-A1 Cancer HCDAHOZ B44962 W0200055200-A1 Immune/Hematopoietic, " Musculoskeletal HCDAR40 B44964 W020Q055200-A1 Cardiovascular, Immune/Hematopoietic, ' Musculoskeletal HCDBE76 B44965 W0200055200-A1 Cancer HCDB032 B44966 W0200055200-A1 Cancer HTDAF68 B45025 W0200058357-A1 Iinmune/Hemato oietic HTWFA88 B45027 WO200058357-A1 ~ Digestive, Immune/Hemato oietic HSDJV40 B45028 W0200058357-A1 Immune/Hematopoietic, Neural/Sensory HSDKA64 . B45029 W020005 8357-A Immune/Hematopoietic, 1 Neural/Sensory HRAAC36 B45030 W0200058357-A1 Excretory, Immune/Hemato oietic HPRCF50 B45031 W0200058357-Al Cancer HUSXP50 B45034 W0200058357-A1 Cardiovascular, Re reductive HSSFP88 B45035 W0200058357-A1 Cancer HOVBS68 ~ B45037 W0200058357-A1 Cancer HOVC053 B45039 W0200058357-A1 Re reductive HOVBI16 B45040 W0200058357-A1 Cancer HOSFR35 B45041 W0200058357-A1 Cancer HNTRB25 B45042 W0200058357-A1 Cancer HUFBP77 X45043 WO200058357-A1 Cancer HUFAP33 B45044 W0200058357-A1 Cancer HSDHD05 B45045 W0200058357-A1 Neural/Sensory HTWFM85 B45046 W0200058357-A1 Cancer HSDJC96 B45048 ' W0200058357-A1 Cancer HTXKH40 B45050 ' W0200058357-A1 Cancer HPQCI62 B45051 W0200058357-A1 Cancer HOFMJ65 B45053 W0200058357-A1 Cancer HMUAN45 B45057 - W0200058357-A1 Cancer HAJAB88 B45059 W0200058357-A1 Cancer HPTTT62 B45067 W0200058357-Al Cancer HSRDW57 ' B45071 W0200058357-A1 Cancer HSRDW57 B45118 W0200058357-Al Cancer HJBCG74 B45121 W0200058467-A1 Cancer HCEC077 B45124 W02Q0058467-Al Cancer HJABC58 B45129 W0200058467-A1 Cancer HJMBK59 B45140 W0200058467-A1 Cancer HJMBPO1 B4.5141 W020005-8467-A1 Cancer HJMBW62 B45143 W0200058467-A1 Re reductive .

HJPAQ19 B45146 W0200058467-A1 Cancer HJPBN96 B45148 W0200058467-A1 Cancer HJPBK28 B45149 W0200058467-A1 Cancer HKABN63 B45152 W0200058467-A1 Cancer HKAFF50 B45159 W0200058467-A1 Cancer HKMSBO1 B45166 W0200058467-A1 Cancer HISEJ52 B45171 W0200058467-A1 Cancer HJBCG74 B45174 W0200058467-A1 Cancer HJBCG74 B45175 W0200058467-A1 Cancer HOFNY15 B45227 W0200063230-A2 Re reductive HNTAF42 B45228 W0200063230-A2 Cancer HPJAW78 B45233 W0200063230-A2 Immune/Hematopoietic, Musculoskeletal, Re reductive HPJBS16 B45234 ~ W0200063230-A2 ConnectivelEpithelial,' Re reductive HPJCV35 B45236 W0200063230-A2 Re reductive HSNAH56 B45239 W0200063230-A2 Cancer HE2FE89 B45246 WO200063230-A2 Cardiovascular, Digestive, Mixed Fetal HPVAF86 B45249 W0200063230-A2 Re reductive HOGCD78 B45257 - W0200063230-A2 Re reductive HRABU56 ~ B45264 W0200063230-A2 Cardiovascular, Excretory, Musculoskeletal HCUBY47 B45267. W0200063230-A2 Digestive, Immune/Hemato oietic HUDBE20 B45270 W0200063230-A2 Re reductive HUDBK47~ B45271 W0200063230-A2 Immime/Hematopoietic, Re reductive HSOAH16 ~ B45318 W0200061628-A1 Di estive ~

HWTBX66 B45320 WO200061628-A1 Cancer HTXD017 B45321 W0200061628-A1 Immune/Hematopoietic, Neural/Sensory, Res iratory HSSDQ20 B45325 W0200061628-A1 Musculoskeletal, Neural/Sensory HTOHM82 B45329 W0200061628-A1 Cancer HTOIH51 B45333 W0200061628-A1 Immune/Hemato oietic HHLBA86 _ B45334 WO200061628-A1 Di estive -HTAEH58 B45335 W0200061628-A1 Immune/Hemato oietic HLTC022 B45338 W0200061628-A1 Cancer HTOJS23 B45343 W0200061628-A1 Immune/Hemato oietic HNHBE21 B45356 W0200061628-A1 Immune/Hemato oietic HSSFE38 B45387 W0200061627-A1 Cancer HTOGB79 B45388 W0200061627-Al Cancer HKABU43 B45389 W0200061627-A1 Cancer .

HSYBV44 B45398 W0200061627-A1. Immune/Hemato oietic HOHBZ10 B45399 W0200061627-Al Canker HWAAQ28 B45400 W0200061627-A1 Cancer HWBBQ70 B45402 . W0200061627-A1 Immune/Hematopoietic~
Neural/Senso HWBCN36 B45403 W0200061627-AY Immune/Hemato oietic HWBCP16 B45404 W0200061627-A1 Immune/Hemato bietic HWHGW09 ~ B45406 WQ200061627-A1 Cancer HWHHA21 B45407 WO200061627-A1 ConnectiveB ithelial HYABE50 B45408 W0200061627-A1 Cancer HBXFA04 B45411 W0200061627-A1 Neural/Sensory HPRCA64 B45412 W0200061627-A1 Cancer HTXA.A20 B45414 W0200061627-A1 Cancer ' HOFAA78 B45423 W0200061627-A1 Re roductive HTOGR38 B45427 W0200061627-A1 Immune/Hemato oietic HUKBT67 B45431 W0200Q61627-A1 Cancer HCEMU42 B45432 W0200061627-A1 Cancer HWHPB78 B45433 W0200061627-A1 Cancer HSYBV44 B45452 W0200061627-A1 Immune/Hemato oietic HNHEN70 B45699 W0200071584-A1 Cancer HLYBN81 B45700 W0200071584-A1 Cancer H7TME50 B45701 W02000T1584-A1 Cancer HDPWP65 B45702 W0200071584-A1 Cancer HDTIE58 B45703 W0200071584-A1 Cardiovascular, Connective/Epithelial, ImmunelHemato oietic H7TPC96 B45704 W0200071584-A1 Cancer H7MAD52 B45705 W0200071584-A1 Re roductive HYASC03 B49502 W0200070076-A1 Endocrine, Immune/Hemato oietic HCE1K90 B49503 W0200070076-A1 Cancer HNTMH2C B49504 W0200070076-A1 Cancer HE8EJ16 B49505 WO200070076-A1 Mixed Fetal, Neural/Sensory, ' Re roductive HFEBD57 B49506 W0200070076-A1 Cancer HOFAD65 B49507 W0200070076-A1 Cancer HAPRB43 B49508 W0200070076-A1 Cancer HCE1K90 B49509 WO200070076-A1 Cancer HE8EJ16 B49510 W0200070076-A1 Mixed Fetal, . NeurallSensory, Re roductive HFEBD57 B49511 W0200070076-A1 Cancer HFEBD57 B49512 W0200070076-A1 Cancer HOFAD65 B49513 WO200070076-A1 Cancer HFPEY75 B49533 WO200061774-A2 Cancer HOHEC84 B49534 W0200061774-A2 Immune/Hematopoietic, Musculoskeletal HFKCD20 B49535 W0200061774-A2 Cancer HKMLR17 B49536 W0200061774-A2 Cancer HTHCW70 B49537 W0200061774-A2 Cancer HOHEC84 B49538 W0200061774-A2 Immune/Hematopoietic, Musculoskeletal HOUCQ17 B50011 ~ W02000,71577-Al Cancer HMADD44 B50378 W0200061614-A2 Cancer HDQER52 B50379 W0200061614-A2 Cancer HTELM46 B50380 . W0200061614-A2 Digestive, ' Immune/Hematopoietic, Re roductive HDPUS73 B50381 WO200061614-A2 Cancer HFCDT50 B50382 W0200061614-A2 Cancer HEMGR64 B50383 W0200061614-A2 Cancer HHFDM26 B50384 W0200061614-A2 Cancer HTTIA36 B50385 W0200061614-A2 Cancer HDQHP22 B50387 W0200061614-A2 Cancer HRDCD90 BS0388 W0200061614-A2 Cancer HEOMG91 BS0389 W0200061614-A2 Cancer HsLGK66 BS0390, W0200061614-A2 Cancer HSIFX64 B50391 W0200061614-A2 Cancer HETCD80 B50392 ' W0200061614-A2 Re roductive HHSGB09 BS0393 W0200061614-A2 Cancer .HLWBT44 BS0394 W0200061614-A2 Cancer ~

HTLJG95 B50395 W0200061614-A2 Cancer HDPDH32 ' BS093S W0200073323-A2 Immune/Hemato oietic HHFMQ22 B50936 W0200073323-A2 Cancer HETCM67 BS0937. W0200073323-A2 Cancer HWBDU78 BS0938 W0200073323-A2 Cancer HTXEM16 BS0939 W0200073323-A2 Cancer HBJEM23 BS0940 W0200073323-A2 Cardiovascular, Musculoskeletal, Re roductive H7TMD22 BS0941 W0200073323-A2 .NeuraIlSenso HDPDH32 BS0942 W0200073323-A2 Immune/Hemato oietic HDPDH32 BS0943 W0200073323-A2 Immune/Hemato oietic HSQAX94 BSI382 W0200058495-Al Cancer HTOFA11 ' BS1383 WO2000S849S-A1 Cancer HFFAHO1 B51384 W0200058495-Al Digestive, Immune/Hematopoietic, Neural/Sensory HNHBI6S BS138S WO2000S849S-A1 Immune/Hemato oietic HNHCP14 B51386 W02000S849S-A1 Immune/Hemato oietic HEAAW54 BS1387 W0200058495-A1 Re roductive HSRDM56 B51393 W0200058495-A1 Cancer ~

HSAXL82 851397 W0200058495-A1 Immune/Hemato oietic HCE3L04 BS1398 W02000S849S-Al Neural/Sensory HEBGM06 BS1402 W02000S849S-A1 Cancer HTWB030 BS~1403 W02000S849S-A1 Cancer .

HSSJF26 BS1404 W02000S849S-A1 Musculoskeletal HUKAD46 BS1412 W02000S849S-A1 Endocrine, Immune/Hematopoietic, Re roductive HPDDT14 BS1413 W02000S849S-A1 Cancer HTEDF78 BS141S W0200058495-A1 Re roductive HSUSB73 B51416 . W02000S849S-A1 Immune/Hematopoietic, Re roductive HSRAA81 B514.17 W020005:8495-A1 Cancer HCABW 10 BS 1420 . W0200058495-A1 Cancer HTWAM19 B51422 W02000S849S-A1 Immme/Hemato oietic HSDZ008 BS1620 WO200061620-A1 Cancer HSLHX1S BS1624 W0200061620-A1 -Musculoskeletal HSNBM34 B5162S W0200061620-A1 Di estive HSWBE76 B51629 W0200061620-A1 Cancer HSXASS9 BS1630 W0200061620-Al Neural/Senso HSXAY60 B51631 W0200061620-A1 Cancer HTEDX07 B51635 WO'200061620-A1 Cancer HTEJY20 ' B51640 W0200061620-A1 Cancer -HLDQU7'9 BS164S W0200061620-A1 Cancer ' HTLBT80 BS1646 W0200061620-A1 Cancer I

HTEAF65 B51648 W0200061620-A1 Excretory, Re roductive HTNBJ1S B51649 W0200061620-A1 Cancer HOUEP77 B51650 W0200061620-A1 Cancer HTOJL95 B51651 W0200061620-A1 Cancer HTTDN24 B51653 W0200061620-A1 Cancer HTXAD75 B51655 W0200061620-Al Cancer HTXDJ21 B51657 W0200061620-A1 Immune/Hemato oietic HKB1E57 B51658 ~ W020006162D-A1 Cancer HA BZ15 . B51659 ~ W0200061620-A1 Cancer HMWAB92 B51661 W0200061620-A1 Cancer HSNBL85 ~ B51663 WO200061620-A1 Cancer HWBDJ08 B51664 W0200061620-A1 Cancer HYABC84 B51667 W0200061620-A1 Cancer HTEDX07 B51682 W0200061620-Al Cancer HOUHQ36 B51724 W0200061625-A1 ConnectivelE ithelial HOUIG92 B51726 W0200061625-A1 Cancer HSAZP90 B51728 W0200061625-A1 Immune/Hemato oietic HSPAY90 B51730 W0200061625-A1 Cancer HWHPU44 B51731 W0200061625-A1 Connective/E ithelial HWACZ33 B51734 W0200061625-A1 Digestive, , mmune/Hematopoietic, I Re roductive HRADA42 B51736 WO200061625-A1 Dancer HRADN25 B51737 W0200061625-A1 Cancer ~

HRADN25 . B51738 W0200061625-A1 Cancer HRADT25 B51739 W0200061625-Al Digestive, Excretory HRADT25 B51740 W0200061625-A1 Digestive, . , Excretory HOHEC84 B51741 W0200061625-A1 Immune/Hematopoietic, Musculoskeletal HRADU15 B51742 W0200061625-A1 Excretory HWDAG96 B51743 W0200061625-A1 Cancer HWDAJO1 ~ B51745 W0200061625-A1 Connective/E ithelial HMBSF85 B51749 W0200061625-A1 Cancer HRGSE38 B51752 W0200061625-A1 Cancer HTLBF46 B51755 W0200061625-A1 Cancer HSRHB59 B51751 W0200061625-A1 Cancer HRDDQ39 B51762 W0200061625-A1 Cancer HJPCH08 ~ B51766- W0200061625-A1 Cancer HOEBJ70 B51767 W0200061625-A1 Cancer HDQER52 B51795 W0200061625-A1 Cancer HTLBF63 B51827 W0200061626-A1 Cancer HTOAT56 B51828 ~ WO200061626-A1 Cancer HSSMY35 B51829 W0200061626-A1 Cancer HBHAA81 B51840 W0200061626-A1 Cancer HOQBG21 B51841 W0200061626'-A1 Cancer HTPCG10 B51842 ~ W0200061626-A1 Cancer HSHAX04 B51848 W0200061626-A1 Cancer -HPEAD23 B51850 W0200061626-A1 Cancer HODDN21 B51857 W0200061626-A1 Re roductive HOABH36 B51859 W0200061626-A1 Cancer .

HOACG07 B51860 W0200061626-A1 Cancer HPMDA80 B51864 WO200061626-A1 Cancer HSKCQ51 B51865 W0200061626-A1 Cancer HRDDS22 B51870 W0200061626-A1 Cancer HTXDT72 B51871 W0200061626-A1 Cancer 46 .

HTXDG92 B51873 W0200061626-A1 Cancer HTXES13 B51874 W0200061626-A1 Cancer HSSEF77 B51875 WO200061626-A1 Cancer HTEGH03 - B51883 W0200061626-A1 Cancer HLMJB64 B51933 WO200058334-A1 Cancer HL,MNA19 B51936 WO200b58334-A1 Cardiovascular, Immune/Hemato oietic HLQAM30 B51937 W0200058334-A1 Cancer HLQCX36 B51942 W0200058334-Al Di estive HLQCY09 B51943 W0200058334-A1 Di estive HLQDM47 B51947 W0200058334-A1 Di estive HLQDU77 B51948. W0200058334-A1 Cancer HLTDA14 B51952 WO200058334-A1 Immune/Hemato oietic HLTDK30 B51955 W0200058334-A1 Cancer HLTDX04 B51958 W0200058334-A1 Cancer HLWAU42 B51964 W0200058334-A1 Cancer HLWAW73 B51965 W0200058334-A1 Cancer ' HLWAX50 B51966 W0200058334-A1 Cancer HLWBJ93 B51968 W0200058334-A1 Cancer HLWCN37 B51970 WO200058334-A1 Cancer HLYAL28 B51975 W0200058334-A1 Immune/Hemato oietic HFXDR47 B52012 W0200061596-A1 Cancer HNHHB10 B52017 W0200061596-A1 Immune/Hematopoietic, . Re roductive HPTRI42 B52019 W0200061596-Al Cancer HTWCE14 B52020 W0200061596-A1 Cancer HPTVH59 B52025 ~ W0200061596-A1 Endocrine, Neural/Sensory HUSGU40 B52027 W0200061596-A1 Cancer HUSYG26 B52028 W0200061596-A1 Cancer HOVCJ71 B52029 W0200061596-A1 Re roductive HSKYR49 B52034 W0200061596-A1 Cancer HTWEG06 B52040 W0200061596-A1 Immune/Hemato bietic HSDJF04 B52041 W0200061596-A1 Cancer HPQAN50 B52044 W0200061596-A1 Re roductive HT5FX76 B52051 W0200061596-A1 Cancer HT5FX79 B52052 W0200061596-A1 Cancer HNTRQ40 B52053 ' W0200061596-A1 Cancer HOUFS04 B52057 W0200061596-A1 Cancer HOGAR71 B52059 W0200061596-A1 Cancer HOFNB74 B52060 W0200061596-A1 Re roductive HOGAR71 B52101 W0200061596-A1 Cancer H7TDB54 B52104 W0200061624-A1 Cancer HOSEM81 B52105 W0200061624-A1 Cancer HTXKF95 B52108 ~ W0200061624-A1 Cancer HTGGM44 B52113 . W0200061624-Al Immune/Hematopoietic, - Musculoskeletal HROBJ10. B52114 W0200061624-A1 Cancer HTXLC05 B52118 W0200061624-A1 Digestive, Immune/Hematopoietic, Res iratory HTXLC45 B52119 W0200061624-A1 Ixnmune/Hemato oietic HNHLD80 B52120 - W0200061624-Al Immune/Hemato oietic HNGKT41 ~ B52124 WO200061624-A1 Immune/Hemato oietic HNHMP15 B52125 W0200061624-A1 Immune/Hemato oietic HNHMY76 ~ B52127 W0200061624-A1 Immune/Hemato oietic, Re roductive HNHND14 B52129 W0200061624-A1 Immune/Hemato oietic HNHOF09 B52131 W0200061624-A1 Immune/Hemato oietic HODEM38 B52132 W0200061624-A1 Digestive, Immune/Hematopoietic, Re roductive HNGMW45 B52137 W0200061624-A1 Immune/Hemato oietic HNGNK44 B52139 W0200061624-A1 ImmunelHemato oietic HTLGL33 B52145 W0200061624-Al Re roductive HTLGY50 B52146 W0200061624-A1 Cancer HNGKY94 B52147 W0200061624-A1 Immune/Hemato oietic HTXNV66 B52150 W0200061624-A1 Cancer HRODG74 B53274 W0200055351-A1 Cancer HTTD045 B53323 W0200055351-A1 Cancer HSIFY77 B53335 W0200055351-A1 Cancer HWMIW26 B53358 WO200055351-A1 Cancer HEAHA84 B53397 W0200055351-A1 Cancer HBKDN33 B53414 W0200055351-A1 Cancer HKAIL83~ B53430 W0200055351-A1 Cancer HBMSK08 853503 W0200055351-A1 Cancer HTELE03 B53617 W0200055351-A1 Cancer HSWAR63 B53774 W0200055351-A1 Re roductive.

HFXAM85 B54142 W0200055320-Al Cancer HISCO10 ~ B54185 ~ W0200055320-A1 Digestive HISBT02 B54226 W0200055320-A1 Di estive HNHLV34 B54251 WO200055320-A1 Cancer HUSX071 B54257 W0200055320-A1 Cardiovascular, Immune/Hematopoietic, Re roductive HLWBY67 B54.277 W0200055320-A1 Cancer HUVDP63 B54282 W0200055320-A1 Cancer HSTAH26 B54290 W0200055320-A1' Connective/E ithelial HWLXE16 B54305 W0200055320-Al Di estive HDQEG93 B54316 W0200055320-A1 Cancer HSLJG12 B54341 W0200055320-A1 Cancer HAOSL81 B54358 W0200055320-A1 Cancer HOFNH33 B54374 W0200055320-A1 Re roductive HAJBV26 B56077 W0200070042-Al Cancer HAPOC74 B56078 W0200070042-A1 Excretory, . ' Immunel~Iematopoietic, Re roductive HATEI47 B56079 W0200070042-A1 Endocrine HNHGD15 B56080 W0200070042-A1 Immune/Hemato oietic HRKAB52 B56081' WO200070042-A1 Cancer HKGAT94 B56082 W0200070042-A1 Digestive, ' Re roductive HODAH46 B56083 W0200070042-A1 Cancer HASCE69 B56084 W0200070042-A1 Cancer HBNBE21 B56085 W0200070042-A1 Cancer HFLSH80 B56086 ' W0200070042-A1 Cancer HRACM44 B56087 W0200070042-A1 Excretory, hnmune/Hemato oietic HBXFR04' B56090 W0200070042-A1 Neural/Senso HNHFM14 B56094 W0200070042-A1 Cancer HEBCM27 B56095 W0200070042-A1' Cancer HNHBM80 B56096 . W0200070042-Al Immune/Hemato oietic, Re roductive HTEAR66 B56098 W0200070042-A1 Re roductive HTLDW38 B56099 W0200070042-Al Immune/Hematopoietic, Neural/Sensory, Re roductive HTOFD28 B56100 W0200070042-A1 Immune/Hemato oietic HFPBW41 B56101 WO20007004.2-Al Neural/Sensory HTSAC80 B56102 W0200070042-A1 Cancer HANGD45 ' B56103 W0200070042-A1 Musculoskeletal HNGJL11 B56106 WO200070042-A1 Immune/Hematopoietic, Musculoskeletal HYBBE75 B56108 W0200070042-A1 Musculoskeletal ~

HCWDS72 B56109 W0200070042-A1 Cancer.

HKPAD17 ' B56110 W0200070042-A1 Excretory HTLGY87 B56114 W0200070042-A1 Cancer HULAGO1 B561I5 W0200070042-A1 Cardiovascular HYAAJ71 B56116 ' WO200070042-A1 Immune/Hemato oietic HE9HY07 ~ B56118 ~ W0200070042-A1 Mixed Fetal, Re roductive' ' HLSAF81 B56121 ' W0200070042-A1 Cancer ' HNGAU09 B56123 W0200070042-A1 Immune/Hemato oietic HTEID16 B56124 W0200070042-Al Re roductive HTWKE60 B56125 W0200070042-A1 Immune/Hemato oietic HHLAB61 B56127 W0200070042-A1 Di estive HRLMB56 B56128 W0200070042-A1 Cancer HCUDW10 B56131 W0200070042-A1 Cancer HNGIQ46 B56133 W0200070042-A1 Immune/Hemato oietic H7TMD22 B56135 WO200070042-A1 Neural/Senso HHFCJ31 856136 W0200070042-A1 Cardiovascular, Connective/Epithelial, Re roductive HLDBW08 B56137 W0200070042-A1 Di estive H6EEW15 B56139 W0200070042-A1 Cancer ~

HNHBM26 B56142 W0200070042-A1 Immune/Hematopoietic, Re roductive HFIVA74 B56144 W0200070042-A1 Musculoskeletal, Re roductive HPWAG46 B56145 W0200070042-A1 Cancer HBJFM34 B56146 ~ W0200070042-A1 ImmunelHemato oietic HRDDSO1 B56147 W0200070042-A1 Musculoskeletal HGBDH53 B56152 W0200070042-Al Cancer HMKCV28 B56154 W0200070042-A1 Neural/Sensory HPLAT69 B56155 W0200070042-A1 Cancer HNGBJ27 B56157 W0200070042-A1 Immune/Hemato oietic HFXH083 ' B56158 W0200070042-A1 Cancer HKGAM07 B56159 . WO200070042-Al Digestive, Endocrine HTXFE73 B56160 W0200070042-A1 Cancer HEBBN36 B56163 W0200070042-A1 Cancer HJPCY06 B56164 W0200070042-A1 Cancer HTEGS19 B56165 W0200070042-A1 Cancer HMJAK63 B56166 W0200070042-A1 Neural/Sensory HNHGE75 B56170 W0200070042-A1 Immune/Hemato oietic HMELA16 B56171 W0200070042-A1 Cardiovascular, Immune/Hemato oietic HNGAJ15 B56172 W0200070042-A1 Immune/Hemato oietic, Neural/Sensory HNHHD40 B56173 W0200070042-A1 Cancer HFPAA06 B56177 W0200070042-A1 Cancer HNGIH43 B56180 WO200070042-A1 Immune/Hematopoietic, .
Re reductive HLSAD65 B56182 WO200070042-A1 Cancer HMDAK33 B56183 W0200070042-A1 NeurallSensory HNALC70 B56184 W0200070042-A1 Cancer -HOUCW42 B56185 W0200070042-A1 Connective/E ithelial HLMMX46 B56186 W0200070042-A1 Immune/Hemato oietic HHSDI68 B56188 W0200070042-A1 Neural/Sensory HLMIV11 B56190 W0200070042-Al ImmunelHemato oietic HBMCI,50 B56193 W0200070042-A1 Immune/Hemato oietic HCRAI47 B56.195 W0200070042-Al Cancer HNHEU34 B56198 W0200070042-A1 ImmunelHemato oietic HPFCR15 . B56199 W0200070042-A1 Digestive, Mixed Fetal, Re reductive HNGJM27 B56201 W0200070042-A1 Immune/Hemato oietic HNHEL19 ' B56202 W0200070042-A1 Immune/Heriiatopoietic, - Re reductive HGOCD38 ~ B56204 W0200070042-A1 Cancer HHGCG53 B56205 W0200070042-A1 Cancer HHSBJ93 B56206 W0200070042-A1 Digestive, Immune/Hematopoietic, Neural/Sensory HLHDS79 B56208 W0200070042-A1 Cancer HNHEA64 B56209 WO200070042-A1 Immune/Hemato oietic HOVAZ13 B56211 W0200070042-A1 Cancer HHGBIC24 B56214 W0200070042-A1 Cancer HILCG67 B56215 W0200070042-A1 Cancer HOSFC36 ~ B56218 W0200070042-A1 Cancer ~

HKGAT94 B56220 W0200070042-A1 Digestive, Re reductive , HBNBE21 B56221 W0200070042-A1 Cancer HFLSH80 B56222 W0200070042-A1 Cancer HGBDH53 B56227 W0200070042-A1 Cancer HMELA16 B56230 _ W0200070042-A1 Cardiovascular, Immune/Hemato oietic HNGAJ15 B56231 W0200070042-A1 ImmunelHematopoietic, Neural/Sensory HCRAI47 B56232 W0200070042-A1 Cancer HNHEL19 B56233 W0200070042-Al Immune/Hematopoietic, Re reductive HOSFC36 B56236 ' W0200070042-A1 Cancer HHSBJ93 B56351 W0200070042-A1 Digestive, Immune/Hematopoietic, Neural/Sensory HJAAT54 B56364 W0200055174-A1 Cancer HPCQS73 B56431 W0200055174-Al Cancer , HPRTL26 B56435 W0200055174-A1 Re reductive HPFEA08 B56518 W0200055174-A1 Re reductive ~

HTEPF49 B56536 W0200055174-A1 Cancer HOFAC67 B56601 WO200055174-A1 Re reductive HNTBH70 B56606 WO200055174-A1 Cancer HMQAI69. B56630 W0200055174-A1 Cancer HDPBI36 B5667I W0200055174-A1 Cancer _ B56687 W0200055174-A1 Immune/Hemato oieticw HHEPI21 B56725 W0200055174-A1 Cancer HAIBC14 B56739 ' W0200055174-A1 Cancer HDQGM08 B56749 W0200055174-A1 Cancer HWHPD31 B56788 WO200055174-A1 Cancer HPJCY94 856791 W0200055174-Ai Musculoskeletal, Re reductive -HDSAK19 B56816 W0200055174-A1 Cancer HTTFG83 B56820 WO200055174-A1 Re reductive HDPVR90 B56824 W0200055174-A1 Cancer HSLJW05 B56860 W0200055174-A1 Cancer HHEPE84 B56876 W0200055174-A1 Cancer HE2LW65 B56909 W0200055174-A1 Cancer HPRTI79 B56925 W0200055174-A1 Cancer HEQAN39 B56926 W0200055174-A1 Cancer HEMFC70 B56931 W0200055174-A1 Cancer HELGM94 B56937 W0200055174-A.1 Cancer HDHMB78 B56950 W0200055174-A1 Cancer HDPQE64 B56987 W0200055174-Al Cancer HDPBQ32 B56996 ~ W0200055174-A1 Cancer HBXGB85 B57056 W0200055174-A1 ~Neural/Sensory HBUAC02 ' B57061 W0200055174-A1 Cancer -HOCOT88 B57077 W0200055174-A1 Cancer HAJAT72 B57101 W0200055174-A1 Re reductive HPJAV43 B57106 W0200055174-A1 Immune/Hematopoietic, Reproductive, Res iratory HRODJ79 B57121 W0200055174-A1 Cancer HE8FD92 B57128 . W0200055174-A1 Cancer HETAM53 ' B57137 W0200055174-A1 Cancer HCHBQ27 B57159 W0200055174-A1 Re reductive HAPSG03 B58194 W0200055180-A2 Cancer HHFFR04 ' B58240 W0200055180-A2 Cancer HCLSC85 B58320 W0200055180-A2 Res iratory -HPAMC60 B58368 W0200055180-A2 Cancer HCE5E24 ~ B58386 W0200055180-A2 Cancer HMADJ17 B58396 W0200055180-A2 Cancer HADCL25 B58403 W0200055180-A2 Cancer HWDA040 B58434 W0200055180-A2 Cancer HRGBG45 B58718 W0200055173-A1 Cancer HOFMM27 B58772 W0200055173-A1 Re reductive HOFMH95 B58829 W0200055173-A1 Re reductive HEMFK40 B58912 W0200055173-A1 Cancer HODBC01 B58913 W0200055173-A1 Re reductive HOGAV29 B58914 W0200055173-A1 Immune/Hematopoietic, Re reductive HOFNI;25 B58917 WO200055173-A1 Re reductive HOFMH12 B58929 W0200055173-A1 Re reductive HOFOC33 B58932 W0200055173-A1 Re reductive HSIFL06 B58996 W0200055173-A1 Cancex HNHBE38 . B59469 W0200077173-A1 Cancer ' HOPBP13 B59470 WO200077173-A1 Cancer ~

HOUDE92 B59472 W0200077173-Al Cancer HPQAJ27 B59473 W0200077173-A1 Cancer ' HTLEV48 B59476 W0200077173-A1 Re reductive HSPAI20 B59478 W0200077173-A1 Digestive, Neural/Sensory HSPAA89 B59479 W0200077173-A1 Di estive H'TWEH94 B59482 W0200077173-A1 Immune/Hemato oietic HTEGS48 ~ B59490 W0200077173-A1 Re reductive HTEIV65 B59491 W0200077173-A1 Re reductive -HOSEI81 B59494 . W0200077173-A1 Digestive, Musculoskeletal HOEFL74 B59495 W0200077173-A1 Cardiovascular, ' ~ Digestive, Musculoskeletal HOGAA41 B59497 W0200077173-A1 Cancer _ HOFMT59 B59499 W0200077173-A1 Re reductive HSYBD33 B59502 W0200077173-AI Immune/Fiemato oietic HTOH021 B59503 W0200077173-A1 Immune/Hemato oietic HTAED89 B59504 WO200077173-A1 Irrimune/Hemato oietic HUSCA09 B60703 W0200076531-A1 Cancer HBXCD59 B60705 W0200076531-A1 Immune/Hematopoietic, Netual/Sensory HDPSZ07 B60706 W0200076531-A1 Immune/Hemato oietic HCLCU75 B60712 W0200076531-A1 Res iratory ' HDABR74 B60714 WO200076531-A1 Cancer HSSEA64 B60721 W0200076531-Al Cancer HSSJF96 B60722 W0200076531-A1 Musculoskeletal ' HT4FV41 B60724 W0200076531-A1 Cancer HBSAJ63 B60725 W0200076531-A1 Cancer ' HTODA92 B60726 W0200076531-A1 Cancer HTTCB60 B60727 W0200076531-A1 Cancer HTTE025 B60728 W0200076531-A1 Cancer HTXDD61 B60733 WO200076531-A1 Cancer HTXJM94 B60734 W0200076531-A1 Cancer ' - HWHRCS1 B60736 W0200076531-A1 Cancer HAGFJ67 B60737 , W0200076531-A1 Digestive, Immune/Hematopoietic, Neural/Senso .
A

HBSAK32 B60739 W0200076531-A1 Cancer ' ~ ~

HCHCG33 B60741 W0200076531-A1 Cancer HE8FD92 B60747 W0200076531-A1 Cancer HSAWB58 B63049 W0200061748-A1 Immtme/Hemato oietic HCE1T53 B63050 W0200061748-A1 Neural/Senso HODCY44 B63057 WO200061748-A1 Re reductive HTEJF31 B63072 ' W0200061748-A1 Re reductive .

HTPCW2I B63077 ~ W020006I748-A1 Digestive, Nettral/Sensory HPFBA54 B63082 W0200061748-Al Re reductive HSABG81 B63083 WO200061748-A1 Cancer HTECB02 B63084 W0200061748-A1 Cancer HTEDJ28 B63086 W0200061748-A1 Cancer HSLEC18 B63092 W0200061748-A1 Cancer HTSG013 B63095 W0200061748-A1 Cancer HTLEM16 B63096 W0200061748-A1' Cancer HTXPD86 B63136 W0200061629-A1 Cancer HWLGP26 B63137 WO200061629-A1 Cancer HAJAY92 B63141 ~W0200061629-A1 Cancer ' HSYBZ94 B63145 W0200061629-A1 Cancer HPRBH85 B63146 W0200061629-A1 Cancer HTECE87 B63I47 W0200061629-AI Cancer HNHGD95 B63148 W0200061629-A1 Cardiovascular, Immune/Hemato oietic HNKAA76 B63150 W0200061629-A1 Cancer HOABP31 B63152 W0200061629-A1 Cancer HOHBC57 B63154 W0200061629-A1 Cancer HOSCZ41 B63156 W0200061629-A1 Cancer HMVEC89 B63157 W0200061629-A1 Cancer HPJBJ51 B63162 W0200061629-A1 Cancer HGBBR29 B63164 W0200061629-A1 Cancer HPMDD27 B63165 W0200061629-A1 Cancer HPRCM72 B63169 WO200061629-A1 Cancer HPTRM02 .B63171' W0200061629-A1 Cancer HPTRW28 B63172 W0200061629-A1 Cancer HRAAZ12 B63175 W020006.1629-A1 Cancer HRDEX93 B63177 W0200061629-A1 Cancer HRDFE30 B63178 W0200061629-A1 Cancer HBJHTO1 B63180 W0200061629-A1 Immune/Hematopoietic, ~ Re roductive HE8FC45 B64422 W0200077255-A1 Cancer HETCI16 B64423 W0200077255-A1 Cancer HFCBL53 B64427 W0200077255-A1 Cancer HE6GR29 B64429 W0200077255-A1 Cancer HBJEA15 B64432 W0200077255-A1 Cancer.

HAPNJ33 B64434 W0200077255-A1 Cancer HTXKB57 - B64435 W0200077255-A1 Cancer HDLAL94 B64438 W0200077255-A1 Cancer HFVHX08 B64440 W0200077255-A1 Cancer HMVCS92 B64441 W0200077255-A1 Cancer HNEDQ02 B64443 W0200077255-A1 Cancer HPWTF53 ' B64.450 W0200077255-Al Cancer HRTAP63' B64451 W0200077255-A1 Cancer HASAU26 B64453 W0200077255-A1 Cancer HPWTF23 B64456 W0200077255-A1 Cancer HSLHG78 B64457 WO200077255-A1 Cancer HTNBJ15 B64461 W0200077255-A1 Cancer HTXJW06 ' B64463 W0200077255-AI Cancer HUKFV37 B64466 W0200077255-A1 Cancer HWBBU75 B64468 W0200077255-A1 Cancer HWBEF34 B64469 ~ W0200077255-A1 Immune/Hematopoietic, Neural/Sensory HDLAL94 ~ B64492 W0200077255-A1 Cancer ' HUKFV37 B64539 W0200077255-A1 Cancer HUKFV37 B64540 W0200077255-A1 Cancer HMSGU30 B64549 W0200077197-A1 Cancer HMSHU20~ B64550 _ W0200077197-A1 Immune/Hematopoietic, ' Re roductive ' HMTAB77 B64551 W0200077197-A1 Cancer HMUBX48 B64552 W0200077I97-A1. Musculoskeletal, - Re roductive HMWCG28 ~ B64553 W0200077197-A1. Cancer HMWF089 B64555 W0200077197-A1 Cancer HMWGM41 B64556 W0200077197-A1 Cancer HMWGV85 B64557 W0200077197-A1 Cancer HNDAC35 B64558 W0200077197-A1 Cancer HNGDN07 B64559 W0200077197-A1 Immune/Hematopoietic, - ~ Re roductive HOFMF63 B64564 W0200077197-A1 Cancer HOSE083 B645'67 WO200077197-A1 Cancer HPIAL55 B64568 W0200077197-A1 Cancer HRAAF59 B64569 W0200077197-A1 Excretory HSDIK31 B64571 WO200077197-A1 Cancer -HSDJG47 B64573 W0200077197-A1 Cancer HSOAT44 B64574 W0200077197-A1 Cancer HTAEF02 B64578 W0200077197-A1 Immune/Hemato -oietic HTLCX82 B64579 ' W0200077197-A1 Cancer HADDP51 B64581 W0200077197-A1 Cancer HAOAG15 B64584 W0200077197-A1 Cancer HATCS79 - B64585 W0200077197-A1 Endocrine, ImmunelHemato oietic HMWGM41 B64604 W0200077197-A1 Cancer HOFMF63 ~ B64612' W02000T7197-A1 Cancer HEMBP72 B64627 W0200077197-AI Cancer HEMBP72 B64628 WO200077197-A1 Cancer HAOAG15 B64657 , W0200077197-A1 Cancer ' HAOAG15 B64658 W0200077197-A1 Cancel HKGD012 B64667 W0200077237-A1 Cancer HLQAD72 B64668 W0200077237-A1 Cancer HFXHM93 B64672 WO200077237-A1 Neural/Sensory HEBCW57 864675 W0200077237-Al Mixed Fetal, Neural/Sensory HAECD28 B64676 W0200077237-A1 Cancer HADXA10 B64677 W0200077237-A1 Cancer HELEL76 864678 W0200077237-A1 Cancer HETBJ88 B64680 W0200077237-A1 Cancer HETCM67 B64681 W0200077237-Al Cancer HFCBL53 B64682 WO200077237-A1 Cancer HFEBK75 . B64683 WO200077237-A1 Connective/E ithelial HFIIZ61 B64684 W0200077237-A1 Cancer HGBDL51 B64688 W0200077237-A1 Cancer HGLDA95 B64689 W0200077237-A1 Cancer HGLDB06 B64690 - W0200077237-A1 Cancer HHBEI14 B64691 W0200077237-A1 Cancer HLDBG17 B64697 W0200077237-A1 Cancer HMCIH27 $64701 W0200077237-A1 Cancer HMEKW71 B64702 W0200077237-A1 Cancer HNGEA90 B64705 W0200077237-A1 Immune/Hemato oietic HNHEN70 B64708 W0200077237-A1 Cancer HOAAH51 B64711 ~ W0200077237-A1 Cancer HORBL77 $64712 W0200077237-A1 Cancer HODAH46 B64713 WO200077237-A1 Cancer HMWEM23 - B64718 W020007723.7-Al Cancer HNEBX72 , B64775 W0200077256-A1 Immune/Hematopoietic, Neural/Senso H6EEA48 $64776 W0200077256-A1 Cancer HACBS22 B64778 - ~ W0200077256-A1 Cancer ' HADDP23 B64779 W0200077256-A1 Cancer HAGFD75 B64782 W0200077256-A1 Cancer - HAGFS57 B64783 ' W0200077256-A1 Cancer -HAHSD51 B64785 W0200077256-A1 Cancer HANKC93 B64787 W0200077256-A1 _Musculoskeletal HAPSH37 B64789 W0200077256-A1 Cancer HATAL05 B64790 W0200077256-Al Cancer ' HCBAB34 B64799 W0200077256-A1 Cancer HCE5H86 B64802 W0200077256-A1 Cancer HCEBF54 B64803 W0200077256-A1 Cancer HCEDN07 B64804 W0200077256-A1 Digestive, Mixed Fetal, NeuravSensory HCEGH74 B64805 W0200077256-Al Cancer HCELB04 B64806 W0200077256-A1 Cancer HDHEA33 B64813 W0200077256-A1 Cancer HDPIF65 B64814 WO200077256-A1 Immune/Hemato oietic HDPMC52 B64816 W0200077256-A1 Digestive, Immune/Hematopoietic, Musculoskeletal HDSA014 B64819 ~ W0200077256-A1 Cancer HDTAR39 B64820 W0200077256-A1 Cancer HBXFWO1 B64844 W0200077256-A1 Neural/Senso HLYEJ14 B64883 W0200076530-A1 Cancer HPJCX13 B64888 W0200076530-A1 Cancer .

HFKEV77 B64889 W0200076530-A1 Cancer HCEOV48 B64890 W0200076530-A1 Cancer ' HCRMR35 B64891 W0200076530-A1 Cancer HDPNJ26 B64893 W0200076530-A1 Cancer .

HDQGD06 B64894 W0200076530-A1 Cancer HDQHM36 B64895 W0200076530-A1 Immune/Hemato oietic HFCBL53 B64901 WO200076530-A1 Cancer HIBC070 B64905 W0200076530-A1 Cancer HLDCR26 B64908 W0200076530-A1 Cancer HLDDM27 B64909 W0200076530-A1 Cancer HMABK52 B64910 W0200076530-A1 Irnmune/Hemato oietic HNGBC53 B64915 W0200076530-A1 Immune/Hemato oietic .

HNGJB41 B64916 W0200076530-A1 Immune/Hemato oietic HNHLS76 B64917 W0200076530-A1 ImmunelHemato oietic HSJAQ10 B64925 W0200076530-A1 Cancer HSLDW54 B64927 W0200076530-A1 Cancer HSLFR59 , B64928 ' W0200076530-A1 Cancer HSNAN38 B64930 W0200076530-Al Cancer HLYEJ14 B64931 W0200076530-A1 Cancer HLYEJ14 B64932 W0200076530-A1 Cancer .

HPMCV08 B64993 W0200075375-A1 Cancer HFKEM67. B64994 ' W0200075375-A1 Excretory, Neiual/Sensory, Re roductive HDTBW53 B64996 W0200075375-A1 Cancer HFICL62 B64997 ' W0200075375-A1 Cancer HKAIA52 B64998 W0200075375-A1' Cancer HEGAK44 B64999 W0200075375-A1 Cancer HFXHC85 B65000 W0200075375-A1 Cancer HSXCV85 B65001 W0200075375-A1 Neural/Sensory, Re roductive HPMCU14 B65002 W0200075375-Al Cancer HYACJ27 B65003 W0200075375-A1 Immune/Hemato oietic HAQBZ15 B65004 W0200075375-A1 . Cancer HBIBX03 B65005 W0200075375-A1 Cancer HBMVI06 B65006 ~ WO200075375-A1 Cancer HDPBA28 865007 ' W0200075375-A1 Cancer HDPUH26 865008 W0200075375-A1 Cancer HJTAD07 865009 W0200075375-A1 Cancer HDPPJ60 B65010 WO200075375-A1 Cancer HLTAU74 865011 W0200075375-A1 Cancer HCFNN16 865012 W0200075375-A1 Cancer HCWUI05 865013 W0200075375-A1 Irnmune/Hemato oietic HCEBC76 865014 W0200075375-AI Neural/Senso HTEGT82 865015 W0200075375-A1 Digestive, Re reductive HLHTP35 865016 W0200075375-AI Cancer HSYAZ63 865017 W0200075375-A1 Cancer HLTCR13 B65018 W0200075375-A1 Cancer HPMCV08 865019 ~ W0200075375-A1 Cancer HEGAK44 B65021 WO200075375-A1 Cancer HEGAK44 B65022 W0200075375-A1 Cancer HSXCV85 B65024 W0200075375-A1 Neural/Sensory, Re reductive HAQBZ15 865025 W0200075375-A1 Cancer HDPMM34 876127 W09517092-A Cancer HAPBR31 876128 W09517092-A Cancer HPTXE69 876818 W09520398-A Cancer HPTGA39 876820 WO9520398-A Cancer HFTDJ13 881567 WO9606169-Al Cancer HPAAA47 888481 W09601270-A1 Cancer HDQAC88 893087 W09605856-A1 .Cancer HCHBM70 W06550 W09639419-A1 Cancer HAPBR31 W07203 W09634891-A1 Cancer HDPMM34 W07204 W09634891-A1 ~ Cancer HDTAX72 W07606 WO9639522-A1 . Cancer HPBCW46 W09405 WO9639158-A1 Mixed Fetal, Neural/Sensory HE9ME29 W09408 WO9639486-AI ~ Cancer ' HDTAX72 W10574 W09624668-A1 Cancer HGCOP28 W 12692 W09639424-Al Cancer HDQAC88 W22670 WO9731098-A1 Cancer HDPJJ70 W22732 W09724929-AI Cancer HSKHZ53 W23663 W09729189-AI Cancer HATCY89 W27087 W09725349-A1 Cancer HNTCF82 W27224 W09735870-A1 Cardiovascular, , Connective/Epithelial, Re reductive HFEBJ25 W29291 WO9735010-A1 Cancer HKMMP34 W29292 W09735010-A1 Cancer HBMBJ94 W31527 WO9737022-A1 Digestive, '''- ~ ~ Immune/Hemato oietic HDPVA94 W31902 W09737021-AI Cancer HFIZF58 W32110 W09738012-A1 Cancer HSLDE91 W32112 WO9734998-A1 Cancer HDPVA94 W32323 ~ W09736915-A1 Cancer HETF052 W35803 ~ WO9734997-A1 Neural/Sensory, Re reductive HETEZIO W35804 W09734997-A1 ~ Cancer ~ ' L HBMT047 ~ W35904 W09738003-A1 ~ Cancer HDQDX59 W37002 W09733902-A1 Cancer H2LAJ93 W37844 W09807749-A1 Cancer HMWIl'18 W37845 W09807749-A1 Cancer HM DN51 W37935 W09808870-A1 Cancer HOECW07 W37946 W09821236-A1 Cancer HTHBJ48 W4I938 W09748807-A1 Digestive, Innnune/Hemato oietic HCHBM70 W46882 US5733748-A Cancer HAHSD23 ~ W48334 W09807881-Al Cancer HTEHH47 W48335 WO9807754-A1 - Cancer HPASD50 W48391 W09807735-A1 Cancer HDQMC88 W52842 . W09807862-A2 ConnectivelEpithelial, Immune/Hemato oietic HKACN58 W53897 W09808969-A1 Cancer HOEAL47 W57635 W09812344-A1 Cancer HAPBR31 W57697 WO9814582-A1 Cancer HDPMM34 W57698 WO9814582-A1 Cancer HE9ME29 W58704 US5780263-A Cancer HDTAX72 W58901 W09814477-A1 Cancer , HISCH47 W61621 . W09831799-A2- _ Cancer --HDPIR89 . W61622 W09831799-A2 Digestive, Immune/Hemato oietic HAIDQ59 W61623 W09831799-A2 Cancer HHFEK40 W61624 WO9831799-A2 Cancer HGBGV89 W61625 W09831799-A2 Di estive HUVBB80 W61626 W09831799-A2 ~ Cancer HFGAG96 W61629 WO9831799-A2' Cancer HDTEA84 W63622 W09830694-A2 Cancer HPRCBS4 W64668 W09830693-A2 Cancer HAGFY16 W67808 W09842738-AI. Cancer HASAV70 W67811 WO9842738-A1 Cancer HBNAF22 W67812 W09842738-A1 Cancer HCDDR90 W67814 W09842738-AI Cancer HCEEF50 W67815 - W09842738-A1 Cardiovascular, Neural/Sensory HCEMU42 W67816 W09842738-A1 Cancer HCENE16 W67817 W09842738-A1 Cancer HMSJJ74 W67818 WO9842738-A1 Cancer HCUBF15 W67819 WO9842738-A1 Immime/Hemato oietic HE2DE47 W67820 WO9842738-A1 Cancer HKMLH01 W67821 W09842738-A1 Cancer HE9DG49 W67822 W09842738-A1 Cancer HELBA06 W67823 W09842738-A1 Cancer HSLFM29 W67824 W09842738-A1 Cancer HELBW38 W67825 W09842738-A1 Cancer HFEAF41 W67828 W09842738-A1 Connective/Epithelial, Di estive .

HFTBE43 W67831 W09842738-A1 Cancer HLHSV96 W67835 W09842738-AI Res iratory HLTBX31 W67837 W09842738-A1 Cancer HLTCJ63. W67838 W09842738-A1 Ixnmune/Hematopoietic, - Neural/Sensory, Re reductive HMQAJ64 W67840 WO9842738-A1 Connective/Epithelial, Immune/Hematopoietic, Re reductive HOABG65 W67841 W09,842738-A1 Musculoskeletal HODCL36 W67842 W09842738-A1 Cancer HODCL50 W67843 W09842738-A1 Re roductive -HODCZ16 W67845 W09842738-A1 Cancer HTOEU03 W67846 ' W09842738-A1 Cancer HPBCJ74 W67847 W09842738-A1 Cancer HSIDQ18 W67850 W09842738-A1 Cancer HSJBQ79 W67852 W09842738-A1 Cancer HTEJN13 W67854 W09842738-A1 Neural/Sensory, Re roductive ~ITHBL86 W67855 W09842738-A1 Immune/Hemato oietic HTSF071 W67856 W09842738-A1 Cancer HAPN080 W67857 W09842738-A1 Cancer HBIBZ09 W67858 W09842738-A1 Cancer HCFLD84 W67859 W09842738-A1 Cancer HE8EZ48 W67861 W09842738-A1 Cancer HEBGF73 W67862 W0984.2738-A1 Cancer HFE'BF41 W67863 W09842738-A1 Cancer HFRBU14 W67864 W09842738-A1 Neural/Sensory HHGC088 W67867 W09842738-A1 Cancer HHGDB72 W67869 W09842738-A1 Cancer HHGDI71 W67870 W09842738-A1 Excreto HHSDI45 W67871 W09842738-A1 Cancer HHSEB66 W67872 W098,42738-A1 Cancer .

HAUAI83 W67873 W09842738-A1 Re roductive HKDBL30 W67874 W09842738-A1 Cancer HLDBQ19 W67875 W09842738-A1 Cancer HMSGT42 W67876 W09842738-A1 Cancer HMWIC78 W67877 W09842738-A1 Cancer HMWIR31 W67878 W09842738-A1 Cancer HNTAC73 W67880 W09842738-A1 Cancer HOSEI45 W67881 W09842738-A1 Cancer HOSFD58 W67882 W09842738-A1 Cancer HSAUM95 W67883 . W09842738-A1 Cancer HSAUR67. W67884 W09842738-A1 Immune/Hemato oietic HSKDI81 W67885 W09842738-A1 Cancer HOUFJ08 W67886 W09842738-A1 Cancer HTLEX50 W67887 W09842738-A1 Cancer HSKIiL65 W67888 W09842738-A1 Cancer HHFGAll W67889 W09842738-A1 Cancer HAQCF47 W67890 W09842738-A1 Cancer HBXFG80 W67891 W09842738-Ai Cancer HFLQB16 W67895 W09842738-A1 Cancer HBMCP89 W67896 W09842738-A1 Cancer HE6DG34 W67897 W09842738-A1 Cancer HE9DG49 W67898 W09842738-A1 Cancer HELBA06 W67899 W09842738-A1 Cancer HMQAJ64 W67900 W09842738-A1 Connective/Epithelial, . Immune/Hematopoietic, Re roductive HODCL36 W67901 W09842738-A1 Cancer HODCL36 W67902 ~ W09842738-A1 Cancer HCMSD80 W67903 W09842738-A1 Cancer HPBCJ74 W67904. W09842738-A1 ~ Cancer HHGDU04 ~ W67905 ~ W09842738-A1 Cancer HTEJN13 . W67907 W09842738-A1 Neural/Sensory, Re reductive HAUCC47 W67909 W09842738-A1 Cancer HOSFD58 W67913 W09842738-A1 Cancer HSKHL65 W67916 W09842738-Al Cancer HHFGA11 W67917 W09842738-A1 Cancer HOEBX83 W67918 W09842738-A1 Cancer HHFGA11 W67919 W09842738-A1 Cancer HTSF071 W67967 W09842738-A1 Cancer HKFBC53 W68002 W09842738-A1 Cancer HSPBS71 ~ W69221 W09828420-A1 Connective/Epithelial, Digestive, Immune/Hemato oietic HDPBT77 W69232 W09831806-A2 Digestive, .
Immune/Hematopoietic, Re reductive HNFFL83 W69233 W09831806-A2 Digestive, Immune/Hexnato oietic HETHE81 W71593 W098339I2-AI Cancer HSVBZ80 W73397 W09854206-A1 Cancer HTAAU21 W73398 W09854206-AI Cancer HUSIR91 W73400 W09854206-A1 Cancer HADMC21 W73401 W09854206-A1 Cancer HAGFM45 W73402 W09854206-AI Cancer HAIBE65 W73403 W09854206-A1 Cancer HAQBH57 W73404 ~ W09854206-A1 Cancer HATCX80 W73405 W09854206-A1 Cancer HLDOT61 W73408 W09854206-AI Cancer HEMCM42 - W73409 W09854206-A1 Cancer HFCDW34' W73411 W09854206-A1 Cancer HTTEU91 W73412 W09854206-A1 Cancer HHGBF89 W73413 WO9854206-A1 Mixed Fetal HKMLN27 W73415 W09854206-A1 Cancer HLYAZ61 W73419 W09854206-Al hnmune/Hemato oietic HMQDT36 W73420 W09854206-A1 Cancer HETFI51 W73428 , W09854206-A1 Cancer HUSIR9I W73429 W09854206-A1 Cancer HHGBF89 W73430 W09854206-A1~ Mixed Fetal HPWBA10 W73432 W09854206-A1 . Immune/Hematopoietic, Re reductive F3PMBQ91 W74413 EP892053-A2 Re reductive HBGBW52 W74732 W09839448-A2 Cancer HCUFQ22 W74734 W09839448-A2 Immune/Hemato oietic HLDOU93 W74738 W09839448-A2 Digestive, Musculoskeletal, ' Re reductive HNGJJ68 W74741 WO9839448-A2 Cancer HCFAW04 W74742 W09839448-A2 mmune/Hemato oietic I

HLMAV65 W74743 W09839448-A2 Cancer HPMFD84 W74744 ~W09839448-A2 Cancer -HE6DB26 W74745 W09839448-A2 Cancer HODBD33 ' W74747 W09839448-A2 Re reductive HBJAE44 W74750 W09839448-A2 Immune/Hemato oietic HCFME41 W74751. W09839448-A2 Cancer HOGC071 W74752 W09839448-A2 Cancer HOSEX08 W74753 W09839448-A2 Cancer HSKNJ72 W74754 W09839448-A2 Digestive, Musculoskeletal HEBEB69 W74755 W09839448-A2 Neural/Sensory, Re roductive HE6EH18 . W74756 W09839448-A2 . Mixed Fetal, Neural/Sensory HSSDM73 W74758 W09839448-A2 Musculoskeletal, ' NeurallSensory, Re roductive HMKCU94 W74761 W09839448-A2 Cancer HRDEW41 W74762 W09839448-A2 Cancer HBGDA21 W74764 W09839448-A2 Cancer HFGAI~75 W74765 W09839448-A2 ~ Cancer HFSAU96 - W74766 W09839448-A2 Cancer HOVCI,83 W74767 W09839448-A2 Cancer HBICM48 W74769 W09839448-A2 Cancer HLTCL35. W74770 W09839448-A2 Cancer HRSAN45 W74771 W098,39448-A2 Cancer HSNBB14 W74772 W09839448-A2 Cancer HMABL38 W74773 W09839448-A2 - Cancer HSKDK47 W7-4774 W09839448-A2 Cancer HOSFH03 W74775 W09839448-A2 Cancer HOGAV75 W74776 W09839448-A2 Cancer HBXD023 W74777 W09839448-A2 Cancer HAGBI17 W74778 W09839448-A2 Cancer HPRCA31 W74780 WO9839448-A2 Cancer HPRCE95 W74781 W09839448-A2 Cancer HHTLC66 ' W74782 W09839448-A2 Cancer HMADJ02 W74783 W09839448-A2 Cancer HPRCU93 W74784 W09839448-A2 Cancer HSAXS65 W74785 W09839448-A2 Cancer HHFHN61 W74787 W09839448-A2 Cancer HCWEF90 W74788 W09839448-A2 Cancer HFRAU10 W74790 W09839448-A2 Neural/Sensory HATDT67 W74791 W09839448-A2 Cancer HOUBG93 - W74792 W09839448-A2 Cancer HMWEX24 W74793 W0983944$-A2 Cancer HTOCD52 W74795 W09839448-A2 Digestive, Immune/Hematopoietic, Re roductive HTGCP16 W74796 W09839448-A2 Cancer HKIXR69 W74797 W09839448-A2 Cancer HE6CN34 W74800 WO9839448-A2 Cancer HSQEL25 W74802 W09839448-A2 Cancer HEBEG68 W74803 W09839448-A2 Cancer HBIAB39 W74804 W09839448-A2 Cancel HOEAS24 W74805 W09839448-A2 Cancer HETDD75 W74806 WO9839448-A2 Cancer HSKNE46 W74807 W09839448-A2 Cancer HPMFL27 ~ W74808 W09839448-A2 Cancer HPRAX55 W74810 W09839448-A2 Cancer HE2PL77 W74812 W09839448-A2 Cancer HLHAU92 W74813 W09839448-A2 Cancer HTPEG42 W74814 W09839448-A2 Cancer .

HAUAV32 - W74816 W09839448-A2 Cancer HNEBI60 W74817 W09839448-A2 Cancer HTSEL31 W74819 W09839448-A2 Cancer HAUBL57 W74820 W09839448-A2 Cancer HE6CT48 W74822 W09839448-A2 Digestive, MixedFeta1 HMDAA61 W74823. ~ W09839448-A2 ~ Cancer HAQBK61 W74824 WO9839448-A2 Cancer HAQBF73 W74825 WO9839448-A2 Cancer HAQBT94 W74826 W09839448-A2 Cancer HLQAB52 W74828 W09839448-A2 Cancer HE2BG03 W74830 ~ W09839448-A2 Cancer HCUBC79 W74832 W09839448-A2 Cancer HSVAF07 W74833 W09839448-A2 Cancer HT3AM65 W74834 W09839448-A2 ' Cancer HE6DK18 W74835 W09839448-A2 Cancer HEBEK93 W74836 WO9839448-A2 Cancer HJPCM10 W74837 WO9839448-A2 Cancer HSXBL78 W74838 ' W09839448-A2 Cancer HOEAW81 W74839 WO9839448-A2 Cancer HEA.AR60 W74841 WO9839448-A2 Cancer HOVBA03 W74843 W09839448-A2 Cancer HGBGK76 W74844. W09839448-A2 , Digestive, Neural/Sensory HBMUW78 W74845 W09839448-A2 Cancer HATCM76 W74848 W09839448-A2 Cancer H6EBJ64 ~ W74849 W09839448-A2 Cancer HDDAD77 W74850 W09839448-A2 Cancer HSPAG15 W74853 W09839448-A2 Cailcer HUSHH48 W74855 W09839448-A2 Cancer HHSCV65 W74857 WO9839448-A2 Cancer HHSDQ41 W74858 WO9839448-A2 Cancer HEBFU93 W74860 WO9839448-A2 Excretory, Neural/Sensory, Re roductive HSGSC60 W74861 WO9839448-AZ Cancer HPMGD24 W74862 WO9839448-A2 Cancer HPTVC60 W74863 W09839448-A2 Cancer HSKNE18 W74864 W09839448=A2 Cancer HMWIF35 W74865 ~ W09839448-A2 Cancer HMWGI25 W74866 W09839448-A2 Cancer HSKGF03 ' W74867 W09839448-A2 ' Cancer HMSKE75 W74868 WO9839448-A2 Cancer HCMSH30 W74869 W09839448-A2 Cancer HTWCB92 W74870 W09839448-A2 ~ Cancer HBMDM46 W74871 ' W09839448-A2 Cancer HFXHL79 W74873 W09839448-A2 Cancer ' HBJFJ73 W74874 W09839448-A2 Cancer HSJAP03 W74875 W09839448-A2 Cancer H6EAD09 W74876 WO9839448-A2 Cancer HTLEF62 W74879 W09839448-A2 . Cancer HTLAD94 W74880 W09839448-A2 Cancer HTSFQ12 W74881 W09839448-A2 Cancer' HCE2K05 W74882 W09839448-A2 Cancer HLTED27 ~ W74884 W09839448-A2 Cancer HMKBA64 ' W74885 W09839448-A2 Cancer .

HNFC049 W74886 W09839448-A2 ' Cancer HCELB21 W74887 WO9839448-A2 Cancer HSAAS44 W74889 W09839448-A2 Cancer HAFAL73 W74890 W09839448-A2 Cancer HSAWF26 W74891 W09839448-A2 Digestive, Immune/Hematopoietic, Musculoskeletal HMQDN51 W74892 W09839448-A2 Cancer H2LA011 W74894 ~ W09839448-A2 Cancer HPTTU11 W74896 W09839448-A2 Cancer HTEDJ34 W74898 WO9839448-A2 Cancer HFTAR26 W74900 W09839448-A2 Cancer H2MBF44 W74901 W09839448-A2 Cancer HE8BI92 W74902 W09839448-A2 Cancel HFTBR48 W74903 W09839448-A2 Cancer HE9CM64 W74904 W09839448-A2 Cancer HATAV51 W74905 W09839448-A2 Cancer HGEEK08 W74907 W09839448-A2 Cancer HAFAU18 W74908 W09839448-A2 Cancer HETBY74 W74909 W09839448-A2 Cancer HTOAF35 W74910 W09839448-A2 Cancer HCRBX32 W74911 W09839448-A2 Cancer -HEBGB80 W74912 W09839448-A2 Cancer HFAMH74 W74913 W09839448-A2 Cancer HLMAV65 W74920 W09839448-A2 Cancer HMAGF23 W74922 W09839448-A2 Cancer HE6EH18 W74929 WQ9839448-A2 Mixed Fetal, Neural/Sensory HMKCU94 W74930 W09839448-A2 Cancer HBGDA21 W74931 W09839448-A2 Cancer HFKFN58 W74932 W09839448-A2 Cancer -HSNBB 14 W74935 W09839448-A2 Cancer HOSFH03 W74937 W09839448-A2 Cancer HAGBI17 W74939 WO9839448-A2 Cancer HPRCA31 W74940 W09839448-A2 Cancer HPRCU93 W74943 W09839448-A2 Cancer HPDDK44 W74944 W09839448-A2 Cancer HCWEF90 W74946 W09839448-A2 Cancer HFRAU10 W74947 W09839448-A2 Neural/Sensory HBIAB39 W74953 W09839448-A2 Cancer HBIAB39 W74954 W09839448-A2 Cancer HOEAS24 W74955 ~ W09839448-A2 Cancer HOEAS24 W74956 W09839448-A2 Cancer HPRAX55 W74958 W09839448-A2 ~ Cancer HTPEG42 ' W74960 W09839448-A2 Cancer ~

HAUAV32 W74961 W09839448-A2 Cancer HNEBI60 W74962 W09839448-A2 Cancer _ HAUBL57 W74963_ W09839448-A2 Cancer HAUBL57 W74964 W09839448-A2 Cancer _ HE6CT48 W74965 W09839448-A2 Digestive, . ' Mixed Fetal HMDAA61 W74966 W09839448-A2 Cancer HAQBK61 W74967 W09839448-A2 Cancer HCUHBO1 W74968 W09839448-A2 ' Cancer HETHE07 W74970 W09839448-A2 Cancer ~HETHE07 W74971 W09839448-A2 Cancer HLQAB52 W74972 W09839448-A2 Cancer HEONN58 W74973 W09839448-A2 Cancer HIBEK16 W74974 WO9839448-A2 Cancer HE2BG03 W74975 W09839448-A2 Cancer HCUBC79 W74976 W09839448-A2 Cancer HSVAF07 W74978 W09839448-A2 Cancer HSVAF07 W74979 WO98394.48-A2 Cancer HT3AM65 W74980 W09839448-A2 Cancer HT3AM65 W74981 ' W09839448-A2 Cancer HJPCM10 W74983 ~ W09839448-A2 Cancer HJPCM10 W74984 W09839448-A2 Cancer .

HOVBA03 W74987 W09839448-A2 Cancer H6EBJ64 W74990 W09839448-A2 Cancer HUSHH48 W74991 ~ W09839448-A2 Cancer ' HEBFU93 W74992 W09839448-A2 Excretory, Neural/Sensory, Re roductive HPTVC60 W74993 W09839448-A2 ~ Cancer HMWIF35~~ W74995 W09839448-A2 Cancer HSKGF03 ~ W74996 W09839448-A2 Cancer HBJFJ73 'W75000 W09839448-A2 Cancer HCFBC03 W75001 W09839448-A2 Cancer HSJAP03 W75002 WO9839448-A2 Cancer HE6FL83 W75005 W09839448-A2 Cancer HPTTU11 W75013 W09839448-A2 Cancer H2MBF44 ~ W75015 W09839448-A2 Cancer HE9CM64 W75018 ~ W09839448-A2 Cancer HAFAU18 W75021 W09839448-A2 Cancer HSHCC16 W75050 ' W09839448-A2 Cancer HGCMD20 W75057 W09839446-A2 Cancer HLDBG33 W75058 W09839446-A2. Cancer HLHEJ14 W75059 W09839446-A2 Cancer HKCSR70 W75060 W09839446-A2 Cancer HBMCY91 W75062 W09839446-A2 Immune/Hemato oietic HSSGE07 W75063 W09839446-A2 ~ Cancer HBMBX59 W75064 . W09839446-A2 ImmunelHematopoietic, Re roductive HNGIT22 W75065 W09839446-A2 Immune/Hemato oietic HERAD57 W75066 W09839446-A2 ConnectivelE ithelial HCENJ40 W75067 WO9839446-A2 Cancer HCSRA90 W75068 W09839446-A2 Cardiovascular, Musculoskeletal HBJFC03 W'75069.. W09839446-A2 Immune/Hemato oietic HTEBY26 W75071 W09839446-A2 Cancer HMABH07 W75072 W09839446-A2 Cancer HSKNY94 W75073 W09839446-A2' Cancer HMCDA67 ~ W75074 W09839446-A2 ~ImmunelHemato oietic ~HOSFF45 W75075 W09839446-A2 Cancer HMJAA51 W75076 W09839446-A2 Cancer HTEBF05 W75077 W09839446-A2 Re roductive HTEAL31 W75078 W09839446-A2 Cancer HSKXE91 W75080 W09839446-A2 Cancer HPWTB39 W75081 W09839446-A2 Mixed Fetal, Re roductive HTLEV12 W75082 W09839446-A2 Re roductive HSPAF93 W75083 W09839446-A2 Di estive HHFGL62 W75084 . W09839446-A2 Cardiovascular HCElUI4 W75085 W09839446-A2 Cancer HTHBA79 W75087 W09839446-A2 Cancer HAGBB70 W75088 W09839446-A2 Cancer HETDG84 W75089 W09839446-A2 Cancer HTEGA81 W75090 W09839446-A2 Cancer HTXAK60 W75091 W098~9446-A2 Cancer HMHBN40 W75092 - W09839446-A2 Cancer HFVGS85 W75093 W09839446-A2 Cancer HERAH81 W75094 W09839446-A2 Cancer HMSEU04 W75095 W09839446-A2 Cancer HNEDJ57. W75096 W09839446-A2 Cancer HNTME13 W75097 WO9839446-A2 Cancer HSXBI25 W75098 W09839446-A2 Cancer HSXCK41 W75099 W09839446-A2 Cancer HE8CJ26 W75100 W09839446-A2 Cancer HTTDS54 W75101 WO9839446-A2 Cancer HHFCW44 W751.02 W09839446-A2 Cancer HMCBP63 W75103 W09839446-A2 Cancer HEMGE83 W75104 W09839446-A2 Cancer HHSDC22 W75105 W09839446-A2 . Digestive, Neural/Sensory HHSDZ57 W75106 W09839446-A2 Cancer HCRBS80 _ W09839446-A2 Cancer - .

HMMAB12 W75108 W09839446-A2 ImmunelHematopoietic, NeuraIlSensory HSI~1DW02 W75109 W09839446-A2 Cancer HWHHL34 W75110 W09839446-A2 Cancer HODAZ50 W75111 W09839446-A2 Re roductive HCEWC82 W75112 W09839446-A2 Cancer HE6ES13 ~ W75113 W09839446-A2 Cancer HSSEP68 W75114 W09839446-A2 Cancer HRDEV41 W75115 ' W09839446-A2 Cancer HILCJO1 W75116 - W09839446-A2 Cancer HSATP28 ~ W75117 W09839446-A2 Cancer HBJEM49 W75119 W09839446-A2 Cancer HSLDJ95 W75120 WO9839446-A2 Cancer, Immune HSREG44 W75121 W09839446-A2 Cancer HTXCT40 W75122 W09839446-A2 Cancer .

HRGDF73 W75123 W09839446-A2 Cancer HKMND45 W75124 W09839446-A2 Cancer HPEBD70 ' W75125 W09839446-A2 Cancer HLMDX11 W75126 ' W09839446-A2 Cancer HKCSR70 W75128 W09839446-A2 Cancer HETBI87 W75129 W09839446-A2 Re roductive HSSGE07 . W75130 - W09839446-A2 Cancer HCENJ40 W75132 W09$39446-A2 Cancer HSNBL85 W75135 W09839446-A2 Cancer HMAAD57 W75137 W09839446-A2 Cancer HMAAD57 W75138 W09839446-A2 Cancer HSKNY94 W75139 W09839446-A2 Cancer HOSFF45 W75140 W09839446-A2 Cancer HMJAA51 W75141 WO9839446-A2 Cancer HTEAL31 W75142 . WO9839446-A2 Cancer ' HSPAF93 W7S145 _ W09839446-A2 Di estive '~ ~

HHFGL62 W75146 W09839446-A2 Cardiovascular HTHBA79 W75148 W09839446-A2 Cancer HTEGA81 W75151 W09839446-A2 Cancer HTEGA81 W75152 W09839446-A2 Cancer HMHBN40 W75154 W09839446-A2 Cancer HLHDL62 W75155 W09839446-A2 Cancer HSXBI25 ~ W75156 WO9839446-A2 Cancer HSXCK41 W75157 ~ W09839446-A2 Cancer HTTDS54 W75159 W09839446-A2 Cancer HHFCW44 W75160 , W09839446-A2 Cancer HHSDZ57 W75161 W09839446-A2 Cancer HAICS58 W75162 W09839446-A2 Cancer HAICS58 W75163 W09839446-A2 Cancer -HSKDW02 W7SI65 W09839446-A2 Cancer HETGL41 W75166 W09839446-A2 ' Cancer HODAZ50 W75167 W09839446-A2 Re roductive HE6ES13 W75168 W09839446-A2 Cancer HSSEP68 W75169 W09839446-A2 Cancer -HRDEV41 W75171 W09839446-A2 Cancer HHFGL41 W75172 W09839446-A2 Cancer HBJEM49 W751'73 WO9839446-A2 Cancel HFTAK35 W75174 W09839446-A2 Cancer HTXCT40 W75175 W09839446-A2 Cancer HRDBF52 W75176 W09839446-A2 Cancer HI~IND45 W75177 W09839446-A2 Cancer HDTBJ30 W75178 - WO9839446-A2 Cancer HLIViDXll W75179 W09$39446-A2 Cancer HCEAB46 W75196 W09840483-A2 Cancer HCEDH81 W75197 W09840483-A2 Cancer HELDY41 W75200 W09840483-A2 Cancer ' ' HETDM20 W75201 W09840483-A2 Cancer HE2DX30 W7S202 W09840483-A2 Cancer HJBCD89 W75204 W09840483-A2 Cancer HJTAA17 W75205 W09840483-A2 Cancer HLTBS22 W75206 ' WO9840483-A2 Cancer HNFCV70 W75208 W09840483-A2 ~ Cancer HNFGF45 ' W7S210 W09840483-A2 Cancer HOVAB12 W75211 WO9840483-A2 Cancer HPMBQ91 W75212 W09840483-A2 Re roductive HRSMC69 W75214 W09840483-A2 ~ Cancer HSQFP46 W7S216 W09840483-A2 Cancer ' HTEAE62 ' W75218 W09840483-A2 Cardiovascular, - Re roductive HTEBY11 W75219 W09840483-A2 Re roductive HTEEB42 W75220 W09840483-A2 Cancer HTPBY11 W75221 W098404$3-A2 Cancer HCEDH81 W7S224 W09840483-A2 Cancer HJBCD89 W7S226 W09840483-A2 Cancer HNFCV70 W75227 W09840483-A2 Cancer HPMBQ91 W7S228 W09840483-A2 Re roductive HBMSHS4 W7S231 W098404$3-A2 Cancer HSDEGO1 W75232 WO9840483-A2 Cancer HSQFP46 W75233 W.O9840483-A2 Cancer , -HTEBY11 W75234 W098404'83-A2 Re roductive HYACC84 W75245 W09840483-A2 Cancer HETAG43 W76253 W09831818-A2 Digestive, Re roductive HOSBI96 W78128 W09856804-A1 Cancer HPDDC77 W78131 W09856804-A1 Cancer HPEBD85 W78132 W09856804-Al Digestive, Re roductive HPMGQ80 W78135 WO9856804-A1 Cancer HSDES04 W78140 W09856804-Al 'Cancer HSHBQ68 W78141 W09856804-A1 Cancer HSKB020 W78142 W09856804-A1 Cancer HSKZE52 W78145 _W09856804-A1 Cancer HWTAZ75 W78146 W09856804-A1 Cancer HSVAG05 W78148 W09856804-A1 Cancer HSVBF78 ' W78149 W09856804-A1 Cancer HSXB051 W78150 W09856804-A1 Cancer HT4AI54 W78152 W09856804-A1 Cancer HTEHU93 W78153 W09856804-A1 Re roductive HMSDG61 W78154 W09856804-A1 Cancer HTLDQ1.1 W78157 W09.8'S6804-A1. ~ Re roductive HTOBX52 W78158 W09856804-Al ' Cancer HTTCN24 W78159 W09856804-A1 Cancer HTXCS21 W78160 W09856804-A1 Cancer HBMBB80 W78164 ~ W098568Q4-A1 Digestive, ImmunelHemato oietic HSXBP68 W78166 W09856804-A1 Cancer HFFAT33 . W78167 W09856804-A1 Cancer ' HFGAG96 W78168 W09856804-A1 Cancer HETFJ05 W78169 WO9856804-A1 Cancer HE8BX01 W78170 W09856804-A1 Cancer HMSJU68 W78171 W09856804-A1 Cancer HOSCZ41 W78172 WO9856804-A1 Cancer HSQEA85 W78174 W09856804-A1 ~ Cancer HSTt1G52 W78175 W09856804-A1 Cancer HBXGP76 W78177 W09856804-A1 Immune/Hematopoietic, Neural/Sensory HE6GL64 W78178 WO9856804-A1 Cardiovascular, Immune/Hematopoietic, Mixed Fetal HESAL35 W78179 . W09856804-A1 Connective/Epithelial, Mixed Fetal HNHAL34 W78183 W098.56804-A1 Cancer HOSFF78 W78184 W09856804-A1 Cancer HPMCC16 W78188 WO9856804-A1 Cancer HOUCQ17 W78189 ~ W09856804-A1 Cancer HTOFC34 W78192 W09856804-A1 Cancer H2CBJ08 ~ W78193 W09856804-A1 Cancer HAGFT48 W78194 W09856804-A1 Cancer HCE5M29 W78195 W09856804-A1 Cancer HCFNNO1 W78197 WO9856804-A1 Digestive, Immune/Hematbpoietic, Neural/Senso HE7TF86 W78198 W09856804-A1 Cancer HHGAU81 W78200 -W09856804-Al Cancer HPTRF90 W78206 W09856804-A1 Cancer ~ ' HSRDHO1 W78207 W09856804-A1 Cancer HSAWD74 W78208 W09856804-A1 Cancer HTEJ012 W78209 W09856804-A1 Digestive, -Re reductive HTLAB43 W78210 W09856804-A1 Cancer -HTWCT03 W78211 W09856804-A1 Immune/Hemato oietic HSDES04 W78213 ~ W09856804-A1 Cancer HT3BE24 W78214 W09856804-Al _Cancer HTTCN24 W78216 W09856804-A1 Cancer HCRAZ77 W78221 W09856804-A1 Cancer HFGAG96 W78222 W09856804-A1 Cancer HADTN61 W78223 W09856804-A1 Cancer HLYBF81 W78224 W09856804-A1 Cancer HSTBE27 W78225 W09856804-A1 Cancer HMSDG61 W78263 W09856804-A1 Cancer HTOBX52 W78274 ~W09856804-A1 Cancer HFGAG96 W78295 W09856$04-A1 Cancer HCE5M29 W78316 W09856804-A1 Cancer HLCAA05 W78321 WO9856804-A1 Cancer HTLEF68 W78326 W09856804-A1 Cancer HSJAR34 W79739 W09846746-A1 Cancer HOUCQ17 W80285 EP874050-A2 Cancer HCWHZ93 W83931, W09845712-A2 IinmunelHematopoietic~
Neural/Sensory HE2FV03 W83933 W09845712-A2 Cancer HCDAG36 W83934 WO9845712-A2 Cancer .

HMQBU44 W83935 W09845712-A2 Cancer HLHCM89 W83938 W09845712-A2 Cancer .

HLHEF26 W83939 W09845712-A2 Cancer HLHE050 W83940 W09845712-A2 'Cancer HDSAE10 W83941 W09845712-A2 Cancer HSKNK73 W83942 W09845712-A2 Cancer HSSMS41 W83943 W09845712-A2 ~ ,Cancer HNGBV36 W83944 W09845712-A2 Cancer HNGDF;27 W83945 W09845712oA2 Immune/Hemato oietic HPFDU90 W83947 W09845712-A2 Cancer HRLMD77 W83948 W09845712-A2 Cancer HRLMF92 W83949 WO9845712-A2 Cancer HLHDZ58 W88535 ~ W09854963-A2 Res iratory HLMMJ13 W88536 W09854963-A2 Immune/Hematopoietic, ' Musculoskeletal, Re reductive HNFED65 W88539 W09854963-A2 Excretory, Immune/Hemato oietic HNHDX07 W88540 W09854963-A2 Immune/Hemato oietic HNHGC82 W88541 W09854963-A2 Immune/Hemato oietic HNHG009 W88542 W09854963-A2 Immune/Hemato oietic HOUBE18 W88543 W09854963-A2 Cancer HOUDL69 W88544 W09854963-A2 Cancer HPMFI71 W88545 W09854963=A2 Cancer HPTBB03 W88548 W09854963-A2 Cancer HPTWA66 W88549 W09854963-A2 Cancer HPTWC08 W88550 W09854963-A2 Cancan HRGCZ46 W88551 W09854963-A2 Cancer .

HSAVU34 W88552 ' W09854963-A2 Cancer HSDFW61 . W88553 W09854963-A2 Cancer ' HSQE084 W88556 W09854963-A2 Cancer HSXAM05 ~ W88557 W09854963-A2 Cancer HSXAS67 W88558 W09854963-A2 Neural/Sensory HTDAF28 W88559 W09854963-A2 ~ Cancer HTOAM21 W88562 W09854963-A2 Immune/Hemato oietic HETCH46 W88563 W09854963-A2 Cancer HJPCD40 W88564 W09854963-A2 Cancer HTWBY48 W88565 W09854963-A2 Immune/Hemato oietic HWTBF59 W88568 W09854963-A2 Cancer HAGFB60 W88570 W09854963-A2 NeuraUSensory HATEF'60 W88571 W09854963-A2 Cancer HCDAR68 W88573 W09854963-A2 Cancer HMDAN54 W88575 WO9854963-A2 Immune/Hematopoietic, Neural/Sensory HCEEC15 W88577 W09854963-A2 Cancer HCESF40 W88578 W098S4963-A2 Immune/-Iematopoietic, Neural/Sensory HCFMV39 W88579 ~ W09854963-A2 Cancer HCNAP62 W88581 . W09854963-A2 Cancer HCUDC07 W88583 W098S4963-A2 Immune/Hemato oietic HCWBB42 W88584 W09854963-A2 ImmunelHemato oietic HE9ND48 W88592 W09854963-A2 Mixed Fetal HEBBW11 W88593 W098S4963-A2 Cancer HEMAE80 W88595 W09$54963-A2 ~ Cardiovascular, . ~ ~ Musculoskeletal, Re reductive HFEBA88 W88596 W09854963-A2 ~ Cancer HGBAJ93 W88599 W09854963-A2 . Cancer HGBBQ69 W88600 WO9854963-A2 Cancer HHFHJ59 W88602 WO9854963-A2 ~ Cancer HHPFD63 W88606 W09854963-A2 Endocrine, -Immune/Hematopoietic, Neural/Sensory HHSEG23 W88607 W09854963-A2 Neural/Sensory HKIXL73 W88609 W09854963-A2 Cancer HKMNC43 W88610 W09854963-A2 Excrete HMEJE31 W88611 WO9854963-A2 Cardiovascular HNFAE54 W88613 W09854963-A2 Cancer HNFJH45 W88614 . W09854963-A2 Immune/Hemato oietic HNGBT31 W88615 W09854963-A2 Immune/Hemato oietic HNGIN60 W88616 WO9854963-A2 - Immune/Hematopoietic, NeurallSensory HNHDW42 W88618 W09854963-A2 ImmunelHemato oietic HNHFL57 W88619 WO9854963-A2. Immune/Hemato oietic ' HOGAR52 W88620 W09854963-A2 Cancer HOSBZ55 W88621 W09854963-A2 Cancer HOSDI92 W88622 W09854963-A2 Cancer HPBCU51 W88623 W09854963-A2 Cancer HNTSU23 W88628 W09854963-A2 Cancer HRDFB85 W88629 W09854963-A2 Cancer HSKGN81 ' . W88631 W09854963-A2~ Cancer .

HSPAH56 W88632 W09854963-A2 Cancer HDTAL71 W88633 W09854963-A2 Cancer HSXCS62 W88634 W09854963-A2 Cancer HTEKM35 W88636 W09854963-A2 NeurallSensory, Re reductive HTGEP89 W88637 W09854963-A2 Immune/Hematopoietic, Neural/Sensory HTPCN79 W88640 W09854963-A2 Digestive, NeurallSensory HTSGM54 W88641 W09854963-A2 Cancer HTWAF58 W88643 W09854963-A2 Immune/Hemato oietic HTWBY29 W88644 W09854963'-A2 Cancer HUKFC71 W88645 WO9854963-AZ Cancer HCE2V74 W88646 W09854963-A2 Cancer HFXBW82 W88652 ~ W09854963-A2 ~ Neural/Sensory HIBED17 W88654 W09854963-A2 Cancer HPMCJ92 W88657 W09854963-A2 Musculoskeletal, Re roductive HPWAZ9S W88658 WO9854963-A2 Re roductive HSUBW09 W88660 WO9854963-A2. Digestive, Immune/Hemato oietic HALSQ59 W88666 W09854963-A2 Cancer HAIBP89 W88667 WO9854963-A2 Cancer HBXGK12 W88669 W09854963-A2 Cancer HFKFJ07 W88670 W09854963-A2 Cancer HGWHZ24 W88672 W09854963-A2 Immune/Iiemato oietic HE2GT20 W88673 W09854963-A2 Cancer .

HFTCT67 W88676 WO9854963-A2 Cancer HUSIT49 W88680 W09854963-A2 Cancer HNHED86~ W88684 W09854963-A2 . Immune/Hemato oietic HNHFQ63 W88686 W09854963-A2 Immune/Hemato oietic HAGDQ47 W88692 W09854963-A2 Cancer HAICP19 W88693 W09854963-A2 Cancer HCEQA68 W88699 - WO9854963-A2 Neural/Sensory HCFNF11 W88701 W09854963-A2 Cancer HCRBL20 W88702 W09854963-A2 Cancer -HDSAP81 W88704 W09854963-A2 Cancer HE2CT29 W88.705 W09854963-A2 Mixed Fetal -HE8MG65 W88706 W09854963-A2 Cancer HE9FB42 W88707 W09854963-A2 Cancer HEMAM41 W88708 WO9854963-A2 Cancer HEMCV19 W88709 W09854963-A2 Cancer ~

HETAR54 W88711 W09854963-A2 Cancer HETBX14 W88712 W09854963-A2 Cancer HFKFI40 W88714 WO9854963-A2 Cancer HFYIiN68 W88715 W09854963-A2 Cancer HGBF079 W88716 W09854963-A2 Cancer HGLAM56 W88717 W09854963-A2 Cancer HHLBA89 W88718 W09854963-A2 Di estive HIASB53 W88723 WO9854963-A2 Cancer HJABZ65 W88724 W09854963-A2 Cancer HJPBB39 W88725 W09854963-A2 Cancer HLHSK94 ~ W88726 WO9854963-A2 Cancer HLMIW92 W88728 ~ W09854963-A2 Cancer HLTDB6S W88730. W09854963-A2 Cancer I-~NFAH08 W88733 W09854963-A2 Cancer HNGBE45 W88735 W09854963-A2 ~ Imrnune/Hematopoietic, Re roductive ~ -HNHCM59 W88737 W09854963-A2 Cancer HCDE095 W88740 ' W09854963-A2 Immune/Hematopoietic, Musculoskeletal, Re roductive ,HLMMJ13 W88741 W09854963-A2, Immune/Hematopoietic, . Musculoskeletal, Re roductive HPTWA66 W88742 WO9854963-A2 Cancer .

HSAVU34 W88743 W09854963-A2 Cancer HSQE084 W88744 WO9854963-A2 Cancer HETCH46 W88745 W09854963-A2 Cancer HWTBF59 W88746 W09854963-A2 Cancer HCESF40 W88747 W09854963-A2 Immune/Hematopoietic, Neural/Senso HOFNZ45 W88748 W09854963-A2 Re roductive HPWAN23 W88749 WO9854963-A2 Cancer HCRBL20 W88754 W09854963-A2 Cancer HE8MG65 W88755 W09854963-A2 Cancer HEMAM41 W88756 W09854963-A2 Cancer HSAVU34 W88760 W09854963-A2 Cancer HFHDN80 W88824 W09854963-A2 Cardiovascular, ~
' . , ' Digestive, ImmunelHemato oietic HHFHR32 W88830 ' WO9854963-A2 Cancer' HSKCP69 W89024 W09854963-A2 Cancer HTLCU04 W89076 ~ W09854963-A2 Cancer HSKHZ53 W92460 US5871969-A Cancer HFIZH13 W94466 W09900415-A1 Cancer HE9SF68 W97350 W09903982-A1 Cancer ' HTECE94 Y00258 W09906423-A1 Cancer HTWAH05 Y00259 W09906423-A1 Cancer HA AN31 Y00260 W09906423-A1 Cancer HAUAQ39 Y00261 W09906423-A1 Cancer HBNAU27 Y00262 W09906423-A1 Cancer HSIDD28 Y00263 ~ W09906423-Al . Cancer HCABR41 . Y00264 WO9906423-A1 Cancer HCUAQ30 Y00265 W09906423-A1 Immune/Hemato oietic.

HE2AF21 Y00266 W09906423=A1 Mixed Fetal HE2DC87 Y00267 W09906423-A1 Mixed Fetal HE2PO86 Y00269 W09906423-A1 . Cancer HFCBD73 Y00272 W09906423-A1 , Cancer HSVAJ05 Y00273 W09906423-A1 Cancer -HLHSA86 Y00274 W09906423-A1 ~ Cancer H2CAA57 Y00278 ~ W09906423-A1 Cancer HADFV30 Y00279 W09906423-A1 Cancer HAIB071 YOb280 W09906423-A1 Connective/Epithelial, Digestive, Immune/Hemato oietic HAPAT76 Y00281 W09906423-A1 Cancer HLHEB47 Y00282 W09906423-A1 Cancer .

HLHEF54 Y00283 W09906423-A1 Cancer HLMMJ78 Y00286 W09906423-A1 Immune/Hemato oietic HLQB 85 Y00287 W09906423-A1 Cancer HLQBRII Y00288 WO9906423-A1 Cancer HLWBZ56 Y00289 W09906423-A1 Cancer HMCAR20 Y00292 W09906423-A1, Cancer HMCAV55 Y00293 W09906423-A1 Immune/Hemato oietic HMEFS61 Y00294 W09906423-A1' Cardiovascular HMEJY78 Y00295 W09906423-A1 Cancer HMWHH16 Y00298 W09906423-A1 Immune/Hemato oietic HNFFC27 Y00300 W09906423-A1 ~ Immune/Hemato oietic HNFFC39 Y00301 . W09906423-A1 Immune/Hematopoietic, Re roductive HNGAM20 Y00302 , W09906423-Al Immune/Hemato oietic HNGDS53 Y00304 W09906423-A1 Immune/Hemato oietic HNGEW13 Y00307 W09906423-A1 Immune/Hemato oietic HNGEY51 ~ Y00308 W09906423-A1 Immune/Hemato oietic HNGEZ47 Y00309 W09906423-A1 Immune/Hemato oietic HNGFQ33 Y00310 W09906423-A1 Immune/Hemato oietic HNGFU38 Y00311 W09906423-A1 Immune/Hemato oietic HSKXE22 Y00313 W09906423-A1 Cancer HNHBE49 Y00314 WO9906423-A1 Immune/Hemato oietic HNHEC59 Y00315 W09906423-A1 Immune/Hemato oietic HNHEI54 ' Y00317 W09906423-A1 , Immune/Hematopoietic, Re roductive HNHER77. Y00318 W09906423-A1 ~ Immune/Hemato oietic HNHES40 Y00319 , W09906423-A1 Immune/Hemato oietic .

HNHEV43 Y00320 W09906423-A1 Immune/Hemato oietic HNHFL46 Y00321 WO9906423-A1 Immune/Hemato oietic HNHFP80 Y00322 WO9906423-A1 Immune/Hemato oietic HNHFS63 Y00323 ' W09906423-A1 Immune/Hemato oietic HNHGC56 Y00324 W09906423-A1 ImmunelHemato oietic -HRDEL61 ~ Y00328 W09906423-A1 Musculoskeletal HSAUC38 Y00329 W09906423-A1 Immune/Hemato oietic HSAUF49 Y00330 W09906423-A1 Immime/Hemato oietic HSAUK57 Y00331 W09906423-A1 Immime/Hemato oietic HSAUL82 Y00332 W09906423-A1 Immime/Hemato oietic HSAXI90 Y00333 ~ W09906423-A1 ~ Immime/Hemato oietic HSDGW43 Y00335 W09906423-A1 Neural/Sensory HSDJM31 Y00336 W09906423-A1 Digestive, Neural/Sensory ~HSDJR23 Y00337 W09906423-A1 Digestive, Neural/Senso HSDMA90 Y00338 - W09906423-A1 Digestive;
Endocrine, Neural/Senso HSVAJOS ~ Y00340 W09906423-A1 Cancer HAPAT76 Y00341 W09906423-A1 Cancer HNGAM20 Y00344 W09906423-A1 Immme/Hemato oietic HTXBK30 Y01135 W09901020-A2 Cancer H2MBB56 Y01136 W09901020-A2 Cancer HIBCW32 Y01138 W09901020-A2 Cancer HLHCI58 Y01139 W09901020-A2 Cancer HLMFG37 ' Y01140 W09901020-A2 Cancer HBCA031 Y01141 W09901020-A2 Cancer HRDDR94 Y01142 W09901020-A2 - Cancer HSIDY06 Y01143 W09901020-A2 Cancer HSKG049 Y01144 WO9901020-A2 Cancer HBXGM67 Y01146 W09901020-A2 Neural/Sensory HUFAC36 ~ Y01147 W09901020-A2 . Cancer . HAGBZ81 Y01148 W09901020-A2 Excretory, _ NeuraIlSensory HBJCK69 Y01150 W09901020-A2 Immune/Hemato oietic HCACJ81 Y01152 W09901020-A2 Cancer HBMWP47 Y01154 W09901020-A2 Cancer HIBCW32 YOI155 W09901020-A2 Cancer HCACJ81 Y01158 W09901020-A2 Cancer HCE3F11 Y01206 W09901020-A2 Digestive, Neural/Sensory HSXBV35 YOI383 WO9903990-A1 Neural/Sensory HTGAW51 Y01385 W09903990-A1 Immune/Hemato oietic HTEGM07 Y01387 WO9903990-A1 Cancer HTWFK09 Y01389 - W09903990-A1 Immune/Hemato oietic HTXDJ88 Y01390 WO9903990-A1 Immune/Hemato oietic HUSGC54 Y01391 , W09903990-A1 Cardiovascular, Immune/Hematopoietic, Neural/Sensory HWTAD49 Y01392 W09903990-Al Cancer HWTBK81 Y01393 W09903990-A1 Cancer HACBH16 Y01394 W09903990-A1 Connective/E ithelial HCUDE16 Y01395 W09903990-A1 Cancer HLWBZ73 Y01397 W09903990-A1 Cancer HNGFR75 Y01398 W09903990-A1 Irnmune/Hemato oietic HNHF029 Y01400 W09903990-A1 Immune/Hemato oietic HONAH29 Y01401 W09903990-AI Cancer HGCAB62 Y01402 W09903990-A1 Cancer HA BI01 Y01403 W09903990-A1 Cancer HDPBA48 Y01405 W09903990-A1 Immune/Hemato oietic HE6CT22 Y01406 W09903990-A1 Mixed Fetal, Re roductive HE6CT56 Y01407 W09903990-A1 Mixed Fetal, _ Neural/Sensory HE6CY88 Y01408' ~~ W09903990-A1 Mixed Fetal HE9FT63 Y01409 W09903990-A1 Cancer HE9ND43 Y01410 W09903990-Al. Digestive, Mixed Fetal, ' Neural/Sensory HERAN63 ' Y01411 . W09903990-A1 Connective/Epithelial, Re roductive HHBAG14 Y01413 W09903990-A1 Cancer HMADU73 YOI417 W09903990-A1 Cancer HMEAI74 YOI418 ~ W09903990-A1 Cancer HPMBZ15 Y01421 W09903990-A1 Cancer HROAEI6 YOI422 W09903990-A1 Cancer HSAYM40- YOI423 W09903990-A1 ~ Immune/Hemato oietic ~

HTBAB28 YOI426 W09903990-A1 Immune/Hemato oietic HAQBT52 Y01428 W09903990-A1 Cancer HBIBL04 YOI429 W09903990-A1 Cancer HBJCI95 Y01430 W09903990-A1 Cancer HBNBQ61 YOI431 ~ W09903990-A1 Re xoductive HE2ID06 ~ YOI432 W09903990-A1 Cancer HEBCM63 YOI433 - W09903990-A1 ~ Cancer HFFAK76 Y01434 WO9903990-A1 Neural/Sensory -HFRBF28 Y01435 W09903990-A1 Neural/Senso HGBHM89 Y01436 W09903990-A1 Cancer HLMBP18 Y01437 ~ W09903990-A1 Immune/Hemato oietic HAGFG63 Y01439 W09903990-A1 Cancer HODAZ55 ' Y01440 W09903990-A1 Re roductive HODDF08 Y01441 W09903990-A1 Re roductive I

HOSDK95 Y01442 W09903990-A1 Musculoskeletal HOUAR65 Y01443 W09903990-A1 Connective/E ithelial HSVAC77 _Y01444 WO9903990-A1 Cancer HRSMC69 Y01445 W09903990-A1 Cancer _ HNECF34 Y01446 WO9903990-A1 Immune/Hemato oietic HAQAI46 Y01447 W09903990-A1 Cancer HAQBI01 Y01448 W09903990-A1 Cancer HJAAT30 Y01453 W09903990-A1 Cancer HPMJI58 ~ Y01458 W09903990-A1 Cancer HNECF34 Y01477 W09903990-A1 Immune/Hemato oietic HCEIA77 Y02650 WO9902546-A1 Cancer HCFCE10 Y02651 WO9902546-A1 Immune/Hemato oietic HCHAA63 Y02653 W09902546-A1 Cancer -HCNSP40 Y02654 W09902546-A1 Cancer HDAAC10 Y02655 W09902546-A1 Cardiovascular, Digestive, Re roductive HE8CV18 Y02656 W09902546-A1 Cancer HFGAL10 Y02659 WO9902546-A1 Mixed Fetal, Neural/Sensory, Re roductive HFKEB72 Y02660 ' W09902546-A1 Excretory, Re roductive HFTCU19 ~ Y02661 W09902546-A1 Cancer HFXHN31 Y02662 WO9902546-A1 Neural/Sensory HCEND31 Y02663 W09902546-A1 ~ Cancer HJABB94 Y02664 WO9902546-A1 - Cancer HLTAI94 Y02666 W09902546-A1 Immune/Hematopoietic, Re roductive HMELR03 Y02668 W09902546-A1 Cardiovascular, Immune/Hematopoietic, Mixed Fetal HMKAH10 Y02669 ' W09902546-A1 Neural/Sensory, Re roductive HMKCW19 Y02670 W09902546-A1 Cancer HMSJW18 Y02671 W09902546-Al Cancer HMWGY01 Y02672 W09902546-Al Immune/Hemato oietic HNFID82 Y02673 W09902546-A1 Immune/Hemato oietic HNFIG36 ~ Y02674 WO9902546-A1 Immune/Hemato oietic HNGEV29 Y02675 W09902546-A1 Immune/Hemato oietic HNGJJ65 Y02677 _ W09902546-A1 Immune/Hemato oietic HSLBF69 Y02687 W09902546-A1 Immune/Hematopoietic, Musculoskeletal, Re roductive HSVBH58 Y02689 W09902546-A1 Cancer -HTADX17 Y02692 W09902546-A1 Immune/Hematopoietic, Re roductive HTDAD22 Y02693 ~ W09902546-A1 Cancer HTEDS39 Y02694 W09902546-A1 Cancer HTEHH53 Y02695 ~ W09902546-A1 Re roductive HTLDP69 Y02696 W09902546-A1 Cancer HTPCS60 Y02698 W09902546-A1 Cancer HUKBH05 Y02699 W09902546-A1 Cancer HADFK68 Y02703 ~ W09902546-A1 Connective/E ithelial HADGG19 Y02704 W09902546-A1' ConnectivelEpithelial, . Musculoskeletal HAEAV45 Y02705 ~ W09902546-Al Caxdiovascular, Re roductive HARAA15 Y02706 W09902546-A1 Neural/Sensory ~

HBAFQ54 Y02708 ~ W09902546-A1 Cancer .

HBIAS26 Y02710 WO9902546-Al Cancer HBJFU48 Y02711 W09902546-A1 Immune/Hemato oietic HBJFV28 Y02712 W09902546-A1 Immune/Hematopoietic, Mixed Fetal, Neural/Sensory HBMWBO1 Y02713 W09902546-A1 Immune/Hemato oietic HBMXN79 Y02714 WO9902546-A1 Cancer HBMXP84 Y02715 W09902546-A1 Cancer HCFMM26 Y02716 W09902546-A1 Immune/Hemato oietic HCNAV36 Y02717 WO9902546-A1 Cancer HCNSBO1 Y02718 W09902546-A1 Cancer HCRBR74 . Y02719 W09902546-A1 Cancer HCUBN59 Y02720 W09902546-A1 Immune/Hemato oietic HCUDB38 Y02721 W09902546-A1 Immune/Hemato oietic HCUFZ62 Y02722 WO9902546-A1 Immune/Hemato oietic HDPC025 Y02724 W09902546-A1 Immune/Hemato oietic HDPHI51 Y02725. W09902546-Al Immune/Hemato oietic HE9FE83 Y02727 W09902546-A1 Immune/Hematopoietic, Mixed Fetal, Musculoskeletal HFPDE69 Y02731 WO9902546-A1 Neural/Senso HGBGV89 Y02732 WO9902546-A1 Di estive HGLDE38 Y02733 W09902546-A1 , Cancer HHGDU58 Y02734 WO9902546-A1 Musculoskeletal HHTLF25 Y02735 W09902546-A1 Cancer HKAFB88 Y02737 W09902546-A1 Cancer HLHFP03 Y02738 -W09902546-A1 Res iratory HLYAF80 Y02741 WO9902546-A1 Immune/Hemato oietic HMKDD07 Y02743 W09902546-A1 . Immune/Hematopoietic, Neural/Senso HMKDS08 Y02744 W09902546-A1 Excretory, Neural/Senso HMSHM14 Y02745 W09902546-Al Immune/Hemato oietic H1VIWDC28 Y02746 ~ W09902546-A1 Cancer HNFIU96 Y02749 WO9902546-A1 ImmunelHemato oietic HNGAX58 Y02751 W09902546-A1 Immune/Hemato oietic HNHDL85 YO2754 W09902546-A1 Immune/Hemato oietic HNHFU59 Y02755 W09902546-A1 Immune/Hemato oietic HNHFW22 Y02756 W09902546-A1 Immune/Hemato oietic HODCJ90 Y02758 W09902546-A1 Cancer HPEBT80 Y02760 W09902546-A1 Re roductive HSDAG05 - Y02761 WO9902546-A1 Cancer HSDGR57 Y02762 W09902546-A1 Cancer HSDJJ82 Y02763 W0990254.6-A1 Neural/Sensory HSDZM95 Y02764 ~ W09902546-A1 Cancer HSKYU29 ~ Y02766 W09902546-A1 Cancer HSNAA55 Y02767 W09902546-A1 Cancer HSQFP66 Y02768 W09902546-A1 Excretory, - . ' Neural/Sensory HJPBB94 Y02769' W09902546-A1 Cancer HSSJN64 Y02770 WO9902546-A1 Musculoskeletal HSVAQ28 Y02771 W09902546-A1 Cancer HFTCUl9 Y02775 W09902546-A1 Cancer HGLAM53 Y02777 W09902546-A1 Immune/Hemato oietic, Neural/Sensory, Re roductive HMKCW 19 Y02778 W09902546-A1 Cancer HMWGY01 Y02779 W09902546-A1 Immune/Hemato oietic HSOAH66 Y02782 W09902546-A1 Di estive HITKEX85 Y02785 WO9902546-A1 Musculoskeletal, -Re roductive HSIDI15 Y02975 - ~ W09902546-A1 Digestive, Immune/Hemato oietic HITKEJ46 Y03850 W09909198-A1 Digestive, Re roductive HPASD50 Y04120 W09909161-Al Cancer HPASD50 Y04121 W09909161-A1 Cancer .

HSDIT06 Y04295 W09910363-A1 Neural/Sensory, - Re roductive HSKEI54 Y04297 W09910363-A1 Cancer HTNAG39 Y04300 W09910363-A1 Cancer HTODL90 Y04301 WO9910363-A1 ImmunelHemato oietic HTWDC20 Y04302 W09910363-A1 Immune/Hemato oietic HUFAT34 Y04303 W09910363-A1 Cancer HAICJ23 Y04305- ~ W09910363-A1 Cancer HAPOF67 Y04306 . W09910363-A1 Digestive, Excretory, Musculoskeletal HE8DG53 Y04308 W09910363-A1 Cancer HFSAY85 Y04309 WO9910363-A1 Cancer HHEDD41 Y04310 W09910363-A1 Cancer HKCS046 Y04311 WO9910363-A1 Cancer HKGAV60 Y04312 W09910363-A1 Cancer HKGDJ66 ' Y04314 W09910363-A1 Cancer HMCDK27 Y04315 W09910363-A1 Cancer HMCDX48 Y04316 W09910363-A1 ~ Cancer HMIAS24 ~Y04317 W09910363-A1 - Immune/Hematopoietic, Neural/Sensory HNFEG11 Y04318 W09910363-A1 Immune/Hemato oietic HNGEP09 Y04319 - W09910363-A1 ~ Immune/Hemato oietic HTXKK52 Y04320 W09910363-A1 ' Immune/Hemato oietic ~

HNGJP90 Y04321 . W09910363-A1 Immune/.Hemato oietic HFVTF40 - Y06461 - W09931116-A1 Cancer HFCCQ50 Y06462 ~ W09931116-A1 Cancer HDPIE88 Y06511 W09936565-A1 Cancer HCWHN10 Y07746 WO9909155-A1 Immune/Hemato oietic HDTAE40 Y07748 ' W09909155-Al Digestive, Immune/Hemato oietic HE8DY08 Y07751 W09909155-Al Cancer HE9ND27 Y07753 W09909155-A1 ~ Cancer HCE3G69 Y07754 W09909155-A1 Cancer HEAAX57 Y07755 W09909155-A1 Re roductive HEMGD15 Y07759 W09909155-A1 Cancer HEQBR95 Y07760 W09909155-A1 Cancer HFKGE44 Y07764 W09909155-A1 Cancer -HFPCY39 Y07765 WO9909155-A1 Cancer HFXDX75 Y07768 W09909155-A1 Neural/Sensory HFXJC53 Y07770 W09909155-Al Neural/Sensory, Reproductive, .
- Res iratory HFXJW48 Y07771 W09909155-A1 ~ Cancer HGBGO11 Y07772 W09909155-A1 Cancer HGBHM10 Y07773 W09909155-A1 Cancer HSWAY58 Y07776 ~ W09909155-A1 Cancer HTEIM65 Y07779 . W09909155-Al Immune/Hematopoietic, Re roductive HTHBX95 ' Y07780 ' W09909155-Al Cancer HTLDQ56 Y07781 ~ W09909155-A1 Re roductive HTOFU06 Y07782 W09909155-A1 Immune/Hematopoietic, Musculoskeletal HTWEE31 Y07785 W09909155-A1 Immune/Hemato oietic HUSA056 Y07789 WO9909155-A1 Cancer HUSIJ08 . Y07790 WO9909155-A1 Cancer HAGBD57 Y07791 W09909155-A1 Excretory, ' ' Neural/Sensory HBAFA04 Y07793 W09909155-A1 Cancer HBJES16 Y07794 W09909155-A1 Cancer HCEFZ05 Y07796 W09909155-A1 Mixed Fetal, Neuxal/Senso HCFMX95 Y07797 W09909'155-A1 Immune/Hemato oietic HLYHA71 Y07798 ~ W09909155-A1 Cancer HEBAL06 Y07800 W09909155-A1 Neural/Sensory HEIAB33 Y07801 W09909155-A1 Cancer HEPBC02 Y07802 W09909155-A1 Cancer HFTBY96 Y07803 W09909155-A1 Imrrzune/Hematopoietic, Neural/Sensory, Re roductive HKMMM61 Y07804 W09909155-A1 Cancer HLQB 38 Y07806 W09909155-A1 Cancer HMKCP66 Y07807. W09909155-A1 NeuiallSenso HWTAL40 Y07808 W09909155-Al Cancer 'HNHDR03 Y07809 W09909155-Al Immune/Hemato oietic HNHFH41 Y07810 W09909155-A1 Immune/Hemato oietic HNHFI81 Y07811 WO9909155-A1 ImmunelHemato oietic HOSF 28 - Y07812 ' WO9909155-A1 Cancer HPRAL78 Y07813 W09909155-A1 Cancer HEAAA85 Y07814 W09909155-Al Cancer HDTAR09 Y07816 W09909155-A1 Cancer HLYHA71 ~ Y07843 W09909155-A1 Cancer HCWCH14 Y07852 W09918208-A1 Immune/Hemato oietic HE9MI43 Y07855 W09918208-A1. Cancer HE2PI29 Y07859 WO9918208-A1 Cancer HLHDP83 Y07862 W09918208-A1 Cancer HSIAS17 Y07863 W09918208-A1 ~ Cancer HOSDG32 Y07866 W09918208-A1 Cancer HMUBU59 Y07867 W0991~8208-A1 Cancer HWTCE21 Y07868 W09918208-A1 Cancer HFIUM15 Y07869 W09918208-A1 Cancer HTLAF13 Y07872 WO9918208-A1 Re roductive HTLFI93 Y07873 W09918208-Al , Immune/Hematopoietic, Reproductive, Res iratory HBXGI20 Y07874 W09918208-Al Cancer HTPBH21 Y07875 . W09918208-A1 Connective/Epithelial, Digestive, Re roductive HSQAB87 Y07876. W09918208-A1 Cancer HTEDJ94 Y07877 W09918208-A1 Cancer HKMLM11 Y07878 W09918208-A1 ' Cancer HNEAC05 Y07879 W09918208-A1 Immune/Hemato oietic HETEW02 Y07880 W09918208-A1 Cancer HLMCA59 Y07882 W09918208-A1 Immune/Hemato oietic HOAAC90 Y07883 W099I8208-AI MuscuIoskeIetal HMEJQ68 Y07884 'W09918208-A1 Cancer HRTAE58 Y07888 W09918208-A1 ~ Digestive, Re roductive HSKNB54 Y07889 W09918208-A1 Cancer HSKNT34 Y07890 W09918208-A1 Cancer HTEDY42 Y07891 W09918208-A1 Re roductive HTLAA40 Y07892 W09918208-A1 Re roductive HTNB091 Y07893 - W09918208-A1 Cancer H6BSD90 Y07894 WO9918208-A1 Cancer HBJBQ35 Y07895 W09918208-A1 Immune/Hemato oietic .

HCE1Q89 Y07896 W09918208-A1 Immune/Hematopoietic, Neural/Sensory HCNSB61 Y07897 , W09918208-A1 Digestive, I mmune/Hemato oietic HCDB020 Y07898 W09918208-A1 , Musculoskeletal, ' .
Res iratory HBNAW17 Y07899 WO9918208-A1 Re roductive HEAAH81 Y07902 W09918208-A1. Cancer HEBAE88 Y07903 . W09918208-A1 Immune/Hematopoietic, N eural/Sensory HFXGV31 Y07904 W09918208-A1 Neural/Senso HEAAJ57 Y07905 WO9918208-Al . Immune/Hematopoietic, Re roductive HCFMV71 Y07906 W09918208-A1 Immune/Hemato oietic HGBDL30 Y07910 W09918208-A1 Di estive HFKEN81 Y07911 W09918208-A1 Excretory, Neural/Sensory .

HFPCX36 Y07912 W09918208-A1 Neural/Sensory HFRAN90 Y07913 WO9918208-A1 Neural/Sensory ~

HHGB091 Y07915 W09918208-A1 Digestive, Re roductive HERAN54 Y07917 W09918208-A1 Corznective/E ithelial HFXDE67 ~ Y07918. W09918208-A1 Neural/Sensory HFFAD59 Y07921 W09918208-A1 ' Netual/Sensory HMDAE65 Y07923 W09918208-A1 Neural/Sensory HMEGF92 Y07925 W09918208-A1 Cardiovascular HNGIK36 Y07926 W09918208-A1 Immune/Iiemato oietic HMEJJ27 Y07927 W09918208-A1 Cardiovascular HNHCY64 Y07928. W09918208-A1 Immune/Hemato oietic HNHCY94 Y07929 W09918208-A1 Immune/Hematopoietic HNEBN76 Y07930 W09918208-A1 Immune/Hematopoietic, Reproductive, .
Res iratory HMEFT54 Y07931 W099I8208-A1 Cardiovascular, Musculoskeletal', Re roductive HLQBE09 Y07932 ' W09918208-A1 Di estive~

HMWBC11 Y07933 W09918208-A1 Immtme/Hemato oietic HNGJR78 Y07934 W09918208-A1 Irnmune/Hemato oietic HNGDP26 Y07935 W09918208-Al Immune/Hemato oietic HNGJH63 Y07936 W09918208-A1 Immune/Hemato oietic HMDAL04 Y07937 W09918208-A1 Neural/Sensory ' HMWHX28 Y07938 W09918208-A1 Immune/Hemato oietic HNHGB09 Y07942 W09918208-A1 Immune/Hematopoietic HNHHA15 Y07943 WO9918208-A1 Immune/Hemato oietic HHGDCO1 Y07944 W09918208-Al Cancer HMWGU74 Y07945 WO9918208-A1 , Immu~e/Hemato oietic HNGCF72 Y07946 W09918208-A1 Immune/Hemato oietic HOACB38 Y07947 W09918208-A1 ~ Musculoskeletal HLMFD11 Y07950 W09918208-A1 Immune/Hemato oietic HLYBA22 Y07952 W09918208-A1 ImmunelHemato oietic HCWCH14 Y07953 W09918208-A1 Immune/Hemato oietic HBMWF85 Y10797 W09907891-A1 . Immune/Hemato oietic ~

HCDEJ37 Y10798 W09907891-A1 Immune/Hematopoietic, Musculoskeletal HCE3L18 ~ Y10799 WO9907891-A1 Neural/Sensory HCYBI42 Y10800 WO9907891-A1 Cancer HE6FB81 Y10801 W09907891-Al Mixed Fetal 'HFAMB72 Y10802 W09907891-A1 Cancer HFCDW42 Y10803 W09907891-A1 Cancer -HFPAE26 Y10804 W09907891-A1 Neural/Senso HFXJM91 Y10805 ' WO9907891-A1 Cancer HJABX32 Y10807 WO9907891-A1 . Cancer HJMBW30 Y10808 W09907891-A1 Cancer HSVAT02 Y10810 WO9907891-A1 Cancer HSVBM90 Y10811 W09907891-A1 Cancer HSYBL17 Y10812 W09907891-A1 Cancer HTEBI28 Y10813 ~ W09907891-A1 Re roductive HTPDS14 Y10814 W09907891-A1 Cancer HTSGG36 Y10815 WO9907891-A1 Cancer HODCJ27 Y10816 W09907891-A1 Cancer HTXDB52 Y10819 W09907891-A1 Immune/Hematopoietic, Musculoskeletal HTXDP60 Y10820 W09907891-A1 Cancer HTXEB42 Y10821 W09907891-A1 Cancer HBAFZ29 Y10824 W09907891-A1 Cancer HBAHA77 Y10826 W09907891-A1 Cancer HBJEW84 Y10827 W09907891-A1 Immune/Hemato oietic HBJFE12 Y10828 ~ W09907891-A1 - Immune/Hemato oietic HCFBM53 Y10830 WO9907891-A1 Cancer HCFBQ8.1 Y10831. W09907891-A1 Immme/Hemato oietic HCFCI07 Y10832 W09907891-A1 ImmLmelHemato oietic HCFDD76 Y10833 W09907891-A1 Cancer -HCFMJ81 Y10834 W09907891-A1 Cancer HCFOG45 Y10835 W09907891-A1 Cancer HCUBN71 , Y10836 W09907891-A1 Immune/Hematopoietic, Re roductive HHEMA75 Y10837 WO9907891-Al Cancer HHPTJ65 Y10839 W0990789I-A1 Cardiovascular, , Musculoskeletal, Neural/Sensory HHSDRll Y10840 W09907891-A1 Neural/Sensory HLJDQ62 Y10842 W09907891-A1 Cancer HI~GBS49 Y10843 W09907891-A1 Re roductive HKISA27 Y10844 ~ W09907891-A1 Cancer HKIXE06 YI0845 W09907891-A1 Cancer HKMMV77 Y10846 W09907891-A1 Excretory, Re reductive HLYAB80 Y10850 W09907891-A1 Cancer HLYAG19 Y1.0851 ' W09907891-A1 Digestive, Immune/Heniato oietic HLYBY48 Y10852 W09907891-A1 Immune/Hemato oietic HMUAW28 Y10853. W09907891-A1 Immune/Hematopoietic, Musculoskeletal HMWHC36 Y10854 W09907891-AI Cancer HNFIS82 Y10856 _ W09907891-A1 Digestive, Immun~/Hematopoietic, v Re reductive HNGB016 Y10859 W09907891-A1 Immune/Hemato oietic HNGB 90 Y10860 ' WO9907891-A1 ,.Cancer HNGBV72 Y10861 W09907891-AI' Immune/Hemato oietic HNGEG08 Y10863 W09907891-A1 Irnmune/Hemato oietic HNGFI02 YI0864 W0990789I-A1 ' Imniune/Hemato oietic HNGGF85 Y10865. W09907891-A1 Immune/Hemato oietic HNGHM75 Y10866 W09907891-AI Immune/Hemato oietic HNGIN84 Y10867 WO9907.891-A1 Digestive, Endocrine, Immune/Hemato oietic HNGJI308 Y10869 W09907891-A1 Immune/Hemato oietic HNHAHO1 ~ Y10870 W09907891-AI Immune/Hemato oietic HNHET53 Y10871 W09907891-A1 Immune/Hemato oietic HOABP2I Y10872 WO9907891-AI Cancer HODAA12 Y10873 W09907891-A1 Immune/Hematopoietic, Neural/Sensory, Re reductive HFKDH44 Y10874 W09907891-A1 Cancer HOVAP06 Y10875 W09907891-A1 Re reductive HPEAE34, Y10876 W09907891-AI Re reductive HPTR086 Y10877 W09907891-A1 Cancer HSAXJ60 Y10878 W09907891~A1 hnmune/Hemato oietic HSAXM32 Y10879 W09907891-A1 Cancer HSKND71 Y10882 _ W09907891-A1 Mixed Fetal,.
Musculoskeletal, Neural/Sensory HSOAC84 Y10883 W09907891-A1 Di estive HFKCF'34 Y10884 ' W09907891-AI Cancer HSAA030 Y12916 WO9911293-A1 Cancer HSQBL21 Y12917 W09911293-A1 Cancer HTEFU41 Y12919 . W09911293-A1 Immune/Hematopoietic, Re reductive HDPSP54 Y12920 W09911293-A1 Cancer HELFQ07 Y12921 . W09911293-A1 Cancer HBSAJ16 Y12923 W09911293-A1 Connective/Epithelial, Musculoskeletal, Re reductive HCEOC4M Y12924 W09911293-AI Cancer HCUE060 Y12926 W09911293-A1 Immune/Hemato oietic HDHEB60 Y12927 W09911293-A1. Cancer HE6AJ31 ~ Y12928 W09911293-A1 Mixed Fetal HFCED59 Y12929 W09911293-A1 Immune/Hemato oietic, 79' Neural/Sensory HFXKJ03 Y12931 W09911293-A1 Cardiovascular, Immune/Hematopoietic, Neural/Sensory HHFDG44 Y12932 W09911293-A1 Cardiovascular, Endocrine, Immune/Hemato oietic HJACG02 Y12933 W09911293-A1 Digestive, Immune/Hemato oietic -HKGAJ54 Y12934 W09911293-AI Cancer HKMAB92 Y12935 ~ W09911293-A1 Cancer HLMFC54 . Y12937 WO9911293-Al Immune/Hemato oietic HLWBZ21 Y12939 W09911293-A1 ImmunelHematopoietic, Re reductive HMJAX71 Y12940 W09911293-A1 NeuraIlSenso HNECU95 Y12941 W09911293-A1 Connective/Epithelial, Immune/Hemato oietic HNFCK41 Y12942 W09911293-A1 Cancer HNFHD08' Y12943 W09911293-A1 Cancer HNGEW65 Y12944 - W09911293-A1 Endocrine, Immune/Hemato oietic HNHEN68 Y12946 W09911293-A1 . Immune/Heinato oietic HNHFGOS Y12947 W09911293-A1 Immune/Hemato oietic HODBF19 Y12948 W09911293-A1 Cancer HOEBK34 Y12949 W09911293-A1 Digestive, Musculoskeletal HPBCC51 Y12950 W09911293-Al' Cancer HRGDC48 Y12951 W0991129_3-A1 Immune/Hematopoietic, Musculoskeletal HSDJB13 Y12952 W09911293-A1 Cancer HTEHR24 Y12953 W09911293-A1 Cancer HAR.AO51 Y12957 W09911293-A1 Cancer HATAA15 Y1295$ W09911293-A1 Cancer HATCK44 Y12959 W09911293-Al Cancer HBIAE26 Y12960 W09911293-A1 ' Neural/Sensory;
Re reductive HBMXG32 Y12961 W09911293-A1 Immune/Hemato oietic HCDAT43 Y12963 W09911293-A1 Cancer HSLJB89 Y12964 WO99M 1293-A1 Cancer HBAFC77 Y12966 W099I1293-AI ' Cancer HSAA030 Y12969 W09911293-Al Cancer HFCET92 Y14078 ' . W09921575-Al Cancer HSIDU19 Y14411 W09919339-Al Di estive HPRSB76 Y14412 W09919339-A1 Re reductive HTEIL66 Y14413 W09919339-A1 Re reductive HSABG21 Y14415 W09919339-A1 Cancer HSAXB32 Y14416 W09919339-A1 ' Immune/Hemato oietic HPEAD48 Y14417 W09919339-A1 Re reductive HPVAB94 Y14418 W09919339-A1 Re reductive HSAXB81 Y14419 W09919339-A1 ~ Immune/Hemato oietic HSLCU73 Y14421 W09919339-A1 Musculoskeletal HTEIP36 Y14423 ~ W09919339-A1 Re reductive HYBAY77 Y14424 W09919339-A1 Immune/Hematopoietic, Musculoskeletal, ' Re reductive . ' HROAE78 ~ Y14425 9919339-A1 Digestive HSAVP17 Y14426 W09919339-A1 Immune/Hemato oietic HSIEA14 Y14427 W09919339-A1 Di estive HPEAD79 Y14430 W09919339-A1 Re reductive HRDED19 Y14431 W09919339-A1 Musculoskeletal HSAYS89 Y14432 WO9919339-A1 Imrinne/Hemato oietic HTODK73 Y14433 W09919339-A1 Cancer HSVAM10 Y14434 W09919339-A1 Cancer HSPAA60 Y14439 WO9919339-Al Di estive HFAEF57 Y14440 W09919339-A1 NeuravSensory HEGAH43 Y14441 WO9919339-A1 Digestive, Re reductive HNGBX63 Y14443 W09919339-A1 . Immune/Hemato oietic HE2AG50 Y14444. W09919339-A1 Digestive, ' Mixed Fetal, Neural/Sensory HCUIN80 Y14445 WO9919339-A1 Immune/Hemato oietic HADCL29 Y14446 WO9919339-A1 ConnectivelE ithelial HAPPS89 Y14447 W09919339-A1 Cancer HFGAH44 Y14448 WO9919339-A1 ' Cancer HFIHZ96 Y14449 W09919339-A1 Musculoskeletal HFIUR10 ~ Y14450 ' _ WO9919339-A1 Digestive, Immune/Hematopoietic, Musculoskeletal HLDNA86 Y14451 W09919339-A1 Cancer HCUI020 Y14453 W09919339-A1 Immune/Hemato oietic HLTEF12 Y14454 W09919339-A1 Cancer HCFBJ91 Y14455 W09919339-A1 Immune/Hemato oietic HHFHP90 Y14456 W09919339-A1 Cardiovascular .

HLYCQ48 Y14457 W09919339-A1 Immune/Hemato oietic HHLAB07 Y14458 W09919339-A1 Digestive, ImmunelHemato oietic HFOXE30 Y14459 ~W09919339-A1 Musculoskeletal HBJEL68 . Y14460 W09919339-A1 Immune/Hematopoietic;
Neural/Sensory HFILTR35 Y14462 ~W09919339-A1 Musculoskeletal HFIZF58 Y16587 ~ US5916769-A Cancer HNGDJ72 Y19443 ~ W09922243-A1 Immune/Hemato oietic ' HNGE029 Y19444 WO9922243-A1 Immune/Hemato oietic HNHDL95 Y19445 W09922243-A1 Immune/Hemato oietic HAGDS35 Y19446 W09922243-A1~ Cancer HNGEQ48 Y19447 WO9922243-A1 Immune/Hemato oietic HNGDG40 Y19448 W09922243-A1 ImmunelHemato oietic HNGEN81 Y19449 ' W09922243-A1 Imniune/Hemato oietic I-I2MAC30 Y19450 W09922243-A1 Cancer ..

HNHFB16 Y19451 W09922243-A1 ImmunelHemato oietic HPFCL43 Y19452 W09922243-A1 Cancer HSATR82 Y19453 W09922243-A1 Immune/Hemato oietic HNHIC21 Y19455 W09922243-A1 Immune/Hemato oietic HOVCA92 Y19456 W09922243-AI Immune/Hematopoietic;
Re reductive HSDIL30 Y19458 W09922243-A1 NeurallSensory HATDB65 Y19459 W09922243-Al Endocrine, Reproductive, Res iratory HTTEA24 ~ Y19461 W09922243-A1 Digestive, Reproductive HAGDS20 Y19462 W09922243-A1 Neural/Sensory, Re reductive HSDJM30 Y19463 WO9922243-A1 Digestive, .
Neural/Sensory HNHEE88 Y19464 W09922243-A1 Immune/Hemato oietic HSLFD55 Y19465 W09922243-A1 Musculoskeletal HSAXJ29 Y19466 W09922243-A1 Immune/Hemato oietic HSFAM39 Y19467 W09922243-Al Re reductive HADDZ85 Y19469 W09922243-A1 Connective/Epithelial, Immune/Hematopoietic, .
Neural/Sensory HDPCM26 Y19470 W09922243-A1 Cancer HSZAA13 Y19471 W09922243-A1 Cancer HDTBP04 Y19472 W09922243-A1 Digestive, Immune/Hemato oietic HHGCQ54 Y19473 W09922243-A1 Cancer HSNAB12 Y19474 W09922243-A1 Cardiovascular HBJID05 Y19475 WO9922243-A1 Immune/Hemato oietic HSNBM49 Y19476 W09922243-A1 . Cancer HJMBF77 Y19477 W09922243-A1 Cancer HJMBM38 Y19478 W09922243-A1 Cancer HHGCL33 Y19479 W09922243-A1 Cancer HCEWE20 Y19480 W09922243-A1 Endocrine, Immune/Hematopoietic, Neural/Sensory HCUHL13 Y19481 W09922243-A1 Immune/Hemato oietic HBJH068 Y19482 W09922243-A1 ' Immune/Hemato oietic HCWDV84 Y19483 W09922243-A1 ' ' Immune/Hemato oietic HBXFC78 Y19484 W09922243-A1 Cancer HE2FI45 ~ Y19485 W09922243-A1 Cancer HEOMG13 Y19486 WO9922243-A1 Digestive, hrimune/Hematopoietic, Re reductive HFAMH77 Y19487 W09922243-A1 Cancer HSVCF20 Y19488 W09922243-A1 Cancer HISAG02 Y19489 W09922243-A1 Cancer HCDAF84 Y19490 W09922243-A1 Musculoskeletal HHAAC17 Y19491 W09922243-A1 Digestive, Musculoskeletal, .
Neural/Sensory HEQAG39 . Y19493 W09922243-A1 ~ Cancer HKACH44 Y19494 W09922243-A1 Cancer HBNBG49 Y19495 ~ W09922243-A1 Cancer HE2EN04 Y19496 W09922243-A1 Cancer HSVAA10 Y19497 ~ W09922243-A1 Cardiovascular HFPBA88 Y19498 WO9922243-A1 ' Cancer -HHEBW54 Y19500 ~ W09922243-A~1 Cancer ~

HFEBH21 Y19501 W09922243-A1 Connective/Epithelial, ' Re reductive HFTDZ36 Y19502 W09922243-A1 Cancer HGLAW96 Y19503 - W09922243-Al Immune/Hematopoietic.,.
- Neural/Sensory HKAFK41 Y19504 W09922243-A1 Cancer HOSEG51 Y19505 W09922243-A1 , Endocrine, Immune/Hematopoietic, Musculoskeletal HTEJT39 Y19506 W09922243-A1 Neural/Sensory, Re roductive ~

HPTRH45 Y19507 WO9922243-A1 Cancer HDHMA72 Y19508 W09922243-A1 Cancer HNTBL27 Y19509 W09922243-A1 Cancer '. HCFMX35 Y19510 W09922243-AI Immune/Hemato oietic HMUAO2I YI95I2 W09922243-AI- Cancer HCHAR28 Y19513 W09922243-A1 Cancer HLYDU25 Y19514 W09922243-A1 Immune/Hemato oietic HOEJH89 - Y19515 W09922243-A1 Cancer HPFDG48 Y19516 W09922243-A1 Immune/Hematopoietic, _ r .
Re roductive HWTBM18 Y19517 W09922243-A1 Immune/Hematopoietic, Musculoskeletal HCFOM18 Y19518 W09922243-A1 Immune/Hemato oietic HMWF002 Y19519 W09922243-A1 Immune/Hemato oietic HNGAV42 Y19520 W09922243-A1 Itnmune/Hemato oietic HSDSE75 Y19522 W09922243-A1 Musculoskeletal, Neural/Sensory, Res iratory HLMFD85.~ Y19523 W09922243-A1 Immune/Hemato oietic HLQCJ74 Y19524 ~ W09922243-A1 Digestive, Immune/Hemato oietic HTEFU65 ~ Y19526 W09922243-A1 Excretory, Immune/Hematopoietic, Re roductive HLYBF22 Y19527 W09922243-A1 ' Immune/Hematopoietic, Mixed Fetal HMDAP35 Y19528 WO9922243-A1 NeurallSensory .

HWBCN75 Y19530 WO9922243-A1 . Cancer HROAH06 Y19531 W09922243-A1 Digestive, Immune/Hemato oietic HSAXA83 Y19532 W09922243-A1 Immune/Hemato oietic HSDJE10 Y19533 W09922243-A1 Cancer HBAMA40 Y19534 W09922243-A1 Excreto HBAMB34 ' Y19535 ' W09922243-A1 Excretory, Re roductive HCWKC15 Y19536 W09922243-A1 - Immune/Hemato oietic HDTDM65 Y19537 WO9922243-A1 Cancer HMMBF71 Y19538 W09922243-A1 Immune/Hemato oietic HPBDH41 Y19539 W09922243-A1 Immune/Hematopoietic, Musculoskeletal HPBEN24 ~ Y19540 W09922243-A1 Cancer HCUIM65 Y19541 W09922243-A1 ~ Cancer HKNAA95 Y19542 W09922243-A1 . Digestive, , . Excretory, - Immune/Hemato oietic HKIYH57 Y19543 W09922243-A1 ~ Cancer HBJMG49 Y19546 W09922243-A1. Immune/Hemato oietic H6EDC19 Y19547 W09922243-A1 Cancer ~

HSKHZ81 Y19548 22243-A1 ' Cancer HBJFX78 Y19549 W09922243-A1 Cancer HEMFS60 Y19550 W09922243-Al Cancer HKACB56 Y19551 W09922243-A1 Connective/E ithelial HTXJX80 Y19552 . W09922243-A1 Digestive, Immune/Hemato oietic HAFBD61 Y19553 W09922243-A1 Cancer HBJJU28 Y19554 W09922243-A1 Immune/Hematopoietic, Neural/Sensory HNHEI47 Y19555 W09922243-A1 Immune/Hemato oietic HPMFY74 Y19556 W09922243-A1 ' Re reductive HLYAP91 ' Y19559 . W09922243-A1 Digestive, ' - Immune/Hematopoietic, Re reductive HSKNB56 Y19560 W09922243-A1 Cancer HHGCW91 Y19561 W09922243-A1 Digestive, Immune/Hemato oietic HKIYE96 Y19562 W09922243-A1 Excretory HLYAN59 Y19563 ~ W09922243-A1 Immune/Hemato oietic HNEEE24 Y19564 . W09922243-A1 Immune/Hemato oietic HAPRK85 Y19565 W09922243-A1 Cancer HLTEJ06 Y19566 W09922243-A1 Immune/Hemato oietic HMEKT48 Y19567 W09922243-A1 Cancer HNGHR74 Y19568 WO9922243-A1 Immune/Hemato oietic HNHED17 Y19569 ' W09922243-A1 Immune/Hemato oietic HNHEP59 . Y19570 W09922243-A1 Immune/Hemato oietic HNHFJ25 Y19571 W09922243-A1 Immune/Hemato oietic HCPAA69 Y19572 W09922243-A1 Neural/Senso HEAAR07 . Y19573 W09922243-A1 Re reductive HHGDW43 Y19574 W09922243-A1 Cancer HHSDX28 Y19575- W09922243-A1 Immune/Hematopoietic, Neural/Sensory HE8ER60 Y19576 W09922243-A1 Cancer HMEJQ66 Y19577 W09922243-A1 Cardiovascular HRDAD66 Y19578 W09922243-A1 Cancer HCMST14 Y19579 W09922243-A1 Cancer HCEBA03 Y19580 W09922243-A1 Neural/Sensory HJAAM10 Y19582 W09922243-A1 Cancer -HOHCC74 Y19584 W09922243-A1 Cancer HPMFY57 Y19585 W09922243-A1 Immune/Hematopoietic, -Neural/Sensory, Re reductive HFXDN63 ~ Y19586 W09922243-A1 Neural/Sensory HADCL76 Y19587 . - W09922243-A1 Cancer.

HMMAS76 Y19588 W09922243-A1 ' Endocrine, Immune/Hemato oietic -HMKCG09 . Y19589 WO9922243-Al Digestive, ~ .
Endocrine, ' NeurallSensory HFPBA88 Y19590 W09922243-A1 Cancer HMIAH29 Y19596 W09922243-A1 Cancer -HEMFS60 Y19757 W09922243-A1 Cancer HDPVA94 Y25708 ' W09938882-A1 - Cancer HDPNE25 Y25709 W09938882-A1 Cancer HASCG84 Y25711 ~ W09938881-A1 Cancer HDPCY37 Y25712 . W09938881-Al Cancer HHEBB10 Y25713 W09938881-A1 Cancer HNGJA38 Y25714 W09938881-A1 Immune/Hemato oietic HHENL07 Y25715 W09938881-A1 .Immune/Hemato oietic . HKADQ91 Y25716 ' W09938881-A1 Cancer ' HPMCV18 Y25717 W09938881-A1 ' Musculoskeletal, ' Re reductive HKGAK22 Y25718 W09938881-A1 Endocrine, Excretory, .
Neural/Sensory HTEHU31 Y25719 WO9938881-A1 Cancer HFXAM76 Y25720 W09938881-A1 Cancer HFXDZ79 Y25721 ~-W09938881-A1 Neural/Sensory HOHBC68 Y25722 W09938881-A1 Cancer HSVAM81 Y25723 W09938881-A1 Cancer HTXDG40 Y25724 W09938881-A1 Immune/Hemato oietic HE2FC81 Y25725 WO9938881-A1 Mixed Fetal HJACE05 Y25726 W0993888I-A1 Cancer HADCW30 Y25727 W09938881-A1 Connective/E ithelial HBMDK25 Y25728 W09938881-A1 Immune/Hemato oietic HFXKK25 Y25729 W09938881-A1 Cancer HHEM080 Y25730 W09938881-Al Immune/Hemato oietic HNGEJ53 Y25731 W09938881-A1 Immune/Hemato oietic HTBAA70 Y25732 W09938881-A1 Connective/Epithelial, TinmunelHematopoietic, Re roductive HSAYB43 ~ Y25734 W09938881-Al Immune/Hemato oiefic HSLDS32 Y25735 W09938881-A1 Cancer HMIAV27 Y25736 W09938881-A1 Cancer HSQEH50 ~ Y25737 WO9938881-A1 Cancer HKMMU22 Y25738 W09938881-A1 Excretory HKMMD13 Y25739 W09938881-A1 Excretory HLDNK64 Y25740 WO9938881-A1 Cancer HRDESO1 Y25741 W09938881-A1 Musculoskeletal HDTDZ50 Y25742 W09938881-A1 Cancer HETAB45 Y25743 W09938881-A1 Cancer HFPBD47 Y25744 W09938881-A1 Cancer HJMBI18 Y25745 W09938881-A1 Cancer HFXHK73 Y25746 WO9938881-A1 Neural/Senso HJMBT65 Y25747 W09938881-A1 Cancer HWHGZ26 Y25748 W09938881-A1 Cancer HADFY83 Y25749 W09938881-A1 Cancer HBMTV78 Y25750 W09938881-A1 Digestive, ' Immune/Hemato oietic HTXJM03 Y25751 W09938881-A1 Cancer HUSAT94~ Y25752 W09938881-A1 Cancer HCUEN88 Y25753 W09938881-A1 Immune/Hemato oietic HCE3F70 Y25754 W09938881-A1 Cancer HCE5F43 Y25755 WO9938881-A1' Cancer HL2AC08 Y25756 WO9938881-A1 Cancer HCNSM70 Y25757 . W09938881-A1 Cancer .

HDPTQ73 Y25758 ~ W09938881-A1 Cancer HTODG13 Y25759 W09938881-A1 Digestive, Immune/Hematopoietic, , Re roductive HE8DR25 Y25760 W09938881-A1 Excretory, _ _ Mixed Fetal, Neural/Sensory HSAA065 Y25761 W09938881-A1 Cancer HKGDE09 Y25762 W09938881-A1 Cancer HMVBS69 Y25763 W09938881-A1 Cardiovascular, Immune/Hemato oietic HSIDU42 Y25764 W09938881-A.1 Cancer HSKCT36 Y25765 W09938881-A1 Cancer HSXBU59 Y25766 ' W09938881-AI . Immune/Hematopoietic, Neural/Sensory HSSGG82 Y25767 W09938881-A1 Cancer HE8CH92 Y25768 W09938881-A1 Cancer HYBARO1 Y25769 W09938881-A1 Musculoskeletal HTLEF73 Y25770 W0993888I-A1 Cancer HEOMW84 Y25771 ~ W09938881-A1 Connective/Epithelial, Immune/Hemato oietic HKGAR66 Y25772 W09938881-A1 Cancer HHPDX20 Y25773 W09938881-A1 Neural/Sensory HSICV24 Y25774 W09938881-A1 Cancer HCWBE20 Y25775 W09938881-A1 Immune/Hemato oietic HSXBM30 Y25776 W09938881-A1 Cancer HDPCY37 Y25778 W09938881-AI' Cancer HOSFQ65 - Y25791 W09938881-A1 Cancer HSXBH24 Y25807 W09938881-A1 Cancer HUSIG64 ~ Y27567 W09924836-A1 Cancer HATCI78 ~ Y27568 ' W09924836-A1 Endocrine HSIDR70 Y27569 W09924836-A1 Digestive HFADD53 Y27570 W09924836-AI Excretory, NeuraIlSensory HPMGT51 Y27571 W09924836-A1 Immune/Hematopoietic, Re roductive' HFVAB79 Y27572 ~ W09924836-A1 , Cardiovascular, -Digestive, Re roductive HDTBP51 Y27573 W09924836-A1 Digestive, .
Immune/Hematopoietic, Re roductive HLHFR19 Y27574 ~ W09924836-A1 Neural/Sensory, Res iratory HMEET96 Y27575 W09924836-A1 Cancer HTXCV12 Y27576 W09924836-A1 Cancer HCEFB70 Y27577 W09924836-A1 Immune/Hematopoietic, Neural/Senso HDTAV25 Y27578 - W09924836-A1 Cancer HSATA21 Y27579 W09924836-A1 Immune/Hemato oietic $KIXI03 ~ Y27580 W09924836-A1 Excretory HDTDC56 ~ . Y27581 W09.924836-A1 Cancer HLTBF35 Y27582 W09924836-Al Cancer .

HEPAB80 Y27583 W09924836-A1 Re roductive HFOXB13 Y27584 W09924836-A1 Musculoskeletal HTOAK16 Y27585 W09924836-A1 . Cardiovascular, Connective/Epithelial, ImmunelHemato oietic HBXDC63 Y27586 W09924836-A1 Neural/Sensory HASAU43 Y27587 W09924836-A1. Imrnune/Hemafo oietic HAGEA31 Y27588 W09924836-A1 Cancer HTXHB33 Y27590 ' W09924836-A1 Immune/Hemato oietic HMWFT65 Y27591 W09924836-A1 hnmune/Hemato oietic HNGA268 Y27592 . W09'924836-A1. Cardiovascular, . Immune/Hemato oietic HTWFH07 Y27593 W09924836-A1 Immune/Herriato oietic HMQDF'12 Y27594 W09924836-A1 Cancer HFABH95 Y27595 W09924836-A1 Di estive, Neural/Sensory, - Re roductive HNGDD48 Y27596 W09924836-A1 Immune/Hemato oietic HPMBY46 Y27597 W09924836-A1 Cancer HRKPA09 Y27598 W09924836-A1 Cancer HAGAQ26 Y27599 W09924836-A1 Cancer HCWFL55 Y27600 W09924836-A1 Immune/Hemato oietic HK.AAE44 Y27601 W09924836-A1 Cancer HNGEU90 Y27602 W09924836-A1 Immune/Hemato oietic HCFCC07 Y27603 ~ W09924836-A1 Digestive, Immune/Hemato oietic HLWBI63 Y27604 W09924836-Al Cancer HDUAC77 Y27605 WO9924836-A1 Immime/Hematopoietic, Mixed Fetal, Neural/Sensory HFOYV27 Y27606 WO9924836-A1 ~ Cancer HGBHI35 Y27607 WO9924836-Al Cancer HRDEU27 Y27608 W09924836-A1 Musculoskeletal HNGJE50 Y27609 W09924836-Al Immune/Hemato oietic HNHDU48 Y27610 W09924836-Al ~ ImmurielHemato oietic HFXJU68 Y27611 W09924836-A1 Immune/Hematopoietic, Neural/Senso HMMAH60 Y27612 W09924836-A1 Immune/Hemato oietic HNGFR31 Y27613 W09924836-A1 Immune/Hemato oietic HFPDB26 Y27614 W09924836-A1 .Immime/Hematopoietic, ' Neiiral/Sensory, Re' roductive HFRAW86 Y27615 W09924836-A1 Neural/Sensory HTEDX90 ' Y27616 W09924836-A1 Re roductive HTXGG45 Y27617 W09924836-A1 Immune/Hemato oietic HTXJI95 Y27618 WO9924836-A1 Immune/Hematopoietic, Re roductive HLYBD32 Y27619 W09924836-A1 Immune/Hemato oietic HROAJ03 Y27621 W09924836-A1 Cancer HTXAJI2 Y27622 W09924836-A1 ~ Immune/Hemato oietic HKAEL80 Y27623 W09924836-A1 . Connecfive/Epithelial, Immune/Hemato oietic HNHFL04 Y27624 W09924836-A1 Immune/Hemato oietic HPCAM01 Y27625 W09924836-A1 Cancer HJACA79 Y27626 W09924836-A1 Immune/Hemato oietic HMSFI26 ' Y27628 W09924836-A1 - ~ Immune/Hemato oietic HMSJR08 Y27629 W09924836-A1 Immune/Hemato oietic HMWI093 - Y27630 W09924836-A1 Cancer HNGAK47 Y27631 W09924836-A1 ' Immune/Hemato oietic ~HNGAL31 Y27632 W09924836-A1 ~ Immune/Hemato-oietic HNGIZ06 Y27633 W09924836-A1 Immune/Hemato oietic HNHBI75 Y27634 W09924'836-A1 Immune/Hemato oietic HOFNT24 Y27635 W09924836-A1 Re roductive HSAXI95 -. Y27636 W09924836-A1 Immune/Hemato oietic HCMTB45 Y27637 WO9924836-A1 Cardiovascular, Immune/Hematopoietic, Mixed Fetal HE9CP41 Y27638 W09924836-A1 Immune/Hematopoietic, Mixed Fetal HHENV10 Y27639 W09924836-A1 ImmunelHemato oietic HSKDD72 Y27640 W09924836-Al Di estive, _ Musculoskeletal ~

HAGD020 Y27641 W09924836-A1 Cancer HCFBH15 Y27642 W09924836-A1 ~ Immune/Hemato oietic HSYBX48 Y27643 W09924836-A1 Cancer HATDQ62 Y27644 WO9924836-A1 Cancer HMEJE13 Y27645 W09924836-A1. Cancer HNAAF65 Y27646 W09924836-A1 Cancer HNFHY30 Y27647 W09924836-A1 Immune/Hemato oietic HNFIR81 Y27648 W09924836-A1 Cancer HNTBI57 Y27649 W09924836-A1 Cancer HSAYR13 Y27650 W09924836-Al Immune/Hemato oietic HTOHV49 Y27651 ~7V09924836-A1 Immune/Fiemato oietic HSFAG37 Y27652 W09924836-A1 Cancer HTXBU52 Y27653 W09924836-A1 Cancer HLHFP18 Y27654 ' W09924836-A1 Cancer HFXBW09 Y27655 W09924836-A1 Neural/Sensory HNGI059 Y27656 W09924836-A1 Immune/Hemato oietic HNGJF92 Y27657 W09924836-A1 Immune/Hemato oietic HMEED18 Y27658 W09924836-A1 Cancer.

HMIAM45 Y27659. W09924836-A1 Neural/Sensory HSAVK10 Y27660 W09924836-A1 Immune/Hemato oietic HSDHC81 Y27661 W09924836-A1 ImmunelHematopoietic, Neural/Sensory HSLCT04 Y27662 W09924836-A1 Mixed Fetal, Musculoskeletal HMDAB56 Y27663 W09924836-A1 Immune/Hematopoietic, Neural/Sensory HUDBZ89 Y27664 WO9924836-A1 Cancer HLYCT47 Y27665 WO9924836-A1 Digestive, Immune/Hemato oietic HOSDJ25 ' Y27666 W09924836-A1 Cancer HADAO89 Y27667 W09924836-A1 Connective/E ithelial HMSGB14 . Y27658 -WO9924836-A1 Cancer HPMGDO1 Y27669 W09924836-A1 Cancer HNHFU32 Y27670 W09924836-A1 Immune/Hemato oietic HMIAL40 Y27671 W09924836-A1 Musculoskeletal, Neural/Sensory HAMFY69 Y27672 W09924836-A1 Cancer HBMCT17 Y27673 W09924836-A1 Immune/Hematopoietic, Neural/Sensory HEBFI91 Y27674 WO9924836-A1 Neural/Sensory HHEAH86 Y27675 W09924836-A1 Cancer HTPCS72 Y27677 W09924836-A1 Cancer HFFAL36 Y27678 W09924836-A1 Neural/Sensory HFXBT12 Y27679 W09924836-A1 Immune/Hematopoietic, Neural/Sensory HNGJF70 Y27680 W09924836-A1 Inimune/Hemato oietic HATEE46 Y27681 W09924836-A1 Cancer HJMBN89 Y27682 - W09924836-A1 Cancer HNHEK61 Y27683 W09924836-A1 Iminune/Hemato oietic HEQA065. Y27684 W09924836-A1 Cancer HFCDV54 Y27685 W09924836-A1 Cancer HHEAD14. Y27686 W09924836-A1 Cancer HGBHE57 Y27687 W09924836-A1 Cancer HGLAF75 Y27688 W09924836-A1 Digestive, Immune/Hemato oietic, Re roductive .

HHEMQ28 Y27689 W09924836-A1 Digestive, Immune/Hematopoietic, Neural/Sensory HERAR44 Y27691 WO9924836-A1. Connective/Epithelial, Re roductive HYBAV65 Y28640 W09940183-A1 Immune/Hematopoietic, Musculoskeletal HETBA38 Y28643 , ' W09940183-A1 ' Digestive, ' ' Mixed Fetal, Re roductive HCE1Q30 , X30701 W09943693-A1 ImmunelHematopoietic, Neural/Sensory HAGBP70 Y30702 W09943693-A1 ~ Cancer HBCAY27 Y30703 W09943693-A1 Immune/Hematopoietic~
Neural/Sensory HCACU58 Y30704 W09943693-A1 Immune/Hemato oietic HCWI:,D74 Y30705 W09943693-A_1 Immune/Hemato oietic HDPFP29 Y30706 W09943693-A1 Cancer HDPPH47 Y30707 W09943693-A1 Cancer '' HFEAN33 Y30708 W09943693-A1 Cancer HFEAT91 Y30709. W09943693-A1 Connective/Epithelial, , Re roductive HFPA071 Y30710 W09943693-A1 Cancer HLWAA17 Y30711 W09943693-A1 Cancer HLYCQ18 Y30712 W09943693-A1 Immune/Hemato oietic HOSFG70 Y30713 W09943693-A1 Cancer HSSAJ29 Y30714 W09943693-A1 Cancer HUSIF44 Y30715 W09943693-A1 ' Cancer H6EDX46 Y30716 W09943693,-A1 Cancer HABAG37 Y30717 W09943693-A1 Cancer HACBD9~1 Y30718 W09943693-A1 Cancer HADEH21 Y30719 W09943693-A1 Cancer HAGHD57 Y30720 W09943693-A1 Cancer HAGHR69 Y30721 W09943693-A1 - Cancer HAHDB16 Y30722 W09943693-A~l Cardiovascular HAHDR32 Y30723 W09943693-A1 Cancer HAJAW93 Y30724 W09943693-A1 Cancer HAJBR69 1'30725 ~ WO9943693-A1 Connective/Epithelial, ~ImmunelHematopoietic, ' Musculoskeletal HAMG032 Y30726 W09943693-A1 Re roductive HATBR65 Y30727 W09943693-A1 Cancer HBJLD29 Y30728 WO9943693-A1 Immune/Hemato oietic HBJNB13 Y30729 W09943693=A1 ' Immune_/Hemato oietic HCE2F54 Y30730 W09943'693-A1 Cancer HCE3C52 Y30731 ~ ~ W09943693-A1 Cancer ~

HCEEA88 Y30732 WO9943593-A1 Cancer HCEFE96 Y30733 W09943693-A1 Cancer HCEIF12 Y30734 W09943693-A1 Cancer HCEOR67 ~Y30735 W09943693-A1 Neural/Sensory HCEVB76 Y3Q736 W09943693-A1 Cancer HNTOA17 Y30737 W09943693-A1 Cancer HDPOW86 Y30811 W09940100-A1 Cancer HSYAG26 Y30812 W09940100-A1 Cancer HLHCH40 Y30813 W09940100-A1 Cancer .

HPLBM85 Y30814 W09~940100-A1 Cancer HLMB076 Y30815 W09940100-A1 Excretory, Immune/Hematopoietic, Re roductive HLQDR48 Y30816 W09940100-A1 Di estive HOHBY12 Y30817 W09940100-A1 Musculoskeletal HOSEI~86 Y30818 W09940100-A1 Cancer HAJBZ75 Y30819 W09940100-A1 Cancer HAGCH75 Y30820 WO9940100-A1 Neural/Sensory HE8MH91 Y30821~ W09940100-A1 Cancer HISCJ55 Y30822 W09940100-A1 Di estive HKISB57 Y30823 W09940100-A1 Cancer HTEBJ71 Y30824 W09940100-A1 Cancer HCWGA40 Y30825 W09940100-A1 Cancer HFCEW05 Y30826 W09940100-Al Cardiovascular, Neural/Sensory HCEPF19 , Y30827. W09~40100-A1 Cancer HTACZO1 Y30828 W09940100-A1 ImmunelHemato oietic HUDAM89 Y30829 W09940100-A1 Re roductive HSAXF60 - Y30830 W09940100-A1 Immurle/Hemato oietic HTOGR42 Y30831 W09940100-A1 ' Immune/Hemato oietic HMVBN46 Y30832 W09940100-A1 Immune/Hematopoietic, Neural/Sensory HUVEB53 Y30833 W09940100-A1 Cancer HSVBU91 Y30834 ' W09940100-A1 Cancer HTXFL30 Y30835 W09940100-A1 Cancer HAGAM64 Y30836 W09940100-A1 Neural/Sensory HE2PH36 Y30837 WO9940100-A1 Digestive, Immune/Hematopoietic, Mixed Fetal HGBDY06 Y30838 W09940100-A1 Cancer HWBA062 Y30839 W09940100-A1 Connective/Epithelial, - Immune/Hemato oietic -HBAFJ33 Y30840 W09940100-A1 Cancer HFXDJ75 Y30841 W09940100-A1 NeurallSensory HFPCY04 Y30842 W09940100-A1 Neural/Sensory HSNBG78 Y30843 W09940100-A1 Connective/Epithelial, ', Digestive, - Immtme/Hennato oietic HBQAB27 Y30844 ~ W09940100-A1 Endocrine, .
Neural/Sensory HTOJY21 Y30845 W09940100-Al Cancer HHTMM30 Y30846 W09940100-A1 Cancer HLTAF58 - Y30847 W09940100-A1 Digestive, Immune/Hemato oietic HELFG13 Y30848 WO9940100-A1 Cancer HHFDM48 Y30849 WO9940100-A1' Cardiovascular, . - Neural/Sensory, Re roductive HKABI84 Y30850 W09940100-Al Cancer HMVAX72 Y30851 W09940100-A1 Cancer HODDN60 ' Y30852 W09940100-A1 Cancer HPMEI44 Y30853 W09940100-A1 Cancer HNGJP69 Y30854 WO9940100-A1 " Immune/Hemato oietic HPWBA10 Y30855 ' W09940100-A1 Immune/Hematopoietic, Re roductive HLHCH40 Y30856 W0.9940100-A1 Cancer HTACZO1 Y30857 W09940100-A1 Immune/Hemato oietic HTOGR42 Y30858 W09940100-A1 ~ Immune/Hemato oietic HTAEK53 Y31811 W09947538-A1 Cancer HFCCQ50 Y36224 W09931117-Al Cancer HTLAI54 Y36225. W09931117-A1 Re roductive HLWBF94 Y36227 - W09931117-A1 Endocrine, Neural/Sensory, Re roductive HFKFF78 Y36228 W09931117-A1 Excreto HSYBG37 Y36229 W09931117-A1 Cancer HTHCA77 Y36230 W09931117-A1 Immune/Hemato oietic HNHEZ51 Y36231 W09931117-A1 Immune/Hemato oietic HFIAX46 Y36232 W09931117-A1 Cardiovascular, Musculoskeletal HFOXO72 Y36233 W09931117-A1 Cancer HODDW40 . Y36234 W09931117-A1 Cardiovascular, ' ' ImmunelHematopoietic, . Re roductive HSAWG42 Y36235 ~ W09931117-A1 Immune/Hemato oietic HBMSK09 Y36236 W09931117-A1 Digestive, Immune/Hematopoietic, Musculoskeletal .

HDPAU16 -Y36237 W0993111.7-Al Cancer HFEBE12 ' Y36238 W09931117-A1 Cancer HFLNB64 Y36239 W09931117-A1 Cancer HSAWZ41 , Y36240 W09931117-A1 Immune/Hemato oietic HNFJF07 Y36241 W09931117-A1 Immune/Hematopoietic, Neural/Sensory HNGJ057 Y36242 W09931117-A1 Immune/Hemato oietic HE7TM22 Y36243 W09931117-A1 Mixed Fetal HFRBR70 Y36244 W09931117-Al Cancer HTHBK35 Y36245 W0993I117-Al Immune/Hemato oietic HWABA81 Y36246 W09931117-Al Irninune/Hemato oietic HKGAA73 Y36247 . W09931117-A1 Cancer HKIYP40 Y36248 W09931117-A1 Cancer HKM1VIW74 Y36249 W09931117-A1 Excreto .
.

HLFBI27 Y36250 W09931117-A1 Res irato HLQCW84 Y36251 W09931117-A1 Di estive HBNAV22 Y36252 W09931117-A1 ~. Digestive, , Re roductive ' HTEAM34 Y36253 W09931117-A1 Re roductive HTHDK34 Y36254 W09931117-A1 Digestive, Immune/Hemato oietic H6BSG32 Y36255 W09931117-Ai Cardiovascular, Immune/Hematopoietic, Musculoskeletal HAECA01 Y36256 W09931117-A1 Cancer HDTEL03 Y36257 W09931117-A1 Cancer HFXDT43 Y36258, WO993I117-A1 Neural/Sensory HNGHQ09 Y36259 W09931117-A1 Immune/Hemato oietic HHGDF16 ~ Y36260 W09931117-A1 Cancer HJBCG12 Y36261 W09931117-A1 Cancer HOGAW62 Y36262 W09931117-Al Immune/Hematopoietic, Re roductive .

HSWBJ74 Y36263 W09931117-A1 Cancer HGBHR26 Y36264 W09931117-A1 Di estive HKDBF34 Y36265 W09931117-A1 Cancer H6EAB28 Y36266 W09931117-A1 Cancer HLWA022 Y36267 W099311-17-A1 Cancer HAGFH53 Y36268 W09931117-A1 Cancer HHENQ22 Y36269 W09931117-A1 Immune/Hemato oietic HKMLK53 Y36270 W09931117-A1 Excretory, Mixed Fetal HSKGQ58 Y36271 W09931117-A1 Cancer HADXB45 Y36272 W09931117-A1 Cancer HAIBZ39 Y36273 W0993l 117-Al Cancer HBXFP23 Y36274 W09931117-Al Cancer HEQBF32 Y36275 WO9931117-A1 Cancer HETHE81 Y36276 WO9931117-A1 Cancer HFPAC12 Y36277 W09931117-A1 Cancer H6EFA77 Y36278 W09931117-A1 Cancer HFXHD88 Y36279 W09931117-A1 Neural/Sensory HFOXV65 ' Y36280 W09931117-A1 Immune/Hematopoietic, .
Musculoskeletal;
Re roductive HKADX21 Y36281 W09931117-A1 Cancer HPZAB47 Y36282 W09931117-A.1 Cancer ' HAGFE79 Y36283 W09931117-A1 Cancer HCE1X60 Y36284 WO9931117-A1 Neural/Sensory HFXKD36 ' Y36285 W09931117-A1 Digestive, Musculoskeletal, Neural/Sensory HBMCU71 Y36286 W09931117-A1. Immune/Hemato oietic HTEIV80 Y36287 W09931117-A1 Re roductive HFIAP16 ' Y36288 W09931117-A1 Musculoskeletal HODAV86 Y36289 W09931117-A1 Re roductive HTEDF80 Y36290 W09931117-A1 Re roductive HTODJ69 Y36291 W09931117-A1 Immune/Hemato oietic HE6GR02 . Y36292 W09931117-A1 Immune/Hematopoietic, ' Mixed Fetal HAPNY86 Y36293 WO9931117-A1 Cancer HTLDR33 Y36294 W09931117-A1 Immune/Hematopoietic, Re roductive HACBI61 Y36295 W09931117-A1 Cancer HMEIK34 Y36296 W09931117-Al Cancer.

HKAAK02 Y36297 W09931117-A1 Cancer HEPAA46 Y36298 W09931117-A1 Re roductive HFPCX09 Y36299 WO9931117-A1 Mixed Fetal, Neural/Senso HLWAA88 Y36300 W09931117-A1 Cancer HOHBV89 Y36301 - - W099311r17-Al Musculoskeletal, Re roductive HCEFL57 Y36302 W09931117-A1 Cancer HMEKU83. Y36303 W09931117-A1 Cardiovascular, ' Immune/Heinatopoietic, Re roductive HOSBY40 Y36304 W09931117-A1 Digestive, Immune/Hematopoietic, Musculoskeletal HKFBH93 _ Y36305 W09931117-A1 Digestive, ' .
Re roductive HMTAD67 Y36306 W09931117-A1 Cancer' HTEBP77 Y36307 W09931117-A1 Immune/Hematopoietic, Re roductive HE9C069 Y36308 W09931117-A1 Cancer HCACV51 Y36309 W09931117-A1 Cancer HHPBI45 Y36310 W09931117-A1 Cardiovascular, Neural/Senso HLQDH79 Y36311 W099311.17-A1 Cancer HNGFJ67 Y36312 W0993111'7-A1 Immune/Hemato oietic HEIAC52 Y36313 W09931117-Al Cancer HFXKL58 Y36314 W09931117-A1 - Cancer HMVAM60 Y36315 W09931117-A1 Cancer HMVBR22 Y36316 W09931117-A1 Cancer HPJCW04 Y36317 W09931117-A1 ~ Re roductive HSIDJ81 Y36318 W09931117-A1 Digestive HSLFUQS ' Y36319 W09931117-A1 Cancer HEQAK71 Y36320 ~ S W09931117-A1 Cancer HOSEQ49 Y36321 W09931117-A1 Cancer HRAAM50 Y36322 W09931117-A1 Excretory, Immurie/Hematopoietic, Mixed Fetal HSDFW45 Y36323 W09931117-A1 Neural/Sensory HSLCQ82 Y36324 W09931117-A1 Cancer HSSFT08 Y36325 WO9931117-A1 Musculoskeletal HTOIW31 Y36326 , W09931117-A1 ImmmelHematopoietic, Neural/Sensory, Re roductive HTXKQ85 Y36327 W09931117-A1 Immune/Hematopoietic, Musculoskeletal, Re roductive HUFBK08 Y36328 WO9931117-A1 Digestive, Musculoskeletal HBJEE48 Y36330 W09931117-A1 Cancer HBXGH74 Y36331 W09931117-A1 Neural/Sensory HISBM03 Y36332 W09931117-A1 Cancer HETCH46 Y36333 W0993111~7-A1 - Cancer HFPCX09 Y36335 W09931117-A1 Mixed Fetal, NeurallSensory HLWAA88 Y36336 W09931117-A1 Cancer HCEFL57 Y36337 W09931117-A1 Cancer HETHE81 Y36650 W09931117-A1~ Cancer HTGAU75 Y38386 W09935158-A1 Immune/Hemato oietic.

HTTDP47 ' Y38387 W09935158-A1 ~ Cancer HTXJQ11 Y38388 WO9935158-A1 - Cancer HADCO45 Y38389 WO9935158-A1 Cancer HMIAL37 Y38390 W09935158-A1 Cancer HNGDU40 Y38391 WO9935158-A1 Immune/Hemato oietic HFXB084 Y38392 W09935158-A1 Neural/Sensory HLLAX19 Y38393 WO9935158-A1 Cancer HPMAG94 Y38394 W09935158-A1 ~ Cancer HSVAK93 Y38395 W09935158-A1 Cancer HM B088 Y38396 W09935158-A1 Cancer HMQBU45 Y38397 W09935158-A1 Immune/Hemato oietic HMWAJ53 Y38398 W09935158-A1 Immune/Hemato oietic HCUG012 Y38401 W09935,158-A1 Digestive, .
Immune/Hemato oietic, Mixed Fetal HPFCX44 Y38402 W09935158-A1 Cancer HCUBV79 Y38403 ' ' W09935158-A1 Immune/Hematopoietic, Neural/Sensory HLQBV04 Y38404 . W09935158-A1 Cancer HMADW66 Y38405 W09935158-A1 Cancer HLDBE54 Y38406 WO9935158-A1 Digestive, Re roductive HFTAB66 Y38407 W09935158-A1 Digestive, Neural/Sensory HEOMQ63 Y38408 W09935158-A1 Digestive, ' ImmunelHemato oietic HDPJM30 Y38409 W09935158-A1 Immune/Hematopoietic, Neural/Sensory HCFMG62 Y38410 W09935158-A1 Cancer HJMAG88 Y38411 W09935158-A1 Cancer HKAAH36 Y38412 W09935158-A1 Connective/Epithelial, - Re roductive HMADS41 Y384'13 W09935158-A1 Cancer HMEFT85 Y38414 W09935158-A1 Cancer HMSBX80 Y38415 W09935158-A1 ~ Immune/Hematopoietic, - Re roductive HNGCL23 Y38416 W09935158-A1 Immune/Hemato oietic HPIB015 Y38418 W09935158-A1 Cancer HCYBG92 Y38419 WO9935158-A1 Cancer HMDAQ29 Y38420 W09935158-A1 Neural/Sensory, Re roductive HSYBI49 Y38421 W09935158-A1 Cancer HDTAB58, Y38422 W09935158-A1 Cancer HFTAB66 Y38423 W09935158-A1 Digestive, NeurallSensory HDPBX23 Y38424 W09935158-A1 Immune/Hematopoietic, Neural/Senso HCFMG62 ~ Y38425 W09935158-A1 Cancer HKAAH36 Y38426 W09935158-A1 Connective/Epithelial, - ' Re roductive HKAAH36 Y38427 W09935158-A1 Connective/Epithelial, Re roductive HMADS41 Y38428 W09935158-A1 Cancer HNTBI26 Y38429 W09935158-A1 Cancer HCYBI36 Y38430 W09935158-A1 Cancer HTHBJ48 Y41161 US5981231-A Digestive, Immune/Hemato oietic HD AC88 Y41164 US5981230-A Cancer HKGCR51 Y41308 W09947540-A1 Immune/Hematopoietic, Mixed Fetal, .
Neural/Sensory HPMDK28 Y41309 W09947540-A1 Cancer HLDCD04 Y41310 W09947540-A1 Cancer ~HLDON23 Y41311 W09947540-A1 Cancer HLDRM43 Y41312 W09947540-A1 Digestive, Re roductive HLQAM28 Y41313 W09947540-A1 Digestive, - Re roductive HLTDE74 Y41314 ~ W09947540-Al Cancer HLTFA64 Y41315 W09947540-A1 Cancer-HMCFY13 Y41316 W09947540-A1 Immune/Hemato oietic HMMBD35 Y41317 W09947540-A1 Cancer HMQCY03 Y41318 WO9947540-Al Digestive, Immune/Hemato oietic HMSBX84 Y41319 W09947540-A1 Immune/Hemato oietic HMSKI86 Y41320 W09947540-A1 Cancer HMVBS81 Y41321 W09947540-Al Cancer HMWEB02 Y41322 WO9947540-A1 Cancer HMZAD77 Y41323 W09947540-A1 Cancer HNFIY77 Y41324 W09947540-A1 Cancer HNHEK85 Y41325. W09947540-A1 Immune/Hematopoietic, Mixed Fetal HNHEU93 Y41326 W09947540-A1 Immune/Hemato oietic HODAH74 Y41327 W09947540-A1 Connective/Epithelial, ' .
Reproductive, Res iratory HODCU34 Y41328 W09947540-A1 Cancer HODCZ09 Y41329 W09947540-A1 Re roductive HISCF16 Y41330 W09947540-A1 Cancer ~HOGAG15 Y41331 W09947540-A1 ' Cancer HPIB048 Y41332 WO9947540-A1 Cancer HPMFP40 Y41333 W09947540-A1 Re roductive HPRCU95 Y41334 W09947540-A1 Musculoskeletal, Re roductive ' HPTTG19 Y41335 W09947540-A1 Endocrine, Immune/Hemato oietic HRDDV47 Y41337 WO9947540-A1 ~ Cancer HRDEN56 Y41338 W09947540-A1 Musculoskeletal HSFAN12 Y41339 W09947540-A1 Cardiovascular HSQCM10 Y41340 W09947540-A1 Cancer HSVAT68 ~ Y41341 W09947540-Al Excretory, Re roductive HSXEC75 Y41342 W09947540-A1 Cancer HTDAI54 Y41343 W09947540-A1 ' Cancer ' HTEIT45 Y41344 W09947540-A1 Re roductive HTGBE48 Y41345 W09947540-A1 , Immune/Hematopoietic, Re roductive HTLEP53 Y41346 ~ W09947540-A1 Neural/Sensory, Re roductive HTTBI76 Y41347 W09947540-A1 Cancer HTWKG71 Y41348 WO9947540-Al Immune/Hemato oietic HTXDN32 Y41349 WO9947540-A1 Cancer HTSGX80 Y41350 W09947540-A1 Cancer HTXEY51 Y41351 . W09947540-A1 , Endocrine, Immune/Hematopoietic, Mixed Fetal HTXFH55 Y47.352 W09947540-A1 Cardiovascular, Immune/Hemato oietic HTXJW17 Y41353 - W09947540-A1 Digestive, Immune/Hemato oietic HUFCJ~O Y41354 W09947540-A1 Cancer HWAAP70 Y41355 ' W09947540-A1 Immune/Hemato oietic HWABW49 Y41356 W09947540-A1 Immune/Hemato oietic HWBDP28 Y41357 W09947540-A1 Cancer HWDAC39 Y4T358 ~ WO9947540-A1 Connective/E .ithelial HWHGQ49 Y41359 W099.47540-A1 Cancer HJPAD75 Y41360 W09947540-Al Cancer HLDRP33 Y41361 W09947540-A1 Digestive, Neural/Sensory HMSIE02 Y41362 W09947540-A1 Cancer HNGFE55 Y41363 W09947540-A1 Immune/Hemato oietic HRAAJ19' Y41365 W09947540-A1 Cancer HSAWV96 Y41366 W09947540-A1 Immune/Hematopoietic, Neural/Sensory HSBBT37. Y41367 W09947540-A1 Cancer HSDZR57 Y41368 -W09947540-A1 Cancer HCECQ07 1'41369 W09947540-A1 ~ Cancer HWBCP79 Y41370 W09947540-A1 Immune/Hematopoietic, ' Re xoductive HYAAL70 Y41371 WO9947540-A1 Cancer HYAAY86 Y41372 W09947540-A1 Immune/Hemato oietic HAPBS03 Y41373 W09947540-A1 Cancer HBJLCO1 Y41374 W09947540-A1 Immune/Hemato oietic HBLKD56 Y41375 W09947540-A1 Musculoskeletal HCENK38 Y41376 ~ W09947540-A1 Cancer HE6GA29 Y41379 W09947540-A1 Mixed Fetal HETH095 Y41381 W09947540-A1 Digestive, Re roductive HFCFJ18 Y41382 W09947540-A1 Cancer HFPBM30 ~ Y41383 W09947540-A1 Neural%Sensory HFXKT05 Y41384 W09947540-A1 Cancer HKB1E57 Y41385 W09947540-A.1 Cancer HLWAD77 Y41386 W09947540-A1 Cancer HLWAY5,4 Y41387 W09947540-A1 Immune/Hematopoietic, ' Neural/Sensory, Re roductive HNGBU28 Y41388 W09947540-A1 Iiximune/Hemato oietic HOUHH51 Y41389 W09947540-A1 Cancer HRAAB15 Y41390 W09947540-A1 Digestive, - Excretory ' HSAVH65 Y41391 . W09947540-A1 Digestive, Immune/Hematopoietic, Re roductive HSDGN55 Y41392 W09947540-A1 Cancer HSXAH81 Y41393 W09947540-A1 Cancer .

HSXBX80 Y41394 W09947540-A1 Cancer HTEHVb8 Y41395 W09947540-A1 ~ Cancer HUFAK67 Y41396 W09947540-A1 Digestive, - , Immune/Hematopoietic, Re roductive HUSXS50 Y41397 W09947540-A1 Cancer HAPON17 Y41398 W09947540-A1 Cancer ' .

HATAC53 Y41399 W09947540-A1 Cancer HAMFK58 Y41400 W09947540-A1 Cancer HLYCH68 ~ Y41401 W09947540-A1 Cancer HCUHK65 Y41402 W09947540-Al ~ Cancer HLDCD04 Y41403 W09947540-A1 Cancer HOUHH51 Y41404 W09947540-Al Cancer HSLCQ82 Y41571 W09947540-A1 Cancer HCGMD59 Y45257 W09946289-A1 Cancer HCNSD76 Y45258 W09946289-A1 Di estive . , HCNSD93 Y45259 W09946289-A1 Di estive HCWBE22 Y45260 W09946289-A1 Immune/Hematopoietic, Neural/Sensory HFEAN33 Y45261 W09946289-A1 Cancer HCWUM50 Y45262 W09946289-A1 Cancer _ HDHIA94 Y45263 W09946289-A1 Excretory, Neural/Sensory.

HDPAE76 Y45264 WO9946289-A1 Cancer HDPI054 Y45265 W09946289-A1 Immune/Hematopoietic, Re roductive HDPNC61 Y45266 W09946289-A1 Cancer HDPND46 Y45267 W09946289-A1 ImmunelHemato oietic HDPSU13 Y45268 W09946289-A1 Immune/Hemato oietic , HDTGC73 Y45269 W09946289-A1 Cancer HE2PD49 Y45270 WO9946289-A1 Cancer HEEAJ02 Y45271 WO9946289-A1 ~ Cancer HELHD64 Y45272 W09946289-A1 Cancer HEPAD91 Y45273 W09946289-A1 Digestive,.
Re roductive HEQBH65 Y45274 W09946289-A1 Irnmune/Hematopoietic, Re roductive HETC002 Y45275 W09946289-A1 Cancer HFAU078 Y45276 W09946289-A1 Cancer HFKEE48 Y45277 WO9946289-A1 Cancer HFKFG02 Y45278 - W09946289-A1 Excretory, Immune/Hematopoietic, Neural/Sensory H2CBNl4 Y45279 W09946289-AI Cancer HHFFJ48 Y45280 W09946289-A1 Cardiovascular, , ' Immune/Hemato oietic HILCF66 Y45281 W09946289-A1 Cancer HKABN45 Y45282 W09946289-A1 Cancer HKDBK22 Y45284 W0994628.9-Al Excreto HKGAZ06 Y45286 W09946289-A1 Immune/Hemato oietic HKGCK61 Y45287 W09946289-A1 Cancer HFEAN33 Y45288 W09946289-A1 Cancer HDHIA94 Y45289 W09946289-A1 Excretory, Neural/Sensory HDPJ039 . YS2479 WO9940184-A1 . Cancer HNTCF82 Y58185 US6004780-A . Cardiovascular, Connective/Epithelial, .
Re roductive HETAB62 Y59285 W0200004183-A1 Cancer HSYAE36 Y59286 WO200004183-A1 Cancer HKAPI15 Y68800 W0200005371-A1 Connective/E ithelial HUJCT9C Y72090 W0200068247-A2 Cancer HMGBM65 ~ Y72091 W0200068247-A2 Cancer HATEE38 Y72092 W0200068247-A2 Cancer HCHAK72 Y72093 W0200068247-A2 Cancer HHFBJ67 .Y72094 W0200068247-A2 Cardiovascular, Neural/Senso HTTJKSC Y72095 W0200068247-A2 Cancer HWLGJ11 Y72096 W0200068247-A2 Di estive HTLEG15 Y72097 W0200068247-A2 Cancer HAGAS16 Y72098 W0200068247-A2 Neural/Sensory HATEE38 Y72108 W0200068247-A2 Cancer HKABZ65 Y76124 W09958660-A1 ' Connective/E ithelial HNGIC80 Y76125 W09958660-A1 ' Immune/Hemato oietic HDPUG50 Y76126 WO9958660-A1 Cancer HAEAB66 Y76127 WO9958660-A1 Cancer HHEPF59 Y76128 ~ W09958660-A1 Cancer HE9BK23 Y76129 W09958660-A1 Digestive, ' Mixed Fetal HCYBI36 Y76130 W09958660-A1 Cancer HSS17X51 Y76131 W09958660-A1 Cancer -HSDAJ46 Y76132 W09958660-A1 Cancer HRACG45 Y76133 W09958660-A1 ~ Cancer HAPPW30 Y76134 W09958660-A1 Cancer HE2ES51 Y76135 - W09958660-A1 Cancer HTXDW56 Y76136 - W09958660-A1 Cancer HDPKI93 Y76138 W09958660-A1 Cancer HDLAC10 Y76139 WO9958660-A1 Cancer HDPOH06 ' Y76140. W09958660-A1 Cancer HCE4G61 Y76141 ' WO9958660-A1 Cancer HCWUI13 Y76142 W09958660-A1 Immune/Hemato oietic HDPSPO1 Y76143 W09958660-Al Cancer -HHPEN62 ~ Y76144 W09958660-A1 Cancer HUKBT29 Y76145 W09958660-A1 Cancer HARAP48 Y76146 ~ W09958660-A1 Cancer HBIMB51 ~ Y76147 W09958660-A1 Connective/Epithelial, Re roductive HE8DX88 Y76148 W09958660-A1 Mixed Fetal HNGHT03 Y76149 W09958660-A1 Immune/Hemato oietic HWABU17 - Y76150 W09958660-A1' Cancer HCE5F84 Y76151 W09958660-Al < Cancer HBXCD55 Y76152 WO9958660-Al ' Cancer HOVCB25 ' ' Y76153 W09958660-A1 Re roductive HSYAV66 Y76154 W09958660-A1 Digestive, Immune/Hemato oietic HFPCT29 Y76155 W09958660-A1 Neural/Sensory HAWAT25 Y76156 W09958660-A1 Cancer HNHFR04 Y76157 W09958660-A1 Immune/Hemato oietic HOSFT61 Y76158 WO9958660-Al Cancer HBJI081 ' Y76159 W09958660-A1 Immune/Hemato oietic HADCL55 Y76160 - W09958660-A1 Cancer HAGGJ80 Y76161 W09958660-A1 Cancer HAIB081 Y76162 W09958660-A1 ' Neural/Sensory HBBBC37 Y76163 W09958660-A1 Cancer HBJMX85 Y76164 W09958660-A1 Cancer HCEES66 Y76165 W09958660-A1 Digestive, Neural/Sensory .

HCEMP62 Y76166 W09958660-A1 Cancer HE2FB90 Y76167 W09958660-A1 Cancer HE9DS56 Y76168 ' W09958660-A1 Cancer .

HTOHJ89 Y76169 W09958660-A1 Immune/Hemato oietic HASCE69 Y76171 W09958660-A1 Cancer .

HHTLH52 Y76172 . W09958660-A1 Neural/Sensory, Re roductive HOUCT90 Y76174 W09958660-A1 Connective/E ithelial HCFLR78 Y76175 W09958660-A1 Cancer HTOHT18 Y76176 ~ W09958660-A1 Cancer HKPMB11 Y76177 W09958660-A1 Digestive, Excretory, Musculoskeletal HNFHS38 Y76178 W09958660-A1 Cancer HAIBU10 Y76179 W09958660-Al Cancer HAPOK30 Y76180 W09958660-A1 Cancer HCWUA22 Y76182 WO9958660-Al ImmunelHemato oietic HDSAG91 Y76183 W09958660-Al Immune/Hemato oietic HNEDJ35 Y76184 W09958660-A1 Immune/Hemztopoietic, Re reductive HTHBH29 Y76185 W09958660-Al Immune/Hematopoietic, Mixed Fetal, ' Re reductive H7TBA62 Y76186 W09958660-A1 Cancer HNGI050 Y76187 W09958660-Al ImmunelHemato oietic HMIAW81 Y76188 W09958660-A1 Immune/Hematopoietic, Neural/Sensory, Re reductive HMMCJ60 Y76189 , W09958660-A1 Immune/Hematopoietic, .Musculoskeletal HDPI009 Y76190 W09958660-A1 Cancer .

HHFHH34 Y76191 WO9958660-A1 Cardiovascular HISCL83 Y761.92 ' W09958660-A1 Di estive HTOAI70 Y76193 W09958660-A1 Immune/Hemato oietic HSDER95 Y76194 W09958660-A1 Digestive, Neural/Sensory HNECL25 Y76195 W09958660-A1 - Immune/Hemato oietic HNFGZ45 Y76196 W09958660-Al Cardiovascular, Digestive, Immune/Hemato oietic HHGCU49 Y76197 W09958660-A1 Cancer HETDT$1 Y76199 W09958660-A1 Digestive, -Immune/Hematopoietic, Re reductive HHLBA14 Y76200 W09958660-A1 Cancer HLTBU43 Y76201 W09958660-A1 Immune/Hemato oietic HNTSJ84 Y76202 W09958660-A1 Cancer HOHCG16 Y76203 W09958660-A1 Digestive, Musculoskeletal HTHCB31 Y76204 W09958660-A1 Immune/Hematopoietic, Mixed Fetal, Neural/Sensory , HUKAM16 Y76205 W09958660-A1 Cancer HLDOJ66 Y76206 W09958660-A1 Digestive HTXKF10 Y76207 W09958660-A1 ~ Immune/Hemato oietic HPMAI22 Y76208 W09958660-A1 ~ Re reductive HL2AG57 Y76209 .W09958660-A1 Cancer HUSAM59 Y76210 W09958660-A1 Cancer HNGGR26 Y76211 W09958660-A1 Immune/Hemato oietic HTLCX30 Y76212 W09958660-A1 Re reductive HCEBC87 Y76213 W09958660-A1 Cancer HATCB92 Y76214 W09958660-A1 Endocrine HLHAL68 Y76216 W09958660-A1 Res iratory HEOMR73 Y76217 W09958660-A1 Immune/Hemato oietic HETIB83 Y76218 W09958660-A1 Cancer HJPDD28' Y76219 WO9958660-Al Cancer HBAMB15 Y76220, W09958660-A1 Cardiovascular, Excretory, 99 .

Re reductive HBAFQ33 Y76221 W09958660-A1 ~ Cancer HTOAI70 Y76222 W09958660-A1 Immune/Hemato oietic HJPDD28 Y76223 ' W09958660-A1 Cancer HRACG45 Y76266 WO9958660-A1 Cancer HBXCD55 Y76303 W09958660-A1 Cancer HOSFT61 Y76325 W09958660-A1 Cancer HWBBP10 Y86215 W09966041-A1 Immune/Hematopoietic, Neural/Sensory HWBD080 Y86216 W09966041-A1 Immune/Hematopoietic, Musculoskeletal, ' ' Re reductive HWHGU54 Y86217 W09966041-A1 Connective/E ithelial HYACI76 Y86218 W09966041-A1 Cancer HBHMA23 ' Y86219 W09966041-A1 Cancer HCE3G20 Y86220 W09966041-A1 Cancer HCEJP80 Y86221 W09966041-A1 Cardiovascular, Neural/Sensory HCUDD24. Y86222 ' W09966041-A1 Digestive, ' Immune/Hematopoietic, Re reductive HDPTD15 Y86223 W09966041-A1 Immune/Hemato oietic HDPWU34 . Y86224 W09966041-A1 Cancer HEOOV79 Y86225 W09966041-A1 Cancer HFKET93 Y86226 W09966041-A1 Excretory, Immune/Hematopoietic, Neural/Senso HFTDL56 Y86227 W09966041-A1 ' Cancer HFXJX44 Y86228 W09966041-A1 Cancer HKACU58 Y86229 W09966041-A1 Cancer HKFBC53 Y86230 W09966041-A1 Cancer HLTHR66 Y86231 W09966041-A1 Cancer HLYBA69 Y86232 W09966041-A1 Cancer HNTMX29 Y86233 W09966041-A1 Cancer HNTNC20 Y86234 W09966041-A1 Cancer HNTNI01 Y86235 WO9966041-A1 Cancer HPIBW65 Y86236 W09966041-A1 Cancer HSMBE69 Y86237 W09966041-A1 Cancer HT4FW61 , Y86238 W09966041-A1 .Connective/Epithelial, Immune/Hematopoietic, Re reductive HYABK95 Y86239 W09966041-A1 Cancer HYACE88 Y86240 W09966041-A1 Cancer HOABR60 Y86241 W09966041-A1 Cancer HAPOM45 ' Y86243 W09966041-A1 Cardiovascular, Di estive HCEJQ69 Y86244 W09966041-A1 Cancer HAGFI62 Y86245 W09966041-A1 Cancer HAGGS43 Y86246 W09966041-A1 .Neural/Sensory HBJHP03 Y86247 W09966041-A1 Iznmune/Hematopoietic, Re reductive HCHPF68 Y86248 W09966041-A1 Re reductive HDPJF37 Y86249 W09966041-A1 Cancer HSDEZ20 Y86250 W09966041-A1 Neural/Sensory HTEKU58 Y86251 W09966041-A1 Cancer HLTBL58 Y86252 W09966041-A1 Immune/Hemato oietic, Musculoskeletal, Neural/Sensory HPWDJ42 Y86253 WO9966041-A1 Digestive,.
Re roductive HRACD15 Y86254 W09966041-A1 Cancer HSIAC80 Y86255 W09966041-A1 Cancer HAGFD18 Y86256 W09966041-A1 Cancer HAJAP76 Y86257 W09966041-A1 Cancer HDTGC86 Y86258 W09966041-A1 Digestive, Immune/Hematopoietic, Re roductive HAGDI35 Y86259 WO9966041-A1 Cancer HELHN47 Y86260 ' WO9966041-A1 'Cancer HPRBC80 ' Y86261 W09966041-A1 Cancer HAQAR23 Y86262 W09966041-A1 Cancer HAIFL18 Y86263 W09966041-A1 Digestive, Immune/Hemato oietic HJPAY76 Y86264 W09966041-A1 Cancer HUSXE77 Y86265 W09966041-A1 Cancer HLTFEF62 Y86266 W09966041-A1 Di estive .HTWJK32 Y86267 W09966041-A1 Cancer HTWDF76 Y86268 W09966041-A1 Immune/Hematooietic HTPBN68 Y86269 WO9966041-A1 Di estive HTOIY21 Y86270 W09966041-A1 Immune/Hemato oietic ' HTLDD53 Y86271 W09966041-A1 ~ Connective/Epithelial, Digestive, Re roductive HTLFG05 Y86272 W09966041-A1 ~ Cancer HDPXR23 Y86273 W09966041-A1 Digestive, Iinmune/Hemato oietic HSIA.C45 Y86274 ' WO9966041-A1' Digestive, Immune/Hemato oietic HSRGW16 Y86275 W09966041-A1 Cancer HSSJC35 ' Y86276~ W09966041-A1 ~ Cancer HTEAX23 Y86277 W09966041-A1 Re roductive HTGCH22 Y86278 W09966041-A1 Immune/Hematopoietic, Mixed Fetal, Re roductive HTJMA95 ~ Y86279 WO9966041-A1 Cancer HHEAA08 Y86280 WO9966041-A1 ImmlmelHemato oietic HBQAA49. Y86281 ~ W09966041-A1 Neural/Sensory HDPBI32 Y86282 ,~~ ' W09966041-A1 Excretory, ' ImmunelHematopoietic, Neural/Sensory HBIBF16 Y86283 W09966041-A1 Neural/Sensory HBCAY05 Y86284 W09966041-A1 Cancer .HCUCK44 Y86285 W09966041-A1 Cancer HCE2W56 Y86286 WO9966041-A1 Cancer HCWAGO1 Y86287 W09966041-A1 Immune/Hemato oietic HDRMI82 Y86289 W09966041-A1 Cancer HEPCU48 Y86290 ' W09966041-Al Cancer HDPRK33 Y86291 WO9966041-Al Immune/Hematopoietic, ' Mixed Fetal HKGAX42 Y86292 . WO9966041-A1 Digestive, ' ~ Immune/Hematopoietic, Re roductive HLMAZ95 Y86293 W09966041-A1 Cancer HLMFC07 Y86294 W09966041-A1 Digestive, Immune/Hemato oietic HL2AG87 Y86295 W09966041-A1 Immune/Hematopoietic, Neural/Sensory, Re roductive HKGC027 Y86296 W0996604T-A1 Cancer HLDCE79 Y86297 W09966041-A1 Di estive .

HERAD40 Y86298 W09966041-A1. Connective/E ithelial HFOXB55 Y86299 W09966041-Al Cancer -HFVGZ42 Y86300 W09966041-A1 Cancer HNHAF39 Y86301 W09966041-A1 Immune/Hemato oietic HNTSW57 Y86302 W09966041-A1 Cancer HOGCK20 Y86303 W09966041-A1 Cancer HLYES38 Y86305 WO9966041-A1 Immune/Hematopoietic, Re roductive HMECK83 Y86306 W09966041-A1 Cardiovascular HMQAG66 Y86308 ~~ W09966041-A1 Immune/Hemato oietic HWBBP10 Y86309 W09966041-A1 Immune/Hematopoietic, Neural/Sensory HAPAK52 Y86310 W09966041-A1 Cancer HDPWU34 Y86311 W09966041-A1 Cancer HKACU58 Y86312 ' WO9966041-A1 Cancer HLDBQ19 Y86314 WO9966041-A1 Cancer HNTMX29 Y86315 W09966041-A1 Cancer HOABR60 Y86316 W09966041-A1 Cancer HPWDJ42 Y86317 W09966041-A1 Digestive, Re roductive HPWDJ42 Y86318 WO9966041-Al , Digestive, Re roductive HRACD15 Y86319 W09966041-Al Cancer HPRBC80 Y86320 W09966041-A1 Cancer HUFEF62 Y86321 W09966041-A1 Di estive HTLFGOS Y86322 W09966041-A1 Cancer HDPXR23 Y86323 W09966041-A1 Digestive, Immune/Hemato oietic HSRGW16 Y86324 W09966041-A1 Cancer HDPBI32 Y86327 W09966041-A1 Excretory, Immune/Hematopoietic, . Neural/Sensory HDRMI82 Y86328 W09966041-A1 Cancer.

HKGCO27 Y86330 W09966041-A1 Cancer , HNTSW57 Y86332 W09966041-A1 Cancer HOGCK20 Y86333 W09966041-A1 Cancer HNTMX29 Y86388 W09966041-A1 Cancer HPRBC80 Y86463 W09966041-A1 ~ Cancer HTLFGOS Y86488 W09966041-A1 Cancer HDPXR23 Y86489 W09966041-A1. Digestive, ' Immune/Hemato oietic HSRGW16 Y86496~ W09966041-A1 ~ Cancer HDRMI82 Y86532 - W09966041-A1 Cancer HNTSW57 Y86571 W09966041-A1 Cancer HISCN02 Y87064 W0200004140-A1 Di estive HHGDM70 Y87065 W0200004140-A1 Immune/Hemato oietic HHPG040 Y87066 W0200004140-A1 Cancer HAMGG68 Y87067 W0200004140-A1 Cancer HAPOM49 _ Y87068 WO200004140-A1 Cancer HBGBA69 Y87069 W0200004140-A1 Cancer HBJFJ26 Y87070 W0200004140-Al Cancer HCEDH38 Y87071 W0200004140-A1 Mixed Fetal, NeuraIlSensory HDPOJ08 Y87072 W0200004140-A1 Cancer HDPRX82 Y87073 W0200004140-A1 Cancer HELGK31 Y87074 W0200004140-A1 Cancer HFPCX64 Y87075 W0200004140-A1 Mixed Fetal, Neural/Sensory HFXD060 Y87076 W0200004140-A1 Neural/Sensory HAUAI83 Y87077 W0200004140-A1 Re roductive HKGAH42 Y87078 W0200004140-A1 Neural/Sensory HMIAP86 Y87079 W0200004140-A1 Cancer HMUAP70 Y87080 W0200004140-A1 Cancer HRACJ35 Y87081 W0200004140-A1 Cancer HTWDE26 Y87082 W0200004140-A1 Cancer HBGBB44 Y87083 W0200004140-A1 Cancer HBAFA02 Y87084 ~ W0200004140-A1 Cancer H2CBT75 Y87085 W0200004140-A1 Cancer HAGDQ42 Y87086 W0200004140-A1 Cancer HBMCJ42 Y87087 'W0200004140-A1 Iinmune/Hematopoietic, - ~ Re roductive HLCDA16 Y87089 W0200004140-A1 Cancer HELHL48 Y87090 W0200004140-A1 Cancer -HISAQ04 Y87091 W0200004140-A1 Digestive, NeurallSensory, Re roductive HJACB89 Y87092 W0200004140-A1 Caneer .

HTECCOS Y87093 W0200004140-A1 Cancer HBJLFO1 Y87094 W0200004140-A1 Cancer HBXGP60 ,Y87095 WO200004140-A1 Cancer HCESB20 Y87096 W0200004140-A1 Mixed Fetal, , Neural/Senso HCMSQ56 Y87097 W0200004140-Al Cancer HCNAH57 Y87098 W0200004140-A1 Di estive HCUEP91 ~ Y87099 WO200004140-Al Immune/Hemato oietic HDPCJ91 Y87100 WO200004140-A1 Cancer HDPGK25 Y87101 WO200004140-A1 Cancer HE2DY70~ Y87102 W0200004140-A1 Immune/Hematopoietic, Mixed Fetal, Musculoskeletal HE2NV57 - Y87103 W0200004140-A1 Cancer ' HETBR16 Y87104 W0200004140-A1 Digestive, a Imrnune/Fiematopoietic, Re roductive HFXDG13 Y87105 W0200004140-A1~' Cancer HFXKY27 . Y87106 W0200004140-A1 NeurallSensory -HHPEC09 Y87107 ' W0200004140-Al Cancer HISAD54 Y87108 W0200004140-A1 Cancer HJBCY35 Y87109 W0200004140-A1 Cancer HKAEA19 Y87110 'WO200004140-A1 Cancer HKGDL36 Y87111 W0200004140-A1 Cancer HLDBS43~ Y87112 W0200004140-A1 Cancer -HLWAD92 Y87113 W0200004140-A1 Cancer HLYBI15 Y87114 W0200004140-A1 Immune/Hemato oietic HMEJE05 Y87115 W0200004140-A1 Cancer HNGIX55 Y87116 W0200004140-A1 Immune/Hemato oietic HNHEX30 ' Y87117 W0200004140-A1 Immune/Hemato oietic HPJBI33 Y87118 W0200004140-A1 Re roductive HRABA80 Y87119 W0200004140-A1 Excretory HRACD80 Y87120 ~ W0200004140-A1 Excretory, Re roductive HSLCX03 Y87121 W0200004140-A1 Cancer HT5GJ57 Y871.22 W0200004140-A1 Cancer HTACS42 Y87123 W0200004140-A1 Cancer HTEKE40 Y87124 ~ W0200004140-A1 Cancer HTOBX69 Y87125 W0200004140-A1 Cancer HWE077 Y87126 W0200004140-A1 Re roductive H2CBG48 Y87127 W0200004140-A1 Cancer H2CBU83 Y87128 WO200004140-A1 Cancer HAPNY94 Y87129 W0200004140-A1 Cancer HBJHZ58 Y87130 W0200004140-A1 Immune/Hematopoietic, - Re roductive HCE2B33 Y871.31 WO200004140-A1 Cancer HDPBQ02 Y87132 W0200004140-A1 Immune/Hemato oietic ' HFIYI70 Y87133 W0200004140-A1' Cancer HDPOZ56 Y87134. W0200004140-A1 Cancer .

HAPOM49 Y87136 W0200004140-A1 Cancer HBJFJ26 Y87137 WO200004140-A1 Cancer HCNUA40 Y87138 W0200004140-A1 Cancer HCEBW71 Y87139 W0200004140-A1 Mixed Fetal, NeurallSensory HCEBW71 Y87140 W0200004140-A1 Mixed Fetal, Neural/Sensory HAUAI83 Y87141 W0200004140-A1 Re roductive HFLQB16 Y87143 W0200004140-A1 Cancer HAGFY16 Y87144 W0200004140-A1 Cancer HFLQB16 Y87146 W0200004140-A1 Cancer HAGFY16 Y87147 WO200004140-Al, Cancer HMHBN40 Y87149 W0200004140-A1 Cancer HDPBQ71 Y87150 . W0200004140-A1 Cancer HSKCT36 Y87151 W020000414.0-A1 Cancer HRACD80 Y87152 W0200004140-A1 Excretory, Re roductive HSLCX03. Y87153 W0200004140-A1 Cancer, H2CBU83 Y87154 W0200004140-A1 Cancer HFLQB16 Y87180 W0200004140-A1 Cancer HAGFY16 Y87181 W0200004140-A1 Cancer HFLQB16 Y87183 W0200004140-A1 Cancer -HAGFY16 Y87184 W0200004140-A1 Cancer HMHBN40 Y87187 W0200004140-A1 Cancer HDPBQ71 Y87188 W0200004140-A1 Cancer HSKCT36 Y87192 W0200004140-Al Cancer HRACD80 Y87205 W0200004140-A1 Excretory, ~ Re roductive HSLCX03 Y87208 W0200004140-A1 Cancer H2CBU83 Y87215 W0200004140-A1 Cancer HISCH47 Y87784 US6054289-A Cancer HADCD24 , Y87789 US6054289-A Cancer HDTEA84 Y90357 WO200052028-A1 Cancer HKGCN17 Y91346 WO200011014-A1 Immune/Hemato oietic, l04 Neural/Sensory, Re roductive HETAD68 Y91347 W0200011014-A1 Cancer HPIAT78 Y91348 W0200011014-A1 Cancer HHFHG52 Y91349 WO200011014-A1 Cancer HDTAB58 Y91350 W0200011014-A1 Cancer HEOMQ62 Y9135I W02000I10I4-AI Cancer ' HWLJQ88 Y91352 W0200011014-A1 Di estive HMICP03 Y91353 W0200011014-A1 Cancer ~HAJABOl Y91354 W020Q011014-A1 Cancer HE2AT09 Y91355 W0200011014-A1 Cancer HSDJA15 Y91356 W0200011014-A1 Cancer HAMGW29 Y91357 W0200011014-A1 Cancer HAPSR85 Y91358 W0200011014-A1 Digestive, , Endocrine HTOHD42 Y91359 W0200011014-A1 Immune/Hemato oietic HWLIH65 Y91360 WO200011014-A1 Cancer HTOJA73 Y91361 WO200011014-A1 Immune/Hemato oietic HPMGJ45 Y91362 W0200011014-A1 Cancer HFVIC62 Y91363 W0200011014-A1 Digestive, Immune/Hematopoietic, Re roductive HHENW77 Y91364 - W0200011014-A1 Cancer HMSIV91 Y91365 WO200011014-A1 Cancer HMSKC04 Y91366 ~ W0200011014-A1 Immune/Hemato oietic HSAZG33 Y91367 W0200011014-A1 Irnmune/Hemato oietic HTEBC92 Y91368 W0200011014-A1 Cancer HTXEL29 Y91369 ~ W0200011014-A1 Immune/Hemato oietic HDPAW44 ~ Y91370 . W0200011014-A1 Cancer HMACS20 Y91371 WO20001,1014-A1 Cancer HAJAY88 Y91372 W0200011014-A1 Immune/Hemato oietic HBOEG69 Y91373 W0200011014-A1 Cancer .

HWLEQ37 Y91374 W0200011014-A1 Cancer HE9CS37 Y91375 W0200011014-A1 . Cancer HNGEI34 Y91376 W0200011014-A1 Immune/Hemato oietic HTOAT76 Y913'77 W020b01.1014-A1 Excretory, Immune/Hemato oietic HDPVH60 Y91378 W0200011014-A1 Cancer .

HLYCR65 Y91379 W0200011014-A1 Cancer HARAY91 Y91380 , W0200011014-A1 Immune/Hematopoietic, Mixed Fetal, Neural/Sensor HCHNT03 Y91381 W0200011014-A1 Digestive, Re roductive HCLJBW95 Y91382 WO200011014-A1 Immune/Hematopoietic, Neural/Senso HDPLV95 Y91383 W0200011014-A1 Immune/Hematopoietic, Re roductive HEMGB12 Y91384 W0200011014-A1 Cancer , HHENP27 Y91385 W0200011014-A1 Cancer HSPBF70 Y91386 W0200011014-A1 Cancer HTXKB57 ~ Y91387 ' ' W0200011014-A1 Cancer HI_JKAA55- Y91388 W0200011014-A1 Digestive, .
Immune/Hematopoietic, Re roductive .

HFXGT58 ' Y91389 ~ W0200011014-A1 Neural/Sensory 105 ' .

HUSFF19 Y91391 W0200011014-A1 Cancer HUVDJ43 Y91393 W0200011014-A1 Cardiovascular, Re roductive HTLCU49 Y91394 WO200011014-A1 Cancer HDTAB58 Y91395 W0200011014-A1 Cancer HWLJQ88 Y91396 W0200011014-A1 Di estive HUVDJ43 Y91399 W0200011014-A1 Cardiovascular, Re roductive HUVDJ43 Y91400 W0200011014-A1 Cardiovascular, Re roductive HTLCU49 Y91401 W0200011014-A1 Cancer HUVDJ43 Y91446 W0200011014-A1 Cardiovascular, Re roductive HUVDJ43 Y91448 WO200011014-A1 Cardiovascular, Re roductive HFKIB49 Y91449 ' W0200011014-A1 Cancer HDPTK41 Y91451 W0200006698-A1 Cancer ' HFXGT26 Y91452 W0200006698-A1 Cancer HLTGX30 Y91453 WO200006698-A1 Immune/Hemato oietic HLTHG37 Y91454 W0200006698-A1 Cancer HNTMZ90 Y91455 W0200006698-A1 Digestive, _ ' Re roductive HPIBX03 Y91456 W0200006698-A1 Cancer H6EDY30 Y91457 W0200006698-A1 Cancer HAMGR28 Y91458 W0200006698-A1 Cancer HAPNZ94 Y91459 W0200006698~-Al' Cancer HATCP77 Y91460 W0200006698-A1 Cancer HDABR72 ' Y91461 W0200006698-Al Cancer HDPKB18 . Y91462 W0200006698-A1 ImmunelHemato oietic ' HEQCC55 Y91463 W0200006698-A1 Cancer HETDE26 Y91464 W0200006698-A1 Cancer HOEDH84 Y91465 W0200006698-A1 Cancer HPIBT55 Y91466 W0200006698-A1 Cancer HSLCS05 Y91467 W0200006698-A1 Cancer HDPDD03 Y91468 W0200006698-A1 Cancer HDTDQ23. Y91470 W0200006698-A1 Cancer HE2PY40 Y91471 W0200006698-A1 Mixed Fetal , HEONM66 Y91472 W0200006698-A1' Immune/Hemato oietic HKAEG43 Y91473 WO200006698-A1 Cancer ' HLHDP65 Y91474 W0200006698-A1 Cancer HLMD003 Y91475 W0200006698-A1 Cancer HMAGK93 Y91476 W0200006698-A1 Cancer HMEAL02 Y91477 W0200006698-A1 Cardiovascular HMKCH52 Y91478 W0200006698-A1 Neural/Sensory HCEFB69 Y91479 W0200006698-A1 Cancer HKAD1VI92 Y91480 W0200006698-A1 Cancer HSPMG77 Y91481 ~ W0200006698-A1 Di estive HSQAC69 Y91482 W0200006698=A1 Cancer HSTBJ86 Y91483 W0200006698-A1 Connective/E ithelial HUVDJ43 . Y91485 WO200006698-A1 Cardiovascular, Re roductive HADCP14 Y91486 W0200006698-A1. Cbnnective/E ithelial HBXCF95 Y91487 W0200006698-A1 Cancer HEQBU15 Y91488 W0200006698-A1 Cancer HL1BD22 Y91489 W0200006698-A1 Cancer HOEEU24 Y91490 W0200006698-A1 Cancer HTTBR96 Y91491. W0200006698-A1 Re roductive HWHQS55 Y91492 W0200006698-A1 Cancer HCEEK50 Y91493 - W0200006698-A1 Cancer HCWBU94 Y91494 W0200006698-A1 Ixnmune/Hemato oietic HE2NR62 Y91495 W0200006698-Al Cancer HHSGH19 Y91496 WO200006698-Al. Neural/Sensory HDPGTO1 Y91497 W0200006698-A1 Cancer HOHCA35 Y91499 W0200006698-A1 Cancer HPMGP24 Y91500 W0200006698-Al Mixed Fetal, Re roductive r HSDIE16 Y91501 W0200006698-A1 Neural/Sensory HSOBK48 Y91502 W0200006698-A1 Di estive HTADH39 Y91503 W0200006698-A1 Cancer HUSGT36 Y91504 W0200006698-A1 Cardiovascular HVAAE95 Y91505 W0200006698-A1 Di estive HHEAH25 Y91506 W0200006698-A1 Cancer HBJIY92 Y91507 W0200006698-A1 Cancer HCLCW50 Y91508 W0200006698-A1 Res iratory HDRMF68 Y91509 . W0200006698-A1 Digestive, ~ ' - Res iratory HOUGG12 Y91510 W0200006698-A1 Cancer HEEAQ1I Y91511 W0200006698-A1 Re roductive HEEAZ65 Y91512 W0200006698-A1 Musculoskeletal, Re roductive HEGAN94 Y91513 W0200006698-A1 Re roductive HFXBL33 Y91514 W0200006698-A1 Cancer HLIBD68 Y91515 W0200006698-Al Cancer HLTC033 Y91516 W0200006698-A1 Immune/Hematopoietic, ' . Neural/Sensory, Re roductive HLYAC95 Y91517 WO200006698-A1 Immune/Hemato oietic HNHKS18 Y91519 W0200006698-A1 Immune/Hemato oietic HSLJW78 Y91520 W0200006698-A1 Musculoskeletal HHFHDO1 Y91521 W0200006698-A1 Cardiovascular, ' Musculoskeletal, Neural/Sensory HLWAE11 Y91522 W0200006698-A1 Cancer HCYBN55 Y91523 W0200006698-A1 Cancer HEONX38 Y91524 - ' W0200006698-A1 Cancer HLDQU79 Y91525 ' ~ W0200006698-A1 Cancer );ISYBK21 Y91526 W0200006698-A1 Cancer HTHDS2S Y91528 - W0200006698-A1 Endocrine, Immune/Hemato oietic ~IFIH070 Y91529 W0200006698-A1 Cancer HPMEI86 Y91530 W0.200006698-A1 Cancer HSOBV29 Y91531 W0200006698-A1 Cancer HWABY10 Y91532 W0200006698-A1 Cancer HACCI17 Y91533 WO200006698-A1 Cancer HAPQT22 Y91534 W0200006698-Al hnmune/Hemato oietic HDPB081 Y91535 W0200006698-A1 Digestive, Immune/Hematopoietic, Re roductive HDPGI49 Y91536 W02000b6698-A1 Cancer HDTBV77 ~Y91537 W0200006698-A1 Cancer HFIUE82 Y91538 W0200006698-A1 Cancer HHEND31 Y91539 W0200006698-A1 Cancer HKMNDO1 Y91540 W0200006698-A1 Excretory HLDBI84 Y9154.1 W0200006698-A1 Cancer HLTEK17 Y91542 W0200006698-A1 Cancer HEBEJ18 Y91543 W0200006698-A1 Cancer HMEAI48 Y91544 W0200006698-A1 Cardiovascular HNHGN91 Y91545 W0200006698-A1 Digestive, Endocrine, Immune/Hemato oietic HODAE92 Y91546 W0200006698-A1 Cancer HODDF13 Y91547 W0200006698-A1 Re roductive HATEF60 Y91548 W0200006698-A1 Cancer HLTHG37 Y91549 W0200006698-A1 dancer HAMGR28 Y91550 : W0200006698-A1 Cancer HDPKB18 Y91551~ W0200006698-A1 Immune/Hemato oietic HEQCC55 Y91552 W0200006698-A1 Cancer HEONM66 Y91554 W0200005698-A1 Immune/Hemato oietic HKAEG43 Y91555 W0200006698-A1 Cancer HLHDP65 Y91556 W0200006698-A1 Cancer HOEEU24 Y91557 W0200006698-A1 Cancer HHEAH25 Y91558 W0200006698-A1 Cancer HCYBN55 Y91559 W0200006698-A1 Cancer HEONX38 Y91560 WO200006698-A1 Cancer HFIH070 Y91561 W0200006698-A1 Cancer HACCI17 Y91562 W0200006698-A1 Cancer HDPB081 Y91563 W0200006698-A1 Digestive, Immune/Hematopoietic, Re roductive HAMGR28 Y91599 W0200006698-A1 Cancer HDPKB18 Y91603 WO200006698-A1 Immune/Hemato oietic HEQCCSS Y91604 W0200006698-A1 Cancer HLHDP65 Y91631 W0200006698-A1 Cancer -HOEEU24 Y91643 W0200006698-A1 Cancer HHEAH25 Y91647 W0200006698=A1 Cancer HHEAH25 Y91648 W0200006698-A1 Cancer HLIBD68 Y91656 W0200006698-A1 Cancer HCYBN55 Y91670 ~ W0200006698-A1 Cancer HEONX38 Y91672 W0200006698-A1 Cancer _ HFIH070 Y91679 W0200006698-A1 Cancer HMKBA64 Y91681 . W0200006698-A1 Cancer HACCI17 Y91683 W0200006698-A1 Cancer HMKEA94 Y93650 W0200036105-A1 . Cancer HE9SF68 Y93973 WO200042189-A1 Cancer HTSGS30 , Y93974 W0200042189-A1 Digestive, - Immune/Hematopoietic, Mixed Fetal HDQAC88 Y95534 W0200040726-A1 Cancer HDPMM34 Y96280 W020b028035-A1 Cancer HKABZ65 Y96962 W0200039327-A1 Connective/E ithelial HWHGB15 Y96963 W0200039327-A1 Connective/E ithelial ~

HCDDP40 Y96964 W0200039327-A1 hnmune/Hematopoietic, Musculoskeletal HETBE01 B03767 US6066724-A Cancer HETGI70 B03768 US6066724-A Cancer HETDK42 B03769 US6066724-A ' Cancer ' HTEMZ33 B07705 W0200043493-A2 Cancer .

HE8AW20 B0.794.1 US6103871-A Cancer .

HNEDU15 B08659 W0200050597-A2 Cancer HLTBT71 B08661 W0200050597-A2 Cancer HBICD95 B08785 W0200050620-A2 Cancer IiE9CC44 B08786 US6110893-A ~ Cancer ' HPRCC57 B 10293 US6077692-A Cancer HPRCC57 B10304 US6077692-A Cancer HPRCC57 ~ B10310 US6077692-A Cancer HPRCC57 B 10311 . US6077692-A Cancer HPRCC57 B 10312 US6077692-A Cancer HPRCC57 B10313 US6077692-A Cancer HPRCC57 B10316 US6077692-A Cancer HPRCC57 B 10320 US6077692-A Cancer HILBX90 B11125 _ Cancer HCQAS 17 B 12900 US6080722-A Digestive, Mixed Fetal, Re reductive HBMSE33 B15366 W0200042165-A2 Cancer HE2BG16 B15413 US6090575-A Cancer HT4CC72 B18618 W0200053223-A1 Immune/Hemato oietic HAPOR40 B18750 W0200055204-A1 Cancer HTSGS30 B18755 W0200055204-A1 Digestive, Immune/Hematopoietic, ' Mixed Fetal HFGAM58 B18803 W0200053210-A1 Cancer HSDFB55 B19550 W0200053793-A1 Cancer HUVE091 ~ B19863 W0200066608-A1 Cancer HCDDP40 B25583 W0200029435-A1 Immune/Hematopaietic, Musculoskeletal HMELK96 B26981 W0200056862-A1 Cancer HMELK96 B26987 W0200056862-A1 Cancer HTTBN61 B26990 W0200056862-Ai Cancer HCUDS60 B26991 W0200056862-AI Cancer HLYBX88 B26992 W0200056862-A1 Cancer HILBI36 ~ B28524 US6130051-A Cancer HLYBX88 B29790 W0200066156-A1 Cancer HCEMP60_ ' B29923 US6130061=A Cancer HE8AE45 B33821 W0200056753-A1 Cancer HE20A95 B33822 W0200056753-A1 Cancer HJACE54 B35705 W0200063221-A2 Cancer HTTBN61 B36265 W0200064465-A1 Cancer.

HPRCB54 ~ B36696 W0200071150-Al Cancer HSDME38 B39392 W0200057903-A2 Cancer HSDME38 B39393 W0200057903-A2 Cancer HPDDY64 B43604 W0200055350-A1 Cancer HPABA51 B44685 W0200058339-A2 Cancer ~

HPMSM24 845376 W0200061628-A1 Cancer HOUCQ17 B50002 W0200071577-A1 Cancer HODAH63 B50272 W0200071567=A2 Neural/Sensory, Re reductive HODAH63 B50282 W0200071567-A2 Neural/Sensory, Re reductive HODAH63 BS0283. W0200071567-A2 Neural/Sensory;
Re reductive HCEGY95 BS0289 W0200071582-A1 Immune/Hematopoietic, _ Mixed Fetal, .
Neural/Sensory HE9CC44 B50293 W0200071'715-A1 Cancer HAGAT55 B50294 W0200071715-A1 Cancer HAGAT55 B50704 W0200071152-A1 Cancer HKABO35 B50892 WO200073321-A1 Cancer HETJY78 B51152 US6153739-A Cancer HPRGC57 B58248 WO200055180-A2 Cancer HHFCU19 B58276 W0200055180-A2 Cancer HNFAG09 B58319 W0200055180-A2 Cancer HBZSD43 B58925 W0200055173-Al Cancer HHFHJ57 B58970 W0200055173-A1 Cancer HPRCC57 B60201 W0200072872-A1 Cancer HPRCG57 B60204 W0200072872-A1 Cancer HPRCC57 B60206 W0200072872-A1 Cancer HPRCC57 B60207 W0200072872-A1 Cancer HPRCC57 B60208 W0200072872-A1 Cancer HPRCC57 B60209 W0200072872-A1 Cancer HPRCC57 B60210 W0200072872-A1 Cancer HPRCC57 B602I2 W0200072872-A1 Cancer HPRCC57 B60214 W0200072872-A1 Cancer .

HRGB 38 B64643 - W0200077197-A1 Cancer HRGB 38 B64644 W0200077197-AI Cancer HRGBQ38 B64645 W0200077197-A1 Cancer HRGBQ38 B64646 W0200077197-A1 Cancer HLTBT71 B64873 W0200077256-Al Cancer HTEIX55 B64953 W0200076530-A1 Cancer HPABAS 1 875085 ZA9403789-A Cancer .

HAPAT57 876127 W09517092-A Cancer HWFBD68 876128 WO95I7092-A . Cancer .

HiVIPSA79 877649 W09532282-A1 Cancer -HGBAB73 879008 ' W09520678-Al. Cancer HLTAW73 879009 W09520678-A1 Cancer HFCAW 19 880095 ' WO9527781-A1 Cancer HHFBT80 880575 W09524474-A1 Cancer HFKCU96 881309 W095I9985-A1 Cancer HSRAW34 R8I46I W09605226-AI Cancer HOSBD47 882686 W09524473-A1 Cancer HOSBH74 882720 W09524182-A1 Cancer HE8AE45 882987 W09524466-A1 Cancer HLFBE10 884522 W09524411-A1 Cancer HAGAT55 885650 W09524414-A1 Cancer HIBEC52 887954 W09530428-A1 Cancer HTEAH87 888390 W09531539-A1 Cancer HFBEH64 888405 W09531538-A1 Cancer HAFAK86 888419 W09535372-A1 Cancer HASSB35 888452 W09600242-A1 Cancer HPAAA47 88848.1 W09601270-A1 Cancer HJPAH22 890703 W09600297-A1 Cancer HIBCL76 890764 W09603415-A1 Cancer HIBEJ89 890765 W09603415-A1 Neural/Sensory HLFBE49 890919 W09601896-A Cancer HIBCL22 890989 W09605225-A1 Cancer HSSAW84 891929 W09612791-Ai Cancer .

HSNME29 892220 W09604928-A1 Cancer HSNME29 892753 W09605221-A . Cancer HGBAN46 893086 W09605856-AI~ ' Cancer ' HE9DR66 893087 W09605856-A1 Cancer HTPAN40 893118 W09606862-A Cancer HILBI36 893156 W09608557-A1 Cancer HJBAQ29 894350 W09609311-A1 Cancer HASAC73 89460.1 W09611259-AI Cancer HPLAP22 894602 W09611259-A1 Cancer HT2SA16 895634 WO96I4394-A1 Cancer HLHAC42 895692 W09615806-AI Cancer HE2CA82 895830 WO9613603-A1 Cancer HTOBA30 895831 W09613603-A1 Cancer HFSBE16 897222 W09616087-A1 Cancer HHFCU19 897565 W0~9621736-A1 Cancer HE8AW20 897739 W09615222-A1 Cancer HSBBC75 897978 W09615147-A1 Cancer HLFBG09 898224 W09612501-AI ~ Cancer HHPEC49 898261 W09611946-A1 Cancer HFGAM58 898265 W09618725-A1 Cancer HUVCT01 898994 WO9617931-A1 Cancer HFSAG79 899329 W09624668-A1 Cancer HATBG78 899353 W09627009-A1 Endocrine HUVE091 899453 W 09614328-A 1 Cancer HPRCC57 W00176 W09625422-A1 Cancer HCAAA02 W00482 W0962I724-A1 Cancer HETAN67 W01097 WO9629401-AI Cancer HSSNBO1 W01098 W09629401-A1 Cancer HETJY78 ' W01619 W09635778-A1 Cancer HPRAJ70 W01730 W09639435-A1 ~ Cancer HNFAG09 W02151 W09625432-A1 Cancer HFSBC65 W02613 W09618730-A1 Cancer HE2BG16 W04247 W09630406-A1 Cancer HTECE68 W05295 W09630524-A1 - Cancer HRGBQ38 W05313 W09623410-A1 Cancer HFCCE09 W05314 W09623410-A1 Cancer HGOCA18 W05315 WO9623410-A1 Cancer HT1SB52 W05809 W09634095-A1 Cancer HFGAN72 W06124 W09634877-A1 Cancer HHFBT80 ~ W06539 W09639431-A1 Cancer HCNAY46 W06545 W09639419-A1 Cancer HCQDM23 W06546 W09639419-A1 , Digestive, Re roductive HCNUB65 W06548 W09639419-A1 Cancer HCNSE58 W06550 W09639419-A1 Cancer HCNBB33 W06551 W09639419-Al - Cancer HKLSA58 W0,6552 W09639419-A1 Cancer HCNSD13 W06553 W09639419-Al Cancer HLQBII4 W06575 W09639520-A1 Cancer HAECD08 W07202 W09634891-A1 Cancer HWFBD68 W07203 WO9634891-A1 ', Cancer HAPAT57 W07204 W09634891-A1 Cancer HDGNR10 W07602 W09639437-A1 Digestive, Immune/Hematopoietic, Re roductive HMSDB49 W07604 W09639521-A1 Immune/Hematopoietic, Re roductive HFSAG79 ~ W07605 W09639522-A1 Cancer HTOEX74 W07606 WO9639522-A1 Cancer HMWCF06 W07611 W09639421-A1 Cancer HIBEB69 W07617 W09639438-A1 Cancer HGBER32 W07618 W09639434-A1 Di estive HETGQ23 W07619 WO9639436-A1 Cancer HE20A95 W07663 ~ W09636709-A1 Cancer HCEGY95 W08079 W09639506-A1 Immune/Hematopoietic, Mixed Fetal, Neural/Sensory HIBEF51 W08101 W09639441-Al NeurallSenso HTNAD29 W08141 WO9639442-A1 Cancer HE9CC44 W08142 W09639507-A1 Cancer HDGRC02 W09110 W09639440-A1 Cancer HPTTT24 W09111 W09639420-A1 Digestive, Endocrine HUVDR03 W09404 ~ W09639485-A1 Cancer HPBCB95 W09405 W09639158-A1 Cancer HE9NG77 W09408 , W09639486-A1 Cancer HATCK89 . W09432 W09639509-AI Cancer HTOEX74 W10574 W09624668-A1 Cancer HOSBD47 W11478 W09639515-A1 Cancer HCQAS17 ' W12691 WO9639541-A1 Digestive, Mixed Fetal, Re reductive HCACU62 W12692 W09639424-A1 Cancer HAQBM60 W12693 W09639418-A1 Connective/Epithelial, Immune/Hematopoietic, Re reductive HLTDG74 W12695 W09639433-A1 Immune/Hemato oietic HODAH63 W12696 W09639508-A1 Neural/Sensory, Re reductive HSSAW84 W17043 US5618717-A Cancer HHSAN40 W17838 WO9717358-A1 Cancer HTPBS22 W19632 W09722623-A1 Cancer HSATU68 W19780 W09725340-A1 Cancer HFCBS02 W22408 W09711970-A1 Cancer HGBAN46 W22669 W09731098-A1 Cancer HE9DR66 W22670 W09731098-A1 Cancer HE9DR66 W22671 W09731098-A1 Cancer HE9DR66 W22672 W09731098-A1 Cancer HE9DR66 W22673 W09731098-A1 Cancer HE9DR66 W22674 W09731098-A1 Cancer HE9DR66 W22675 W09731098-A1 Cancer HPMSM24 ~ W22732 W09724929-A1 Cancer HPABA51 W22882 US5635616-A ~ Cancer HESAJ20 W23663 W09729189-A1 Cancer HALTA54 W24137 W09723640-A1 Cancer HCEMP60 W24847 W09718224-A1 Cancer HFCCE09 W25112 US5650313-A Cancer HGOGA18 W25113 US5650313-A Cancer HRGBQ38 W25114 US5650313-A Cancer HTPAN40 ~ W26464 US5654172-A Cancer HTECD31 W27087 W09725349-A1 Cancer HLHDC84 W27118 ' W09725338-A1 Cancer HTPAN08 W27134 W09733899-A1 ' Cancer .

HFKET35 W27152 W09734013-A1 Cancer HTTER36 W27224 W09735870-A1 Cardiovascular, - _ Connective/Epithelial, Re reductive HTOBH93 W27561 WO9727747-A1 Cancer HE6BK61 W29291 W09735010-A1 Cancer HE6BK61 W29292 W09735010-A1 Cancer HTOJK64 W30193 W09735976-A2 Cancer HLMBA70 W30891 W09735028-A1 Immune/Hematopoietic;
. Mixed Fetal, - - Re reductive HMEIP65 W31512 W09732993-A1 ~ Cancer HTTBN61 W31517 W09733904-Al Cancer HFLQA68 W31527 WO9737022-A1 ' Cancer HE8AW20 ~ W31692 US5695980-A ' Cancer ' HTXEI33 W31759 W09733898-A1 Cancer HCUDE60 W31902 W09737021-A1 Cancer HCABA58 W32110 W09738012-A1 Cancer.

HMEAN51 W32112 ' W09734998-A1 Cancer HT4CC72 W32255 W09734911-A1 Immune/Hemato oietic HCUDE60 W32323 W09736915-A1 .Cancer HSAAU35 W33603 W09747742-A1 Connective/Epithelial, Musculoskeletal, Re reductive HETBE01 W35802 WO9734997-A1 Cancer HETGI70 W35803 WO9734997-A1 Cancer HETDK42 W35804 W09734997-A1 Cancer HBJEL88 W35904 W09738003-A1 Cancer HSHCL68 W36449 W09735027-A1 Cancer HLTBT71 W37002 W09733902-Al Cancer HPDD012 W37003 ~ W09733902-A1 Cancer HHPEC49 W37799. US5750370-A Cancer HCQAJ72 W37844 W09807749-A1 Cancer HMECG71 W37845 W09807749-A1 Cancer HSIEH63' W37846 W09807749-A1 Di estive HBICD95 W37847 v WO9807880-A1 Cancer HMQBM23 W37935 'W09808870-A1 Cancer HOEBG39 W37946 W09821236-A1 Cancer HOSBH74 W39216 EP812916-A2 ~ Cancer HOSBH74 W39264 EP812916-A2 Cancer HOSBH74 W39265 EP812916-A2 Cancer HOSBH74 W39266 EP812916-A2 Cancer HOSBH74 W39267 EP812916-A2 Cancer HOSBH74 W39268 EP812916-A2 Cancer HODAH63 W40077 US5728546-A Neural/Sensory, Re reductive HFBEH64 W41362 US5723311-A ~ Cancer HSAAU35 W41502 EP812913-A2 Connective/Epithelial, ' . . Musculoskeletal, Re reductive -HSAAU35 W41520 W09747741-A1 Connective/Epithelial, Musculoskeletal, Re reductive HOSBH74 W41645 W0974.7642-A1 Cancer HTSEX82 W41938 W09748807-A1 , Digestive, Immune/Hematp oietic HIBCL76 W42995: US5710019-A Cancer ' HIBEJ89 W42996 US5710019-A Neural/Sensory HILBI36 W46518 US5716806-A Cancer HCNAY46 W46876 US5733748-A Cancer HCQDM23 W46877 US5733748-A Digestive, Re roductive HCNUB65 W46879 US5733748-A Cancer HCNSE58 W46882 US5733748-A Cancer HCNBB33 W46883 US5733748-A Cancer HKLSA58 W46884 US5733748-A Cancer HCNSD13 W46885 US5733748-A ~ Cancer HEMEM90 W48334 ~ W09807881-A1 Cancer HE9BK24 W48335 W09807754-A1 Cancer HPASD50 W48391 W09807735-A,1 Cancer HETAN67 W48762 W09812204-A1 Cancer HHFHJ57 W49032 W09825957-A2 Cancer HGBER32 W49807 US5776729-A Di estive HATCK89 W49826 US5773252-A Cancer HCEPR64 W51244 W09821242-A1 Cancer HPRCC57 W52581 WO9806844-Al Cancer HPRCC57 W52582 W09806844-A1 Cancer HPRCC57 . W52583 WO9806844-A1 Gancer HPRCC57 W52584 W09806844-A1 Cancer HPRCC57 W52585 v W09806844-A1 Cancer HPRCC57 W52586 W09806844-A1 Cancer HPRCC57 W52587 W09806844-A1 Cancer HPRCC57 W52588 W0980.6844-A1 Cancer HPRCC57 W52590 W09806844-A1 Cancer HPRCC57 W52591 WO9$06844-A1 Cancer HPRCC57 W52592 W09806844-A1 Cancer HPRCC57 W52593 W09806844-A1 Cancer HPRCC57 W52594 W09806844-A1 Cancer HPRCC57 W52595 W09806844-A1 Cancer HPRCC57 W52596 W09806844-A1 ' Cancer HPRCC57 W52597. W09806844-A1 Cancer HPRCC57 W52598 W09806844-A1 ~ Cancer HPRCC57 W52599 W09$06844-A1 dancer HDQMB53 W52842 W09807862-A2 Cancer HWFBD68 W52843 W09807862-A2 Cancer HPMFW51 W53121 W09806859-A1 Cancer' HPiVIFW51 W53122 W09806859-A1 Cancer HPRCC57 W53787 W09806844-A1 ~ Cancer HPRCC57 W53792 ' W09806844-A1 Cancer HPRCC57 W53793 W09806844-A1 Cancer HMEEJ22 W53897 . W09808969-A1 Cancer HE9CC44 W54036 US5763214-A Cancer HM CD14 W55884 W09806733-A1 Cancer HUVDE75 W56249 W09806839-A1 Cancer HCNBB33 W56503 WO9815624-A1 Cancer HTPBR22 W56504 W09815624-A1 .Cancer HETAS87 W56505 ' W09815624-A1 Cancer HETAS87 W56506 ' W09815624-A1 Cancer HPRAJ70 . W56641 US5756309-A Cancer HAICL46 W57044 W09811138-A1 Cancer HAECD08 W57688 W09814582-Al Cancer HAECD08 W57691 W09814582-A1 Cancer HAECD08 W57692 W09814582-A1. Cancer HAECD08 W57693 W0981.4582-A1 Cancer HAECDO8 ' W57694 W09814582-A1 Cancer HAECD08 W57695 W09814582-A1 Cancer HWFBD68 W57697 W09814582-A1 Cancer HAPAT57 W57698 W09814582-A1 Cancer HAECD08 W57699 W09814582-A1 Cancer HAECD08 W57701 W09814582-A1 Cancer HMSDB49 W57881 W09824908-A1 Immune/Hematopoietic, Re roductive HNEDU15 W58391 W09818921-A1 Cancer HE9NG77 W58704 US5780263-A Cancer HFSAG79 W58900 W09814477-A1 Cancer HTOEX74 W58901 W09814477-A1 Cancer HTOEX74 W58902 WO9814477-Al Cancer HTOEX74 W58903 W09814477-A1 Cancer HTOEX74 W58904 W09814477-A1 Cancer HTOEX74 W58905 W09814477-A1 Cancer HTOEX74 W58906 W09814477-A1 Cancer HTOEX74 W58907 W09814477-A1 Cancer HTOEX74 W58908 W09814477-A1 Cancer HTOEX74 W58909 W09814477-A1 Cancer HTOEX74 W58910 W09814477-A1 Cancer HTOEX74 W58911 W09814477-A1 Cancer HTOEX74 W58912 W09814477-A1 Cancer HTOEX74 W58913 W09814477-A1 Cancer HTOEX74 W58914 WO9814477-A1 Cancer ' HTOEX74 W58915 WO9814477-A1 ~ Cancer HTOEX74 W58916 W09814477-A1 Cancer HTOEX74 W58917 W09814477-A1 Cancer HTOEX74 W58918 W09814477-A1 Cancer HTOEX74 W58919 W09814477-A1 Cancer HTOEX74 W58920 W09814477-A1 Cancer HTOEX74 W58921 W09814477-A1 Cancer HTOEX74 W58922 W09814477-A1 Cancer HTOEX74 W58923 WO9814477-A1 Gancer HTOEX74 W5892,4 W09814477-A1 Cancer HTOEX74 W58925 W09814477-A1 Cancer HTOEX74 W58926 WO9814477-A1 Cancer HTOEX74 W58927 W09.814477-A1 Cancer HTOEX74 W58928 WO9814477-A1 Cancer HTOEX74 W58929 W09814477-A1 Cancer HTOEX74 W58930 W09814477-A1 Cancer HTOEX74 W58931 - ~ W09814477-A1 Cancer HTOEX74 W58932 . W09814477-A1 Cancer HTOEX74 W58933 W09814477-A1 Cancer HTOEX74 W58934 W09814477-A1 Cancer HTOEX74 W58935 W09814477-A1 Cancer HTOEX74 W58936 WO9814477-A1 Cancer HTOEX74 W58937 ~ W09814477-Al Cancer _ W58938 W09814477-A1 Cancer HTOEX74 W58939 WO9814477-A1 Cancer HTOEX74 W58940 W09814477-A1 Cancer HTOEX74 W58941 W09814477-A1 Cancer HFSAG79 W58942 W09814477-A1 Cancer HFSAG79 W58943 W09814477-A1 Cancer HFSAG79 W58944 W09814477-A1 Cancer HFSAG79 W58945 W098.14477-A1 Cancer HFSAG79 W58946 W09814477-Al Cancer HFSAG79 W58947 WO9814477-A1 Cancer HFSAG79 W58948 W09814477-A1 Cancer HFSAG79 W58949 W09814477-A1 Cancer HFSAG79 W58950 W09814477-A1 Cancer HFSAG79 W58951 W09814477-A1 Cancer HFSAG79 W58952 WO9814477-A1 Cancer HFSAG79 W58953 WO9814477-A1 Cancer HFSAG79 W58954 W09814477-A1 Cancer HFSAG79 W58955 W09814477-A1 Cancer HFSAG79 W58956 W09814477-A1 ' Cancer HFSAG79 W58957 WO9814477-A1 Cancer HFSAG79 W58958 W09814477-A1 Cancer HFSAG79 W58959 -W09814477-A1 Cancer HFSAG79 W58960 W09814477-A1 Cancer HFSAG79 ' W58961 W09814477-A1 Cancer HFSAG79 W58962 W09814477-A1 Cancer HFSAG79 .W58963 W09814477-A1 Cancer HFSAG79 W58964 W09814.477-A1 Cancer HFSAG79 W58965 W09814477-A1 Cancer HFSAG79 W58966 W09814477-A1 Cancer HFSAG79 W58967 W09814477-A1 Cancer HFSAG79 ' W58968 WO9814477-A1 Cancer.

HFSAG79 W58969 WO9814477-A1 Cancer HFSAG79 W58970 W09814477-A1 Cancer HFSAG79 W58971 W09814477-A1 Cancer HFSAG79 W58972 W09814477-A1 Cancer HFSAG79 W58973 W09814477-A1 Cancer HFSAG79 W58974 W09814477-A1 Cancer HFSAG79 W58975 W09814477-A1 Cancer HCEGH45 W59666 W09824900-A1 ~ Immune/Hematopoietic, Mixed Fetal, Neural/Sensory HHFCU19 W59753 US5786193-A Cancer HLMBP36 W59872 W09831792-A1 Cancer HEMFI85 W59873 W09831800-A2 Cancer -HTXET53 W59874 W09831800-A2 Cancer HBZAK03 W59876 W09831800-A2 Cancer HLFBD44 W59877 WO9831800-A2 Cancer HEBGM49 W59878 W09831800-A2 ~ Cancer HNGBH54 W59879 W09831800-A2 Cancer HSAAL25 W59880 W09831800-A2 Cancer HSXCK4I W59882 W0983I800-A2 Cancer HFKFY79 W59883 W09831800-A2 Cancer HAICH28 W59884 W09831800-A2 Cancer HT1SB52 ' W60045 W09818824-A1 Cancer HSDFB55 W60054 W09816643-A1 Cancer HEBBC23 W60607 WO9820110-A1 Immune/Hematopoietic, Musculoskeletal, Neural/Sensory HTPBS22 W61600 W09831798-A1 Cancer HMACR70 W61616 W09831799-A2 Cancer ' HTEDK48 W61617 W09831799-A2 Cancer HTPEF86 W61619 W09831799-A2 Cancer HSBBF02 W61620 W09831799-AZ Cancer HLTAH80 W61621 W09831799-A2 Cancer HTPBA27 W 61622 - WO9831799-A2 Cancer HAIDQ59 W61623 W09831799-A2 Cancer HHFEK40 W61624 W09831799-A2 Cancer - HGBGV89 W61625 W09831799-A2 Di estive HUVBB80 W61626 W09831799-A2 Cancer HJACE54 W61627 W09831799-A2 Cancer HROAD63 W61628 W09831799-A2 Connective/Epithelial, Di estive HMWGS46 W61629 W09831799-A2 Cancer HNFGW06 W61630 W09831799-A2 Cancer HFCAR05 W61912 W09820042-A1 Cancer HHFHG78 W62595 WO9827932-A2 Cancer HBGBA67 W63123 W09833915-A1 Cancer HPHAE52 ' ~W63622 W09830694-A2 Cancer HTPCH84 W63623 W09830694-A2 Cancer HEBCI67 W64433 W09829438-A2 Cancer HCUDS60 W64483 W09832856-A1 Cancer HPRCB54 W6466& W09830693-A2 Cancer HTOCD71 W69220 W09828421-A1 Cancer HSGSA61 W69221 WO9828420-A1 Cancer HSLAZ11 W69229 W09831801-A1 Cancer HCEBJ50 W69230 W09831801-A1 Cancer HMQD020 W69231 W09831806-A2 Cancer HDPMK33 W69232 W09831806-A2 Cancer HMPAP73 W69233 W09831806-A2 Immune/Hemato oietic HMSHH46 W69234 W09831806-A2 - Cancer HMAAB68 W69235 W09831806-A2 Digestive, Immune/Hemato oietic HSDME38 W69508 W09828422-A1 Cancer HOEBN05 W70~86 W09833920-A2 Cancer HDPMJ44 W70287 WO9835039-A1 Cancer HODAH63 W70330 ~ ~ W09823749-A1 Neural/Sensory, Re roductive HETDW91 W70458 - W09838311-A1 Cancer HE8CV92 W70459 W09838311-A1 Cancer HIBCL22 - W70501 US5817477-A Cancer HKFBA76 W70525 W09844111-A1 Cancer HKFBA76 W70526 W09844111-A1 Cancer HMSAF34 W70594 W09844118-A1 Cancer HMSAF34 W70596 W09844118-A1 Cancer HMSAF34 W70597 W09844118-A1 Cancer HRDCD54 W71592 W09833912-A1 Cancer HIBEC52 W73130 US5830744-A Cancer HSRAW34 W73635 USS$61272-A Cancer HBWAL95 W76212 W09837194-A1 Cancer HTEJQ70 W76251 ~ W09831818-A2 Cancer HETBWQS W76253 W09831818-A2 . Digestive, Re roductive HATBG78 W77493 US5798223-A Endocrine HMWGS46 W78168 W09856804-A1 Cancer HOUCQ17 W78189 W09856804-A1 Cancer HMWGS46 W78295 W09856804-A1 . Cancer HLYBX88 W79083 W09841629-A2 Cancer HTAAW41 W80212 W09844112-A1 Cancer HOUCQ17 W80285 EP874050-A2 Cancer HMELK96 W81059 WO9856892-A1 Cancer HLJBI75 W81071 W09851794-A1 Cancer HFCBS02 W81106 W09844109-A1 Cancer HHPGS02 W81576 W09850549-A2 Cancer HTOBH93 W83929 US5844081-A Cancer HSSAE30 W84184 W09853069-A2 Cancer HCQAS17 W84274 US5861494-A Digestive, Mixed Fetal, Re roductive HRGB 38 W85561 US5849286-A Cancer HFCCE09 W85562 US5849286-A Cancer HGOCA18 W85563 US5849286-A Cancer HMSIB42 W87769 W09854199-A1 Cancer HTECE68 W89575 US5858705-A Cancer HESAJ20 W92460 US5871969-A Cancer HESAJ20 ' W92469 US5871969-A . Cancer HTXEI33 W92523 US5874240-A Cancer HTXEI33 W92524 US5874240-A Cancer HKAB035 W92792 W09854202-A1 Cancer HCEGH45 W94074 US5869632-A . Immune/Hematopoietic, Mixed Fetal, NeuraIlSensory HNFIR05 W94466 W09900415-A1 Cancer HTTBN61 W95538 JP11000170-A Cancer HPFCA19 W96192 W09900498-A1 Cancer HPFCA19 W96193 W09900498-A1 Cancer HTSGS30 W97350 W09903982-A1 Digestive, Immune/Hematopoietic, Mixed Fetal HDTAH85 Y01098 W09910364-A1 Cancer HFJAB36 Y02608 W09923106-A1 Cancer HDTBS70 Y03231 W09909152-A1 Cancer.

HNGEF08 Y03849 W09909198-A1 Immune/Hematopoietic, Re roductive HUKEJ46 Y03850 W09909198-A1 Digestive, .
Re roductive HPASD50 Y04120 W09909161-A1 Cancer HPASD50 Y04121 W09909161-A1' Cancer HAGFE38 Y05451 ' W09857989-A1 Cancer HFVIF40 Y06461 WO9931116-A1 Cancer HFCCQ50 Y06462 WO9931116-A1 Cancer HT4CC72 Y06473 W09935262-A2 Immune/Hemato oietic HDPIE88 Y06511 W09936565-A1 Cancer HWFBG79 Y10797 W09907891-A1 Cancer HDGRC02 Y13736 ~ US5928890-A Cancer HFCET92 Y14078 W09921575-A1 Cancer HUVE091 Y14132 W09923105-A1 Cancer HUVE091 Y14133 W09923105-A1 Cancer HCABA58 Y16587 US5916769-A Cancer HOSBD47 Y22320 US5932540-A ' Cancer HOSBD47 Y22321 US5932540-A Cancer HPRCC57 . Y23761 W09932135-A1 Cancer HMEAA94 Y23884 W09935160-A1 Cancer HL1AP03 Y23885 W09935160-A1 Cancer HSYBM46 Y23886 W09935160-A1 Cancer HFKBC47 Y23887 W09935160-Al Cancer HSSAW84 Y24249 US5929225-A Cancer HCUDE60 Y25708 W09938882-A1 Cancer HHFCU19 Y27005 US5928924-A Cancer HMWJH67 Y28640 W09940183-A1 Cancer HKAFV61 Y28642 - W09940183-A1 Cancer HETDK50 Y28643 W09940183-A1 Cancer HKAEF09 Y28644 WO9940183-A1 Cancer HOSBD47 Y30518 WO9946364-Al Cancer HOSBD47 Y30519 WO9946364-A1 Cancer HILBI36 Y31242 US5955339-A Cancer HTAEK53 Y31810 W09947538-A1 Cancer HT4CC72 Y31885 W09942584-A1 Immune/Hemato oietic HLMBA70 Y32504 US5945309-A hnmune/Hematopoietic, Mixed Fetal, Re roductive HPRCC57 Y32888 W09941282-Al Cancer HPRCC57 Y32895 W09941282-A1 Cancer HPRCC57 Y32896 W09941282-Al Cancer HPRCC57 Y32897 W09941282-A1 Cancer HPRCC57 Y32898 W09941282-Al Cancer HPRCC57 Y32901 W09941282-A1 Cancer HPRCC57 Y32905 W09941282-A1 Cancer HPRCC57 Y32916 W09941282-Al ' Cancer HMEIP65 Y33847 US5952197-A Cancer .

HFCCQ50 Y36339 W09931117-A1 Cancex HFCCQ50 Y36342 W09931117-A1 Cancer HRDCD54 Y36648 WO9931117-A1 Cancer HRDCD54 Y36650 W09931117-A1 Cancer HRDCD54 Y36673 W09931117-A1 Cancer HTSEX82 Y41161 US5981231-A Digestive, Immune/Hemato oietic HGBAN46 Y41163 US5981230-A Cancer HE9DR66 Y41164 US5981230-A Cancer HRGBQ38 Y42150 ~ US5968797-A ~ Cancer HFCCE09 . Y42151 US5968797-A Cancer HGOCA18 Y42152 ~ US5968797-A ~ Cancer HNFEM05 Y42165 W09927078-A1 Cancer .

HJACE54 Y44510 W0200001728-A1 Cancer HKAEF92 Y44664. WO9962934-A1 Cancer HBZSD43 Y45003 ~ WO200006589-A1 Cancer HUVEO91 Y45032 W0200008139-A1 Cancer HTOBH93 ~ Y49535 US5977309-A Cancer HAPOR40 Y49946 W09914240-A1 Cancer HHEAC71 Y52158 W09920758-A1 ConnectivelEpithelial, - Immune/Hemato oietic HCFAZ22 Y52159 W09920758-A1 Cancer HT5EA78 Y52160 W09920758-A1 _ Connective/Epithelial, Immune/Hemato oietic HDPJ039 Y52479 W09940184-A1 Cancer HBICD95 Y53061 US5998171-A Cancer HTGED19 Y53890 W09961617-A1 Immune/Hematopoietic HFPBX96 Y53891 W09961617-A1 Cancer HFKCU96 Y54900 _US5986069-A Cancer HSBBC75 Y55748 US5994103-A Cancer HLFBE10 Y55750 US5994103-A Cancer HLFBE10 Y57166 US5994301-A Cancer HIBCL22 Y57167 US5994506-A ' Cancer HTTER36 Y58185 US6004780-A Cardiovascular, Connective/Epithelial, Re roductive HWHGU74 Y59247 W09962927-A1 Cancer HSDFB55 Y67239 US6008020-A Cancer HE2BG16 Y67356 US5998164-A Cancer HKAPI15 Y68800 W0200005371-A1 Connective/E ithelial HTWAF38 Y69674 US6013483-A Cancer HATCK89 Y69675 - US6013477-A Cancer HAPOR40 Y70591 W0200015759-A1 Cancer HMUAN45 Y70785 W0200023572-A1 Cancer HATCK89 Y718~84 W0200067775-A1 Cancer HKGDL36 Y71959 ~ W0200066778-A1 Cancer HCUDS60 Y72022 W0200067793-A1 Cancer HCUDS60 Y72023 W0200067793-A1 Cancer HETAN67 Y78790 US6013469-A Cancer HDGNR10 Y80128 US6025154-A Digestive, Immune/Hematopoietic, Re roductive HBGBA67 Y87779 US6054289-A Cancer HE2CB95 Y87780 US6054289-A Immune/Hematopoietic, . Mixed Fetal HPTTK55 Y87782 US6054289-A Cancer HARA063 Y87783 US6054289-A Cancer HLHAR55 Y87787 US6054289-A Cancer HSRDG78 Y87788 US6054289-A Cancer HCCAA03 Y87789 US6054289-A Cancer HWLLM34 Y90351 W0200052136-A2 Cancer HA5AA37 ' Y90352 ~ W0200052136-A2 Cancer HDPAK85 Y90353 W0200052136-A2 Cancer HPHAE52 Y90357 W0200052028-A1 Cancer HTPCH84 Y90358 W0200052028-A1 Cancer HMKEA94 Y93650 ~ W0200036105-Al Cancer HOEDH76 Y93912 W0200039166-A1 Cancer HOGCC45 Y93951 W0200039136-A2 Cancer HTSGS30 Y93973 W0200042189-A1 Digestive, ' Immtme/Hematopoietic, Mixed Fetal HTSGS30 ' Y93975 W0200042189-A1 Digestive, Immune/Hematopoietic, Mixed Fetal HMWCF06 Y94802 W0200009148-A1 Cancer HE9DR66 Y95534 W0200040726-A1 Cancer HGBAN46 ~ Y95535 W0200040726-A1 Cancer HE9DR66 Y95563 W0200040726-A1 Cancer HE9DR66 Y95565 W0200040726-A1 Cancer HE9DR66 Y95566 W0200040726-A1 Cancer HE9DR66 Y95567 ~W0200040726-A1 Cancer HE9DR66 Y95568 W0200040726-Al Cancer LHE9DR66 Y95569 ~ W0200040726-Al ~ Cancer HE9DR66 Y95570 W0200040726-Al Cancer HE9DR66 Y95571 W0200040726-A1 Cancer HE9DR66 Y95572 ~ W0200040726-Al Cancer HE9DR66 Y95573 W0200040726-A1 Cancer HE9DR66 Y95574 ~ W0200040726-A1 Cancer HE9DR66 Y95575 W0200040726-A1 Cancer HE9DR66 Y95576 W0200040726-A1 Cancer HE9DR66 Y95577 WO200040726-A1 Cancer HE9DR66 Y95578 W0200040726-A1 Cancer HHEAC71 Y95879 W0200050459-A1 Connective/Epithelial,.
Immune/Hemato oietic HCFAZ22 Y95880 W0200050459-A1 Cancer HTSEA78 Y95881 W0200050459-A1 Connective/Epithelial, Immune/Hemato oietic ~

HDPAK85 Y96099 W0200052135-A2 Cancer HWLLM34 Y96100 W0200052135-A2 'Cancer HA5AA37 Y96101 WO200052135-A2 Cancer HAPAT57 ' Y96280 W0200028035-A1 Cancer HAPAT57 Y96282 W0200028035-A1 Cancer HKABZ65 Y96962 W0200039327-A1 Connective/E ithelial HWHQB15 Y96963 . W0200039327-A1 Connective/E ithelial HCDDP40. Y96964 W0200039327-Al Immune/Hematopoietic, Musculoskeletal HOSBD47 Y97144 W0200045835-A1 Cancer HOSBD47 Y97145 W0200045835-A1 Cancer HFITF82 SEQ ID N0:73 Immune/Hematopoietic, Musculoskeletal HFITF82 SEQ ID NO:74 Immune/Hematopoietic, Musculoskeletal .

HFITF82 SEQ ID N0:75 Immune/Hematopoietic, Musculoskeletal HFITF82 SEQ ID NO:76 Immune/Hematopoietic, Musculoskeletal HBZAI19 SEQ ID N0:77 ~ Immune/Hematopoietic, Re roductive HBZAI19 . SEQ ID N0:78 Immune/Hematopoietic, , Re roductive HBZAI19 SEQ ID N0:79 Immurie/Hematopoietic, Re roductive HDPDI45 SEQ ID N0:80 Cancer HDPDI45 SEQ ID N0:81 Cancer HETHW90 SEQ ID N0:82 Cancer HETHW90 SE ID N0:83 ~ Cancer HETHW90 SEQ ID N0:84 Cancer HIBEB47 SEQ ID N0:85 ' Digestive, ' Mixed Fetal, Neural/Sensory HIBEB47 SEQ ID N0:86 ' Digestive, Mixed Fetal, Neural/Senso HIBEB47 SEQ ID NO:87 ' Digestive, Mixed Fetal, Neural/Sensory HIBEB47 SEQ ID N0:88 Digestive, Mixed Fetal, , Neural/Sensory HLHFR58 SEQ ID N0:89 Cancer HLHFR58 SEQ ID N0:90 Cancer HLHFR58 SEQ ID N0:91 Cancer HLHFR58 SEQ ID N0:92 Cancer HNGGK54 SEQ ID N0:93 Cancer HNGGK54 SEQ ID N0:94 ' Cancer HNGGK54 SEQ ID NO:95 Cancer HNGGK54 SEQ ID N0:96 Cancer HUSIE23 SEQ ID N0:97 Cancer HUSIE23 SEQ ID N0:98 Cancer HARMB79 SEQ ID NO:99 Cancer HARMB79 SEQ ID NO:100 Cancer ' HJBCY84 SEQ ID NO:101 Cancer HJBCY84 SEQ ID N0:102 Cancer HJBCY84 SEQ ID N0:103 Cancer HCMSC92 SEQ ID N0:104 Cancer HCMSC92 SEQ ID NO:105 Cancer HE2AX96 SEQ ID NO:106 Mixed Fetal HE2AX96 SEQ ID N0:107 Mixed Fetal .

HE2AX96 SEQ ID N0:108~ Mixed Fetal ' HHPDV90 SEQ ID N0:109 Cancer HHPDV90 SEQ ID NO:110 Cancer HHPDV90 SEQ ID NO:111' ' Cancer HT2SG64 SEQ ID NO:112~ Digestive, Immune/Hemato oietic HT2SG64 SEQ ID N0:113 Digestive, Immune/Hemato oietic HT2SG64 SEQ ID NO:114. Digestive, Immune/Hemato oietic HAGAN21 SEQ ID NO:115 Digestive, Immune/Hematopoietic, Neural/Sensory HAGAN21 SEQ ID N0:116 Digestive, Immune/Hematopoietic, Neural/Senso HAGAN21 SEQ ID N0:117~ Digestive, Immime/Hematopoietic, Neural/Sensory HAGAN21 SEQ ID N0:118 Digestive, ImmLme/Hematopoietic, Neural/Sensory HAGAN21 SEQ ID N0:119. . Digestive, Immune/Hematopoietic, Neural/Sensory HEBAH57 SEQ ID N0:120 Neural/Sensory HEBAH57 SEQ ID N0:121 Neural/Sensory HEBAH57 SEQ ID N0:122 Neural/Sensory HETDB76 SEQ ID N0:123 Musculoskeletal, Re roductive HETDB76 SEQ 1D N0:124 Musculoskeletal, Re inductive HETDB76 SEQ ID N0:125' Musculoskeletal,.
Re roductive HETDB76 SEQ ID NO:126 Musculoskeletal, Re roductive HE8SE91 ~Q ID N0:127 ~ Cancer ~

HE8SE91 SEQ ID N0:128 Cancer HE8SE91 SEQ ID N0:129 Cancer HRGBL78 SEQ ID N0:1.30 Cancer HRGBL78 SEQ ID N0:131 Cancer HRGBL78 SEQ ID N0:132 Cancer HRGBL78 SEQ ID N0:133 Cancer HHFUC40 SEQ ID N0:134 Cardiovascular HHFUC40 SEQ ID N0:135 Cardiovascular ' HETCP58 SEQ ID N0:136 Immune/Hematopoietic, Re roductive HETCP58 ' SEQ ID NO:137 Immune/Hematopoietic, Re roductive HETCP58 SEQ ID N0:138 Immune/Hematopoietic, Re roductive HTTBM40 SEQ ID N0:139 Cancer HTTBM40 SEQ ID N0:140 Cancer HTTBS64. SEQ ID N0:141 Re roductive HTTBS64 SEQ ID NO:142 Re roductive HTTBS64 ~ SEQ ID NO:143 Re roductive HCEVB32 SEQ ID N0:144 Cancer HCEVB32 SEQ ID N0:145 Cancer HCEVB32 SE ID NO:146 Cancer HCEVB32 SEQ ID N0:147 Cancer HHPFU18 SEQ ID N0:148 Cancer HHPFU18 SEQ ID N0:149 Cancer HPRCA90 SEQ ID NO:150 Cancer HPRCA90 SEQ ID NO:151 Cancer HPRCA90 SEQ ID N0:152 Cancer HPRCA90 ' SEQ ID N0:153 Cancer HPRCE33 SEQ ID N0:154 Cancer HPRCE33 SE ID NO:155 Cancer -HHFFU55 ~ SEQ ID NO:156 Cardiovascular, Immune/Hernato oietic HHFFU55 SEQ ID N0:157 Cardiovascular, Immune/Hemato oietic HUVDP63 SEQ ID N0:158 Cancer HUVDP63 SEQ ID N0:159 Cancer ' HUVDP63 SEQ ID N0:160 Cancer HUVDP63 SEQ ID N0:161 Cancer . HUVDP63 SEQ ID N0:162 Cancer HCEFI77 SEQ ID N0:163 Neural/Sensory HCEFI77 SEQ ID N0:164 Neural/Sensory HCEFI77 SEQ ID N0:165 Neural/Sensory HHFDH56 SEQ ID N0:166 Cancer HHFDN48 SEQ ID N0:167 Cancer HHFDN48 SEQ ID N0:168~ ' Cancer HHFDN48 . SEQ ID N0:169 Cancer HHFDN48 SEQ ID N0:170~ Cancer HHFDN48 SEQ ID N0:171 Cancer HHFDN67 SEQ ID NO:172 Cardiovascular HHFDN67 SEQ ID N0:173 Cardiovascular HHFDG51 SEQ ID N0:174 Connective/Epithelial, Musculoskeletal HHFDG51 SEQ ID N0:175~ Connective/Epithelial, Musculoskeletal HHFDG51 SEQ ID N0:176 Connective/Epithelial, -Musculoskeletal HE8A036 SEQID N0:177 Cancer HE8A036 SEQ ID N0:178 Cancer HE8A036 SEQ ID N0:179 Cancer HTPAB57 SEQ ID N0:180 Cancer HTPAB57 SEQ ID N0:181 Cancer HTPAB57 SEQ ID N0:182 Cancer HTPAB57 SEQ ID N0:183 Cancer HFXAX45 SEQ ID N0:184 Neural%Senso HFXAX45 SE ID N0:185 Neural/Sensory HFXAX45 SE ID N0:186 Neural/Sensory HTLBE23 SEQ ID N0:187 Re roductive HTLBE23 SEQ ID N0:188 Re roductive HCQAM33 SEQ ID N0:189 Musculoskeletal, - Re roductive HCQAM33 - SEQ ID N0:190 Musculoskeletal, Re roductive HCQAM33 SEQ ID N0:191 Musculoskeletal, Re roductive HCEWE17 SEQ ID N0:192 Digestive, . Neural/Sensory HCEWE17 SEQ~ID N0:193 Digestive, Neural/Sensory HCEWE17 . SEQ ID N0:194 Digestive, Neural/Sensory HTEGI42 SEQ ID N0:195 Cancer HTEGI42 SEQ ID N0:196 Cancer HTEGI42 SEQ ID N0:197 Cancer HTEGI42 SEQ ID N0:198. Cancer HTEGI42 SEQ ID N0:199 Cancer HCEIE80 . SEQ ID N0:200 Cancer HCEIE80 SE ID N0:201 Cancer HCEIE80 SEQ ID N0:202 Cancer .

HCEIE80 SEQ ID N0:20~ ~ Cancer HLMCA92 SEQ ID N0:204 Digestive, ' Immune/Hematopoietic, Neural/Sensory HLMCA92 SEQ ID N0:205 Digestive, ~Immune/Hematopoietic, Neural/Sensory HLMCA92 SEQ ID N0:206 Digestive, Immune/Hematopoietic;
Neiual/Sensory HLMCA92 . S.EQ ID N0:207. ~ Digestive, . Immune/Hematopoietic, Neural/Sensory HLHCF36 SEQ ID N0:208 Res iratory HLHCF36 SEQ ID N0:209 Res iratory HLHCF36 SE ID N0:210 Res iratory HCEZR26 SEQ ID N0:211 Cancer HCEZR26 SEQ ID N0:212 Cancer HGBC051 SEQ ID N0:213 Cancer HGBC051 SEQ ID N0:214 Cancer HGBC051 SEQ ID N0:215 Cancer HGBC051 SEQ ID N0:216~ Cancer HTABP30 SEQ ID N0:217 Cancer HTABP30 SEQ ID N0:218 Cancer HUKCD 10 SEQ ID. N0:219 Cancer HUKCD 10 SEQ ID N0:220 Cancer HUKCD10 SEQ ID N0:221 Cancer HOUHT39 SEQ ID NO:222 Cancer HOUHT39 SEQ ID N0:223~ Cancer HOUHT39 SEQ ID N0:224 Cancer HTXBN56 SEQ ID NO:225' Cancer HTXBN56 5EQ ID N0:226 Cancer HTXBN56 SEQ ID N0:227 Cancer HETEU28 SEQ ID N0:228 Cancer HETEU28 SEQ ID N0:229 Cancer HODDD43 SE ID N0:230 Cancer HODDD43 SEQ ID NO:231 Cancer HODDD43 SEQ ID NO:232 Cancer HPWAL61 SEQ ID N0:233 Musculoskeletal, Re roductive HPWAL61 SEQ ID N0:234 Musculoskeletal, Re roductive HPWAL61 SEQ ID N0:235 Musculoskeletal, Re roductive HPWAL61 SEQ ID N0:236 Musculoskeletal, Re roductive HTSER67 SEQ ID NO:237 Cancer HTSER67 SEQ ID N0:238 Cancer HMSDL37 SE ID N0:239 Cancer HMSDL37 SEQ ID N0:240~ Cancer HMSDL37 SEQ ID N0:241 Cancer HMSDL37 SEQ ID N0:242 Cancer HSDAJ53 SEQ ID N0:243 Cancer HSDAJ53 SEQ ID N0:244 Cancer HSDAJ53 SEQ ID N0:245~ Cancer HSDAJ53 SEQ ID N0:246 Cancer HEBDF05 SEQ ID N0:247 Neural/Sensory HEBDF05 SEQ ID NO:248' Neural/Sensory HEBDF05 SEQ ID N0:249 Neural/Sensory HSQFT30 SEQ ID N0:250 Cancer HSQFT30 ~ SEQ ID N0:251~ . - Cancer HSIDX71 SEQ ID N0:252 Digestive, Neural/Sensory HSIDX71 SEQ ID N0:253 Digestive, - Neural/Senso HSAUA82 SEQ ID N0:254 Immye/Hematopoietic, Re roductive HSAUA82 ~ SEQ ID NO:255, Immune/Hematopoietic, Re roductive HPWAY46 SEQ ID N0:256 Cancer HPWAY46 SEQ ID N0:257 Cancer HPWAY46 SEQ ID N0:258 Cancer HSSEN70 SEQ ID N0:259 Cancer HSSEN70 SEQ ID N0:260. Cancer HTOHB55 SEQ ID N0:261 Cancer HTOHB55 ' SEQ ID N0:262 Cancer HTOHM15 SEQ ID NO:263' Cancer HTOHM15 ' SEQ ID N0:264 Cancer .

HTOHM15 SEQ ID N0:265 Cancer ' HTOHM15 SEQ ID N0:266 Cancer ' HHNAB56 SEQrID NO:267 Digestive HHNAB56 SEQ ID N0:268- Digestive HHNAB56 SEQ ID N0:269 Digestive HJABL02 SEQ ID N0:270 Cancer HJABL02 SEQ ID N0:271 Cancer HJACG30 SEQ ID NO:272 Iznmune/Islemato oietic HJACG30 SEQ ID N0:273 Immune/Hemato oietic HJACG30 ' SEQ ID N0:274 Immune/Hemato oietic HTAEE28 SEQ ID N0:275 Digestive, hnmune/Hematopoietic, Mixed Fetal HTAEE28 SEQ ID NO:276 Digestive, Immune/Hematopoietic, Mixed Fetal HTAEE28 , SEQ ID N0:277 Digestive, Immune/Hematopoietic, Mixed Fetal HTHBG43 - SEQ ID N0:278' Immune/Hemato oietic HTHBG43 SEQ ID N0:279 Immune/Hemato oietic HJPCE80 SEQ ID NO:280 Cancer HJPCE80 SEQ ID N0:281 Cancer HJPCE80 SEQ ID NO:282 Cancer HTOIZ02 ~ SEQ ID N0:283 Cancer HTOIZ02 SEQ ID N0:284 Cancer HJPCR70 SEQ ID N0:285 Cancer HJPCR70 SEQ ID N0:286' Cancer HJPCR70 SEQ ID N0:287 Cancer HJPCR70 SE ID N0:288 Cancer HJPCP42, SEQ ID N0:289 Digestive, Immune/Hemato oietic HJPCP42 SEQ ID N0:290_ Digestive, . Immune/Hemato oietic HJPCP42 ' SEQ ID N0:291 Digestive,' Immune/Hemato oietic HJPCP42 SEQ ID N0:292 Digestive, Immune/Hemato oietic HNFFD47 SEQ ID N0:293 Immune/Hemato oietic HNFFD47 SEQ ID NO:294 Immune/Hemato oietic HNFFD47 SEQ ID N0:295 Immune/Hemato oietic HNFFI46 SEQ ID N0:296 Cancer HNFFI46 SE ID N0:297 Cancer HNFFI46 SEQ ID N0:298 Cancer HNFFI46 SEQ ID N0:299. ' Cancer HNFFI46 . SEQ ID N0:300 Cancer HTOIQ42 SEQ ID N0:301 Cancer HTOIQ42 SEQ ID N0:302 Cancer HLTDW13 SEQ ID NO:303 Cancer HLTDW13 SEQ ID N0:304~ Cancer HLTDW 13 SEQ ID NO:305 Cancer -HLTDW13 SEQ ID N0:306 Cancer HLTDW13 SEQ ID N0:307 Cancer HLTDY51 SEQ ID N0:308 Cancer HLTDY51 SEQ ID NO:309 Cancer HNFFZ56 SEQ ID N0:310 Cancer .

HNFFZ56 SEQ ID N0:311. Cancer HNGAV54 SEQ ID N0:312 ImmunelHemato oietic HNGAV54 SEQ ID N0:313 Immune/Hemato oietic HSLCA15 SEQ ID N0:314 Cancer HSLCA15 SEQ ID N0:315 Cancer HSLCA15 SEQ ID N0:316 Cancer HSLCA15 SEQ ID N0:317 Cancer HSLCA15 SEQ ID N0:318 Cancer ' HSLCA15 SEQ ID N0:319 Cancer HSLCP57 SEQ ID N0:320 Cancer HSLCP57 SEQ ID N0:321 Cancer HTOJP95 SEQ ID N0:322 Immune/Hemato oietic HTOJP95 SEQ ID N0:323 Immune/Hemato oietic HBMVI55 SEQ ID N0:324 Cancer HBMVI55 SEQ ID N0:325~ Cancer HBMVI55 SEQ ID N0:326 Cancer HBMVI55 SE ID N0:327 Cancer HBMVI55 SEQ ID N0:328 Cancer HFXBS68 SEQ ID N0:329 Neural/Sensory HFXBS68 . SEQ ID N0:330 Neural/Senso HFXBS68 SEQ ID N0:331 Neural/Senso ' ' HFXBS68 SEQ ID N0:332 Neural/Sensory HNGBC07 SEQ ID N0:333 Immune/Hemato oietic HNGBC07 SEQ ID N0:334 Immune/Hemato oietic HNGBC07 SEQ ID N0:335 Immune/Hemato oietic HMSFK67 SEQ ID N0:336 Cancer HMSFK67 SEQ ID N0:337 Cancer .

HMSFK67 SEQ ID N0:338 Cancer HCE1P80 SEQ ID N0:339 Cancer HCE1P80 SEQ ID N0:340 Cancer .

HCE1P80 SEQ ID N0:341'~ Cancer HOUDU29 ' SEQ ID N0:342' ~ Cancer ' HOUDU29 SE'Q ID NO:343 Cancer HOUDU29 SEQ ID N0:344 Cancer HOUDU29 SEQ ID NO:345 Cancer HOUDU29 SE ID N0:346 Cancer HHFEC49 SEQ ID N0:347 Cancer ' ' HCE3T57 SEQ ID N0:348. Immune/Hematopoietic, Neural/Sensory, Re reductive HCE3T57 SEQ ID N0:349 Immune/Hematopoietic, Neural/Sensory, Re reductive HCE3T57 SEQ ID NO:350 Immime/Hematopoietic, Neural/Sensory, Re reductive HCE3T57 SEQ ID N0:351 ImmunelHematopoietic, Neural/Sensory, Re reductive HCE3T57 SEQ ID N0:352 hnmunelHematopoietic, ' Neural/Sensory, Re reductive HCE4Y07 SEQ ID NO:353 Cancer HCE4Y07 SEQ ID N0:354' Cancer HCE5G23 SEQ ID N0:355 Cancer HCE5G23 SEQ ID N0:356 Cancer HCE5G23 SEQ ID N0:357 Cancer HFCEP45 SEQ ID N0:358 Neural/Sensory HFCEP45 SEQ ID NO:359- Neural/Sensory HFCEP45 SEQ ID N0:360 Neural/Sensory HFCEP45 SEQ ID N0:361 Neural/Sensory HMWEJ52 SEQ ID N0:362 Immune/Hemato oietic ~EJ52 SEQ ID N0:363 hrimune/Hemato oietic HMWEY26 SEQ ID N0:364 Cancer HMWEY26 ~ SEQ ID N0:365 Cancer HMWEY26 SEQ ID N0:366 Cancer HMWEY26 SEQ ID NO:367 Cancer HMWEY26 SEQ ID N0:368 Cancer HATDM46 SEQ ID N0:369 Cancer HATDM46 SEQ ID N0:370 Cancer HATDM46 SEQ ID N0:371 Cancer HATDM46 SEQ ID N0:372 Cancer HATDM46 SEQ ID N0:373 Cancer HATDM46 SEQ ID N0:374 Cancer HHFHD37 SEQ ID N0:375 Cardiovascular"
Immune/Hematopoietic, Res iratory HHFHD37 SEQ ID N0:376, ' Cardiovascular, - Immune/Hematopoietic, Res iratory HHFHI76 SEQ ID N0:377 Cancer .

HHFHI76 SEQ ID N0:378 Cancer HATDZ29 SEQ ID N0:379 Endocrine, Immune/Hemato oietic HATDZ29 SEQ ID N0:380 Endocrine, - Immune/Hemato oietic HFVGE32 SEQ ID N0:381 Digestive, Immune/Hemato oietic HFVGE32 SEQ ID N0:382 Digestive, Inunune/Hemato oietic HLHFE92 SE ID N0:383 Cancer HLHFE92 SEQ.ID N0:384 Cancer HLHFE92 SEQ ID N0:385 Cancer HMKAI25 SEQ ID N0:386 Cancer HMKAI25 SEQ ID N0:387 Cancer HMKAI25. SEQ ID N0:388 Cancer ' HMKAI25 SEQ ID N0:389 Cancer HMKAI25 SEQ ID N0:390 Cancer HNHEI42 SEQ ID N0:391 Endocrine, Immiuie/Hemato oietic HNHEI42 SEQ ID N0:392 Endocrine, Immvme/Hemato oietic HNHEI42 SEQ ID N0:393. Endocrine, Immune/Hemato oietic HNHEI42 SEQ ID N0:394 Endocrine, Immune/Hemato oietic HNHEI85 SEQ ID N0:395 Digestive, M ImmunelHematopoietic, usculoskeletal HNHEI85 SEQ ID N0:396 Digestive, ImmunelHematopoietic, Musculoskeletal HOEDE28 SEQ ID N0:397 Cancer 12~

HOEDE28 ' SEQ ID N0:398 Cancer H2CBH03 SEQ ID N0:399 Cancer HTHCA18 SEQ ID N0:400 Immune/Hemato oietic HTHCA18 SEQ ID N0:401 Immune/Hemato oietic HTHC079 SEQ ID NO:402 Cancer HTHC079 SEQ ID N0:403 Cancer ' HNGFB76 SEQ ID N0:404'. Digestive, ' Immune/Hematopoietic, Neural/Senso HNGFB76 . SEQ ID N0:405, Digestive, Immune/Hematopoietic, Neural/Sensory HNGFB76 SEQ ID~N0:406 Digestive, a Immune/Hematopoietic, Neural/Sensory HNGFB76 SEQ ID N0:407 Digestive, Immune/Hematopoietic, Neural/Senso HOQBJ82 SEQ ID NO:408 Cancer HOQBJ82 SEQ ID NO:409- Cancer HNFHY51 SEQ, ID N0:410- Immune/Hematopoietic, Re reductive HNFHY51 SEQ ID N0:411~. Immune/Hematopoietic, Re reductive HNFHY51 SEQ ID N0:412 IrnmunelHematopoietic, Re reductive .

HNFHY51 SEQ ID N0:413 Immune/Hematopoietic, ' Re reductive HNEEB45 SEQ ID N0:414. Immune/Hematopoietic, Mixed Fetal HNEEB45 SEQ ID N0:415 Immune/Hematopoietic, Mixed Fetal HSDFA44 SE ID N0:416 Neural/Sensory HSDFA44 SEQ ID N0:417 NeurallSensory HSDFA44 SEQ ID N0:418. NeurallSensory HAGEB14 ~ SEQ ID N0:419 Cancer HAGEB14 ~ SEQ ID N0:420 Cancer HCGBE81 SEQ ID N0:421 Neural/Sensory, Re reductive HCGBE81 SEQ ID N0:422 Neural/Sensory, Re reductive HEOMX53 SEQ ID N0:423, Digestive, .

Immune/Hematopoietic, Neural/Sensory HEOMX53 SEQ ID N0:424 Digestive, Ixnmune/Hematopoietic, Neural/Sensory HEOMX53 SEQ ID N0:425 Digestive, Immune/Hematopoietic, NeuraIlSensory HEONC95 SEQ ID N0:426 Cancer HEONC95 SEQ ID N0:427 Cancer HKMLP68 SEQ ID-N0:428 Excretory, Mixed Fetal, Re reductive HKMLP68 SEQ ID N0:429 Excretory, ' Mixed Fetal, Re roductive HKMLP68 SEQ ID N0:430 Excretory, Mixed Fetal, Re roductive HMWIG83 SEQ ID N0:431 Cancer HMWIG83 SEQ ID N0:432 Cancer HMSKH19 SEQ ID N0:433 Cancer HMSKH19 SEQ ID N0:434 Cancer HMSKH19 SEQ ID N0:435 Cancer HFAME37 SEQ ID N0:436 Neural/Sensory HFAME37 SEQ ID N0:437 Neural/Sensory HFAME37 SEQ ID N0:438 Neural/Sensory HFXFG45 SEQ ID N0:439 Immune/Hematopoietic, Neural/Sensory HFXFG45 SEQ ID N0:440 Immune/Hematopoietic, . Netual/Sensory HFXFG45 SEQ ID N0:441 ImmunelHematopoietic, NeurallSenso HFXFG45 SEQ ID N0:442 Immune/Hematopoietic, Neural/Sensory HFXFH04 SEQ ID N0:443 Immune/Hematopoietic, Neural/Sensory HFXFH04 SEQ ID N0:444 Immune/Hematopoietic, Neural/Sensory HFXFH04 SEQ ID NO:445 Immune/Hematopoietic, Neural/Sensory HFXFH04 SEQ ID N0:446 Immune/Hematopoietic, , Neural/Sensory HGCAC66 SEQ ID N0:447 Cancer HGCAC66 SEQ ID N0:448 Cancer HSSJF55 SEQ ID NO:449 Musculoskeletal HSS.TF55 SEQ ID N0:450~ Musculoskeletal HFXHM17 SEQ ID N0:451 Cancer HFXHM17 SE ID N0:452 Cancer HFXHM17 ~ SEQ ID N0:453 Cancer HFXHM17 SEQ ID N0:454 Cancer HOSFQ65 SEQ ID N0:455 Cancer HOSFQ65 SE ID NO:456 Cancer .

HOSFQ65 SEQ ID N0:457 Cancer HOSFQ65 SEQ ID N0:458 Cancer HOSFQ65 SEQ ID N0:459 Cancer HKGAS32 SEQ ID N0:460~ Connective/Epitheliai, Neural/Sensory HKGAS32 SEQ ID N0:461' Connective/Epithelial, Neural/Sensory HKGAU45 SEQ ID N0:462 ImmunelHemato oietic HKGAU45 SEQ ID N0:463 Immune/Hemato ~oietic HKGAU45 . SEQ ID N0:464 Immune/Hemato oietic HKGBH24 SEQ ID N0:465 Cancer HKGBH24 SEQ ID N0:466' Cancer HKGBH24 SEQ ID N0:467 Cancer HKGBSO1 SEQ ID N0:468 Cancer HKGBSO1 SE ID N0:469 Cancer HKGBSO1 SEQ ID N0:470 Cancer HACCL63 SEQ ID N0:471 Cancer HACCL63 SEQ ID N0:472 Cancer HACCL63 SEQ ID N0:473 Cancer HACCL63 SEQ ID N0:474 Cancer HFIIN69 SEQ ID N0:475~ , Musculoskeletal, Neural/Sensory, Re roductive HFIIN69 ~ SEQ ID N0:476 Musculoskeletal, Neural/Sensory, Re roductive HFIIN69 SEQ ID N0:477 Musculoskeletal, Neural/Sensory, Re roductive HFIIZ70 SEQ ID N0:478 Cancer HFIIZ70 SEQ ID N0:479 Cancer HMIAJ30 SEQ ID N0:480 Cancer HMIAJ30 SEQ ID NO:481' Cancer HMIAJ30 SEQ ID N0:482 Cancer HMIAJ30 SEQ ID N0:483 Cancer HMIAV73 SEQ ID N0:484 Cancer HMIAV73 SEQ ID N0:485 .Cancer HMIAV73 SEQ ID N0:486~ Cancer HMIAV73 SEQ ID N0:487. Cancer .

HAPOD80 SEQ ID N0:488- Cancer -HISBL03 SEQ ID NO:489 Cancer HISBL03 SEQ ID NO:490 Cancer HISBL03 SEQ ID N0:491 Cancer HISBL03 SEQ ID N0:492 Cancer HISBL03 SEQ ID N0:493 Cancer HISBL03 SEQ ID N0:494 Cancer HISBL03 SEQ ID N0:495 Cancer HMICK94 SEQ ID NO:496 Cancer HMICK94 SEQ JD N0:497 Cancer HMICK94 SEQ ID N0:498' Cancer HISBF60 SEQ ID N0:499. ' Cancer HISBF6 0 -. -Cancer - _ . SEQ ID NO:500 HISBF60 SEQ ID N0:501 Cancer HISBF60 SEQ ID N0:502 Cancer HISBF60 SE ID N0:503 Cancer HMVAV54 SEQ ID N0:504~ Immune/Hemato oietic HMVAV54 SEQ ID N0:505 Immune/Hemato oietic HMVAV54 SEQ ID N0:506 Immune/Hemato oietic HMVAV54 SEQ ID N0:507' Immune/Hemato oietic HMVAV54 SEQ ID N0:508 Immune/Hemato oietic HPICB53 ~ SEQ ID N0:509 Cancer HPICB53 ~ SEQ ID N0:510 Cancer HPICC86 SEQ ID N0:511 Re roductive HPICC86 SEQ ID N0:512~ Re roductive HPICC86 SEQ ID N0:513 Re roductive HPICC86 SEQ ID N0:514 Re roductive HPICC86 SEQ LD N0:515 Re roductive HPJAP43 SEQ ID N0:516 Cancer ~

HPJAP43 SEQ ID N0:517 Cancer HPJAP43 SEQ ID N0:518 Cancer HPJCG42 , SEQ ID N0:519 Immune/Hematopoietic, -Re roductive HPJCG42 SEQ ID N0:520 Immune/Hemato oietic, Re reductive HPJCG42 SEQ ID N0:521 Immune/Hematopoietic, Re reductive HPJCG42 SEQ ID N0:522 Immune/Hematopoietic, . Re reductive HPJCG42 SEQ ID N0:523 Immune/Hematopoietic, Re reductive HPJBK11 SEQ ID N0:524 Cardiovascular, Neural/Sensory, Re reductive HPJBK11 SEQ ID N0:525 Cardiovascular, Neural/Sensory, Re reductive HPJBK11 _ SEQ ID NO:526 Cardiovascular, Neural/Sensory, _ Re reductive HPJBK12 SEQ ID N0:527 Re reductive HPJBK12 SEQ ID N0:528 Re reductive HPJBK12 SEQ ID N0:529 Re reductive HPJBK12 SEQ ID N0:530~ Re reductive HPJCT08 SEQ ID N0:531 Connective/Epithelial, Re reductive HPJCT08 SEQ ID N0:532 Connective/Epithelial, Re reductive HPJCT08 SEQ ID N0:533 Connective/Epithelial, Re reductive HT4ES80 SEQ ID NO:534 Cancer HT4ES80 SEQ ID N0:535 Cancer HT4ES80 SEQ ID N0:536 Cancer HNTNB49 SE ID N0:537 Cancer ' HNTNB49 SEQ ID N0:538 Cancer HNTRS57 SEQ ID N0:539 Cancer HNTRS57 SEQ ID N0:540' Cancer HNTRS57 SEQ ID N0:541 Cancer HNTRS57 SE ID N0:542 ~ Cancer HNTRS57 SEQ ID N0:543 Cancer HNTSL47 SEQ ID N0:544. , Cardiovascular, Di estive HNTSL47 SEQ ID N0:545. Cardiovascular, Di estive HNTSL47 SEQ ID NO:546 Cardiovascular, -Di estive HBJLR70 SEQ ID NO:547 Immune/Hematopoietic, ' Neural/Senso HBJLR70 . SEQ ID N0:548~ Immune/Hematopoietic, Neural/Senso HNTSY18 SEQ ID N0:549 Cardiovascular, Re reductive HNTSY18 SEQ ID N0:550, Cardiovascular, Re reductive HBHME51 SEQ ID N0:551 Reproductive, . Res irate .

HBHME51 SEQ ID N0:552 Reproductive, Res iratory HBHME51 SEQ ID N0:553 Reproductive, Res iratory HMCHR48 SEQ ID N0:554 Connective/Epithelial, ImmunelHematopoietic, Re reductive HMC.HR48 SEQ ID N0:555 Connective/Epithelial, Immune/Hematopoietic, Re reductive HMCHR48 SEQ ID N0:556 Connective/Epithelial, Immune/Hematopoietic, Re reductive HMCIJ07 SEQ ID N0:557~ ImmunelHemato oietic HMCIJ07 SEQ ID N0:558 Immune/Hemato oietic HSIFL06 SEQ ID N0:559 Cancer HSIFL06 SE ID N0:560 Cancer HMZME33 SEQ ID N0:561. Connective/Epithelial, Di estive HMZME33 SEQ ID N0:562 Connective/Epithelial, Di estive HMZMF54 SEQ ID N0:563 Di estive HMZMF54 SEQ'ID N0:564 Di estive HMZMF54 . SE ID N0:565 Di estive HMVCQ82 SE ID N0:566 - Immune/Hemato oietic HMVCQ82 SEQ ID N0:567 Immune/Hemato oietic HMVCQ82 SEQ ID N0:568 Immune/Hemato oietic HMVDP35 SEQ ID N0:569 Immune/Hematopoietic, Re reductive HMVDP35 SEQ ID N0:570 Immune/Hematopoietic, Re reductive HMVDP35 SEQ ID N0:571 Immune/Hematopoietic, Re reductive HMVDF54 SEQ ID N0:572 Cancer HMVDF54 SEQ ID N0:573 Cancer HMVDF54 -SEQ ID N0:574 Cancer HROBM46 SEQ ID N0:575 Connective/Epithelial,~
Di estive HROBM46 SEQ ID N0:576 Connective/Epithelial, - Di estive HCNDR47 SEQ ID N0:577 Cancer HCNDR47 SEQ ID N0:578 Cancer ' HCNDR47 SEQ ID N0:579 Cancer ' HCNDV12 SEQ ID N0:580 Digestive, Re reductive HCNDV12 , SEQ ID N0:581_ Digestive, Re reductive .

HCNDV12 SEQ ID N0:582 Digestive, ' Re reductive HSODE04 SEQ ID N0:583 Di estive HSODE04 SEQ ID N0:584 Di estive HBFMC03 ~. SEQ ID N0:585 Digestive, Musculoskeletal, Re reductive HBFMC03 SEQ ID N0:586 Digestive, M usculoskeletal, Re reductive HHSFB67 SEQ ID N0:587 Neural/Sensory HHSFB67 SEQ ID N0:588 Neural/Sensory HHSFB67 SEQ ID N0:589 Neural/Sensory HHSFB67 SEQ ID N0:590-, Neural/Sensory HHSGW69 SEQ ID N0:591 Cancer HHSGW69 SEQ ID N0:592 Cancer HHSGW69 SEQ ID N0:593 ' Cancer HCLCJ15 SEQ ID N0:594 Cancer HCLCJ15 SEQ ID N0:595 Cancer HCLCJ15 SEQ ID N0:596~ Cancer HCLCJ15 SEQ ID N0:597 Cancer HSLJG37 SEQ ID N0:598 Cancer -HSLJG37 SEQ ID N0:599 Cancer HSLJG37 SEQ ID N0:600 Cancer HWLEC41 SEQ ID N0:601 Cancer HWLEC41 SEQ ID N0:602' Cancer HWLEC41~ SEQ ID N0:603 Cancer HSXEQ06 SE ID N0:604 Cancer HSXE 06 SE ID N0:605 Cancer HSXEQ06 SEQ ID N0:606 Cancer HEEA.A16 SEQ ID N0:607 Cancer HEEAA16 SEQ ID NO:608 Cancer HEEAA16 SEQ ID N0:609 Cancer HEEAM62 SEQ ID N0:610 Re roductive HEEAM62 SEQ ID N0:611 Re reductive HEEAM62 SEQ ID NO:612~ Re reductive HEEAM62 SEQ ID N0:613 Re reductive HNHKI,90 SEQ ID N0:614 Immune/Hemato oietic HNHKL90 SEQ ID N0:615 Immune/Hemato oietic HNHKL90 SEQ ID N0:6 Immune/Hemato oietic i 6 HWLFQ64 SEQ ID N0:617 Digestive HWLF 64 SEQ ID N0:618 Di estive HWLFR02 SEQ ID N0:619 Cancer HWLFR02 SE ID N0:620 Cancer HWLFR02 SE ID N0:621 Cancer HBKED 12 SEQ ID N0:622 Cancer HBKED 12 SEQ ID N0:623 Cancer HBKED 12 SEQ ID N0:624 Cancer HBKED12 SEQ ID N0:625 Cancer HBKED 12 SEQ ID N0:626 Cancer HWLFJ10 SEQ ID N0:627 Cancer HWLFJ10 SEQ ID N0:628 Cancer HCRN087 SEQ TD N0:629 Cancer HCRN087 SEQ ID N0:630 Cancer HCRN087 SEQ ID NO:631 Cancer HCRN087 ' SEQ ID NO:632 Cancer HWLJX42 SEQ ID NO:633 Cancer HWLJX42 SEQ ID N0:634' Cancer HWLJX42 SEQ ID N0:635 Cancer HSPBY63 SEQ ID N0:636' Di estive HSPBY63 SEQ ID N0:637 Di estive HSPBY63 SEQ ID N0:638 Di estive HAPSO15 SEQ ID N0:639 Cancer HAPSO15 SEQ ID N0:640 Cancer HAPS015 SEQ.ID N0:641~ Cancer HE8QG24 SEQ ID N0:642 Mixed Fetal HE8QG24 SEQ ID N0:643 Mixed Fetal HE8QG24 SEQ ID N0:644 Mixed Fetal ' HE8QV43 SEQ ID N0:645 Cancer HE8QV43 SE ID NO:646 Cancer HE8QV43 SEQ ID N0:647 Cancer HE8QV43 SEQ ID NO:648 Cancer HE9QN39 SEQ ID NO:649 Cancer HE9QN39 SEQ ID N0:650 Cancer HE9R044 SEQ ID N0:651. Immune/Hematopoietic, ,. Mixed Fetal HE9R044 SEQ ID N0:652 Immune/Hematopoietic, Mixed Fetal HE9R044 SEQ ID N0:653 Immune/Hematopoietic, ' Mixed Fetal HE9SE18 SEQ ID N0:654 Digestive, Mixed Fetal HE9SE18 SEQ ID N0:655 Digestive, Mixed Fetal HE9SE18 SEQ.ID N0:656 Digestive, Mixed Fetal HISCV60 SEQ ID N0:657 Digestive HISCV60 SE ID N0:658 Di estive ' HE8UT25 SEQ ID N0:659 Mixed Fetal .

HE8UT25 SEQ ID NO:660 Mixed Fetal HE8UT25 SE ID N0:661 Mixed Fetal HE8UY36 SEQ ID N0:662 Cancer HE8UY36 SEQ ID N0:663~ Cancer HNHNT13 SEQ ID N0:664 Immune/Heinato oietic HNHNT13 SEQ ID N0:665 Immune/Hemato oietic HNHNT13 SEQ ID NO:666 Immune/Hemato oietic HODEB50 SEQ ID N0:667 Re roductive HODEB50 ~ SEQ ID N0:668~ ' Re roductive HODEB50 SEQ ID N0:669 Re roductive HNGMJ91 SEQ ID N0:670 Immune/Hemato oietic HNGMJ91 SEQ'ID N0:671 Immune/Hemato oietic HNGMJ91 SEQ ID N0:672 Immune/Hemato oietic HNGNB69 SEQ ID N0:673 Immune/Hemato oietic HODFW41 SEQ ID N0:674 Re roductive HODFW41 ' SEQ ID N0:675 Re roductive HNGOI12 SEQ ID N0:676. . Immune/Hemato oietic ' HNGOI12 SEQ ID N0:677 Immune/Herizato oietic HNGOI12 SEQ ID N0:678 Immune/Hemato oietic HNGPM78 SEQ ID NO:679. Immime/Hematopoietic, Neural/Sensory HNGPM78 SEQ ID N0:680. Immune/Hematopoietic, Neural/Sensory HYASC80 SEQ ID N0:681 Cancer ' HYASC80 SEQ ID N0:682 Cancer HWLHM66 SEQ ID NO:683 Cancer HWLHM66 SEQ ID N0:684 Cancer HWLHM66 SEQ ID N0:685 Cancer HWLHM66 SEQ ID N0:686 Cancer HBBBC71 SEQ ID N0:687 Cancer HBBBC71 SEQ ID N0:688 Cancer HBBBC71 SEQ ID N0:689 Cancer HLJBF86 SEQ ID'N0:690 Cancer HLJBF86 SEQ ID NO:691 Cancer HLJBF86 SEQ ID NO:692 Cancer .

135 .

HLJBJ61 SEQ ID N0:693 Cancer HLJBJ61 SEQ ID N0:694_ Cancer HHBCS39 SEQ ID N0:695 Cancer HHBCS39 SEQ ID N0:696 Cancer HHBCS39 SE IID N0:697 Cancer HLJEA01 SEQ ID NO:698 Res irate HLJEA01 SEQ ID N0:699 Res iratory HLEDB 16 SEQ ID N0:700 Cancer HOGCK63 SEQ ID N0:701 Cancer HOGCK63 SEQ ID N0:702- Cancer HOFMQ33 SEQ ID N0:703 Re reductive HOFMQ33 SEQ ID N0:704 Re reductive HOFMQ33 SEQ ID N0:705 Re reductive HOFMQ33 SEQ ID N0:706 Re reductive HOFMT75 SEQ ID N0:707~ Re reductive HOFMT75 SEQ ID N0:708 Re reductive HOFMT75 SEQ ID N0:709 Re reductive HOFMT75 SEQ ID N0:710 Re reductive HOGCS52 SEQ ID N0:711 Cancer HOGCS52 SEQ ID N0:712~ Cancer HOGCS52 SEQ ID N0:713 Cancer HOFNM53 SEQ ID NO:714 Re reductive HOFNM53 SEQ ID N0:715 Re reductive HOFNM53 SEQ ID N0:716 Re reductive HOFNM53 SEQ ID N0:717 Re reductive HOFOB27 SE ID N0:718 Cancer HOFOB27 SE ID N0:719 Cancer HOFOB27 . SEQ ID N0:720 Cancer HOFOB27 SEQ ID N0:721 Cancer _ SEQ ID N0:722 Re reductive HOFOC33 SEQ ID N0:723 Re reductive HOFOC33 SEQ ID NO:724 Re reductive HOFOC33 SEQ ID NO:725 Re reductive HOFOC33 SEQ ID N0:726 Re reductive HOFOG33 SEQ ID N0:727 Re reductive HOFOC73 SE ID N0:728 Cancer HOFOC73 SEQ ID N0:729 Cancer HOFOC73 SEQ ID N0:730 Cancer HOFOC73 SEQ ID N0:731 Cancer HNTAC64 SEQ ID N0:732 Cancer HNTAC64 SEQ ID N0:733 Cancer HNTAC64 SEQ ID NO:734 Cancer HNTAC64 SEQ ID N0:735 Cancer HDTBD53 SE ID NO:736 Cancer HDTBD53 SEQ ID NO:737 Cancer HDTAQ57 SEQ ID NO:738 Cancer HDTA 57 SEQ ID N0:739 Cancer ' HDTAR06 SEQ ID N0:740 Cancer HDTAR06 SEQ ID N0:741 Cancer HDPML23 SEQ ID N0:742~ Immune/Hematopoietic, ' Neural/Sensory HDPML23 SEQ ID N0:743 Immune/Hematopoietie, Neural/Sensory HDPML23 SEQ ID N0:744. ' Immune/Hematopoietic, Neural/Sensory HDPML23 SEQ ID N0:745 Immune/Hematopoietic, Neural/Sensory HDPML23 SEQ ID N0:746 Immune/Hematopoietic, Neural/Senso HDPMM88 SEQ ID N0:747 Cancer HDPMM88 SE ID NO:748 Cancer HDPMM88 SEQ ID N0:749 Cancer HDPMM88 SEQ ID N0:750 Cancer HDPMM88 SEQ ID N0:751 Cancer HDPMM88 SEQ ID N0:752 Cancer HDPMM88 SEQ ID N0:753 Cancer HDPMS12 SEQ ID N0:754 Cancer HDPMS 12 SEQ ID NO:755 Gancer HDPMS12 SEQ ID N0:756 Cancer HDPMS12 SEQ ID N0:757 Cancer HDPMS12 SEQ ID N0:758 Cancer HDPMS 12 SEQ ID N0:759 Cancer HDPAP35 SEQ ID N0:760 Excretory, Immune/Hematopoietic, Neural/Sensory HDPAP35 ~ SEQ ID N0:761 Excretory, - Immune/Hematopoietic, NeurallSensory HDPAP35 SEQ ID N0:762 Excretory, Immune/Hematopoietic, NeurallSensory HDPAP35 SEQ ID N0:763 Excretory, Immune/Hematopoietic, Neural/Sensory HDPAQ55 SEQ ID N0:764 Digestive, - ' ~ Immune/Hematopoietic, Re reductive HDPAQ55 SEQ ID N0:765 Digestive, I mmune/Hematopoietic, Re reductive HDPAQ55 SEQ ID N0:766 Digestive, Immune/Hematopoietic, Re reductive HDPAQ55 SEQ ID N0:767, Digestive, ' Immune/Hematopoietic, Re reductive HKAAV61 SE ID N0:768 Connective/E ithelial HKAAV61 SEQ ID NO:769 Connective/E ithelial HKAAV61 SEQ ID N0:770 Connective/E ithelial HDPCJ43 SEQ ID N0:771 Cancer ' HDPCJ43 SEQ ID N0:772 Cancer HDPCJ43 SEQ ID N0:773~ Cancer HDPCJ43 SEQ ID N0:774 Cancer HI~ACM93 SEQ ID N0:775 Cancer HI~ACM93 SEQ ID N0:776 Cancer HKACM93 SEQ ID N0:777 Cancer HKACM93 SEQ ID N0:778 Cancer HI~AFT66 SEQ ID N0:779. Connective/Epithelial, Digestive, Immune/Hemato oietic HKAFT66 SEQ ID N0:780 Connective/E ithelial, Digestive, Immune/Hemato oietic HKAFT66 SEQ ID N0:781 ConnectivelEpithelial, Digestive, Immune/Hemato oietic HHEMM74 SEQ ID N0:782 Cancer HHEMM74 SEQ ID N0:783 Cancer HHEMM74 SEQ ID N0:784 Cancer HHEMM74 SEQ ID N0:785 Cancer HAMFC93 SEQ ID N0:786 Cancer HAMFC93 SEQ ID N0:787 Cancer HAMFC93 SEQ ID N0:788 Cancer HSYAZ50 SEQ ID N0:789 Cancer HSYAZ50 SEQ ID N0:790 Cancer HSYAZSO SEQ ID NO:791 Cancer HSYAZSO SEQ ID NO:792 Cancer HLWAX42 SEQ ID N0:793 Cancer HLWAX42 SE ID N0:794 Cancer HLWAX42 SEQ ID N0:795' Cancer HLWAZ70 SEQ ID NO:796 Cancer HLWAZ70 SEQ ID NO:797' Cancer HLWAZ70 SEQ ID N0:798 Cancer HLWAZ70 SEQ ID NO:799 Cancer .

HLWBG83 SEQ ID NO:800 Cancer HLWBG83 SEQ ID NO:801 Cancer HLWBG83 SEQ ID N0:802 Cancer HLWBG83 SEQ ID N0:803 Cancer HLWBG83 SEQ ID N0:804 Cancer HLWBH18 SEQ ID N0:805 Re roductive HLWBH18 SEQ ID N0:806 Re roductive.
~

HRABS65 SEQ ID N0:807. Cancer HRABV43 SEQ ID N0:808 Cancer HRABV43 SEQ ID N0:809 Cancer HRABV43 SEQ ID N0:810 Cancer HHEPG23 SEQ ID N0:811 Cancer HHEPG23 SEQ ID N0.:812 Cancer HHEPG23 SEQ ID N0:813 Cancer HHEPJ23 SEQ ID N0:814 Cancer HHEPJ23 SEQ ID N0:815. Cancer HDPIW06 SEQ ID N0:816 Digestive, ImmunelHematopoietic, Neural/Sensory HDPIW0 SEQ ID N0:8176 Digestive, _ Immune/Hematopoietic, Neural/Sensory HDPIW06 SEQ ID.N0:818 Digestive, Immune/Hematopoietic, Neural/Senso -HDPIW06 S~Q ID N0:819 Digestive, Iminune/Hematopoietic, Neural/Sensory HDPIW06 SEQ ID N0:820~ Digestive, Immune/Hematopoietic, Neural/Sensory HDPPA04 . SEQ ID N0:821 Cardiovascular, v Connective/E ithelial, .

~13 8 Immune/Hemato oietic HDPPA04 SEQ ID N0:822' Cardiovascular, - Connective/Epithelial, Immune/Hemato oietic HDPPA04 SEQ ID N0:823 Cardiovascular, Connective/Epithelial, Immune/Hemato oietic HDPPN86 SEQ ID N0:824 Cancer HDPPN86 SEQ ID N0:825 Cancer HDTEK44 SEQ ID N0:826 Connective/Epithelial, Immune/Hematopoietic, Re reductive HDTEK44 SEQ ID N0:827 Connective/Epithelial, ImmunelHematopoietic, Re reductive HDTEK44 SEQ ID NO:828 Connective/Epithelial, Immune/Hematopoietic, . ~ Re reductive HDTEK44 SEQ ID N0:829 Connective/Epithelial, - ~ Immune/Hematopoietic, ' Re reductive HOHBL42 SEQ ID N0:830 Cancer HOHBL42 SEQ ID N0:831 Cancer HOHBL42 5EQ ID NO:832 Cancer HOHBL42 SEQ ID NO:833 Cancer HOHBP82 SE ID N0:834 Musculoskeletal HOHBP82 SEQ ID N0:835 Musculoskeletal HOHBP82 SEQ ID N0:836 Musculoskeletal HOHBP82 SEQ ID N0:837 Musculoskeletal HOHBY44 SEQ ID N0:838 Cancer HOHBY44 SEQ ID N0:839 Cancer HOHBY44' SEQ ID N0:840 Cancer HWBADO1 SEQ ID NO:841' Immune/Hemato oietic HWBADO1 SEQ ID N0:842 Immune/Hemato oietic HWBADO1 SEQ ID N0:843 Immmie/Hemato oietic HOHCJ90 SEQ ID N0:844 Cancer HOHCJ90 SEQ ID N0:845 Cancer HWABE12 SEQ ID N0:846 Cancer HWABE12 SEQ ID N0:847 Cancer HWABE12 SEQ ID N0:848 Cancer HWBAR14' SEQ ID N0:849-. - C~cer HWBAR14 SEQ ID N0:850 Cancer HWBAR14 SEQ ID N0:851 Cancer HWBAR14 SEQ ID N0:852 Cancer HWBAR88 SEQ ID N0:853 Cancer HWBCH13 SEQ ID N0:854 Immune/Hemato oietic HWBCH13 SEQ ID N0:855 Immune/Hemato oietic HWBCH13 SEQ ID N0:856 Immune/Hemato oietic HWBCH13 SEQ ID N0:857 Immune/Hemato oietic HWBCM79 SEQ ID N0:858 Immune/Hemato oietic HWBCV72 SEQ ID N0:859- Cancer HWBCV72 SEQ ID N0:860~ Cancer HWBCV72 SEQ ID N0:861- Cancer HWBCV72 SEQ ID N0:862 Cancer HWBDM62 ..SEQ ID N0:863' Endocrine, Immune/Hemato oietic HWBDM62 SEQ ID N0:864 Endocrine, - Immune/Hemato oietic HWBDM62 SEQ ID N0:865 Endocrine, Immune/Hemato oietic HWBDM62 SEQ ID N0:866 Endocrine, Immune/Hemato oietic HMTAL77 SEQ ID N0:867 Cancer HMTAL77 SEQ ID N0:868 Cancer HDPRH52 SEQ ID N0:869 Cancer HDPRH52 SEQ IDN0:870 Cancer HDPSB18 SEQ ID N0:871' Cancer HDPSB18 SEQ ID N0:872 Cancer ~

HDPSB18 SEQ ID N0:873 Cancer HDPSB18 SEQ ID N0:874 Cancer HDPSH53 SEQ ID N0:875 Immune/Hematopoietic, Re roductive HDPSH53 SEQ ID N0:876 Immune/Hematopoietic, Re roductive HDPLO25 SEQ ID NO:877 Cancer -HDPL025 SEQ ID N0:878 Cancer HDPL025 SEQ ID N0:879 Cancer HDPRN70 SEQ ID N0:880 Immune/Hemato oietic HDPRN70 SEQ ID N0:881 Immtme/Hemato oietic HDPTW24. SEQ ID N0:882 Immune/Hemato oietic HDPTW65 SEQ ID NO:883 Excretory HDPTW65 SEQ ID N0:884 Excretory HDPTW65 SEQ ID NO:885 Excretory HDPWN93 SEQ ID N0:886 Cancer HDPWN93 SEQ ID N0:887 Cancer HDPWN93 SEQ ID N0:888 Cancer HDPXY01 SEQ LD N0:889' Cancer HDPXY01 SEQ ID N0:890 Cancer ' HDPXY01 SEQ ID N0:891 Cancer HDPXY01 SEQ ID N0:892 Cancer HWHPM16 SEQ ID N0:893 Cancer HWHPM16 SEQ ID N0:894' Cancer HLDQA07 SEQ ID N0:895 Di estive HLDQA07 SE ID N0:896 Di estive HDTFE17 SEQ ID N0:897 Cancer HDTFE17 SEQ ID N0:898 Cancer HDTFE17 SEQ ID N0:899 Cancer HWDAD17 SEQ ID NO:900 Cancer HWDAD 17 SEQ ID NO:901 Cancer ~

HWEAC77 SEQ ID N0:902 Connective/E ithelial HWEAC77 SEQ ID N0:903 Connective/E ithelial HWBEM18 SEQ ID N0:904 Cancer HWBEM18 SEQ ID N0:905 Cancer .

HWBEM18 SEQ ID N0:906 Cancer HWBFE57 SEQ ID N0:907 Cancer HWBFE57 ~ SEQ ID NO:908 Cancer HWBFE57 SEQ ID N0:909 Cancer HOHDF66 SEQ ID N0:910 Musculoskeletal HOHDF66. SEQ ID N0:911 Musculoskeletal HOHDF66 SEQ ID N0:912 Musculoskeletal HOHDC86 . SEQ ID NO:913 Musculoskeletal HOHDC86 SEQ ID NO:914 M_usculoskeletal HOHDC86. SEQ ID N0:915. Musculoskeletal HRA.DO01 SEQ ID N0:916 Excretory .

HR.ADO01 SEQ ID N0:917 Excretory HRADO01 SEQ ID NO:918 Excretory HRAEE45 SEQ ID N0:919 Connective/Epithelial, ' Excretory, Immune/Hemato oietic HRAEE45 SEQ ID N0:920. Connective/Epithelial, ' Excretory, Immune/Hemato oietic HRAEE45 SEQ ID NO:921 Connective/Epithelial, Excretory, Immune/Hemato oietic HRAEH37 SE ID N0:922 Cancer HRAEH37 SE ID NO:923 ' Cancer HRAEH37 SEQ ID N0:924 Cancer HWDAH38 SEQ ID N0:925 Cancer HWDAH38 SEQ ID N0:926 Cancer HLWCP78 SEQ ID N0:927 Cancer HLWCP78 SEQ ID N0:928 Cancer HLWCP78 SEQ ID NO:929 Cancer HLWCP78 SEQ ID N0:930 Cancer HTJML75 SEQ ID N0:931 Cancer HTJML75 SEQ ID N0:932 Cancer HTJNX29 SEQ ID N0:933 Connective/Epithelial, Digestive, Immune/Hemato oietic HTJNX29 SEQ ID N0:934~ Connective/Epith_ elial,.
Digestive, Immune/Hemato oietic HTJNX29 SEQ ID N0:935 Connective/Epithelial, Digestive, Immune/Hemato oietic HHESQ62 SEQ ID N0:936~ Immune/Hemato oietic HHESQ62 SEQ ID N0:937 Immune/Hemato oiefic HHES 62 SEQ ID N0:938 Immune/Hemato oietic HHESQ62 SEQ ID N0:939 Immune/Hemato oietic HHESQ62 SEQ ID Nb:940~ Immune/Hemato oietic' HDQG029 SEQ ID N0:941 hnmune/Hemato oietic HDQG029 SEQ ID N0:942 Immune/Hemato oietic HDQG029 SEQ ID N0:943 Immune/Hemato oietic ' HDQG029 SEQ ID N0:944 Immtme/Hemato oietic HDQHY04 SEQ ID N0:945- Cancer HDQHY04 SEQ ID N0:946~ Cancer HDQHY04 SEQ ID N0:947 Cancer HBXAB02 SE ID N0:948 Cancer HBXAB02 SEQ ID N0:949~ Cancer HBXAB02 SEQ ID N0:950 Cancer HCWAU23 SEQ ID N0:951 Immune/Hemato oietic .

HCWAU23 SEQ ID N0:952 Immune/Hemato oietic ~

HCWAU23 SEQ ID N0:953 Immune/Hemato oietic HBXAM53 SEQ ID N0:954 Cancer HBXAM53 SEQ ID N0:955 Cancer HBXAM53 SEQ ID N0:956 Cancer HCWBP34 SEQ ID N0:957 Immune/Hemato oietic HCWBP34 SEQ ID N0:958 Immune/Hemato oietic HCWBP34 SEQ ID N0:959 Immune/Hemato oietic HBXCT44 SEQ ID N0:960 Cancer HBXCT44 SEQ ID N0:961- Cancer HBXCT44 SEQ ID N0:962 Cancer HBXCT44 SEQ ID NO:963 Cancer HCWDY64 SEQ ID N0:964~ Excretory, Immune/Hemato oietic HCWDY64 SEQ ID N0:965 Excretory, ImmunelHemato oietic HCWDY64 SEQ ID N0:966 Excretory, Immune/Hemato oietic HCWEB58 SEQ ID N0:967 Cancer HCWEB58 SEQ ID NO:968 Cancer HBXED80 SEQ ID N0:969 Immune/Hematopoietic, Neural/Sensory HBXED80 SEQ ID N0:970 Immune/Hematopoietic, Neural/Senso HBXED80 SEQ ID N0:971 Immune/Hematopoietic, Neural/Sensory HBXED80 . SEQ ID N0:972 Immune/Hematopoietic, Neural/Sensory HCWFT79 SEQ ID N0:973 Immune/Hemato oietic HCWFT79 SE ID N0:974 Immune/Hemato oietic HCWFT79 SEQ ID N0:975 Immune/Hemato oietic ' HCWFU77 SEQ ID NO:976 Cancer HCWFU77 SE ID N0:977 Cancer HCWFU77 SEQ ID N0:978 Cancer HBXFZ38 SEQ ID N0:979 Cancer HBXFZ38 SEQ ID N0:980 Cancer HBXFZ38 SEQ ID N0:981 Cancer HCUGC55 SEQ ID N0:982 Immune/Hemato oietic HCUGC55 SEQ ID N0:983 Immune/Hemato oietic HCUGC55 SEQ ID N0:984~ Immune/Hemato oietic ~iCWGU37 SEQ ID N0:985 Immune/Hematopoietic, NeurallSensory, Re reductive HCWGU37 SEQ ID N0:986 Immune/Hematopoietic, Neural/Sensory, Re rodiictive HCWHV88 SEQ ID N0:987 Digestive, Immune/Hematopoietic, Re reductive HCWHV88 SEQ ID N0:988 Digestive, Immune/Hematopoietic, Re reductive HCWHX82 SEQ ID N0:989~ Immune/Hematopoietic, Neural/Senso HCWHX82 SEQ ID N0:990 Immune/Hematopoietic, Neral/Sensory HCWHX82 SEQ ID N0:991 Immune/Hematopoietic, Neural/Sensory HCWFZ59 SEQ ID NO:992 Immune/Hemato oietic HCWFZ59 SEQ ID N0:993 Immune/Hemato oietic HCWFZ59 SEQ ID N0:994 Immune/Hemato oietic HCWFZ59 SEQ ID N0:995 Immune/Hemato oietic HBWCB95 SEQ ID N0:996 NeurallSensory HBWCB95 ~ SEQ ID Neural/Sensory N0:997 HBWCB95 SEQ ID N0:998 Neural/Sensory HBWBR94 SEQ ID N0:999 Neural/Sensory HBWBR94 SEQ ID NO:1000. Neural/Sensory ' HBWBR94 SEQ ID NO:1001 Neural/Senso HBWCF75 SEQ ID N0:1002 Neural/Sensory HBWCF75 SEQ ID N0:1003 Neural/Sensory HBWCF75 SEQ ID N0:1004~ Neural/Sensory HBWCM83 SEQ ID N0:1005 Digestive, Immune/Hematopoietic, Neural/Senso H$WCM83 SEQ ID N0:1006 Digestive, Immune/Hematopoietic;
' Neural/Senso HBWCM83 . SEQ ID N0:1007 Digestive, Immune/Hematopoietic, Neural/Sensory HBWCM83 SEQ ID N0:1008, Digestive, Immune/Hematopoietic, Neural/Sensory HRSMQ86 SEQ ID N0:1009 Cancer HRSMQ86 SEQ ID NO:1010 Cancer HFCAA91 SEQ ID NO:1011 Neural/Sensory HFCAA91 SEQ ID N0:1012 NeurallSensory HFCAA91 SEQ ID N0:1013 Neural/Senso HFCAL39 SEQ ID N0:1014 Cancer HFCAL39 SEQ ID N0:1015 Cancer ' HFCAL39 SEQ ID N0:1016 Cancer HCEBN44 SEQ ID N0:1017 NeurallSensory HCEBN44 SEQ ID N0:1018 Neural/Senso HHFCP32 SEQ ID N0:1019 Cancer HGBAJ60 SEQ ID N0:1020 Cancer HGBAJ60 SEQ ID N0:1021 Cancer HHFCW75 SEQ ID N0:1022 Cardiovascular HHFCW75 SEQ ID N0:1023 Cardiovascular HHFCW75 SEQ ID N0:1024~ Cardiovascular HHFCZ67 SEQ ID N0:1025 Cancer HHFCZ67 SEQ ID N0:1026 Cancer HHFCZ67 SEQ ID N0:1027 Cancer HHFCZ67 SEQ ID N0:1028 Cancer HJBARO1 SEQ ID N0:1029' Cancel HJBARO1 SEQ ID NO:1030 Cancer HETAR42 SEQ ID N0:1031 Cancer HETAR42 SEQ ID N0:1032 Cancer HETAR42 SEQ ID N0:1033 Cancer HETAR42 SEQ ID N0:1034- Cancer .

HETAM53 SE ID N0:1035 Cancer HETAM53. SEQ ID N0:1036 Cancer HETAM53 SE ID N0:1037 Cancer HETAM53 SEQ ID N0:1038 Cancer HETAM53 SEQ ID N0:1039 Cancer HTPBG16 , SEQ ID N0:1040 Digestive, Immune/Hemato oietic HTPBG16 . SEQ ID N0:1041' Digestive, .
~ Immune/Hemato oietic ,. . -~~.3 HTPBG16 SEQ ID N0:1042~ Digestive, _ Immune/Hemato oietic HJAAJ58 SEQ ID N0:1043 Immune/Hemato oietic HJAAJ58 SEQ ID N0:1044 Immune/Hemato oietic HJAAJ58 SEQ ID N0:1045 Immune/Hemato oietic HJAAJ58 SEQ ID N0:1046 Immune/Hemato oietic HSBBT12 SEQ ID N0:1047 Cancer HSBBT12 SEQ ID N0:1048 Cancer HSBBT12 SEQ ID N0:1049 Cancer HE8MH77 -SEQ ID N0:1050 Immune/Hematopoietic, Mixed Fetal, Neural/Sensory HE8MH77 SEQ ID N0:1051 Immune/Hematopoietic, Mixed Fetal, NeurallSensory HE8MH77 SEQ ID N0:1052 Immune/Hematopoietic, Mixed Fetal, Neural/Senso HTEDJ85 SEQ ID N0:1053 Cancer HTEDJ85 SEQ ID N0:1054 Cancer HTEDJ85 SEQ ID NO:1055~ Cancer HTEDJ85 SEQ ID N0:1056~ Cancer HOVAF78 SEQ ID N0:1057 Cancer HOVAF78 SEQ ID N0:1058 Cancer HOVAF78 SEQ ID NO:1059 Cancer HOVAF78 SEQ ID N0:1060 Cancer HOVAF78 SEQ ID N0:1061 Cancer HHGDE24 SE ID N0:1062~ Cancer HHGDE24 SEQ ID N0:1063- Cancer .

HHGDE24 SEQ ID N0:1064~ Cancer HOUFU35 SEQ ID N0:1065 Connective/E ithelial HOUFU35 'SEQ ID N0:1066 Connective/E ithelial HOUFU35 SEQ ID N0:1067 Connective/E ithelial HOUFU35 SEQ ID N0:1068 Connective/E ithelial HSIGD79 SEQ ID N0:1069 Cancer HSIGD79 SEQ ID N0:1070 Cancer HCQCT05 SEQ ID N0:1071 Digestive, a Endocrine, Re roductive HCQCT05 SEQ ID N0:1072~ Digestive, Endocrine, Re roductive HMVDL30 SEQ ID N0:1073 Cancer HMVDL30 SEQ ID NO:1074 Cancer HMVDL30 SEQ ID NO':1075 Cancer HMVDL30 SEQ ID N0:1076 Cancer HTGG035 SEQ ID N0:1077 Cancer HTGG035 - SEQ ID NO:1 Cancer b78 HTGG035 SEQ ID N0:1079 Cancer HCLBW50 ~ SEQ ID N0:1080 Cancer HCLBW50 ~ SEQ ID N0:1081 Cancer HCLBW50 SEQ ID N0:1082 Cancer HCLBW50 SEQ ID N0:1083 Cancer HWLEV32 SEQ ID N0:1084 Cancer HWLEV32 SEQ ID N0:1085 Cancer .

HWLEV32 SEQ ID N0:1086 Cancer HWLEV32 SEQ ID N0:1087 Cancer HWLFE89 SEQ ID NO:1088 Cancer HWLFE89 SEQ ID N0:1089~ Cancer HWLFE89 SEQ ID N0:1090 Cancer HE8PW38 SEQ ID N0:1091 Neural/Sensory HE8PW38 SEQ ID NO:1092 Neural/Sensory HE8PW38 SEQ ID N0:1093 Neural/Sensory HE9R027 SEQ ID N0:1094 Connective/Epithelial, Mixed Fetal HE9R027 SEQ ID N0:1095 ConnectivelEpithelial, Mixed Fetal HE9R027 SEQ ID N0:1096 Connective/Epithelial, Mixed Fetal HCRPV17 SEQ=IDN0:1097 Cancer HCRPV17 SEQ ID N0:1098 Cancer HCRPV17 SE ID N0:1099 Cancer HCRPV17 - SEQ ID NO:1100 Cancer HHBGF77 SEQ ID NO:1101 Cancer HHBGF77 SEQ ID N0:1102w Cancer HLUDB47 . SEQ ID N0:1103' Cancer HLUDB47 SEQ ID NO:1104 Cancer HLUDB47 SEQ ID N0:1105 Cancer HHENZ16 SEQ ID N0:1106 Cancer HHENZ16 SEQ ID N0:1107 Cancer HHENZ16 SEQ ID NO:l Cancer HSYBZ44 SEQ ID N0:1109 Cancer HARNB 17 ' SEQ ID NO:1.110 Cancer HARNB 17 SEQ ID NO:1111 Cancer HARNB 17 SEQ ID N0:1112 Cancer HARNB92 SEQ ID N0:1113 Cancer HARNB92 SEQ ID N0:1114 Cancer HARNB92 SEQ ID N0:1115 Cancer HAMGV47 SEQ ID N0:1116 Cancer HAMGV47 SEQ ID NO:1 Cancer -HAMGV47 SEQ ID N0:1118 Cancer HDTMK50 SEQ ID N0:1119 Cancer HDTMK50 SEQ ID N0:1120 Cancer HDTMK50 SEQ ID N0:1121 Cancer HARBA09 SEQ ID N0:1122~ Cancer HARBA09 SEQ ID N0:1123 Cancer HARBA09 SEQ ID N0:1124 Cancer HARBA09 SEQ ID N0:1125~ Cancer HE80K73 SEQ ID N0:1126 Mixed Fetal, Neural/Sensory HE80K73 . SEQ ID NO:1127 Mixed Fetal, Neural/Sensory HE80K73 SEQ ID N0:1128' Mixed Fetal, NeurallSensory HSDJL42 SEQ ID N0:1129 Cancer HSDJL42 SEQ ID N0:1130 Cancer HSDJL42 SEQ ID N0:1131 Cancer HCE2P86 SEQ ID N0:1132- Cancer HCE2P86 SEQ ID N0:1133 Cancer HCE2P86 SEQ ID N0:1134 Cancer HNGNN78 SEQ ID N0:1135 Cancer HNGNN78 SEQ ID NO:l Cancer HNGNN78 SEQ ID N0:1137 Cancer HTLHC59 SEQ ID N0:1138. Digestive, Re roductive HTLHC59 SEQ ID N0:1139 Digestive, , Re roductive HTLJF15 SEQ ID NO:1140 Immune/Hematopoietic, Re roductive HTLJF15 ' SEQ ID N0:1141 Immune/Hematopoietic, Re roductive HTLJF15 SEQ ID N0:1142 Immune/Hematopoietic, Re roductive HPJCC05 SEQ D7 N0:1143 Re roductive HPJCC05 SE ID N0:1144 Re roductive HPJCC05 SEQ ID N0:1145 Re inductive HDPVW 11 SE ID N0:1146 Cancer HDPVW11 SEQ ID NO:1147 Cancer HDPWP69 SEQ ID N0:1148 Cancer -HDPWP69 SEQ ID N0:1149 Cancer HDPWP69 SEQ ID N0:1150~ Cancer HWHHD11 SEQ ID N0:1151 Cancer HWHHD11 SEQ ID NO:1152 Cancer HWHHD11 SEQ ID N0:1153 Cancer HBIMT93 SEQ ID N0:1154 Cancer HBIMT93 SEQ ID N0:1155 Cancer HBIMT93 SEQ ID NO:1156 Cancer HHATA33 SEQ ID N0:1157 Cancer HHATA33 SEQ ID N0:1158 Cancer HNTDL21 SEQ ID N0:1159 Cancer HNTDL21 SEQ ID N0:1160 Cancer ' HNT'NK95 SEQ ID N0:1161 Cancer HNTNK95 SE ID N0:1162 Cancer HNTNK95 SEQ ID N0:1163 Cancer HWEAD64 SE ID N0:1164 Cancer HWEAD64 SEQ ID N0:1165 Cancer' HWLHZ28 SEQ ID N0:1166~ Cancer HWLHZ28 SEQ ID N0:1167~ Cancer HWLHZ28 SE ID N0:1168 Cancer HWLHZ28 SEQ 117 N0:1169 Cancer HWLJE21 SEQ ID N0:1170 Cancer HWLJE21 SEQ ID N0:1171~ Cancer HWLJE21 SEQ ID N0:1172 Cancer HPASD51 SEQ ID N0:1173 Digestive, ' Excretory, Re roductive HPASD51 . SEQ ID N0:1174, Digestive, .
Excretory, Re roductive HSICQ15 SEQ ID N0:1175 Cancer HSIC 15 SEQ ID N0:1176 Cancer ' HFEBP27 SEQ ID N0:1177~ ~ Cancer HFEBP27 SE ID N0:1178. Cancer HFEBP27 SEQ ID N0:1179 Cancer HTOIZ28 ~ SEQ ID NO:1180 Cancer HTOIZ28 SEQ ID NO:1181 Cancer HTOIZ28 SEQ ID N0:1182. Cancer .

HTOIZ28 SEQ ID N0:1183~~ C_ancer HCE4L28 SEQ ID N0:1184 Cancer HCE4L28 SEQ ID N0:1185 Cancer HCE4L28 SEQ ID N0:1186 Cancer HCE4L28 SEQ ID NO:1187 Cancer HFVGM16 SEQ ID N0:1188 Cancer HFVGM16 SEQ ID N0:1189 Cancer HPMGR66 SEQ ID N0:1190 Cancer HPMGR66 SEQ ID NO:l Cancer 191 ~

HLYDU43 SEQ ID N0:1192 Cancer HLYDU43 SEQ ID N0:1193~ Cancer HPJCK10 SEQ ID N0:1194 Cancer HPJCK10 SEQ ID N0:1195 Cancer HTSEK75 SEQ ID NO:1196 Cancem HT5EK75 SEQ ID N0:1197 Cancer HT5EK75 SEQ ID NO:1198 Cancer HWLEZ82 SEQ ID N0:1199 . Cancer HWLEZ82 SEQ ID N0:1200 Cancer HWLEZ82 SEQ ID N0:1201 Cancer HWLEZ82 SEQ ID N0:1202 Cancer HDRMB 11 SEQ ID N0:1203 Di estive HDRMB 11 SEQ ID N0:1204 Di estive HDRMB 11 SEQ ID N0:1205 Di estive HCRNC80 SEQ ID N0:1206~ Cancer HCRNC80 SEQ ID N0:1207' Cancer ' HCRNC80 SEQ ID N0:1208 Cancer HCRNF14 SEQ ID N0:1209' Cancer HCRNF14 SEQ ID N0:1210' Cancer HCRNF14 SEQ ID N0:1211 Cancer HE9PF45 SEQ ID N0:1212 Cancer HE9PF45 SEQ ID N0:1213 Cancer HE9PF45 SEQ ID NO:1214 Cancer HISEN93 SEQ ID N0:1215 Cancer HISEN93 SEQ ID N0:1216 Cancer HISEN93 SEQ ID N0:1217 Cancer HODEA51 SEQ ID N0:1218 Cancer ' HODEA51 SEQ ID N0:1219 Cancer HODEA51 SEQ ID N0:1220 Cancer HODEA51 SEQ ID N0:1221 Cancer HUSJN32 SEQ ID N0:1222 Cancer HUSJN32 SEQ ID N0:1223 Cancer HUSJN32 SEQ ID N0:1224 Cancer HNGNW50 SEQ ID N0:1225, Immune/Hematopoietic, Mixed Fetal, , Re roductive HNGNW50 SEQ ID N0:1226 Immune/Hematopoietic, w Mixed Fetal, Re roductive HNGNW50 SEQ ID N0:1227 Immune/Hematopoietic, Mixed Fetal;
Re reductive' HUVFB80 SEQ ID N0:1228 Cancer ' HUVFB80 SE ID N0:1229 Cancer HFIDQ92 ' SEQ ID NO:1230 Cancer HFIDQ92 SEQ ID N0:1231 Cancer HFIDQ92 SEQ ID N0:1232 Cancer .

HTLJC07 SEQ ID N0:1233 Immune/Hematopoietic, Neural/Sensory, Re reductive _ _ HTLJC07 SEQ ID N0:1234 Immune/Hematopoietic, Neural/Sensory, Re reductive HTLJC07 ' SEQ ID N0:1235 Immune/Hematopoietic, Neural/Sensory, Re reductive HMSOW51 SEQ ID N0:1236 Cancer HMSOW51 SEQ ID N0:1237- Cancer HPJEZ38 SEQ ID N0:1238 Cancer HPJEZ38 SEQ ID N0:1239 Cancer HPJEZ38 SEQ ID N0:1240~ Cancer . HTAGN51 SEQ ID N0:1241 Immune/Hematopoietic, Neural/Sensory, Re reductive HTAGN51 SEQ ID N0:1242 Immune/Hematopoietic, Neural/Sensory, Re reductive HHFLH45 SEQ ID N0:1243. Cardiovascular, Re reductive HHFLH45 SEQ ID N0:1244 Cardiovascular, a - Re reductive HHFLH45 ' SEQ ID N0:1245 Cardiovascular, Re reductive HFKLE15 SEQ ID N0:1246 Cancer HFKLE15 SEQ~ID N0:1247~ Cancer HNSAA27 SEQ ID N0:1248 Di estive HNSAA27 SEQ ID N0:1249' Di estive HUVFY29 SEQ ID N0:1250 Cancer HUVFY29 SEQ ID N0:1251 Cancer HAVITR23 SEQ ID N0:1252 Neural/Sensory HAVCTR23 SEQ ID N0:1253 Neural/Sensory HTPIH83 SEQ ID N0:1254 Digestive, Re reductive . HTPIH83 SEQ ID N0:1255 Digestive, Re reductive HTPIH83 SEQ ID.N0:1256. Digestive, R e reductive HUCNC61 SEQ ID N0:1257 Cancer HIDAF73 SEQ ID N0:1258 Cancer HIDAF73 SEQ ID N0:1259 Cancer HIDAF73 SEQ ID N0:1260 Cancer .

HOFMA42 SEQ ID N0:1261 Re reductive HOFMA42 SEQ ID N0:1262 Re reductive HK.ABW 11 SEQ ID N0:1263 Cancer HKABW11 SBQ ID N0:1264 Cancer HWBA029 SEQ ID N0:1265 Immune/Hematopoietic, . Re reductive HWBA029 SEQ ID N0:1266' Immune/Hematopoietic, Re roducfive HWBA029 SEQ ID N0:1267. Immune/Hematopoietic, Re reductive HDPTM61 ~ SEQ ID N0:1268' Digestive, . Immune/Hemato oietic HDPTM61 SEQ ID N0:1269 Di estive, _ ImmunelHemato oietic HKAHL26 SEQ ID N0:1270 Cancer HKAHL26 SEQ ID N0:1271 Cancer HDQHC29 SEQ ID NO:1272 Cancer.

HDQHQ91 SEQ ID N0:1273 Cancer HDQHQ91 SEQ ID N0:1274 Cancer HDQHQ91 SEQ ID N0:1275 Cancer HDTLR06 SEQ ID N0:1276 Cancer HDTLR06 SEQ ID N0:1277 Cancer --HNTDE84 SEQ ID N0:1278 Cancer _ HNTDE84 SEQ ID N0:1279 Cancer HWAFT87 SEQ ID N0:1280 Cardiovascular, - . Immune/Hemato oietic HWAFT87 SEQ ID N0:1281 Cardiovascular, Immune/Hemato oietic HWAFT87 SEQ ID N0:1282 Cardiovascular, Immune/Hemato oietic HOGCE48 SEQ ID N0:1283 Cancer HOGCE48 ~ SEQ ID N0:1284 Cancer HB1N558 SEQ ID N0:1285 Connective/Epithelial, Re roductive HBINS58 SEQ ID N0:1286- Connective/Epithelial, Re roductive HHAUQ28 SEQ ID N0:1287 Cancer HHAUQ28 SEQ ID N0:1288 Cancer HBIOH81 SE ID N0:1289- Cancer HBIOH81 SEQ ID N0:1290 Cancer HOGDP46 SEQ ID N0:1291. Cancer HOGDP46 SEQ ID N0:1292~ Cancer HWHIH.10 SEQ ID N0:1293 Cancer HWHIH10 SEQ ID N0:1294 Cancer HCWCT62 SEQ ID N0:1295 Immune/Hemato oietic HCWCT62 SEQ ID N0:1296. Immune/Hemato oietic HCWCT62 SEQ ID N0:1297 ImmunelHemato oietic HBXCL50 SEQ ID N0:1298 Digestive, Excretory, Neural/Senso HBXCL50 SEQ ID_ N0:1299~ Digestive, - - ' Excretory, .
Netual/Sensory HACAA29 SEQ iD NO:1300 Cancer HACAA29 SEQ ID N0:1301 Cancer HAJAR23 SEQ ID N0:1302 Cancer HAJAR23 SEQ ID N0:1303 Cancer HAJAR23 SEQ ID N0:1304 Cancer HDPQN12 SEQ ID N0:1305 Cancer HDPQN12 SEQ ID N0:1306- Cancer -HDQFN31 SEQ ID N0:1307 Cancer HDQFN31 SEQ ID N0:1308~ Cancer HDQIH54 SEQ ID N0:1309 Irnmune/Hemato oietic HDQIH54 SEQ ID N0:1310 Immune/Hemato oietic HETKL27 SE ID N0:13.11 Cancer HETKL27 SEQ ID NO:1312 Cancer HETKL27 SEQ ID NO:1313 Cancer HETKL27 SEQ ID N0:1314 Cancer .

HFIHQ89 ' SEQ ID N0:1315 Cancer HFIHQ89 SEQ ID N0:1316 Cancer _ HFKHW50 SEQ ID N0:1317 Cancer HFKHW50 SEQ ID NO:1318 Cancer HFI~HHW50 SEQ ID NO:1319 Cancer HMEJL08 SEQ ID N0:1320 Cancer HMEJL08 SEQ ID N0:1321 Cancer HMEJL08 SEQ ID N0:1322 Cancer HMSCT72 SEQ ID N0:1323 Connective/Epithelial, Immune/Hemato oietic HMSCT72 SEQ ID N0:1324 Connective/Epithelial, -Immune/Hemato oietic HMSCT72 SEQ ID N0:1325 Connective/Epithelial, Immune/Hemato oietic HPJEX20 SEQ ID N0:1326. IminunelHematopoietic, Re roductive HPJEX20 SEQ ID N0:1327 Immune/Hematopoietic, Re roductive HPJEX20 SEQ ID N0:1328 Immune/Hematopoietic, Re roductive HPJEX20 SEQ ID N0:1329 Immune/Hematopoietic, Re roductive HSLGM21 SEQ ID N0:1330 Cancer HSLGM21 SEQ ID N0:1331 Cancer - HSLHI86 SE ID N0:1332 Cancer HSLHI86 SE ID N0:1333 Cancer -HSLHI86 SEQ ID N0:1334 Cancer HSLHI86 SE ID N0:1335 Cancer HUCNP80 SEQ ID N0:1336 Cancer HUCNP80 SEQ ID N0:1337 Cancer HBINK72 SEQ ID N0:1338 Cancer HBINI~72 SEQ ID N0:1339 Cancer HBINI~72 SEQ ID N0:1340 Cancer HIABC55 SEQ ID N0:1341' Cancer HIABC55 SEQ ID N0:1342 Cancer HIABC55 SEQ ID N0:1343 Cancer HIABC55 SEQ ID N0:1344 Cancer HGBA.R55 SEQ ID N0:1345 Cancer HGBAR55 SEQ ID N0:1346 Cancer _ HGBAR55 SE ID N0:1347 Cancer HE2FE45 SEQ ID N0:1348 Cancer ' HE2FE45 SEQ ID N0:1349 Cancer HE2FE45 SEQ ID N0:1350 Cancer HMRAD54 SEQ ID N0:1351' Cancer HMRAD54 SEQ ID N0:1352 Cancer HMRAD54 SEQ ID N0:1353 Cancer HCEFB80 SEQ ID N0:1354 Cancer .

HCEFB80 SE ID N0:1355 Cancer HFTBN23 SEQ ID N0:1356 Cancer HFTBN23 SEQ ID N0:1357 Cancer HFTBN23 SEQ ID N0:1358. Cancer HFTBQ52 SEQ ID N0:1359 Cancer HFTBQ52 SEQ ID N0:1360 Cancer HMEEJ79 SEQ ID N0:1361 Cardiovascular, Neural/Sensory, Re roductive HMEEJ79 SEQ ID N0:1362 Cardiovascular, Neural/Sensory, Re rdductive .

HROAJ39 SEQ ID N0:1363 Cancer HROAJ39 SEQ ID N0:1364 Cancer HROAJ39 SEQ ID N0:1365 Cancer HFEBV76 SEQ ID N0:1366 Cancer HFEBV76 SEQ 117 N0:1367 Cancer HTADC09 SEQ ID N0:1368 Cancer HTADC09 SEQ ID N0:1369 Cancer HFXBJ12 SEQ ID N0:1370 Neural/Senso HFXBJ12 SEQ ID N0:1371 Neural/Sensory ' HFXBJ12 SEQ ID N0:1372 Neural/Sensory HMHBN86 ~ SEQ ID N0:1373 Cancer HMHBN86 SEQ ID N0:1374 Cancer HMHBN86 SEQ ID N0:1375 Cancer HFKFL92 SEQ ID N0:1376 Cancer HFKFL92 ~ SEQ ID N0:1377 Cancer HFKFL92 SEQ ID N0:1378 Cancer HASAW52 SEQ ID N0:1379 Cancer HTLDT76 . SEQ ID N0:1380~ , Cardiovascular, . Neural/Sensory, Re reductive HTLDT76 SEQ ID N0:1381 Cardiovascular, Neural/Sensory, Re reductive HTLDT76 SEQ ID N0:1382 Cardiovascular, ' Neural/Sensory, Re reductive HTLEC34 SEQ ID N0:1383 Immune/Hematopoietic, ~ Neural/Sensory, ' - .
HTLEC34 SEQ ID N0:1384 Re reductive Immune/Hematopoietic, Neural/Sensory, .
Re reductive HNHFB60 SEQ ID N0:1385 Immune/Hemato oietic HNHFB60 SEQ ID N0:1386 Immune/Hemato oietic HNHFB60 SEQ ID N0:1387 ImmunelHemato oietic H2CBK33 SEQ ID N0:1388 Cancer H2CBK33 SEQ ID N0:1389 Cancer .

H2CBK33 SEQ ID N0:1390~ ' Cancer ~

HNGEY29 SEQ ID N0:1391 Cancer HNGEY29 SEQ ID N0:1392 Cancer HUSFE58 SEQ ID N0:1393 Cancer HUSFE58 SEQ ID N0:1394- Cancer HMSHS36 SEQ ID N0:1395 Immune/Hemato oietic HMSHS36 ' SEQ ID N0:1396 Immune/Hemato oietic HMSKC10 SEQ-ID N0:139'7 Immune/Hemato oietic HMSKC10 SEQ ID N0:1398 Immune/Hemato oietic HMSKC10 SEQ ID N0:1399 Immune/Hemato oietic HSLGU75 SEQ ID N0:1400 Cancer HSLGU75 SEQ ID NO:1401 Cancer HSLGU75 SEQ ID N0:1402 Cancer HDABU01 SEQ ID N0:1403' Cancer HDABU01 SEQ ID N0:1404 Cancer HDABU01 SEQ B7 N0:1405 Cancer HADGD 17 SEQ ID NO:1406 Connective/E ithelial HADGD17 SEQ ID N0:1407 Connective/E ithelial HADGD 17 SEQ ID N0:1408 Connective/E ithelial HFIUE67 SEQ ID N0:1409 Cancer HKGAM29 SEQ ID N0:1410 Cancer HACBD86 SEQ ID N0:1411 Cancer HACBD86 SEQ ID N0:1412 Cancer HACBD86 SEQ ID N0:1413 Cancer HEGAK23 SE ID N0:1414 Cancer HEGAK23 SEQ ID N0:1415 Cancer HEGAK23 SEQ ID NO:1416 Cancer HEGAK23 SEQ ID N0:1417 Cancer HCHAR90 SE ID N0:1418 Cancer .

HCHAR90 ~ SE ID N0:1419 Cancer .

HCHAR90 SEQ ID N0:1420 Cancer HLYCK27 SEQ ID N0:1421 Immune/Hemato oietic HMVBP38 SEQ ID N0:1422 Cancer HMVBP38 SEQ ID N0:1423 Cancer HMVBP38 SEQ ID NO:1424 Cancer HFACI31 SEQ ID N0:1425 Neural/Sensory HFACI31 SEQ ID N0:1426 Neural/Senso HFACI31 SEQ ID N0:1427 Neural/Senso HBJKC04 SEQ ID N0:1428 Immune/Hemato oietic HBJKC04 SEQ ID N0:1429 Immune/Hemato oietic HBJKC04 SEQ ID NO:1430 Immune/Hemato oietic HBJIT60 SEQ ID N0:1431 Immune/Hemato oietic HBJIT60 SEQ ID N0:1432 Immune/Hemato oietic HBJIT60. SEQ ID NO:1433 Immune/Hemato oietic HPJBK03 SEQ ID N0:1434 Cancer HPJBK03 SE ID N0:1435 Cancer HPJCL22 SEQ ID N0:1436 Cancer ' HPJCL22 SEQ ID N0:1437 Cancer HPJCL22 ~ SEQ ID N0:1438 Cancer HTWJB71 _ SEQ ID N0:1439 Immune/Hematopoietic, ' Neural/Sensory HNTOE45 SEQ ID N0:1440 Cancer HNTOE45 SEQ ID N0:1441 Cancer HNTRW30 SEQ ID N0:1442' . Digestive, Immune/Hematopoietic, Mixed Fetal HNTRW30 SEQ ID N0:1443 Digestive, ' hnmune/Hematopoietic, Mixed Fetal HCHPU32 SEQ ID N0:1444 Cancer HCHPU32 SEQ ID N0:1445 Cancer HCHPU32 SEQ ID N0:1446 Cancer HGCNC48 SEQ ID NO:1447 Re roductive HGCNC48 SEQ ID N0:1448 Re roductive HLTH084 SEQ ID N0:1449 Cancer HSLIA81 SEQ ID N0:1450 Cancer HSLIA81 SEQ ID NO:1451 Cancer HSLIA81 SEQ ID N0:1452 Cancer HSLIA81 SEQ ID N0:1453 Cancer HBFMA07 ~ SEQ ID N0:1454~ - Cancer HBODE48 SEQ ID N0:1455 Digestive, Excretory, Immune/Hemato oietic HBODE48 SEQ ID N0:1456 Digestive, Excretory, - Immune/Hemato oietic HBODE48 SEQ ID N0:1457- Digestive, , Excretory, Immune/Hemato oietic HBODE48 SEQ ID NO_ ' Digestive, :1458 Excretory,. , Immune/Hemato oietic HCRME12 SEQIDNO:1459 Cancer HCRME12 SE ID NO:1460 Cancer HBODQ16 SEQ ID N0:1461 Cancer HBODQ16 . SEQ ID N0:1462' Cancer HASMB80 SEQ ID N0:1463 Cancer HASMB80 SEQ ID N0:1464 Cancer HBOEGi 1 SEQ ID N0:1465. Cancer HBOEG11 SEQ ID N0:1466 Cancer HCRNU76 SEQ ID N0:1467 Cancer HCRNU'76 SE ID N0:1468~ Cancer HAPSQ21 SEQ ID N0:1469 Reproductive, ' Res iratory HAPSQ21 SEQ ID N0:1470 Reproductive, - Res iratory HAPSQ21 SEQ ID N0:1471. Reproductive, Res iratory HWLNF33 SEQ ID N0:1472 Cancer HWLNF33 SEQ ID N0:1473 Cancer HE8Q053 SEQ ID NO:1474~ Cancer HE8Q053 SEQ ID N0:1475 Cancer HE8QV67 SEQ ID N0:1476 Cancer HE8QV67 SEQ LD N0:1477 Cancer HE8TB68 SEQ ID N0:1478 Cancer HE8TY90 SEQ.ID N0:1~.79- ~ Cancer HE8TY90 SEQ ID N0:1480 Cancer HE8TY90 SEQ ID N0:1481- Cancer .

HE8TY90 SEQ ID'N0:1482 Cancer ' HETLM70 SEQ ID N0;1483 Digestive, Excretory, Re roductive HETLM70 SEQ ID N0:1484. Digestive, , Excretory, Re roductive HETLM70 SEQ ID N0:1485~ Digestive, ' Excretory, Re roductive HISES66 SEQ ID N0:1486 Digestive, Re roductive HISES66 SEQ ID N0:1487 Digestive, Re roductive HISES66 SEQ ID N0:1488 Digestive, , Re roductive HTXKV29 SE ID N0:1489 Cancer -HTXKV29 SEQ ID N0:149.0 Cancer HTXI~V29 SEQ ID N0:1491 Cancer HTXLH48 ' SEQ.ID N0:1492' Immune/Hemato oietic HTXLH48 SEQ ID N0:1493- Immune/Hemato oietic 15.3 HTXLH48 SEQ ID N0:1494 Immune/Hemato oietic HTEMD27 SEQ ID N0:1495 Cancer HTEMD27 SEQ ID N0:1496 Cancer HTEME02 SEQ ID N0:1497 Cancer HTEME02 SEQ ID NO:1498 Cancer HTEME02 SEQ ID N0:1499 Cancer HNHLD23 SEQ ID N0:1500 Immune/Hemato oietic HETLT82 SEQ ID N0:1501 Immune/Hematopoietic, Re reductive HETLT82 . SEQ ID NO:1502 Immune/Hematopoietic, Re reductive HETLT82 SEQ ID N0:1503 Immune/Hematopoietic, Re reductive HNGLH60 SEQ ID N0:1504 Immune/Hematopoi~tic, Musculoskeletal HNGLH60 SEQ ID NO:1505 Immune/Hematopoietic, Musculoskeletal HNGLH60 SEQ ID N0:1506 Immune/Hematopoietic, Musculoskeletal HNHPG05 SEQ ID N0:1507 Immune/Herriato oietic HNHPG05 SEQ ID N0:1508 ImmunelHemato oietic HNHPG05 SEQ ID N0:1509 Immune/Hemato oietic HUSIY89 SEQ ID N0:1510, Cardiovascular, Immtme/Hemato oietic HUSIY89 , SEQ ID N0:1511. Cardiovascular;
Immune/Hemato oietic HUSJM25 SEQ ID N0:1512 Cancer HUSJM25 SEQ ID N0:1513 Cancer HTXNL31 SEQ ID N0:1514 Digestive, Immune/I3ematopoietic, Re reductive HTXNL31 SEQ ID N0:1515v Digestive, Immune/Hematopoietic, Re reductive HBGNQ12 SEQ ID N0:1516 . Cancer HBGNQ12 SEQ ID N0:1517' Cancer HNGNS74 SEQ ID N0:1518. Cancer HNGNS74 SEQ ID N0:1519~ ~ Cancer HNGOD80 SEQ ID N0:1520 Cancer ' HNGOD80 SEQ ID N0:1521 Cancer HODHK19 SEQ ID NO:1522 Re reductive HODHK19 SEQ ID N0:1523 Re reductive HODHK19 SEQ ID N0:1524 Re reductive HTLHR26 SEQ ID N0:1525 Immune/Hematopoietic, Re reductive HTLHR26 SEQ ID N0:1526 Immune/Hematopoietic, Re reductive ~HTLHR26 SEQ ID N0:1527 Immune/Hematopoietic, Re reductive HUSZS75 SEQ ID N0:1528 Cancer HUSZS75 SEQ ID N0:1529 Cancer ~

HLQDY81 SEQ ID N0:1530 Cardiovascular, Digestive, . Musculoskeletal HBGNU56 SEQ ID N0:1531 Cancer .

HBGNU56 SEQ ID ' Cancer N0:1532 HODGL52 SEQ ID N0:1533_ Cancer HODGL52 SEQ ID NO:1534 Cancer HTXNV67 SEQ ID N0:1535 Cancer HTXNV67 SEQ ID N0:1536' Cancer HTXNV67 SEQ ID N0:1537 Cancer HOCNE30 SEQ ID N0:1538 Digestive, Musculoskeletal, Neural/Sensory HOCNE30 SEQ ID N0:1539 Digestive, Musculoskeletal, Neural/Senso HOCNE30 SEQ ID N0:1540 Digestive, .
Musculoskeletal, , Neural/Sensory HMSOC30 SEQ ID N0:1541 Cancer HMSOC30 SEQ ID N0:1542 Cancer HWMAF61 SE ID N0:1543 Di estive HWMAF61 SEQ ID N0:1544 Di estive HWMAF61 SEQ ID N0:1545 Di estive HWMAF61 SEQ ID N0:1546 Digestive HWMAF61 SEQ ID N0:1547 Di estive HWMAH36 SEQ ID N0:1548 Immune/Hemato oietic HWMAH36 SEQ ID N0:1549 Immune/Hemato oietic HXOAC69 SEQ ID N0:1550 Cancer HXOAC69 SEQ ID N0:1551 Cancer HPJDA23 SEQ ID N0:1552 Mixed Fetal, Neural/Sensory, Re roductive HPJDA23 SEQ ID N0:1553 Mixed Fetal, . Neural/Sensory, ' Re roductive HPJEE14 SEQ ID N0:1554 Re roductive HPJEE14 SEQ ID N0:1555 Re roductive HPJEG57 SEQ ID N0:1556 Re roductive HPJEG57 SEQ ID N0:1557 Re roductive .

HPJEG57 SE ID N0:1558 Re roductive HPJEV11 SEQ ID N0:1559 Cancer HTTKT43 SEQ ID N0:1560 Cancer HTTKT43 SEQ ID NO:1561 Cancer HTTKT43 SEQ ID N0:1562 Cancer HHFKM76 SEQ ID N0:1563 Cancer HHFKM76 SEQ ID N0:1564 Cancer HHFKM76 SEQ ID N0:1565 Cancer HHFML08 SEQ ID N0:1566- Cardiovascular, Immune/Hematopoietic, Mixed Fetal HHFML08 SEQ ID N0:1567. Cardiovascular, - Immune/Hematopoietic, Mixed Fetal HHFML08 SEQ ID N0:1568- , Cardiovascular, Immune/Hematopoietic, ' Mixed Fetal ' HTPFX69 - SEQ ID N0:1569 Cancer HTPFX69 SEQ ID NO:1570 Cancer HTPFX69 SEQ ID N0:1571 Cancer -HTPFX69 SEQ ID N0:1572' Cancer HFKLX38 SEQ ID N0:1573- Excretory, Res iratoi HFKLX38 SEQ ID N0:1574 Excretory, Res iratory HFI~LX38 SEQ ID N0:1575 Excretory, Res iratory HFKME15 SEQ ID N0:1576 Excretory HFKME15 SEQ ID N0:1577 Excreto HLTVFH14 SEQ ID N0:1578 Cancer HUVFH14 SEQ ID NO:1579 Cancer HLJVFH14 SEQ ID N0:1580 Cancer HE2KK74 SEQ ID N0:1581 Cancer HE2KK74 . SEQ ID N0:1582 Cancel HE2KK74 SEQ ID N0:1583. Cancer HMALI42 SEQ ID N0:1584 Imrnune/Hemato oietic HE2LW65 SEQ ID N0:1585 Cancer HE2LW65 SEQ ID N0:1586 Cancer HE2LW65 SEQ ID N0:1587~ Cancer HTFOS57 SEQ ID N0:1588 Cancer ' HTFOS57 SEQ ID N0:1589. Cancer HTFOS57 SEQ ID N0:1590 Cancer HUVHI35 SEQ ID N0:1591 Cancer HUVHI35 SE ID NO:1592 Cancer HLTVHI35 SEQ ID N0:1593 Cancer -HUVHI35 SEQ ID N0:1594 Cancer HTPHS66 SEQ ID N0:1595 Cancer HTPHS66 SEQ ID NO:1596 Cancer HTPHS66 SEQ ID NO:1597 Cancer ~

HHFOJ29 SEQ ID N0:1598 Cancer HHFOJ29 SEQ ID NO:1599 Cancer HHFOJ29 SEQ ID N0:1600 Gaiicer HMAMI15 SE ID N0:1601 Cancer HTXQM57 SEQ ID N0:1602 Immune/Hematopoietic, ' Mixed Fetal HE2R022 SEQ ID N0:1603 Mixed Fetal HE2R022 SEQ ID N0:1604 Mixed Fetal HE2SI26 SEQ ID N0:1605 Cancer HTXRE15 SEQ ID NO:1606 Cancer HTXRE15 SEQ ID N0:1607. Cancer HUCPD31 SEQ ID N0:1608 Cancer HUGPD31 SEQ ID N0:1609 Cancer HFPHA80 SEQ ID N0:1610 NeurallSensory HFPHA80 SEQ ID N0:1611 Neural/Sensor ' HFPHA80 ~SEQ ID N0:1612 Neural/Sensory ' I-IFPHA80 SEQ ID N0:1613 NeurallSenso HFPHB92 SEQ ID N0:1614 Excretory, ' Neural/Sensory HFPHS77 SEQ ID N0:1615 Cancer HFPHS77 SEQ ID N0:1616 Cancer HFPHS77 SEQ ID N0:1617 Cancer HIPAJ43' SEQ ID N0:1618' Cancer HIPAJ43 ' SEQ ID N0:1619 Cancer HDDMW90 SEQ ID N0:1620 Cancer HDDMW90 SEQ ID NO:1621 Cancer HBCPB32 SEQ ID N0:1622 Neural/Sensory, . Re roductive HFVKC95 SEQ ID N0:1623 Cancer ~

HFVKC95 SEQ ID N0:1624 Cancer HFVKC95 SEQ ID N0:1625 Cancer HCOMM91 SEQ ID N0:1626 Cancer HCOMM91 SEQ ID N0:1627 Cancer HVVAM64 SEQ ID N0:1628 Cancer HVVAM64 SEQ ID N0:1629 Cancer HVVAM64 SEQ ID N0:1630 Cancer HNBUC50 SEQ ID N0:1631 Cancer HNBUC50 SEQ ID N0:1632 Cancer HNBUC50 SEQ ID N0:1633 Cancer HNBUC50 SE ID N0:1634 Cancer ' HUUDF48 SEQ ID N0:1635 Immune/Hemato oietic HUUDF48 SEQ ID N0:1636~ Immune/Hemato oietic HBC L32 SE ID N0:1637 Cancer HBCQL32 SE ID N0:1638 Cancer HCBND16 SE ID N0:1639 Cancer HCBND 16 SE ID N0:1640 Cancer HNNBM45 SEQ ID N0:1641- Immune/Hematopoietic, .
Re reductive HNNBM45 SEQ ID N0:1642 Immune/Hematopoietic, Re reductive HWMGN33 SEQ ID NO:1643 Di estive HWMGN33 SEQ ID N0:1644 Di estive HWMLN52 SEQ ID N0:1645, Digestive, Immune/Hemato oietic HWMLN52 SEQ ID N0:1646 Digestive, - Immune/Hemato oietic HWMLN52 SEQ ID N0:1647 Digestive, Immune/Hemato oietic HVARW53 SEQ ID N0:1648 Di estive HVARW53 SEQ ID N0:1649 Di estive HAHFU44 SEQ ID N0:1650 Cardiovascular, , Digestive, Musculoskeletal HAHFU44 SEQ ID N0:1651 Cardiovascular, . Digestive, Musculoskeletal HAHFU44 SEQ ID N0:1652 Cardiovascular, Digestive, Musculoskeletal HCOOS80 SEQ ID N0:1653 Cancer HCOOS80 SEQ ID N0:1654 Cancer HCOOS80 SEQ ID N0:1655 Cancer . .

HNKC080 SEQ ID N0:1656- Cancer HNKC080 SEQ ID N0:1657 Cancer HLTIP27 SEQ ID N0:1658 Immune/Hemato oietic HLTIP27 SEQ ID N0:1659 Immune/Hemato oietic HLTIP94 SEQ ID N0:1660, ImmunelHematopoietic, Mixed Fetal, NeuraIlSensory HLTIP94 SEQ ID N0:1661 Immune/Hematopoietic, ' ~ Mixed Fetal, NeurallSenso HLTIP94 SEQ ID N0:1662 Immune/Hematopoietic, Mixed Fetal, 15.7 NeurallSensory HOCPM23 SEQ ID N0:1663 Re reductive HOCPM23 SEQ ID N0:1664 Re reductive .

HPDWP28 SEQ ID N0:1665 Re reductive HPDWP28 SEQ ID N0:1666 Re reductive HLCND09 SEQ ID N0:1667 Cancer HLCND09 SEQ ID N0:1668. Cancer HEEBI05 SEQ ID NO:1669 Digestive, Re reductive HEEBB55 SEQ ID N0:1670 Cancer HEEBB55 SEQ ID NO:1671 Cancer HEEBB55 SEQ ID N0:1672 Cancer HEGCL11 SEQ ID N0:1673 Cancer HEGCL11 SE ID N0:1674 Cancer HNTPB82 SE ID NO:1675~ Cancer HNTPB82 . SEQ ID NO:1676 Cancer HOFMM69 - SE II5 N0:1677 Re reductive HOFMM69 SEQ ID NO:1678 Re reductive HLDAB75 SEQ ID N0:1679 Cancer HLDAB75 SEQ ID N0:1680 Cancer HKACC80 SEQ ID N0:1681~ Cancer HKACC80 ~ SEQ ID N0:1682 Cancer HKACC80 SEQ ID N0:1683 Cancer HKAEL28 SEQ ID N0:1684 Connective/Epithelial, Immune/Hematopoietic, Re reductive HKAEL28 SEQ ID N0:1685 ConnectivelEpithelial, Immune/Hematopoietic, Re reductive HDPGT25 SEQ ID N0:1686 Cancer.

HDPGT25 SEQ ID N0:1687 Cancer HLWBT09 SEQ ID N0:1688 Excretory, Re reductive HLWBT09 SEQ ID N0:1689 Excretory, Re reductive HHEDN80 SE ID N0:1690 Cancer HHEDN80 SE ID N0:1691s Cancer HHEDN80 SEQ ID N0:1692 Cancer HDFQB 14 SEQ ID N0:1693 Immune/Hematopoietic, NeuraIlSensory, Re reductive HWAAW33 SEQ ID N0:1694~ Cardiovascular, Immune/Hematopoietic, a Musculoskeletal HWAAW33 SEQ ID N0:1695 Cardiovascular, - - .
- Immune/Hematopoietic, Musculoskeletal HWABF47 SEQ ID N0:1696 Cancer HWABF47 SEQ 117 NO:1697 Cancer HWABI12 SEQ ID NO:1698 Immune/Hemato oietic HWABI1'2 SEQ ID N0:1699 Immune/Hemato oietic HWBBT49 SEQ ID N0:1700 Cancer HWBBT49 SEQ ID N0:1701 Cancer HWBBT49 SEQ ID N0:1702 Cancer HAMGG89 SEQ ID NO:1703 Immune/Hematopoietic, - ~ Neural/Sensory, 15~

Re reductive HAMGG89 SEQ ID N0:1704 ImmunelHematopoietic, Neural/Sensory, Re reductive HAJBW16 SEQ ID N0:1705 Neural/Sensory HAJBW 16 SEQ ID N0:1706 Neural/Sensory .

HNTAI35 ' SEQ ID N0:1707 Cancer HNTAI35 SEQ ID N0:1708 Cancer HNTAI35 SEQ ID N0:1709 Cancer HNTAI35 SE ID N0:1710 Cancer HNTAI35 SEQ ID N0:1711 Cancer.

HNTBN41 SEQ 117 N0:1712 Immune/Hemato oietic HNTBN41 SEQ ID N0:1713' Immune/Hemato oietic HNTBN41 SEQ ID NO:1714' Immune/Hemato oietic HNTBN41 SEQ ID N0:1715 Immune/Hemato oietic HDPRJ60 SEQ ID N0:1716 Cancer HDPRJ60 SEQ ID N0:1717 Cancer HDPRJ60 SEQ 11.7 N0:171 Cancer &

HDPSBO1 SEQ ID N0:1719 Cancer .

HDPSBO1 SE . ID N0:1720~ Cancer HDPSBO1 SE ID N0:1721 Cancer ' HDPSBO1 SEQ ID NO:1722 Cancer HDPSBO1 SEQ ID N0:1723 Cancer HDPTC31 SEQ ID N0:1724 Immune/Hemato oietic HDPTC31 SEQ ID N0:1725 ImmunelHemato oietic HDPTC31 SEQ ID N0:1726. Immune/Hemato oietic HDPXL05 SEQ ID N0:1727~ Immune/Hematopoietic, , Re reductive HDPXL05 SEQ ID N0:1728 Immune/Hematopoietic, Re reductive HDPXL05 SEQ ID NQ:1729 Immune/Hematopoietic, Re reductive HDPXY88 SE ID N0:1730 Cancer HDPXY88 SEQ ID NO:1731 Cancer HDPXY88 SEQ ID N0:1732 Cancer HLDQZ72 SEQ ID N0:1733~ Cancer HLDQZ72 SEQ ID N0:1734 Cancer HLDQZ72 SEQ ID N0:1735 Cancer .

HWBEV57 SEQ ID N0:1736 Immune/Hemato oietic HWBEV57 SEQ ID N0:1737 Immune/Hemato oietic HWBEV57 SEQ ID N0:1738~ Immune/Hemato oietic HAMHH20 SEQ ID N0:1739 Cancer HAMHH20 SEQ ID N0:1740 Cancer HDLAY18 SEQ ID NO:1741 Cancer HDLAY18 SEQ ID N0:1742~ Cancer ' HKAHN23 SEQ ID N0:1743. Connective/Epithelial, Digestive, Mixed Fetal HI~AHN23 SEQ ID N0:1744 Connective/Epithelial, . Digestive, .
Mixed Fetal HKAJW28 SEQ ID N0:1745 Cancer ' HKAJW28 SEQ ID N0:1746 Cancer HDQFU73 SEQ ID N0:1747 Digestive, Immune/Hemato oietic HDQFU73 SEQ ID N0:1748 Di estive, .

Immune/Hemato oietic HDQFU73 SEQ ID N0:1749 Digestive, Immune/Hemato oietic HDTKS69 SEQ ID N0:1750 Cancer HSYDT06 SE ID N0:1751 Cancer HSYDT06 SEQ ID N0:1752 Cancer HSYDT06 SEQ ID N0:1753 Cancer HSYDT06 SEQ ID N0:1754 Cancer HNTEF28 SEQ ID N0:1755 Cancer HNTEF28 SEQ ID N0:1756 Cancer ' HNTEF53 SEQ ID.N0:1757 Cancer HNTEF53 SEQ ID N0:1758 Cancer HNTEF53 ~ SE ID N0:1759 Cancer HNTEF53 SEQ ID N0:1760 Cancer HDQFN60 SE ID N0:1761 Cancer HDQFN60 SEQ ID N0:1762~ Cancer HHEXM06 SEQ ID NO:1763 Immune/Hemato oietic HHEXM06 SEQ ID N0:1764 Immune/Hemato oietic HBINU36 SEQ ID N0:1765 Connective/Epithelial, Immune/Hematopoietic, Musculoskeletal HBINU36 SEQ ID N0:1766' ConnectivelEpithelial, Immune/Hematopoietic, Musculoskeletal HBINLJ36 SEQ ID N0:1767' Connective/Epithelial, Immune/Hematopoietic, Musouloskeletal HUJCQ39 SEQ ID N0:1768~ Cancer HUJC 39 SEQ ID N0:1769 Cancer HUJCQ39~ SEQ Ib N0:1770~ Cancer HCCCG83 SEQ ID N0:1771 Cancer HCCCG83 SEQ ID N0:1772 Cancer HCCCG83 SEQ ID N0:1773 Cancer HWHIM26 SEQ ID N0:1774 Connective/Epithelial, Iri~mune/Hemato oietic HWHIIVI26 SEQ ID N0:1775 Connective/Epithelial, Immune/Hemato oietic HWHKC09 SEQ ID N0:1776 Cancer HWHKC09 SEQ ID N0:1777 Cancer HWHKC09 SEQ ID N0:1778 Cancer HWHKC09 SEQ ID N0:1779 Cancer HWHKR51 SEQ ID N0:1780' Cancer HWHKR51 SEQ ID N0:1781~ Cancer HWHKR51 SEQ ID N0:1782~ Cancer HWHRL06 SEQ ID N0:1783 Cancer HWHRL06 SEQ ID N0:1784 Cancer _H_A7AD32 SEQ ID NO:1785 Cancer HAZAD32 SEQ ID N0:1786 Cancer HPAMY60 SEQ ID NO:1787 Excreto HPAMY60 SEQ ID N0:1788 Excretory _ SEQ ID N0:1789 Re roductive HAOTS04 ' , HAOTS04 SEQ ID N0:1790 Re roductive _H_A7Ap37 SEQ ID N0:1791' Re roductive HKZAS29 SEQ ID NO:1792 Cancer HKZAS29 SEQ ID N0:1793 Cancer .

HOVJP29 SEQ ID N0:1794 Re roductive HOVJP29 SEQ ID N0:1795' .. Re reductive .

HWHSB53 SEQ ID N0:1796 Cancer HWHSB53 SEQ ID NO:I797 Cancer HKZBSO1 SEQ ID N0:1798 Cancer HKZBSO1 SEQ ID N0:1799 Cancer HWHSOI3 SEQ ID NO:I800 Connective/E ithelial HWHS013 SEQ ID N0:1801 Connective/E ithelial HKZCK47 SEQ 117 N0:1802 Immune/Hematopoietic, Re reductive HCUHQ40 SEQ ID N0:1803~ Cancer HCUHQ40 SEQ ID N0:1804 Cancer ' HCUHQ40 ' SE ID N0:1805 Cancer HPJCP79 SEQ ID N0:1806 Cancer HPJCP79. SEQ ID N0:1807 Cancer - HPJCP79 SEQ ID N0:1808 Cancer HPJCP79 SEQ ID N0:1809 Cancer HFXDI56 SEQ ID N0:1810 Immune/Hematopoietic, . Musculoskeletal, Neural/Sensory HFXDI56 SEQ ID N0:1811' Immune/Hematopoietic, Musculoskeletal, Neural/Sensory HFXDI56 ' SEQ ID N0:1812 hnmune/Hematopoietic, Musculoskeletal, Neural/Sensory HFXDI56 SEQ ID N0:1813' Immune/Hematopoietic, Musculoskeletal, Neural/Sensory HRDEP41 SEQ ID N0:1814 Cancer HRDEP41 SEQ ID N0:1815~ Cancer HTEGF16 SEQ ID N0:1816 Cancer HTEGF16 SEQ ID N0:1817 Cancer HTEGF16 SEQ ID N0:1818 Cancer HSUMA53 SEQ ID N0:1819 Cancer HSUMA53 SEQ ID N0:1820 Cancer HSUMA53 SEQ ID NO:1821- Cancer HSUMAS3 SEQ ID N0:1822 Cancer HISET33 SEQ ID N0:1823 Di estive HISET33 SE ID N0:18'24 Di estive HTTIJ3I SEQ ID NO:1825 Re reductive HTTIJ31 SEQ ID N0:1826 Re reductive HTPFX16 SEQ ID N0:1827 Digestive, Reproductive, Res iratory HTPFX16 SEQ ID N0:1828' Digestive, Reproductive, Res irator HTFMX90 SEQ ID N0:1829 Cancer HTFMX90 SEQ ID N0:1830 Cancer HTFMX90 SEQ TD N0:1831 Cancer HE8FD93 SEQ ID'N0:1832 Cancer HE8FD93 SEQ ID N0:1833 Cancer HE8FD93 SEQ ID N0:1834 Cancer HE8FD93 SEQ ID N0:1835 Cancer .

- HKGBJ74 SEQ ID N0:1836 Cancer HKGBJ74 SEQ ID N0:1837 Cancer HKGBJ74 SEQ ID N0:1838 Cancer ~

HKGBJ74 SEQ ID N0:1839 Cancer HEEAG84 SEQ ID NO:1840 Re roductive HEEAG84 SEQ ID N0:1841 Re roductive HEOQX60 SEQ ID N0:1842 Cancer HEOQX60 SEQ ID N0:1843 Cancer HNGGB09 SEQ ID N0:1844' Immune/Hemato oietic HNGGB09 SEQ ID N0:1845 Immune/Hemato oietic HKIYI48 SEQ ID N0:1846 Cancer HKIYI48 SEQ ID N0:1847 Cancer HKIYI48 SEQ ID N0:1848 Cancer HKIYI48 SEQ ID N0:1849 Cancer HSYAB05 SEQ ID N0:1850 Cancer HSYAB05 SEQ ID N0:1851 Cancer HARMJ38 SEQ ID NO:1852 Cancer HARMJ38 SEQ ID N0:1853 Cancer HARMJ38 SEQ ID NO:1854~ Cancer HARMJ38 SEQ ID N0:1855. Cancer HDTJG33 . SEQ ID N0:1856 Cancer HWAGJ85 SEQ ID N0:1857, Cardiovascular, Immune/Hemato oietic HWAGJ85 SEQ ID NO:1858,. . Cardiovascular, ' ' Immune/Hemato oietic HE20W03 SEQ ID NO:1859 Mixed Fetal HE20W03 SEQ ID N0:1860 Mixed Fetal HBQAE92, SEQ ID N0:1861, , Digestive, Neural/Sensory HBQAE92 SEQ ID N0:1862~ Digestive, Neural/Sensory HBQAE92 SEQ ID N0:1863 Digestive, ~ Neural/Sensory HTODL92 SEQ ID NO:1864 Cancer HTODL92 ' SEQ ID N0:1865 Cancer -HTODL92 SEQ ID N0:1866 Cancer HLQBR41 SEQ ID N0:1867 Cancer HLQBR41 SEQ ID N0:1868. Cancer HDSAP92 SEQ ID N0:1869 Cancer HDSAP92 SEQ ID N0:1870 Cancer HTAEC92 SEQ ID N0:1871 Cancer HTAEC92 SEQ ID N0:1872 Cancer HSLCKl l SEQ ID N0:1873 Cancer HSLCK11 SEQ ID N0:1874 Cancer HSLCK11 SEQ ID N0:1875 Cancer HFCDR13 SEQ ID N0:1876 Neural/Sensory HSLDS06 SEQ ID N0:1877 Musculoskeletal' HSLEF58 SEQ ID N0:1878 Cardiovascular, Digestive, Musculoskeletal HPCAO10 SEQ ID N0:1879 Cancer HMEJL61 SEQ ID N0:1880 Cancer HMEJL61 SEQ ID N0:1881~ Cancer HMEJL61 SEQ ID N0:1882 Cancer .

HUSHH92 SEQ ID N0:1883 Cancer HUSHH92 SEQ ID N0:1884 Cancer HUSHH92 SEQ ID N0:1885 Cancer .

HUSHH92 SEQ ID N0:1886 Cancer 162 ' HBZAI90 SEQ ID NO:1887 Immune/Hematopoietic, Re roductive HBZAI90 SEQ ID N0:1888 Immune/Hematopoietic, Re roductive HNGIQ57 SEQ ID N0:1889 Immune/Hemato oietic HNGIQ57 SEQ ID N0:1890 Immune/Hemato oietic HNGJF62 SEQ ID N0:1891 Immune/Hemato oietic HNGJF62 SEQ'ID N0:1892 Immune/Hemato oietic HFXJY38 SEQ ID N0:1893 Neural/Sensory HFXJY38 SEQ ID N0:1894 NeuraIlSensory HFXKR54 $EQ ID N0:1895 Endocrine, Immune/Hematopoietic, NeuraUSensory HFXKR54 - SEQ ID NO:1896 Endocrine, Immune/F3ematopoietic, Neural/Sensory HFXKR54 SEQ ID N0:1897 Endocrine, I mmune/Hematopoietic, Neural/Sensory HAPOB80 SEQ ID N0:1898 Irninune/Hematopoietic, . ' Musculoskeletal HAPOB80 SEQ ID N0:1899 Immune/Hematopoietic, Musculoskeletal HAPOB80 SEQ ID N0:1900 Immune/Hematopoietic, , M usculoskeletal HAPOB80 SEQ ID N0:1901 Immune/Hematopoietic, Musculoskeletal HBJHJ80 SEQ ID N0:1902 Connective/Epithelial, Immune/Hematopoietic, Re roductive HFADF37 SEQ ID N0:1903- Cancer HFADF37 SEQ ID N0:,1904 Cancer HNTSS75 SEQ ID N0:1905 Cancer HCQDE22 SEQ ID NO:1906 Di estive HCQDE22 SEQ ID N0:1907 ~ Di estive HE8NQ42 SEQ ID NQ:1908 Mixed Fetal HE8NQ42 ~ SEQ ID N0:1909 Mixed Feta1 HE8QD31. SEQ ID N0:1910 Digestive, Mixed Fetal, Neuial/Sensory HE8QD31 SEQ ID NO:1911 Digestive, _ ' . ' Mixed Fetal, Neural/Sensory HE9PR39 SEQ ID N0:1912' . Digestive, _ Mixed Fetal, . .

Musculoskeletal HE9PR39 SEQ ID N0:1913. Digestive, Mixed Fetal, Musculoskeletal HE9PR39 SEQ'ID N0:1914 Digestive, , Mixed Fetal, Musculoskeletal HE9PR39 . SEQ ID N0:1915_ Digestive,' Mixed Fetal, Musculoskeletal HNHLA36 SEQ ID N0:1916 Immune/Hematopoietic, Re reductive HNHLA36 SEQ ID NO:1917 Immune/Hematopoietic, Re reductive HNHOD23 SEQ ID N0:1918~ Cancer HNHOD23 SEQ ID N0:1919 Cancer HNHOD23 SEQ ID N0:1920 Cancer HNGNI25 SE ID N0:1921 Immune/Hemato oietic HNGNI25 SEQ ID N0:1922 Immune/Hemato oietic HNGNI25 SE ID N0:1923 Immune/Hemato oietic HNGNI25 SEQ ID NO:1924 Immune/Hemato oietic HNGOQ44 SEQ ID N0:1925 Immune/Hemato oietic HNGOQ44 SEQ ID N0:1926 ImmunelHemato oietic HTLGE31 SE,Q ID N0:1927~ Ixnmune/Hematopoietic, Re reductive HODHE60 SEQ ID NO:1928 Re reductive HODHE60 SEQ ID N0:1929 Re reductive HTLIV19 SE ID NO:1930 Re reductive HOSDW58 SE ID N0:1931 Cancer HOSDW58 SEQ ID N0:1932 Cancer HOSDW58 SEQ ID N0:1933 Cancer HPJDM47 SEQ ID N0:1934 Re reductive HPJDM47 SE ID N0:1935. Re reductive HPJEC20 SEQ ID N0:1936 Cancer HPJEC20 SEQ ID N0:1937 Cancer HTTJK27 SE ID NO:1938 Re reductive HTTJK27 SEQ ID N0:1939' Re reductive HTFOE85 SEQ ID N0:1940 Immune/Hemato oietic HTFOE85 SEQ ID NO:1941 Immune/Hemato oietic ~

HTFOE85 SEQ LD N01942 Immune/Hemato oietic HIPBA31 SEQ ID N0:1943 Cancer HIPBA31 SEQ ID N0:1944 Cancer HFVJY02 SEQ ID N0:1945 Digestive, Mixed Fetal, Neural/Sensory HFVJY02 SEQ ID N0:1946 Digestive, Mixed Fetal, ' Neural/Sensory HFVJY02 SEQ ID N0:1947'~ ~ , Digestive, . Mixed Fetal, Neural/Sensory HFVJY02 ~ SEQ ID N0:1948~ Digestive, Mixed Fetal;
Neural/Sensory HFVJY02 - SEQ ID N0:1949. Digestive, . . Mixed Fetal;
. Neural/Sensory HOC0019 SEQ ID N0:1950 Cancer ' HOCOO19 SEQ ID N0:1951 Cancer HOC0019 SEQ ID N0:1952 Cancer HWMKQ25 SEQ ID N0:1953 Digestive, Re reductive HWMKQ25 SEQ ID N0:1954 Digestive, Re reductive HWMKQ25 SEQ ID N0:1955 Digestive, Re reductive , HCOPG62 SEQ ID NO:1956 Cancer HCOPG62 SEQ ID NO:1957 Cancer HNKEL47 SEQ ID N0:1958 Cardiovascular, Connective/Epithelial, Di estive HNKEL47 SEQ ID N0:1959 Cardiovascular, Coniiective/Epithelial, Di estive HTPIY88 SEQ ID N0:1960 Di estive HTPIY88 SEQ ID NO:1961 Di estive HTPIY88 SEQ ID N0:1962 Di estive HTPIY88 SEQ ID N0:1963 Di estive HEGBS69 SEQ ID N0:1964 NeurallSensory, Re roductive HEGBS69 SEQ ID N0:1965__ Neural/Sensory, Re roductive HOFMU07 SEQ ID N0:1966 Re roductive HOFMU07 SEQ ID N0:1967 Re roductive HLWBM40 SEQ ID NO:1968 Neural/Sensory, Re roductive .

HLWBM40 SEQ ID NO:1969 Neural/Sensory, Re roductive HLWBM40 SEQ ID NO:1970' Neural/Sensory, Re roductive HAMFT10 SEQ ID N0:1971- Cancer HAMFT10 SEQ ID N0:1972 Cancer HNTBP 17 SEQ ID N0:1973 Cancer HNTBP17 SEQ ID N0:1974 Cancer HWDA040 SEQ ID N0:1975 Cancer HWDA040 SEQ ID N0:1976 Cancer HWDA040 SE ID N0:1977 Cancer HAJCL25 SEQ ID N0:1978 Immune/Hemato oietic HAJCL25 SEQ ID N0:~1979 Immune/Hemato oietic HAJCL25 SEQ ID N0:1980 Immune/Hemato oietic HNTE095 SEQ ID NO:1981 Immune/Hemato oietic HNTE095 SEQ ID N0:1982 Immune/Hemato oietic HNTE095 SEQ ID N0:1983 Immune/Hemato oietic ' HWAFG52 SEQ ID N0:1984 Cancer HWAFG52 SEQ ID N0:1985 Cancer HWAFG52 SEQ ID N0:1986~ Cancer HWAFG52 SEQ ID~ N0:1987 Cancer ' HWAHE17 SEQ ID N0:1988 Digestive, Immune/Hemato oietic HWAHEl7 SEQ ID N0:1989 Digestive, Immune/Hemato oietic HWAHE17 SEQ ID NO:1990. Digestive, - Immune/Hemato oietic HUJBK19 ~ SEQ ID N0:1991 Cancer HUJBK19 SEQ ID NO:1992 Cancer HUJBK19 SE ID N0:1993- Cancer ' HWHJD93 SEQ ID N0:1994 Cancer HWHJD93 SEQ ID N0:1995' Cancer HAOST94 ~ SEQ ID N0:1996 Cancer HAOST94 SEQ ID N0:1997- Cancer HKZAH22 SEQ ID N0:1998 Re roductive HKZAH22 SEQ ID N0:1999 Re roductive .

HKZAH22 SEQ.ID N0:2000 Re roductive HKZA035 SEQ ID N0:2001 Re reductive HKZA035 SEQ ID NO:2002 Re reductive HWHSK19 SEQ ID N0:2003 Cancer HWHSK19 SEQ ID N0:2004 Cancer HWHSK19 SEQ ID NO:2005 Cancer HMWFG79 SEQ ID N0:2006 Digestive, ImmunelHematopoietic, Re reductive HMWFG79 SEQ ID N0:2007 Digestive, ' Immune/Hematopoietic, Re reductive HMWFG79 SEQ ID N0:2008 Digestive, - _ ~ Immune/Hematopoietic, Re reductive HMWFG79 SEQ ID N0:2009 Digestive, Immune/Hematopoietic, Re reductive HMWFG79 SEQ ID NO:2010 Digestive, Immune/Hematopoietic, ' , Re reductive HMTAE85 SEQ ID N0:2011 Cancer HMTBI36 SEQ ID N0:2012 Cancer HSUME76 - SEQ ID N0:2013 Cancer HSUME76 SE ID N0:2014 Cancer HTEAF65 SEQ ID N0:2015_ Excretory, Re reductive HTEAT31 SEQ ID N0:2016 Cancer HAJAN23 SEQ ID N0:2017 Cancer HAPRJ16 SEQ ID N0:2018 Cancer ' HDTDT55 ' SEQ ID N0:2019 Cancer HSKDA27 SEQ ID N0:2020 Cancer HSKDA27 SEQ ID' N0:2021 Cancer HWLED11 SEQ ID N0:2022 Cancer HADGD33 . SEQ ID N0:2023. , Connective/Epithelial, Neural/Sensory, Re reductive HCEBF 19 SEQ ID N0:2024 Cancer HCEBF19 SEQ ID N0:2025~ Cancer HDPHH40 SEQ ID N0:2026 Cancer HHEPM33 SEQ ID N0:2027 Cancer HJBAF16 SEQ ID N0:2028 Cancer HJBCU04 SEQ ID N0:2029 Cancer HWABY10 SEQ ID N0:2030 Cancer HWABY10 SEQ ID N0:2Q31 Cancer HWABY10 SEQ ID N0:2032 Cancer HWABY10 SEQ ID N0:2033 Cancer a HDPQN11 SEQ ID N0:2034 Cancer HDPQNl l SEQ ID N0:2035 Cancer HMSAW68 SEQ ID N0:2036 Cancer HMSGP80 SEQ ID N0:2037~ Cancer ' HPJBZ76 SEQ ID N0:2038 Cancer HSIGM62 SEQ ID N0:2039 Cancer.

HSLHS22 SEQ ID N0:2040' Cancer HTXOZ19 SEQ ID N0:2041 Cancer HTXOZ19 SEQ ID N0:2042 Cancer HAPQQ94 SEQ ID N0:2043 Immune/Hemato oietic, Re roductive HAPQQ94 SEQ ID N0:2044 ImmunelHematopoietic, Re roductive HAPSA79 SEQ ID N0:2045 Cancer HAPSA79 SEQ ID N0:2046 Cancer ' HAPSA79 SEQ ID N0:2047 Cancer HDPAJ93 SEQ ID N0:2048 Cancer HELGF34 SEQ ID N0:2049 Cancer HETEQ88 SE ID NO:2050 Cancer HMSAC18 SEQ ID N0:2051 Cancer HMSAC18 SEQ ID N0:2052 Cancer HPQSH59 _ Cancer SEQ ID N0:2053 HSIFV30 SEQ ID N0:2054 Cancer.

HSVCB08 SEQ ID N0:2055 Cancer HT3SF53 SEQ ID,N0:2056 Cancer HARMS04 SEQ ID N0:2057 Connective/Epithelial, ~- Di estive HCDBP36 ~ SEQ ID N0:2058 Musculoskeletal HCEPE30 SEQ ID N0:2059 Excretory, Neural/Sensory HE9RM63 SE ID N0:2060 Cancer HKAJF71 SEQ ID N0:2061 Cancer HNBAF49 SEQ ID'N0:2062 Cancer HSLDJ89 ' SEQ ID N0:2063 Cancer HSXGI47 SEQ ID N0:2064 Cancer HTEAJ18 SEQ ID NO:2065 Re roductive HTTEV40 SEQ ID NO:2066 Cancer HWBCB89 SEQ ID NO:2067 Cancer HWHGZ51 SEQ ID N0:2068 Cancer HADDH60 SEQ ID NO:2069 ConnectivelEpithelial, ' Immune/Hematopoietic, Neural/Sensory HBXCL93 SEQ ID N0:2070 Neural/Sensory, Re roductive HPTRH66 SEQ ID NO:2071 Cancer HNFHD58 SEQ ID N0:2072- Cancer HAGAB58 SEQ ID NO:2073 Cancer HCE3Z39 SEQ ID N0:2074 Cancer HCFCU69 SEQ ID N0:2075 Cancer HCE3Z39 SEQ ID N0:2076 Cancer HCELE47 SEQ ID N0:2077 Cancer HCWHP79 SEQ ID N0:2078 Immune/Hemato oietic HDLAG89 SEQ ID N0:2079 Cancer HDLA028 SEQ ID N0:2080 Cancer HDQGY41 SEQ ID N0:2081 Cancer I-IE8FK78 SEQ ID N0:2082 Cancer HE8FK78 SEQ ID N0:2083, Cancer HETHR73 . SEQ ID N0:2084 Cancer HFIUW36 SEQ ID N0:2085 Cancer HFKKS66 SEQ ID NO:2086 Cancer HFPFK57 SEQ ID N0:2087 Neural/Sensory, Re roductive HFVJP07 SEQ ID N0:2088- Digestive, Immune/Hemato oietic HLQEM64 SEQ ID N0:2089 , Cancer HSSDG41 ' SEQ ID N0:2090 Cancer ' ' HLQGP82 SEQ ID N0:2091 Connective/Epithelial, Digestive, Musculoskeletal HMSMD07 SEQ LD NO:2092 Cancer HNGIR58 SEQ ID N0:2093 Immune/Hemato oietic HMAMI21 SEQ ID N0:2094 Cancer _ HNHNB29 SEQ ID N0:2095 Immune/Hemato oietic HNTE078 SEQ ID N0:2096 Digestive, Immune/Hemato oietic HJPAY76 SEQ ID N0:2097 Cancer HOEEK12 SEQ ID N0:2098 Cancer HOFNC14 ~ SEQ ID N0:2099 Re reductive HOSNU69 ' SEQ ID N0:2100 Cancer HPJCL28 SEQ >D N0:2101 Neural/Sensory, Re reductive HRACI26, SEQ ID N0:2102 Digestive, Excretory HTLIT63 SEQ ID N0:2103~ Re reductive HTEAM34 SEQ ID N0:2104 Re reductive HTEAM34 SEQ ID N0:2105 Reroductive HUFGH53 ~ SEQ ID N0:2106 Cancer -HUSBA88 SEQ ID N0:2107~ Cancer HELHN47 SEQ ID NO:2108 Cancer HELHN47 SEQ ID NO:2109 Cancer HELHN47 SEQ ID N0:2110 Cancer HETAY39 SEQ ID N0:2111 Cancer HFICR14 SEQ ID N0:2112 Cancer HFICR14 SEQ ID NO:2113 Cancer ~

HFKET18 SEQ m NO:2114 Cancer HFXDK20 SEQ ID NO:2115' ' Immune/Hematopoietic, Neural/Sensory HKMLX18 SEQ ID NO:2116~ Cancer HMSCM88 SEQ ID N0:2117~ Immune/Hemato oietic HMABG70 . SEQ >D N0:2118 Connective/Epithelial, ' Immune/Fiematopoietic, Musculoskeletal HMADJ74 SEQ ID N0:2I , Connective/Epithelial, 19 Immune/Hematopoietic, Musculoskeletal HMADJ14 SEQ ID N0:2120 ConnectivelEpithelial, Immune/Hematopoietic, .
Musculoskeletal HMADJ14 SEQ ID N0:2121 . Connective/Epithelial, Immurie/Hematopoietic, Musculoskeletal HMADJ14 SEQ ID N0:2122 Connective/Epithelial, Immune/Hematopoietic, Musculoskeletal HNEBY54 SE ID N0:2123 Cancer.

HNEDD37 SEQ ID N0:2124 Cancer HNGOU82 SEQ ID NO:2125 Imrnune/Hematopoietic, Re reductive HNGOW62 SEQ ID NO:2126 Immune/Hemato oietic HSIC066 SEQ ID N0:2127 Cancer HSID 93 SEQ ID N0:2128 Cancer HSLGM81 SEQ ID N0:2129 Cancer HSYBM41 SEQ ID N0:2130 Cancer HSODB85 SEQ ID N0:2131 Cancer HSRFZ57 SEQ.ID N0:2132 Excretory, Musculoskeletal HSXAZ05 SEQ ID N0:2133 Neural/Sensory, Res iratory HTPCW21 SEQ ID N0:2134' Digestive;
Neural/Sensory HTPCW21 SEQ ID N0:2135 Digestive, Neural/Sensoxy HTXKF95 SEQ ID N0:2136 Cancer HTXKF95 SEQ ID N0:2137' Cancer HUFBC44 SEQ ID N0:2138 Digestive, ' Mixed Fetal, Neural/Sensory HAAAI67 SEQ ID N0:2139 Cancer HFKIA71 SEQ ID N0:2140 Cancer HAMFP32 SEQ ID N0:2141 Cancer HAPQU71 SEQ ID N0:2142 Cancer HAPQU71 SEQ ID N0:2143 Cancer HLHDL42 ~ SEQ ID N0:2144 Cancer HAWG36 ' SEQ ID N0:2145 Cancer HBGNP63 SEQ ID N0:2146 Re reductive HBJNC59 SEQ ID N0:2147 Cancer HAPQT56 SEQ ID N0:2148 Cancer HCABW07 SE ID N0:2149 Cancer HDPFB02 SEQ ID N0:2150 Cancer HMWDB84 SEQ ID NO:2151 Cancer HDPFB02 SEQ ID N0:2152~ Cancer HDPFY41 SEQ ID N0:2153 Cancer HDPIE$5 SEQ ID N0:2154 Cancer I3DPOE32 SEQ ID N0:2155 Cancer HWABL61 SEQ ID N0:2156 Cancer HWABW88 SEQ ID N0:2157 Cancer' HWDAQ83 SEQ ID N0:2158 Cancer ' HWDAQ83 SEQ ID N0:2159 Cancer HWLHZ79 SEQ ID N0:2160 Connective/Epithelial, Digestive, Re reductive HTXJM94 SEQ ID NO:2161~ Cancer HDPQGO1 SEQ ID N0:2162. Cancer HJPAD80 SEQ ID N0:2163 Cancer HDPQGO1 SEQ ID N0:2164 Cancer HFXLF67 SEQ ID N0:2165 Neural/Sensory HE2IO57 SEQ ID N0:2166' Cancer HKGDP17 SEQ ID N0:2167 Res iratory HLQFB 12 SEQ ID N0:2168 Digestive, Re reductive HLQFT18 SEQ ID N0:2169 Digestive, Re reductive HOFNX30 SEQ ID N0:2170 Re reductive HSSDM23 SEQ ID N0:2171~ Cancer HSSDM23 SE ID N0:2172 Cancer HSVBD67 SEQ ID N0:2173 Cancer HSVBD67 SEQ ID N0:2174 Cancer HTGAT51 SEQ ID N0:2175 Cardiovascular, Immune/Hematopoietic, ' Re roductive _ HTLGV 19 SEQ ID N0:2176, Excretory, Re roductive HTPHH74 SEQ ID N0:2177 Caneer HTFOB75 SEQ~ ID N0:2178. Cancer HTPHH74 SEQ ID N0:2179~ ' Cancer HWHGK36 ~ SEQ ID N0:2180 Cancer HLWAD77 SEQ ID N0:2181 Cancer HDTGF15 SEQ ID N0:2182 Cancer HWMBB68 SE ID N0:2183 Cancer HWMBB68 SE ID N0:2184~ ~ Cancer HAGDA35 SEQ ID N0:2185 Cancer HAGDA35 SEQ ID N0:2186 Cancer HAGDA35 SEQ ID N0:2187~ Cancer HRODQ04 SEQ ID N0:2188 Cancer HTOJV86 SE ID N0:2189 Cancer HCEFZ82 SEQ ID N0:2190 Cancer HNGFW58 SEQ ID NO:2191 Cancer HHBGE77 SEQ ID NO:2192 Cancer HADFW77 SEQ ID N0:2193 Cancer HSIED48 SEQ ID N0:2194~ Cancer .

HCEFZ82 SEQ ID N0:2195 Cancer HTTCT46 SEQ ID N0:2196 Cancer HSDEE58 SEQ ID N0:2197~ Cancer HEBCV31 SEQ ID N0:2198 Cancer .

HDPOL27 - SEQ ID N0:2199 Cancer HDPOL27 SEQ ID N0:2200 Cancer HE6DI14 ~ SEQ ID N0:2201 Cancer .

HLYAN43 SE ID N0:2202 Cancer HDPIJM13 SEQ ID N0:2203 Cancer HPLAT62 SEQ ID N0:2204 Cancer HAPQT56 SEQ ID N0:2205 Cancer HACBG1.9 SEQ ID N0:2206 Cancer HACBG19 SEQ ID N0:2207 Cancer HLYAV34 SEQ ID N0:2208 Cancer HCNSM85 SEQ ID N0:2209~ Cancer HTOCG60 SEQ ID N0:2210 Cancer HLYAV34 SEQ ID N0:2211 Cancer HDPWX42 SEQ ID N0:2212 Cancer HOFNF53 SE ID N0:2213 Re roductive .

HOFNF53 SEQ ID N0:2214 Re roductive HMSE015 SEQ ID N0:221,5 Cancer . -HBXFT65 SEQ ID N0:2216 Cancer HFCEQ37 SEQ ID NO:2217 Cancer .

HWNFG66 SEQ ID N0:2218 Di estive HOHCA60 SEQ ID NO:2219' Cancer HOHCA60 SE ID N0:2220 Cancer HOHCA60 SEQ ID N0:2221 Cancer HOHCA60 SEQ ID N0:2222' ' Cancer -HOHCA60 SEQ ID N0:2223 Cancer HLDRR08 SEQ ID N0:2224 ' Di estive HSKNP59 SEQ ID N0:2225 Musculoskeletal HSKNP59 SEQ ID N0:2226 Musculoskeletal HAMHE82 SEQ ID N0:2227 Cancer ' ' HBI0068 SEQ ID'N0:2228_ Cancer HCE3C63 SEQ ID N0:2229 Mixed Fetal, Neural/Sensory HCNDV12 SEQ ID N0:2230 Digestive, Re reductive HMWDW68 SEQ ID N0:2231 Cancer HE2BC57 SEQ ID N0:2232 Cancer HSDEE58 SEQ ID NO:2233 Cancer HE90W91 SEQ ID N0:2234 Cancer HFCFI20 SEQ ID N0:2235 Cancer HELEN05 SEQ ID N0:2236 Cancer HISEL50 SEQ ID N0:2237 Cancer HLHDL62 SE ID N0:2238 Cancer HDFQB93 SEQ ID N0:2239~ ~ Cancer HLHDQ86 SEQ ID N0:2240 Cancer HLNAB24 SEQ ID N0:2241 Immune/Hemato oietic ' HLYBQ90 SE ID N0:2242 Cancer HLYBQ90 SEQ ID N0:2243 Cancer HNHDP39 SEQ ID N0:2244. Endocrine, Immune/Hematopoietic, Re reductive HNTAC64 SEQ ID N0:2245 Cancer HNTMY29 ' SEQ ID N0:2246. Connective/Epithelial, ~ Re reductive HOFOC33 SEQ ID N0:2247 Re reductive HOFOC33 SE ID N0:2248 Re reductive HTWFK18 SEQ ID N0:2249 ConnectivelEpithelial,.
Immune/Hemato' oietic HAPNJ39 SEQ ID N0:2250 Cancer -HDQFU27 SEQ ID N0:2251 Cancer HETJZ45 SEQ ID N0:2252 Cancer HTEMX36 SEQ ID N0:2253 Cancer HNTCH90 SEQ~ID N0:2254 Cancer HWLBP46 SEQ ID NO:2255 Cancer HA5BM53 SEQ ID N0:2256. Cancer HMCEH49 SEQ ID N0:2257 Cancer HKBAL25 SEQ ID N0:2258 Digestive, Musculoskeletal HE8EF43 SEQ ID NO:2259 Cancer HE2RN91 SEQ ID N0:2260'' Cancer .

HTLI020 SEQ ID NO:2261 Immurie/Hematopoietic, Neural/Sensory HBIMF63 SEQ ID N0:2262 Re reductive HE9PM90 SEQ ID NO:2263 Cancer ' HNTDX22 SEQ ID NO:2264 Re reductive ' HHFCE59 SEQ ID N0:2265 Cancer HCGAD44 SEQ ID N0:2266 Cancer HSSJJ51 SEQ ID N0:2267 Cancer In preferred embodiments, the albumin fusion proteins of the invention are capable of a therapeutic activity and/or biologic activity corresponding to the therapeutic activity and/or biologic activity of the Therapeutic protein corresponding to the Therapeutic protein portion of the albumin fusion protein listed in the corresponding row of Table 1.
In further preferred embodiments, the therapeutically active protein portions of the albumin fusion proteins of the invention are fragments or variants of the reference sequence cited in the "Exemplary Identifier" column of Table 1, and are capable of the therapeutic activity and/or biologic activity of the corresponding Therapeutic protein.
Polypeptide ahd Polyuucleotide Fragme~zts and Variants F~c~gmehts The present invention is further directed to fragments of the Therapeutic proteins described in Table 1, albumin proteins, and/or albumin fusion proteins of the invention.
Even if deletion of one or more amino acids from. the N-terminus of a protein results in modification or loss of one or more biological functions of the Therapeutic protein, albumin protein, and/or albumin fusion protein, other Therapeutic activities and/or functional activities (e.g., biological activities, ability to multimerize, ability to bind a ligand) may still ~be retained. For example, the ability of polypeptides with N-terminal deletions to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptides generally will be retained when less than.the majority of the residues of the complete polypeptide are reriaoved from the N-terminus.
Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a mutein with a large number of deleted N-terminal amino acid residues may retain some biological or immunogenic activities. In fact,.peptides composed of as few as six amino acid residues may often evoke an immune response.
Accordingly, fragments of a Therapeutic protein, corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention, include the full length protein as well ~as polypeptides .having one or more residues deleted from the amino terminus of the amino acid sequence of the reference polypeptide (i.e., a Therapeutic protein as disclosed in Table 1). In 'particular, N-terminal deletions may be described by ' 172 the general formula m-q, where q is a whole integer representing the total number of amino acid residues in a reference polypeptide (e.g., a Therapeutic protein referred to in Table 1), and m is defined as any integer ranging from 2 to q-6.
Polynucleotides encoding these polypeptides are also encompassed by the invention.
In addition, fragments of serum albumin polypeptides~corresponding to an albumin protein portion of an albumin fusion protein of the invention, include the full length protein as well as polypeptides having one or more residues deleted from the amino .
terminus of the amino acid sequence of the reference polypeptide (i.e., serum albumin). In particular, N-terminal deletions may be described by the general formula m-585, where 585 is. a whole integer,representing the total number of amino acid residues in serum albumin (SEQ )D N0:18), and m is ' defined as any integer ranging from 2 to 579.
Polynucleotides encoding these polypeptides are also encompassed by the invention.
Moreover, fragments of albumin fusion proteins of the invention; include .the full length albumin fusion protein as well as polypeptides having one or more residues deleted from the amino terminus of the albumin fusion protein. In particular, N-terminal deletions may be described by the general formula m-q, where q is a whole integer representing the total number of amino acid =residues in the albumin fusion protein, and m is defined as any - integer ranging from 2 to q-6: Polynucleotides encoding these palypeptides are also encompassed by the invention.
Also as mentioned above, even if deletion of one or more amino acids from the N-terminus or C-terminus of a reference polypeptide ~ (e.g., a Therapeutic protein and/or - serum, albumin protein) results in modification or loss of one or more biological functions of the protein, other functional activities (e.g., biological activities, ability to multimerize, ability to bind a ligand) and/or Therapeutic activities may still be retained.
For example the ability of polypeptides with C-terminal deletions to;induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptide generally will be retained when less than.the majority of the residues of the complete or mature polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking the N-terminal and/or C-terminal residues of a reference polypeptide retains Therapeutic activity can readily be determined by routine methods described herein and/or otherwise known in the art.
The present invention further provides polypeptides having one or more residues deleted from the carboxy terminus of the amino acid sequence of 'a Therapeutic protein corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention (e.g., a Therapeutic protein referred to in Table 1). In particular, C-terminal deletions may be described by the general formula 1-n, where n is any whole integer ranging from 6 to q-1, and where q is a whole integer representing the total number of amino acid residues in a reference polypeptide (e.g., a Therapeutic protein referred to in Table 1). Polynucleotides encoding these polypeptides are also encompassed by the invention.
In addition, the present invention provides polypeptides having one or more residues deleted from the carboxy terminus of the amino acid sequence of an albumin protein corresponding to an albumin protein portion of an albumin fusion protein of the invention (e.g., serum albumin). In particular, C-terminal deletions may be described by the .general formula 1-n, where n is any whole integer ranging from 6 to 584, where 584 is the whole integer representing the. total number of amino acid residues iri serum albumin (SEQ ID NO:18) minus 1. Polynucleotides encoding these polypeptides are also encompassed by the invention.
Moreover, the present invention provides polypeptides having one or more residues deleted from the carboxy terminus of an albumin fusion protein of the invention.
In particular, C-terminal deletions rnay be described by the general formula-1-n, where n is any whole integer ranging from 6 to q-1, and where q is a whole integer representing the _ total number of amino acid residues in an albumin fusion protein of the invention.
Polynucleotides encoding these polypeptides are also encompassed by the invention. -In addition, any of the above described N- or C-terminal deletions can be combined to produce a N- and C-terminal deleted reference polypeptide. The invention 1 also provides polypeptides having one or more amino acids deleted 'from both the amino and the ' carboxyl termini, which may be described generally as having residues m-n of a reference polypeptide (e.g., a Therapeutic protein referred to in Table l~,.or serum albumin (e.g., SEQ ID N0:18), or an albumin fusion protein of the invention) where n and m are integers as described above. Polynucleotides encoding these polypeptides are also . .encompassed by the invention:
The present application is also directed to proteins containing polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or~ 99% identical to a reference polypeptide sequence (e.g., a Therapeutic protein; serum albumin protein or an albumin fusion protein of the invention) set forth herein, or fragments thereof. In preferred embodiments, the application is directed to proteins comprising polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to reference polypeptides having the amino acid sequence of N- and- C-terminal deletions as described above. Polynucleotides encoding these polypeptides are also encompassed by the invention.
Preferred polypeptide fragments of the invention are fragments comprising, or alternatively, consisting of, an amino acid sequence that displays a Therapeutic activity and/or functional activity (e.g. biological activity) ,of the polypeptide , sequence of the Therapeutic protein or serum albumin protein of which the amino acid sequence is a fragment. ~ - ' Other preferred polypeptide fragments are biologically active fragments.
Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the .
fragments may include an improved desired activity, or a decreased undesirable activity.
Yczriahts "Variant" refers to a polynucleotide or~ nucleic acid differing from a reference nucleic acid or polypeptide, but retaining essential properties thereof.
Generally, variants are overall closely similar, and, in many regions, identical to the reference nucleic acid or polypeptide. , As used herein, "variant", refers o a Therapeutic protein portion of an albumin fusion protein of the invention, albumin portion of an albumin fusion protein of the invention, or albumin fusion protein differing in sequence from a Therapeutic protein (e.g.
see "therapeutic" column of Table 1), albumin protein, and/or albumin fusion protein of the invention, respectively, but retaining at least one functional and/or therapeutic property thereof as described elsewhere herein or otherwise known in the art.
Generally, variants . are overall very similar, and, in many regions, identical- .to the amino acid sequence of the Therapeutic protein corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention, albumin protein corresponding to an albumin protein portion of an albumin fusion protein of the invention, and/or albumin fusion protein of the invention. Nucleic acids encoding these variants axe also encompassed by the invention.
The present invention is also directed to proteins which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, identical to, for example, the amino acid sequence of a Therapeutic protein corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention (e.g., an amino acid sequence disclosed in the "Exemplary Identifier" column of Table l, or fragments or variants thereofj, albumin proteins (e.g., SEQ ID
N0:18 or fragments or, variants thereof) corresponding to an albumin protein portion of an albumin fusion protein of the invention, and/or albumin fusion proteins of the invention:
Fragments of these polypeptides are also provided (e.g.,,. those ,fragments described herein).
Further polypeptides encompassed by the invention are polypeptides encoded by polynucleotides which hybridize to the complement of a nucleic acid molecule encoding an amino acid sequence of the invention under stringent hybridization conditions (e.g., hybridization to filter bound DNA in 6X Sodium chloridelSodium citrate (SSC) at about 45 degrees Celsius, followed by one or more washes in 0.2X SSC, 0.1% SDS at about 50 -65 degrees Celsius), under highly stringent conditions (e.g., hybridization to filter bound DNA in 6X sodium .chloride/Sodium citrate (SSC) at about 45 degrees Celsius, followed by one or more washes in O.1X SSC, 0.2% SDS at about 68 degrees Celsius), or under other stringent hybridization conditions which are known~to those of skill in the art (see, for example, Ausubel, F.M. et al., eds., 1989 Current protocol in Molecular Biology, Green publishing associates, Inc., and John Wiley & Sons Inc., New York, at pages 6.3.1 -6.3.6 and 2.10.3). Polynucleotides encoding these polypeptides axe also encompassed by the invention.
By a polypeptide having an amino acid sequence at least, for example, 95%
"identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95%.identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, or substituted with another amino acid. These alterations of the reference sequence may occur at the amino- or carboxy-terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in . one or .more contiguous groups within the reference sequence.
As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequence of an albumin fusion protein of the invention or a fragment thereof (such as the Therapeutic protein portion of the albumin fusion protein or the albumin portion of the albumin fusion protein), can be determined conventionally using known computer programs. A
preferred method for determining, the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global.
sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci.6:237-245 (1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both arnirio acid sequences. . The result of said global sequence alignment is 'expressed as percent identity. Preferred parameters used in a FASTDB amino acid alignment are:
Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, ~
Randomization' Group Length=0, Cutoff Score=l., Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.
If the subj ect sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to he results. This is because the FASTDB program does not.account for N- and C-terminal tnmcation~ of the subject sequence when calculating global percent identity.
For subject sequences truncated at the N- and C-termini, relative to the query sequence;
the percent . identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence; which are not matchedlaligried with a corresponding subject residue, as a percent of the total bases of the query sequence.
Whether a residue is matched/aligned is determined by results of the FASTDB
sequence alignment. This percentage is then subtracted from the percent identity, calculated by the ~ above FASTDB program using the specified parameters, ~ to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C- terminal residues of the subject sequence.
For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number ~of residues at the N- and C- termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there axe no residues at the N- or C=termini of the subject sequence which are not matchedlaligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.
The variant will usually have at least 75 % (preferably at least about 80%, 90%, 95% or 99%) sequence identity with a length of normal HA or Therapeutic protein which is the same length as the vaxiant. Homology or identity at the nucleotide or amino acid sequence 'level is determined by BLAST (Basic Local. Alignment Search Tool) analysis using the algorithm employed by the programs blastp, blastn, blastx, tblastn and tblastx (Marlin et al., Proc. Natl. Acad. Sci. USA 87: 2264-2268 (1990) and Altschul, J. Mol.
Evol. 36: 290-300 (1993),.fully incorporated by reference) which are tailored for sequence similarity searching.
The approach used by the BLAST program is to first consider similar segments between a query sequence and a database sequence, then to evaluate the statistical significance of all matches that are identified and finally to summarize only those matches which satisfy a preselected threshold of significance. For a discussion of basic issues in similarity searching of sequence databases, see , Altschul et al., (Nature Genetics 6:

I19-I29 (1994)) which i's fiilly incorporated by reference. The search parameters for histogram, descriptions, alignments, expect (i.e., the statistical significance threshold for reporting matches against database sequences), cutoff, matrix and filter are at the default settings. The default scoring matrix used by blastp, blastx, tblastn, and tblastx is the BLOSUM62 matrix (Henikoff et al., Proc. Natl. Acad. Sci. USA 89: 10915-10919 (1992), fully incorporated by reference). For blastn, the scoring matrix is set by the ratios of M
(i.e., the reward score for a pair of matching residues) to N (i.e., the penalty score for mismatching residues), wherein the default values for M and N are 5 and -4, respectively.
Four blastn parameters may be adjusted as follows: Q=10 (gap creation penalty); R=10 (gap extension penalty); wink=1 (generates word hits at .every wink'h position along the query); and . gapw=16 (sets the window ~,vidth within which gapped alignments are generated). The. equivalent Blastp ,parameter settings were Q=9; R=2; wink=l;
and gapw=32. A Bestfit comparison between sequences, available in the GCG package version 10.0, uses DNA parameters GAP=50 (gap creation penalty) and LEN=3 (gap extension penalty) and the equivalent settings in protein comparisons are GAP=8 and LEN=2.
The polynucleotide variants of the invention may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced. by silent substitutions due to the degeneracy of the genetic code are preferred.
Moreover, polypeptide variants in which less than 50, less than 40, less than 30, less than 20, less than 10, or 5-50, 5-25, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host '(change codons in the human mRNA to those preferred by a bacterial host, such as, yeast or E.
coli).
In a preferred embodiment, a polynucleotide encoding an albumin portion of an albumin fusion protein.of the invention is optimized for expression in yeast or mammalian cells. In fLUther preferred embodiment, a polynucleotide encoding a Therapeutic protein portion of an albumin fusion protein of the invention is optimized for expression in yeast or mammalian cells. In a still further preferred embodiment; a polynucleotide encoding an albumin fusion protein of the invention is optimized for expression in yeast or mammalian cells.
In an alternative embodiment, a codon optimized polynucleotide encoding a Therapeutic protein portion of an .albumin fusion protein of the invention does not hybridize to the wild type polynucleotide encoding the Therapeutic protein under stringent hybridization conditions as described herein. In a further embodiment, a codon optimized polynucleotide encoding an albumin portion of an albumin fusion protein of the invention do not hybridize to the wild type polynucleotide encoding the .albumin protein under .
stringent hybridization conditions as described herein. In another embodiment, a codon optimized polynucleotide encoding an albumin fusion protein of the invention do not hybridize to. the wild type polynucleotide encoding the Therapeutic protein portin or the albumin protein portion under stringent hybridization conditions as described herein. -In an additional embodiment, polynucleotides encoding a Therapeutic protein portion of an albumin fusion protein of the invention do not comprise, or alternatively consist of, the naturally occurring sequence of that Therapeutic protein. In a further embodiment, polynucleotides encoding an albumin protein portion of an albumin fusion protein of the invention do not comprise, or alternatively consist of, the naturally occurnng sequence of albumin protein. In an alternative embodiment, polynucleotides encoding an albumin fusion protein of the invention do not comprise, or alternatively consist of, the naturally occurring sequence of a Therapeutic protein portion or the albumin protein portion. .
Naturally occurring variants are called "allelic variants," and refer to one of several y alternate forms of a~ gene occupying a given locus on a chromosome of an organism.
(Genes II, Lewiri, B., ed., John Wiley & Sons, New York (1985)). These allelic variants can vary at either the polynucleotide andlor polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis Using known methods of protein engineering and recombinant DNA technology, variants. may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one ~or more _ amino acids can be deleted from the N-terminus or C-terminus of the polypeptide of the present invention without substantial loss of biological function. As an example, Ron et al. (J. Biol. Chem. 268: 2984-2988 (1993)) reported variant KGF proteins having heparin binding activity even after'deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J: Biotechnology 7:199-216 (1988).)-Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem. 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-la. They used random mutagenesis to generate over 3,500 individual IL-1 a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.
Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking~N-or . C-terminal residues of a protein retains such immunogenic activities can readily be .
determined by routine methods described herein and otherwise known in the art.
Thus, the invention further includes polypeptide variants which have a functional activity (e.g., biological activity and/or therapeutic activity). In highly preferred embodiments the invention provides ,variants of albumin fusion proteins that have a functional activity (e.g., biological activity and/or therapeutic activity) that corresponds to one or more biological and/or therapeutic activities of the Therapeutic protein corresponding to the Therapeutic protein portion, of the albumin fusion protein: Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity.
In preferred embodiments,. the variants of the invention" have conservative substitutions. By "conservative substitutions" is intended swaps within gioups such as replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile;
replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.
Guidance concerning how to make phenotypically silent amino acid substitutions is provided, for example, in Bowie et al., "Deciphering the Message in Protein Sequences:
Tolerance to Amino Acid Substitutions," Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.
The first strategy exploits the tolerance of amino acid substitutions by.natural selection during the. process of evolution. By comparing amino acid sequences in different species., conserved amino acids can be identified. These conserved amino acids are likely important for protein function., In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while, still maintaining biological activity of the protein.
The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. See Cunningham and Wells, Science 244:1081-1085 (1989). The resulting mutant molecules can then be tested for biological activity. , . ' As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to~ be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid.
substitutions involve replacement ~ of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile;
replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr; Met, and Gly.
Besides conservative amino acid substitution, variants of the present invention include (i) polypeptides containing substitutions of one or more of the non-conserved amino acid . residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) polypeptides containing substitutions of one or more of the amino acid residues having a substituent group, or (iii) polypeptides which have been fused with or chemically conjugated to another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), (iv) polypeptide containing additional amino acids, such as, for example, an IgG Fc fusion region peptide, .
Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.
For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may pxoduce proteins with improved ' characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to ' the aggregate's immunogenic activity. See Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967);
Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev.
Therapeutic Drug Carrier Systems 10:307-377 (1993).
In ~ specific embodiments, the polypeptides of the invention comprise, or alternatively, consist of, fragments or variants of the amino acid sequence of a Therapeutic protein described herein and/or human serum albumin, and/or albumin fusion protein of the invention, wherein. the fragments or variants have 1-5, 5-10, 5-25, 5-50;
10-50 or 50-150, amino acid residue additions, substitutions, and/or deletions W hen compared to the reference amimo acid sequence: In preferred embodiments, the amino acid substitutions are conservative. Nucleic acids encoding these polypeptides are also encompassed by the ' invention.
The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic 'methods. Modifications include acetylation, acylation, ADP=
ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization,. disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, ' methylation, myristylation, oxidation pegylation, proteolytic processing, phosphorylation, prenylation, racernization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS -STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H.
Freeman and Company, New York (1993); POST-TRANSLATIONAL COVALENT
MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, NewYork, pgs.
1-12 (1983); Seifter et al., Meth. Enzymol. 182:626-646 (1990); Rattan et al., Ann. N.Y.
Ac.ad. Sci. 663:48-62 (1992)).
Fu~ctionc~l activity "A polypeptide having functional activity" refers to a polypeptide capable of displaying one or more know n functional activities associated with the full-length,.pro-protein, and/or mature .form of a Therapeutic protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide for binding) to an anti-polypeptide antibody], immunogenicity (ability to generate antibody which binds to a specific' polypeptide of the invention), ability to form .. multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide.
"A polypeptide having biological activity" ,refers to a polypeptide exhibiting activity similar to, but not necessarily identical to, an activity of a Therapeutic protein of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to, the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more ~ than about three-fold less activity relative to the polypeptide of the present invention).
In preferred embodiments, an albumin fusion protein of the invention has at least one biological and/or therapeutic activity associated with the Therapeutic protein (or fragment or variant thereof) when it is not fused to albumin.
The albumin fusion proteins of the invention can be assayed for functional activity (e.g., biological activity) using or routinely modifying assays known in the art, as well as assays described herein. Additionally, one .of skill in the art may routinely assay fragments of a Therapeutic protein corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention, for activity using assays referenced in its corresponding row of Table 1. Further, one of skill in the art may routinely assay fragments of an albumin ' protein corresponding to an albumin protein portion.of an albumin fusion protein of the . invention, for activity using assays known in the art and/or as described in the Examples section below. . ~ , For example, in one embodiment where one is ~ assaying for the' ability of an J
albumin fusion protein of the invention to bind or compete with a Therapeutic protein for binding to an anti-Therapeutic polypeptide antibody and/or anti-albumin antibody, various immunoassays. known iri the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA
. (enzyme linked immunosorbent assay), "sandwich" immunoassays, imrnunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western r blots, precipitation reactions,. agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within' the scope of the present invention.
In a preferred embodiment, where a binding partner (e.g., a receptor or a ligand) of a Therapeutic protein is identified, binding to that binding partner by an albumin fusion protein containing that Therapeutic protein as the Therapeutic protein portion of the fusion can be assayed, e.g., by means well-known in the.art, such as, for example, reducing and non-reducing gel chromatography, protein affinity chromatography, and affinity blotting.
See generally, Phizicky et,al., Microbiol. Rev. 59:94-123 (1995). In another embodiment, the ability of physiological correlates of an albumin fusion protein of the present invention to bind to a substrates) of the Therapeutic polypeptide corresponding to the Therapeutic portion of the albumin fusion protein of the invention can be routinely assayed using techniques known in the art.
In an alternative embodiment, where the ability.of an albumin fusion protein of the invention to multimerize is being evaluated, association with other components of the multimer can, be assayed, e.g., by means well-known in,the art, such as, for example, r reducing and. non-reducing gel chromatography, protein affinity.
chromatography, and affinity blotting. See generally, Phizicky et al., supYa.
In preferred embodiments, ark albumin fusion protein of the invention comprising all or a portion of an antibody that binds a Therapeutic protein, has at least one biological andlor therapeutic activity (e.g., to specifically bind a polypeptide or epitope) associated with the.antibody that binds a Therapeutic protein (or fragment or variant thereof) when it is not fused to albumin. .In other preferred embodiments, the biological activity and/or .
therapeutic activity of an albumin fusion protein of the invention comprisirig all or a portion of an antibody that binds a Therapeutic protein is the inhibition (i.e. antagonism) or activation (i.e., agonism) of one or more of the biological activities andlor therapeutic activities associated~with the polypeptide that is specifically bound by antibody that binds a Therapeutic protein:

Albumin fusion proteins of the invention (e.g., comprising at least a fragment or variant of an antibody that binds a Therapeutic protein) may be characterized in a variety of ways. In particular, albumin fusion proteins of the invention comprising at least a fragment or variant of an antibody that binds a Therapeutic protein may be assayed for the ability to specifically bind to the same antigens specifically bound by the antibody that .
binds a Therapeutic protein corresponding to the Therapeutic protein portion of the albumin fusion protein using techniques described herein or routinely modifying techniques known in the art.
Assays for the ability of the albumin fusion proteins of the invention (e.g., comprising at least a fragment or variant of an antibody that binds .a Therapeutic protein) to (specifically) bind a specific protein' or epitope may be performed in solution (e.g., Houghten, Bio/Techniques 13:412-421(1992)), on beads (e.g., Lam, Nature 354:82-(1991)), on chips (e.g., Fodor, Nature 364:555-556 (1993)), on bacteria (e.g., U.S. Patent No. 5,223,409), on spores (e.g., Patent Nos. 5,571,698; 5,403,484; and 5,223,409), on plasmids (e.g., Cull et al., Proc. Natl. Acad. Sci. USA 89:1865-1869 (1992)) or on phage (e.g., Scott and Smith, Science 249:386-390 (1990); Devlin, Science 249:404-406 (1990);
Cwirla et al., Proc. Natl. Acad. Sci. USA 87:6378-6382 (1990);'and Felici, J.
Mol. Biol.
222:301-310 (1991)) (each of these references is incorporated herein in its entirety by reference). Albumin fusion proteins of the invention comprising at least a fragment or variant of a Therapeutic antibody may also be assayed for their specificity and affinity for a specific protein or epitope using or routinely modifying techniques described herein or otherwise known in the art.
The albumin fusion proteins of the invention comprising at least a fragment or variant of an antibody that binds a Therapeutic protein may be assayed for cross-reactivity with other antigens (e.g., molecules that have sequence/stnicture conservation with the molecules) specifically bound by the antibody that binds a Therapeutic protein (or fragment or variant thereof) corresponding to the Therapeutic protein portion of the albumin fusion protein of the invention) by_any method known in the art.
Immunoassays which can be used to analyze (immunospecific) binding and cross-reactivity include, but are not limited to, competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked irnmunosorbent assay), "sandwich" immunoassays, irnmunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, and protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).
Tmmunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X-100, 1% sodium deoxycholate, 0.1 % SDS, 0.1 ~ M NaCl, 0.01 M sodium phosphate at pH 7.2, 1 % Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the albumin fusion protein of the invention (e.g., comprising at least a fragment or variant of an antibody that binds a Therapeutic protein) to the cell lysate, incubating for a period of time (e.g., 1 to 4 hours) at 40 degrees C, adding sepharose beads coupled to an anti-albumin antibody, for example, to the cell lysate, incubating for about an hour or more at 40 degrees C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the albumin fusion protein of the invention to imrnunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the albumin fusion protein to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.
Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20%
SDS-PAGE
depending on the molecular. weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with' 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), applying the albumin fusion protein of the invention (diluted in blocking buffer) to the membrane, washing the membrane in washing buffer, applying a secondary antibody (which recognizes the albumin fusion protein,. e.g., an anti-human serum albumin antibody) conjugated to an enzymatic substrate 188 .

(e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., 32P or 125I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley &
' Sons, Inc., New York at 10.8.1.
ELISAs comprise preparing antigen, coating the well of a 96-well microtiter plate with the antigen, washing away antigen that did not bind the wells, adding the albumin fusion protein (e.g., comprising at least a fragment or variant of an antibody that binds a Therapeutic protein) of the invention conjugated. to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the wells and incubating for a period of time, washing away unbound or non-specifically bound albumin fusion proteins, and detecting the presence of the albumin fusion proteins specifically bound to the antigen coating the well. In ELISAs the albumin fusion protein does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes albumin fusion protein) conjugated to a detectable compound may be added to the well.
Further; instead of coating the well with the antigen, the albumin fusion protein may be coated to the well. In this case, the detectable molecule could be the antigen conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase). One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.
The binding affinity of an albuminlfusion protein to a protein, antigen, or epitope and the off rate of an albumin fusion protein-proteinlantigeri/epitope interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., 3H or lzsl) with the albumin fusion protein of the invention in the presence of increasing amounts of unlabeled antigen, and the' detection of the antibody bound to the labeled antigen. The affinity ~of the albumin fusion protein of the present invention for a specific protein, antigen, or epitope and the binding off rates can be determined from the data by Scatchard plot analysis.
Competition with a second protein that binds the same protein, antigen or epitope as the albumin fusion protein, can also be determined using radioimmunoassays. In this case, the protein, antigen or epitope is incubated with an albumin fusion protein of the present invention conjugated to a labeled compound (e.g., 3H or 12s~ in the presence of increasing .
amounts of an unlabeled second protein that binds the same protein, antigen, or epitope as the albumin fusion protein of the invention.
In a preferred embodiment, BIAcore kinetic analysis is used to determine the binding on and off rates of albumin fusion proteins of the invention to a protein, antigen or . epitope. BIAcore kinetic analysis comprises analyzing the binding and dissociation of albumin fusion , proteins, or specific -polypeptides, antigens or epitopes from chips with immobilized specific polypeptides, antigens or epitopes or albumin fusion proteins, respectively, on their surface.
Antibodies that bind a Therapeutic protein corresponding to the Therapeutic 'protein portion of an albumin fusion protein of the invention may also be described or specified in terms of their binding affinity for a given protein or antigen, preferably the antigen which they specifically bind. Preferred binding affinities include those with, a 'dissociation constant or Kd less than 5 X 10-Z M, 10-z M, 5 X 10-3 M, 10-3 M, 5 X 10~ M, 10'~ M. More preferred binding affinuties include those with a dissociation constant or Kd less than 5 X 10-5 M, 10-5 M~ 5 X 10-6 M, 10-6M, S X 10-' M, 10' M, 5 X 10'$ M
or 10-8 M.
Even more preferred binding affinities include those with a dissociation constant or Kd less than 5 X 10-9 M, 10-9 M, S.X 10'1° M, 10-t° M,-5 X 10-I~ M, 10-11 M, 5 X 10-1z M, lo-iz M, 5 X 10-3 M, 10-13 M, 5 X 10-4~M; 1O-14 M, 5 X 10'15 M, or:l0'is M. In preferred embodiments, albmnin fusion proteins comprising at least a fragment or variant of an ~ , antibody that binds a Therapeutic protein, has an affinity for a given protein or~epitope similar to, that of the, corresponding antibody (not fused . to albumin) that binds a Therapeutic protein, taking .into account the valency of the albumin fusion protein (comprising at least a fragment or variant of an antibody that binds a Therapeutic protein) and the valency of the corresponding antibody. In addition, assays described herein (see Examples and Table 1) and otherwise known in the art may routinely be applied to measure the ability of albumin fusion proteins of the present invention and fragments,.
variants and ~ derivatives thereof to elicit biological activity and/or Therapeutic activity (either in vitro or in vivo) related to either the Therapeutic protein portion and/or albumin portion of the albumin fusion protein of the present invention. Other methods will be known to the skilled artisan and are within the scope of the invention.
Albumin As described above, an albumin fusion protein of the invention comprises at least a fragment or variant of a Therapeutic protein and at least a fragment or variant of human serum albumin, which are associated with one another, preferably by genetic fusion or chemical conjugation.
~ The terms, human serum albumin (HSA) and human albumin (HA) are used interchangeably herein. The terms, "albumin and "serum albumin" axe broader, and encompass human serum albumin (and fragments and variants thereof) as well as albumin from other species (and fragments and variants thereof).
As used herein, "albumin" refers , collectively to albumin protein or amino acid sequence, or an albumin fragment or variant, having one or more functional activities (e.g., biological activities) of albumin. In particular, "albumin" refers to human albumin or fragments thereof (see EP 201 239, EP 322 094 WO 97/24445, W095/23857) especially the mature form of hwnan albumin as shown in Figure 15 and SEQ ID N0:18, or albumin from other vertebrates or fragments thereof, or analogs or variants of these molecules or fragments thereof.
In preferred embodiments, the human serum albumin protein used in the albumin ' ~fusion proteins . of the invention contains one or both of the following sets of point mutations with reference to SEQ ID N0:18: Leu-407 to Ala, Leu-408 to Val, Val-409 to Ala, and Arg-410 to Ala; or Arg-410 to A; Lys-413 to Gln, and Lys-414 to Gln (see, e.g., International Publication No. W095/23857, hereby incorporated in its entirety by reference herein): In even more preferred embodiments, albumin fusion proteins of the invention that contain one or both of above-described sets of point mutations have improved stability/resistance to yeast Yap3p proteolytic cleavage, allowing increased production of recombinant albmnin fusion proteins expressed in yeast host cells.
~ As used herein, a portion of albumin sufficient to prolong the therapeutic activity or shelf life of the Therapeutic protein refers to a portion of albumin sufficient in length or structure to stabilize or prolong the therapeutic activity of the protein so that the shelf life of the Therapeutic protein portion of the albumin fusion protein is prolonged or extended compared to the shelf life in the non-fusion state. The albumin portion of the albumin.
fusion proteins may comprise the full length of the HA sequence as described above or as shown in Figure 15, or may include one or more fragments thereof that are capable of stabilizing or prolonging the therapeutic activity. Such fragments may be of 10 or more amino acids in length or may include about 15, 20, 25, 30, 50, or more contiguous amino acids from the HA sequence or may include part or all of specific domains of HA. For instance, one or more fragments of HA spanning the first two immunoglobulin-like domains may be used.
The albumin portion of the albumin fusion proteins of the invention may be a variant of normal HA. The Therapeutic protein portion of the albumin fusion proteins of the invention may also be variants of the Therapeutic proteins as described herein. The term "variants" includes insertions, deletions and substitutions, either conservative or non conservative, where such changes do not substantially alter one or more of the oncotic, useful ligand-binding' and non-immunogenic properties of albumin, or the active site, or active domain which confers the therapeutic activities of the Therapeutic proteins.
In particular, the albumin fusion proteins of the invention may include naturally occurring polymorphic variants ,of human albumin and fragments of human albumin, for example those fragments disclosed in EP 322 094 (namely HA (Pn), where n is 369 to 419). The albumin may be derived from any vertebrate, especially any manunal, for example human, cow, sheep, or pig. Non-mammalian albumins include, but are not limited to, hen and salmon. The albumin portion of the albumin fusion protein may be from a different animal than the Therapeutic protein portion.
Generally speaking, an HA fragment or variant will ~be at least 100 amino acids long, preferably at least 150 amino acids long. The HA variant may. consist of or alternatively comprise at least one whole domain of HAS for example domains 1 (amino acids 1-194 of SEQ ID N0:18), 2 (amino acids. 195-387 of SEQ ID N0:18), 3 (amino acids 388-585 of SEQ ID N0:18), 1 +Y2 (1-387 of SEQ ID N0:18), 2 + 3 (195-585 of SEQ ZD N0:18) or 1 + 3 (amino acids 1-194.of SEQ ID NO:18 + amino acids 388-585 of . SEQ ID NO:18). Each domain is itself~made up of two homologous subdomains namely 1-105, 120-194, 195-291, 316-387, 388-491 and 512-585, with flexible inter-subdomain linker regions comprising residues Lys106 to G1u119, G1u292 to Va1315 and G1u492 to Alas 11.
Preferably, the albumin portion of an albumin fusion protein of the invention comprises'at least one subdomain or domain of HA or conservative modifications thereof.
If the fusion is based on subdomains, some or all of the adjacent linker is preferably used to link to the Therapeutic protein moiety.
Antibodies that Specifically bind Therapeutic proteins are also Therapeutic proteins The present invention also encompasses albumin fusion proteins that comprise at least a fragment or variant of an antibody that specifically binds a Therapeutic protein disclosed in Table 1. It is specifically contemplated that the term "Therapeutic protein"
. encompasses antibodies that bind a Therapeutic protein (e.g., as Described in column I of Table 1) and fragments and variants thereof. Thus an albumin fusion protein of the invention may contain at least a fragment or variant of a Therapeutic protein, and/or at L
least a fragment or variant of an an antibody that binds a Therapeutic protein.
Antibody structure and background The basic antibody structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about kDa) and one "heavy" chain (about 'S0-70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more , amino acids primarily responsible for antigen recognition. .The carboxy-terminal portion o.f each chain defines a constant region primarily responsible for effector function. Human light chains are 25 classified as kappa and lambda light chains. Heavy chains are classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, lgG, IgA, and IgE, respectively. See generally, Fundamental Immunology Chapters 3-5 (Paul, W., ed., 4th ed. Raven Press, N:Y., (1-998)) (incorporated by reference in its entirety for all purposes). The variable regions of each light/heavy chain pair. form the antibody binding site.
Thus, an intact IgG antibbdy has two binding. sites. Except in bifunctional or ' ' ° bispecific antibodies, the two binding sites are the same.

The chains all exhibit the same general structure of relatively conserved framework regions (FR) joined by , three hypervariable regions, also called complementarity determining regions or ~CDRs. The CDR ' regions, in general, are . the portions of the antibody which make contact with the antigen and determine its specificity.
The CDRs S from the heavy and the light chains of each pair are aligned by the framework regions, enabling binding to a specific epitope. From N-terminal to C-terminal, both light and heavy chains variable regions comprise the domains FR1, CDRl, FR2, CDR2, FR3, CDR3 and FR4. The variable regions are connected to the heavy or light chain constant region. The assignment of amino acids to each domain is in accordance with the definitions of Kabat Sequences of Proteins of Immunological Interest (National Institutes, of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk J Mol. Biol.
196:901-917 (1987); Chothia et al. Nature 342:878-883 (1989).
As used herein, "antibody" refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i:e., molecules that contain an antigen binding site that specifically binds an antigen (e.g., a molecule containing one or more CDR regions of an antibody). Antibodies that may correspond to a Therapeutic protein portion of an albumin, fusion protein include, but are not limited to, monoclonal, multispecific, human, humanized or chirneric antibodies, single chain antibodies (e.g., single chain Fvs), Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic, (anti-Id) antibodies (including, e.g., anti-Id antibodies specific to, antibodies of the invention), and epitope-binding fragments of any of the above (e.g., VH domains, VL domains, or one or more CDR regions). .
Antibodies that bind Therapeutic Proteins The present invention encompasses albumin fusion proteins that comprise at least a fragment or variant of an antibody that binds a Therapeutic Protein (e.g., as disclosed in Table 1) or fragment or variant thereof. ' Antibodies that bind a Therapeutic protein (or fragment or variant thereof) may be from any animal origin, including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, sheep, rabbit, goat, guinea pig, camel, horse, or chicken antibodies. Most preferably, the antibodies are human antibodies.
As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulirl libraries and xenomice or other organisms that have been genetically engineered to produce human antibodies.
The antibody molecules that bind to a Therapeutic protein and that may correspond to a Therapeutic protein portion of an albumin fusion protein of the invention can be of any type (e.g., IgG, IgE, TgM, IgD, IgA and IgY), class (e.g., IgGI, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. In preferred embodiments;
the antibody molecules that bind to a Therapeutic protein and that may correspond to a Therapeutic protein portion of an albumin fusion protein of.the invention are IgGl. In , other preferred embodiments, the immunoglobulin molecules that bind to a Therapeutic protein and that may correspond to a Therapeutic protein portion of an albumin fusion protein of the invention are IgG2. In other preferred embodiments, the immunoglobulin molecules that bind to a Therapeutic protein and that may correspond to ~a Therapeutic protein portion of an albumin fusion protein of the invention are IgG4.
Most preferably the antibodies that bind to a Therapeutic protein and that may correspond'to a Therapeutic.protein portion of an albumin fusion protein of the invention are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')2, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL
or VH
domain. Antigen-binding antibody fragments, including single-chain ;antibodies,, may comprise the variable regions) alone or in combination with the entirety or a portion of the following: hinge region, CHl, CH2, and CH3 domains.
The antibodies that bind to a Therapeutic protein and that may correspond to a Therapeutic protein portion of am albumin fusion protein of the invention may be 25, monospecific, bispecific, trispecific or of greater multispecificity.
Multispecific antibodies may be specific for different epitopes of a Therapeutic protein or may be specific for both a Therapeutic protein as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material: See; ,e.g., PCT publications WO
93/17715; WO
92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol: 147:60-69 (1991); U.S.
Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny' et al., J.
T_m_m__unol. 148:1547-1553 (1992).
Antibodies that bind a Therapeutic protein (or fragment or variant thereof) may be bispecific or bifunctional which means that the antibody is an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites.
Bispecific antibodies can be produced by a variety of methods including fusion of hybridomas or linking of Fab' fragments. See,, e.g., Songsivilai & Lachmann Clin. Exp.
Immunol. 79:
315-321 (1990), Kostelny et al. J Irnmunol. 148:1547 1553 (1992). In addition, bispecific antibodies may be formed as "diabodies" (Holliger et al. "'Diabodies': small bivalent and bispecific antibody fragments" PNAS USA 90:6444-6448 (1993)) or "Janusins"
(Traunecker et al. "Bispecific single chain molecules K (Janusins) target cytotoxic lymphocytes on HIV infected cells" EMBO J 10:3655-3659 (1991) and Traunecker et al.
"Janusin: new molecular design for bispecific reagents" Int J Cancer Suppl 7:51-52 ( 1992)). .
The present invention also provides albumin fusion proteins that comprise, fragments or~ variants (including derivatives) of an antibody described herein or known elsewhere in the art. Standard techniques known to those of skill in the art can be used to introduce mutations in the nucleotide sequence encoding a molecule of the invention, including, for example, site-directed mutagenesis and PCR-mediated mutagenesis which result in amino acid substitutions. Preferably, the variants (including derivatives) encode less than 50 amino acid substitutions, less than 40 amino acid subsitutions, less than 30 amino acid substitutions, less than 25 amino acid substitutions, less than 20 amino acid substiW tions, less than 15 amino acid substitutions, less than 10 amino acid substitutions, less than 5 amino acid substitutions, less than 4 amino acid substitutions, less than 3 amino acid substitutions, or. less than 2 amino acid substitutions relative to the reference VH domain, VHCDRl, VHCDR2, VHCDR3, VL domain, VLCDR1, .VLCDR2, 'or VLCDR3. In specific embodiments, the variants encode substitutions of VHCDR3.
In a _ preferred embodiment, the variants have conservative amino acid substitutions at one or more predicted non-essential .amino acid residues. .
Antibodies that bind to a Therapeutic protein and that may correspond to a Therapeutic protein portion of an albumin fusion protein of the invention -may be described or specified in terms of the epitope(s) or portions) of a Therapeutic protein which they recognize or specifically bind. Antibodies which specifically bind a Therapeutic protein or a specific epitope of a fiherapeutic protein may also be excluded.
Therefore, the present invention encompasses antibodies that specifically bind Therapeutic proteins, and allows for the exclusion of the same. In preferred embodiments, albumin fusion proteins comprising at least a fragment or variant of an antibody that binds a Therapeutic protein, binds the same epitopes as the .
Antibodies that bind to a Therapeutic protein and that may correspond to a' Therapeutic protein portion of an albumim fusion protein of the invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a Therapeutic protein are included.
Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least' 60%, at least 55%, and at least 5.0%
identity (as calculated using methods known in the art and described herein) to a Therapeutic protein are also included in the present invention. In specific embodiments, antibodies that bind to a~ Therapeutic protein and that may, correspond to a Therapeutic protein portion of an albumin fusion protein of the invention cross-react with marine, rat andlor rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using ,methods known in the art and described herein) to a Therapeutic protein are also included in.the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combinations) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. .In preferred embodiments, albumin fusion proteins comprising at least a fragment or variant of an antibody that binds a Therapeutic protein, has similar or substantially identical cross reactivity characteristics compared to the .
Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to. a polynucleotide encoding a Therapeutic protein under stringent hybridization , conditions (as described herein).
Antibodies that bind to a Therapeutic protein and that may correspond to a Therapeutic protein portion of an albumin fusion protein of the invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with~a dissociation constant or Kd less than 5 X 10-Z M, 10-2 M, 5 X 10-3 M, 10-3 M, .
5 X 10~ M; 10~. M. M~re preferred binding affinities include those with a dissociation constant or Kd less than 5 X 10-5 M, 10-5 M, 5 X 10-6 M, 10-6M, S X 10-~ M, 10' M, S X
10-g M or 10-g M. Even more preferred binding affinities include those with a dissociation constant or Kd less than S X 10-9 M, 10-9 M, S X 10-1o M, 10-1° M, S X
10-11 M, 10-11 M, S
X 10-~z M, ~o-iz M, S X 10-13 M, 10-13 M, S X 10-14 M, 10-14 M, S X 10-I5 M, or 10-I5 M. In S preferred embodiments, albumin fusion proteins comprising at least a fragment or variant of an antibody that binds a Therapeutic protein, has , an affinity for a given protein or epitope similar to that of the corresponding antibody (not fused to albumin) that binds a Therapeutic protein, taking into account the valency of the albumin fusion protein (comprising at least a fragment or variant of an antibody that binds a Therapeutic protein) and the valency of the corresponding antibody The invention also provides antibodies-that competitively inhibit binding of an antibody to an epitope of a Therapeutic protein as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein.
In preferred embodiments, the antibody competitively inhibits binding to the epitope by at 1S least 9S%, at least 90%, at least 8S %, at least 80%, at least 7S%, at least 70%, at least 60%, or at least SO%. In preferred embodiments, albumin fusion proteins comprising at least a fragment or variant of an antibody that binds a Therapeutic protein, competitively inhibits binding of an antibody to an epitope of a Therapeutic protein as well as the , competitively inhibits binding of an antibody to an epitope of a Therapeutic protein. In other preferred embodiments, albumin fusion proteins comprising at least a fragment or variant of an antibody that binds a Therapeutic protein, competitively inhibits binding of the to an epitope of a Therapeutic protein by at least 95%, at least 90%, at least 8S %, at least 80%, at least 7S%, at least 70%, at least 60%,~or at least SO%:
Antibodies that bind to a Therapeutic protein and that may correspond to a 2S Therapeutic protein portion of an albumin fusion protein of the invention may act as agonists or antagonists of the Therapeutic protein. For example, the present invention includes antibodies which diswpt the receptor/ligand interactions with the polypeptides of the invention . either partially or fully.- The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. _ For example, receptor activation can be determined by detecting the 198 , phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described supra).
In specific embodiments, antibodies are provided that inhibit ligand activity or receptor - activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of.the antibody.
In preferred embodiments, albumin fusion proteins comprising at least a fragment or variant of an antibody that binds a Therapeutic protein, has similar or substantially similar characteristics with regard to preventing ligand binding and/or , preventing receptor activation compared to the .
The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand .
complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the Therapeutic protreins (e.g. as disclosed in Table 1). The above antibody agonists can be made using methods known in the art. See, e.g., PCT
publication WO 96/40281; U.S. Patent No., 5,811,097; Deng et al., Blood 92(6):1981-1988 (1998);
Chen et al., Cancer Res. 58(16):3668-3678 (1998); Harrop et al., J. Immunol.
1.61(4):1786-1794 (1998); Zhu et al., Cancer Res.-58(15):3209-3214 (1998);
Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998);
Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997); Carlson et aL, J. Biol. Chem. 272(17):11295-11301 (1997);
Taryman et al., Neuron 14(4):755-762 (1995); Muller et al., Structime 6(9):1153-1167 (1998);
Bartunek'~et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties). In preferred embodiments, albumin fusion proteins comprising at least a fragment or variant of an antibody that binds a Therapeutic protein, have similar or substantially identical agonist or antagonist properties as the .
Antibodies that bind to a Therapeutic protein and that may correspond to a Therapeutic protein portion of an albumin fusion protein of the ixiventioxi may be used, for example, to purify, detect, and target Therapeutic proteins, including both in in vitro and,in vivo diagnostic and therapeutic methods. For example, the antibodies have utility in immunoassays for qualitatively and quantitatively measuring levels of the Therapeutic protein in biological samples. See, e.g., Haxlow et al., Antibodies: A
Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); incorporated by reference herein in its entirety. Likewise, albumin fusion proteins comprising at least a fragment or variant of an antibody that binds a Therapeutic protein, may be used, for example, to purify, detect, and target Therapeutic proteins, including .both in in vitro and ~in vivo diagnostic and therapeutic methods.
Antibodies that bind to a Therapeutic protein and' that may correspond to a ~ Therapeutic protein portion of an albumin fusion protein include derivatives that are .
modified, i.e, by the covalent attachment of any type of molecule to the antibody. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, 20. linkage to a cellular ligand or other protein, etc.. Any of numerous chemical modifications may be earned out by known techniques, including, but not limited to specific chemical cleavage; acetylation, formylation, metabolic synthesis of tunicamycin, etc.
Additionally, the derivative may contain one or more non-classical amino acids. Albumin fusion proteins of the invention may also be modified as described above.
Methods of Producing Antibodies that bind Therapeutic Proteins The antibodies that bind to a Therapeutic protein and that may correspond to a Therapeutic protein portion of an albumin fusion protein of the invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of interest can be produced by various~procedures well known in the art. For example, a Therapeutic protein may be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calrriette-Guerin) and corynebacterium parvum..
Sllch adjuvants are also well known in the art. . , .' Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridorna techniques including those known in the art and taught, for example, in Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed.
. 1988); Hammerling, et al.,, in: Monoclonal Antibodies and T-Cell Hybridomas (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The ' 15 , term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. ,The term ."monoclonal antibody'.' refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage'clone, and not the method by which it is produced.
Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art. In a non-limiting example, mice can be immunized' with a Therapeutic protein or fragment or variant thereof or a cell expressing such a Therapeutic, protein or fragment or variant thereof. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques ~to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution.
The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.
Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culW ring a hybridoma cell secreting an antibody wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.
Another well known method for producing both polyclonal and monoclonal human B cell lines is transformation using Epstein Barr Virus (EBV). Protocols for generating EBV-transformed B cell lines are commonly known in the art, such as, for example, the protocol outlined in Chapter 7.22 of Current Protocols in Immunology, Coligan et al., Eds., 1994, John Wiley & Sons, NY, which is hereby incorporated in its entirety by reference. The source of B cells for transformation is commonly human peripheral blood, but B cells for transformation may also be derived from other sources including, but not limited to, lymph nodes, tonsil, spleen, tumor tissue, and infected tissues.
Tissues- are generally made into single cell suspensions prior to EBV transformation.
Additionally, ..
steps may be taken to either physically remove or inactivate T cells (e.g., by treatment with cyclosporin A) in B cell-containing samples, because T cells from individuals seropositive for anti-EBV antibodies can suppress B cell immortalization by EBV.
In general, the sample containing human B cells is~ innoculated with EBV, and cultured for 3-4 weeks. A typical source of EBV is the culture supernatant of the B95-8 cell line (ATCC #VR-1492). Physical signs of EBV transformation can generally be seen towards the end of the 3-4 week culture period. By phase-contrast microscopy, transformed cells may appear large,' clear, hairy and tend to aggregate in tight clusters of cells. Initially, EBV lines are generally ~polyclonal. However, over prolonged periods of cell cultures, EBV lines may become monoclonal or polyclonal as a result of the selective outgrowth of particular B cell clones. Alternatively, polyclonal EBV
transformed lines may be subcloned (e.g., by limiting dilution culture) or fused with a suitable fusion partner and plated at limiting dilution to obtain monoclonal B cell lines. Suitable fusion partners .
for EBV transformed. cell lines include mouse myeloma cell lines (e.g., SP210, Ag8.653), heteromyeloma cell lines (human x mouse; e.g, SPAM-8, SBC-H20, and CB- .
F7), and human cell lines (e.g., GM 1500, SKO-007, RPMI 8226, and KR-4). Thus, the present invention also provides a method of generating polyclonal or monoclonal human antibodies against polypeptides 'of the invention or fragments thereof, comprising EBV-transformation of human B cells.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')2 fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments). F(ab')2 fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.
For example, antibodies that bind to a Therapeutic protein can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry I O the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen . binding domains expressed from a repertoire or combinatorial antibody library (e:g., human or murine).' Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein.
Examples of phage display methods that can be used to make antibodies that bind to a Therapeutic protein include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Imixmnol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J.
Ixnmunol.
24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in linmunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT
publications WO ' 90/02809; . WO 91/10737; WO 92/01047; WO 92/186I9; WO
93/11236; WO 95/15982; WO 95/20401; and LT.S.. Patent Nos. 5,698,426;
5,223,409;
25. 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571',698;
5,427,908; 5,516,637;
5,780,225; 5,658,727; 5,733,743 arid 5,969,108; each of which is incorporated herein by reference in its entirety.
As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')2 fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., BioTechniques 12(6):864-869 (1992); and Sawai et al., AJRI 34:26-34 (1995); and Better et al., Science 240:1041-1043 (1988) (said references incorporated by reference in their entireties).
Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498;
Huston et al., Methods in Enzymology 203:46-88 (1991); Shu et al., PNAS 90:7995-7999 (1993);
and Skerra~et al., Science 240:1038-1040 (1988). For some uses, including ih vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., (1989) J. T_m_m__unol. Methods 125:191-202; U.S.
Patent Nos.
5,807,715; 4,816,567; and 4,816397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity. determining regions (CDRs) from the non-human species and a framework regions from a human iinmunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions axe identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues"important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539;
5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596;
Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).
Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage. display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111;
arid PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO
96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.
Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous ~ immunoglobulins, but which can expxess human imrnunoglobulin. genes. For example, the hmnan heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin , genes may be rendered non-functional separately or simultaneously with the introduction of human iminunoglobulin loci by homologous recombination. In particular, homozygous deletion. of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immmized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention.
Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such' a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszax, Int.
Rev.
Tmmunol. 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096;
WO

96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923;
5,625,126;
5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916;771;
5,939,598;
6,075,181; and 6,114,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to~ provide human antibodies directed against a selected antigen using technology similar to that described above.
Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Biotechnology 12:899-903 (1988)) Polynucleotides Encoding Antibodies The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody and . fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or . alternatively, under lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a Therapeutic protein, and more preferably, an antibody that binds to a polypeptide having the amino acid sequence of a "therapeutic protein X.as discosed in the "Exemplay Identifier" column of Table 1.
The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., BioTechniques 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplif cation of the ligated oligonucleotides by PCR.
Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody) by PCR
amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art (See Example 60).
Once the nucleotide sequence and corresponding amino acid sequence of the 10, antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed" Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties ), to generate antibodies having a different amino acid sequence, for example to create amino acid SllbStltl1t1011S, deletions, and/or insertions.
In a specific embodiment, the amino acid sequence of the heavy andlor light chain variable domains may be inspected to identify the sequences .of the complementarity determining regions (CDRs) by methods that are well know in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA
techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra.
The framework regions may be naturally 'occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et aL, J. Mol.
BioI..278: 457-479 (1998) for a listing of human framework . regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody ' , that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve 'binding of the antibody ~to its antigen.

Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region. cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds.
Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.
In addition, techniques developed for the production of "chimeric antibodies"
(Morrison et al., Proc. Natl. Acad., Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604=608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from 1 a marine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.
Alternatively, techniques described for the production of single chain antibodies ' (IJ.S. Patent No. 4,946,778; Bird, Science 242:423- 42 (1988); Huston et al., .Proc. Natl.
Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a. single chain polypeptide. Techniques for the assembly of functional Fv fragments in E.
coli,may also be used (Skerra et al., Science 242:1038- 1041 (1988)).
Recombinant Expression ofAntibodieS
Recombinant expression of an antibody, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody or a single chain antibody), requires constriction of an expression vector containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an, antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the , art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence. are described herein.
Methods which are well known to those skilled in the art can .be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the.nucleotide sequence encoding the constant region of the antibody .molecule (see, e.g., PCT
Publication WO 86/05807; PCT Publication WO 89101036; and U.S. Patent No.
5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.
The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody..
Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both.the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as .
detailed below:
A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., E. coli, B. subtilis) transformed with recombinant bacteriophage DNA, .plasmid DNA or cosmid DNA
expression vectors containing antibody coding sequences; 'yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV;
tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293; 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian .viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K
promoter). Preferably, bacterial cells such as Escherichia coli, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is. an effective expression system for antibodies (Foecking et al., Gene 45:101 (1986);
Cockett et al., Bio/Technology 8:2 (1990)).
In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an ' antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purred may be desirable. Such vectors include, but are not limited, to the E. coli expression vector pIJR278 (Ruther et al., EMBO J. 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding-region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res.
13:3101-3109 (1985); Van Heeke & Schuster, J. Biol. Chem. 24:5503-5509 (1989)); and the like.
pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned .
target gene product can be released from the GST moiety.
In an insect system, Autographa; californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in Spodoptera frugiperdcz cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV
promoter ,(for example the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or ih vivo recombination.
Insertion in a non- essential region of the viral genome (e.g., region El or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)).
Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of ,the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc.
(see Bittner et al., Methods in Enzymol. 153:51-544 (1987)):
In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen tovensure the correct modification and processing of the foreign protein expressed.
To~ this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, Hela, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.
For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably ~express.the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression 'control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells.to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advaritageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.
A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA
48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgprt- or aprt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., N,atl. Acad. Sci.. USA 77:357 (1980); O'Hare et al., Proc.~ Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12:488-505; Wu and Wu; Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol.
32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann.
Rev. Biochem. 62:191-217 (1993); May, 1993, TIB TECH 11(5):155-215 (1993));
and hygro, which confers resistance to hygromycin (Santerre et al., Gene 30:147 (1984)).
Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley &
Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. .
Mol. Biol. 150:1 (1981), which are incorporated by reference herein in their entireties.

The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, The.use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA
cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene., Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Grouse et al., Mol. Cell. Biol. 3:257 (1983)). ' .
Vectors which use glutamine synthase (GS) or DHFR as the selectable markers can be amplified in the presence of the drugs methionine sulphoximine or methotrexate, respectively. An advantage of glutamine synthase based vectors-are the availabilty of cell lines (e.g., the marine myeloma cell line, NSO) which are glutamine synthase negative.
Glutamine synthase expression systems can also function in glutamine synthase expressing cells (e.g. Chinese Hamster Ovary (CHO) cells) by providing additional inhibitor to prevent the functioning of the endogenous gene. A glutamine synthase expression system and components thereof are detailed in PCT publications: W087/04462;
W086/05807;
W089/01036; W089/10404; and W091/06657 which are incorporated in their entireties by reference herein. Additionally, glutamine synthase expression vectors that may be used according to the present invention are commercially available from suppliers, including, for example Lonza Biologics, Inc. (Portsmouth, NH). Expression and production of monoclonal antibodies using a GS expression system in marine myeloma cells is described in Bebbington et czl., Bioltechhology 10:169(1992) and in Biblia and Robinson Biotechnol.
Prog. 1 l~:l (1995) which are incorporated in their entirities by reference herein.
The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable. equal expression of heavy and light chain polypeptides.
Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies that bind to a Therapeutic protein and that may correspond to a Therapeutic protein portion of an albumin fusion protein of the invention' or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.
Modifications ofAntibodies Antibodies that bind a Therapeutic protein or fragments or variants can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments., the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIA,GEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which axe commercially available. As described in Gentz et al., Proc.
Natl.
Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but' are not limited to, the "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.
The present invention further encompasses antibodies or fragments thereof ,.
conjugated to a diagnostic or therapeutic agent.. The antibodies can be used diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance.
Examples of detectable substances include various enzymes, prosthetic groups,, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting , metals using Var1011S positron emission tomographies, and rionradioactive pararna~etic metal ions. The detectable substance rr~ay be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art: See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use' as diagnostics ' according to the present invention. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, ~r acetylcholinesterase;
examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include 125I, 131I, 111In or 99Tc. Other examples of ~ detectable substances have been described elsewwhere herein.
Further, an antibody of the invention may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, 213Bi. A
cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B,' gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunonibicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to,, antimetabolites '(e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCN~, cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g.; daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin , (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic. agents (,e.g., vincristine and vinblastine).
The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, alpha-interferon, 13-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF-alpha, TNF-beta, AIM I (See, International Publication No. WO 97133899), AIM
II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi et al., Int.
Immuyiol., 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti- angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.
Antibodies may also be attached fo solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylainide, nylon, polystyrene, polyvinyl chloride or polypropylene.
Techniques for conjugating such therapeutic moiety to antibodies are well known.
See, for example, Arnon et al., "Monoclonal Antibodies For .Irmnunotargeting Of Drugs In Cancer Therapy", in Monoclonal Antibodies And Cancer Therapy,' Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom~ et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker;
Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy:
A
' Review", in Monoclonal Antibodies '84: Biological And Clinical 'Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic- Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. ~(eds.), pp. 303-(Academic Press 1985), and Thorpe et' al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev. 62:119-58 (1982).
Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.
An antibody, with or without a therapeutic moiety conjugated to it, administered alone or _30 in combination with cytotoxic factors) and/or cytokine(s) can be used as a therapeutic.
A~ztibody-albumin fusion _ 216 Antibodies that bind to a Therapeutic protein and that may correspond to a Therapeutic protein portion of an albumin fusion protein of the invention include, but are not limited to, antibodies that bind a Therapeutic protein disclosed in the "Therapeutic Protein X" column of Table l, or a fragment or variant thereof.
In specific embodiments, the fxagment or variant of- an antibody that immunospecifcally binds a Therapeutic protein and that corresponds to a Therapeutic protein portion of an albumin fusion protein comprises,. or alternatively consists of, the VH
domain. In other embodiments, ' the fragment or variant of ' an antibody that immunospecifcally binds a Therapeutic protein and that corresponds to a Therapeutic protein portion of an albumin fusion protein comprises, or alternatively consists of, one, two or three VH CDRs. In other embodiments, the fragment or variant of an antibody that r immunospecifcally binds a Therapeutic protein and that corresponds to a Therapeutic protein portion of an albumin fusion protein comprises, or alternatively consists of, the VH
CDRl. In other embodiments, ; the . fragment or variant of an antibody that .
immunospecifcally binds a Therapeutic protein and that corresponds to a Therapeutic protein portion of an albumin fusion protein comprises; or alternatively consists of, the VH
CDR2. In other embodiments, the fragment or variant of an antibody that immunospecifcally binds a Therapeutic protein and that corresponds to a Therapeutic .
protein portion of an albumin fusion protein comprises, or alternatively consists of, the VH
CDR3. .
In specific embodiments, the fragment or variant of an antibody that immunospecifcally binds a Therapeutic protein and that corresponds to a Therapeutic protein portion of an albumin fusion protein comprises, or alternatively consists of, the VL
domain. Tn other . embodiments, the fragment or variant . of ~ an antibody that immunospecifcally binds a Therapeutic protein and that corresponds to a Therapeutic protein portion of an albumin fission protein comprises, or alternatively consists of, one, fi two or three VL CDRs. In other embodiments, the fragment or variant of an antibody that immunospecifcally binds ' a Therapeutic protein and that corresponds to a Therapeutic protein portion of an albumin fusion protein comprises, or alternatively consists of, the VL
_ CDRl. In other embodiments, the fragment or variant of an antibody that immunospecifcally binds a Therapeutic protein and that corresponds to a Therapeutic protein portion of an albumin fusion protein comprises, or alternatively consists of, the VL

CDR2. In other embodiments, the fragment or variant of an antibody that immunospecifcally binds a Therapeutic protein and that corresponds to a Therapeutic protein portion of an albumin fusion protein comprises, or alternatively consists of, the VL
CDR3. ~ ~ ' In other embodiments, the fragment or variant of an antibody that immunospecifcally binds a Therapeutic protein and that corresponds to a Therapeutic protein portion of an albumin fusion protein comprises, or alternatively consists of, one, two, three, four, five, or six VH and/or VL CDRs.
In preferred embodiments, the fragment or variant of an antibody that immunospecifcally binds a Therapeutic protein and that corresponds to a Therapeutic protein portion of ~an albumin fusion protein comprises, or alternatively consists of, an scFv comprising the VH domain of the Therapeutic antibody, linked to the VL
domain of the therapeutic antibody by a peptide linker such as (Gly4Ser)3 (SEQ ID
N0:36). .
Immuriophehotyping The antibodies of the invention or albumin fusion proteins of the, invention comprising at least a fragment or variant of an antibody that binds a Therapeutic protein (or fragment or variant thereof) may be utilized for immunophenotyping of cell lines and biological samples. Therapeutic proteins of the present invention may be useful as cell-specific markers, or more specifically as cellular markers that are differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal - antibodies (or albumin fusion proteins comprsing at least a fragment or variant of an antibody that binds a Therapeutic protein) directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the .
marker.. Various techniques can be utilized using monoclonal antibodies (or albumin fusion proteins comprising at least a fragment or variant of an antibody that binds a Therapeutic protein) to screen for cellular populations expressing the maxker(s), and' include magnetic separation using antibody-coated magnetic beads, "panning"
with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and lVlorrison et al., Cell, 96:737-49 (1999)):
These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i:e. minimal residual disease (IVIRD) in acute leukemic patients) and "non-self' cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as' might be found in human umbilical cord blood.
Characterizing Antibodies that bind a Therapeutic Protein and Albumin Fusion Proteins Comprising a Fragment or Variant of an' Antibody that binds cz Therapeutic Protein The antibodies of the invention or albumin fusion proteins of the invention comprising at least a fragment or variant of an antibody that binds a Therapeutic protein (or fragment or variant_thereofJ may be characterized in a variety of ways. In particular, Albumin fusion proteins of the invention comprising at least a fragment or variant of an antibody that binds a Therapeutic protein may be assayed for the ability to specifically bind to the same antigens specifically bound by the antibody that binds a Therapeutic protein corresponding to- the antibody that binds a Therapeutic protein portion of the albumin fusion protein using techniques described herein or routinely modifying techniques known in the art.
Assays for the ability of the antibodies of the invention or albumin fusion proteins of the invention comprising at least a fragment or variant of an antibody that binds a Therapeutic protein (or fragment or variant thereof) to (specifically) bind a specific protein or epitope . may be performed in solution (e.g., Houghten, Bio/Techniques 13:412-421(1992)), on beads (e.g., Lam, Nature 354:82-84 (199'1)), on chips (e.g., Fodor, Nature 364:555-556 (1993)), on bacteria (e.g., U.S. Patent No. 5,223,409), on spores (e.g., Patent Nos. 5,571,698; 5,403,484; and 5,223,409), on plasmids (e.g., Cull et al., Proc.
Natl. Acad. Sci. USA 89:1865-1869 (1992)) or on phage (e.g., Scott and Smith, Science 249:386-390 (1990); Devlin, Science 249:404-406 (1990); Cwirla et al., Proc.
Natl. Acad.-Sci. USA 87:6378-6382 (1990); and Felici, J. Mol. Biol. 222:301-310 (1991)) (each of these references is incorporated herein in its entirety by reference). The antibodies of the invention or albumin fusion proteins of the invention comprising at least a fragment or variant of an antibody that binds a Therapeutic protein (or fragment or variant thereof) may also be assayed for theix specificity and affnity for a specific protein or epitope using or routinely modifying techniques described herein or otherwise known in the art.
The albumin fusion proteins of-the invention comprising at least a fragment or variant of an antibody that binds a Therapeutic protein may be assayed for cross-reactivity with other antigens (e.g., molecules that have sequence/stnlcture conservation with the, molecules) specifically bound by the antibody that binds a Therapeutic protein (or fragment or variant thereof) corresponding to the Therapeutic protein portion of the albumin fusion protein of the invention) by any method known in the art.
Immunoassays which can be used to analyze (imrnunospecific) binding and cross-' reactivity include, but are not limited to, competitive and non-competitive assay systems ~ using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, and protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. l, John Wiley & Sons Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).
Irnmunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer ( 1 % NP-40 or Triton X-100, 1 % sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented '- with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding an antibody of the invention or albumin fusion protein.of the invention comprising at least a fragment or variant of an antibody that binds a Therapeutic protein (or fragment or variant thereof) to the cell. lysate, incubating for a period of time (e.g., 1 to 4 hours) at 40 degrees C, adding protein A and/or protein G sepharose beads (or beads coated with an~ appropriate anti-iditoypic antibody or anti-albumin antibody in the case when an albumin fusion protein comprising at least a fragment or variant of a Therapeutic antibody) to the cell lysate, incubating for about an hour or more at 40 degrees C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody or albumin fusion protein of the invention to _immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody or albumin fusion protein to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. l, John Wiley & Sons, Inc., New York at 10.16.1.
Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20%
SDS-PAGE
depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3%. BSA or non-fat rnilk), washing the membrane in washing buffer (e.g., PBS-Tween 20), .applying the antibody or albumin fusion protein of the invention (diluted in blocking buffer) to the membrane, washing the membrane in washing buffer, applying ~a secondary antibody (which recognizes the albumin fusion,protein, e.g., an anti-human serum albumin antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., 3aP or 1z5~ diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol~.
l, John Wiley & Sons, Inc., New York at 10.8.1.
ELISAs comprise preparing antigen, coating the well of a 96-well microtiter plate with the antigen, washing away antigen that did not bind the wells, adding the antibody or albumin fusion protein (comprising at least a fragment or variant of an antibody that binds a Therapeutic protein) :of the invention conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the wells and incubating for a period of time, washing away unbound or non-specifically bound albumin fusion proteins, and detecting the presence. of the antibody or albumin fusion proteins specifically bound to the antigen coating the well. In ELISAs the antibody or albumin fusion protein does not have to be conjugated to a detectable compound;
instead, a second antibody . (which recognizes the antibody or 'albumin fusion protein, respectively) '' conjugated to a detectable compound may be added to the.well. Further, instead of coating DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

~~ TTENANT LES PAGES 1 A 221 NOTE : Pour les tomes additionels, veuillez contacter 1e Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME
NOTE POUR LE TOME / VOLUME NOTE:

Claims (36)

What is claimed:
1. An albumin fusion protein comprising a Therapeutic protein:X and albumin comprising the amino acid sequence of SEQ ID NO:18.
2. An albumin fusion protein comprising a Therapeutic protein:X and a fragment or a variant of the amino acid sequence of SEQ ID NO:18, wherein said fragment or variant has albumin activity.
3. The albumin fusion protein of claim 2, wherein said albumin activity is the ability to prolong the shelf life of the Therapeutic protein:X compared to the shelf-life of the Therapeutic protein:X in an unfused state.
4. The albumin fusion protein of claim 2, wherein the fragment or variant comprises the amino acid sequence of amino acids 1-387 of SEQ ID NO:18.
5. An albumin fusion protein comprising a fragment or variant of a Therapeutic protein:X, and albumin comprising the amino acid sequence of SEQ
ID
NO:18, wherein said fragment or variant has a biological activity of the Therapeutic protein:X.
6. The albumin fusion protein of any one of claims 1-5, wherein the Therapeutic protein:X, or fragment or variant thereof, is fused to the N-terminus of albumin, or the N-terminus of the fragment or variant of albumin.
7. The albumin fusion protein of any one of claims 1-5, wherein the Therapeutic protein:X, or fragment or variant thereof, is fused to the C-terminus of albumin, or the C-terminus of the fragment or variant of albumin.
8. The albumin fusion protein of any one of claims 1-5, wherein the Therapeutic protein:X, or fragment or variant thereof, is fused to the N-terminus and C-terminus of albumin, or the N-terminus and the C-terminus of the fragment or variant of albumin.
9. The albumin fusion protein of any one of claims 1-5, which comprises a first Therapeutic protein:X, or fragment or variant thereof, and a second Therapeutic protein:X, or fragment or variant thereof, wherein said first Therapeutic protein:X, or fragment or variant thereof, is different from said second Therapeutic protein:X, or fragment or variant thereof.
10. The albumin fusion protein of any one of claims 1-8, wherein the Therapeutic protein:X, or fragment or variant thereof, is separated from the albumin or the fragment or variant of albumin by a linker.
11. The albumin fusion protein of any one of claims 1-8, wherein the albumin fusion protein has the following formula:
R1-L-R2; R2-L-R1; or R1-L-R2-L-R1, wherein R1 is Therapeutic protein:X, or fragment or variant thereof, L is a peptide linker, and R2 is albumin comprising the amino acid sequence of SEQ ID NO:18 or fragment or variant of albumin.
12. The albumin fusion protein of any one of claims 1-11, wherein the shelf-life of the albumin fusion protein is greater than the shelf-life of the Therapeutic protein:X
in an unfused state.
13. The albumin fusion protein of any one of claims 1-11, wherein the in vitro biological activity of the Therapeutic protein:X, or fragment or variant thereof, fused to albumin, or fragment or variant thereof, is greater than the in vitro biological activity of the Therapeutic protein:X, or a fragment or variant thereof, in an unfused state.
14. The albumin fusion protein of any one of claims 1-11, wherein the in vivo biological activity of the Therapeutic protein:X, or fragment or variant thereof, fused to albumin, or fragment or variant thereof, is greater than the in vivo biological activity of the Therapeutic protein:X , or a fragment or variant thereof, in an unfused state.
15. An albumin fusion protein comprising a Therapeutic protein:X, or fragment or variant thereof, inserted into an albumin comprising the amino acid sequence of SEQ
ID NO:18 or fragment or variant thereof.
16. An albumin fusion protein comprising a Therapeutic protein:X, or fragment or variant thereof, inserted into an albumin comprising an amino acid sequence selected from the group consisting of:

(a) amino acids 54 to 61 of SEQ ID NO:18;
(b) amino acids 76 to 89 of SEQ ID NO:18;
(c) amino acids 92 to100 of SEQ ID NO:18; .
(d) amino acids 170 to 176 of SEQ ID NO:18;
(e) amino acids 247 to 252 of SEQ ID NO:18;
(f) amino acids 266 to 277 of SEQ ID NO:18;
(g) amino acids 280 to 288 of SEQ ID NO:18;
(h) amino acids 362 to 368 of SEQ ID NO:18;
(l) amino acids 439 to 447 of SEQ ID NO:18;
(j) amino acids 462 to 475 of SEQ ID NO:18;
(k) amino acids 478 to 486 of SEQ ID NO:18; and (l) amino acids 560 to 566 of SEQ ID NO:18.
17. The albumin fusion protein of claims 15 or 16, wherein said albumin fusion protein comprises a portion of albumin sufficient to prolong the shelf-life of the Therapeutic protein:X, or fragment or variant thereof, as compared to the shelf-life of the Therapeutic protein:X , or a fragment or variant thereof, in an unfused state.
18. The albumin fusion protein of claims 15 or 16, wherein said albumin fusion protein comprises a portion of albumin sufficient to prolong the in vitro biological activity of the Therapeutic protein:X, or fragment or variant thereof, fused to albumin as compared to the in vitro biological activity of the Therapeutic protein:X , or a fragment or variant thereof, in an unfused state.
19. The albumin fusion protein of claims 15 or 16 wherein said albumin fusion protein comprises a portion, of albumin sufficient to prolong the in vivo biological activity of the Therapeutic protein:X, or fragment or variant thereof, fused to albumin compared to the in vivo biological activity of the Therapeutic protein:X , or a fragment or variant thereof, in an unfused state.
20. The albumin fusion protein of any one of claims 1-19, which is non-glycosylated.
21. The albumin fusion protein of any one of claims 1-19, which is expressed in yeast.
22. The albumin fusion protein of claim 21, wherein the yeast is glycosylation deficient.
23. The albumin fusion protein of claim 21 wherein the yeast is glycosylation and protease deficient.
24. The albumin fusion protein of any one of claims 1-19, which is expressed by a mammalian cell.
25. The albumin fusion protein of any one of claims 1-19, wherein the albumin fusion protein is expressed by a mammalian cell in culture.
26. The albumin fusion protein of any one of claims 1-19, wherein the albumin fusion protein further comprises a secretion leader sequence.
27. A composition comprising the albumin fusion protein of any one of claims 1-26 and a pharmaceutically acceptable carrier.
28. A kit comprising the composition of claim 27.
29. A method of treating a disease or disorder in a patient, comprising the step of administering the albumin fusion protein of any one of claims 1-26.
30. The method of claim 29, wherein the disease or disorder comprises indication:Y.
31. A method of treating a patient with a disease or disorder that is modulated by Therapeutic protein:X, or fragment or variant thereof, comprising the step of administering an effective amount of the albumin fusion protein of any one of claims 1-26.
32. The method of claim 31, wherein the disease or disorder is indication:Y.
33. A method of extending the shelf life of Therapeutic protein:X comprising the step of fusing the Therapeutic protein:X, or fragment or variant thereof, to albumin or a fragment or variant thereof, sufficient to extend the shelf-life of the Therapeutic protein:X, or fragment or variant thereof, compared to the shelf-life of the Therapeutic protein:X , or a fragment or variant thereof, in an unfused state.
34. A nucleic acid molecule comprising a polynucleotide sequence encoding the albumin fusion protein of any one of claims 1-26.
35. A vector comprising the nucleic acid molecule of claim 34.
36. A host cell comprising the nucleic acid molecule of claim 35.
CA002405912A 2000-04-12 2001-04-12 Albumin fusion proteins Abandoned CA2405912A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22935800P 2000-04-12 2000-04-12
US19938400P 2000-04-25 2000-04-25
US25693100P 2000-12-21 2000-12-21
PCT/US2001/011988 WO2001077137A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins

Publications (1)

Publication Number Publication Date
CA2405912A1 true CA2405912A1 (en) 2001-10-18

Family

ID=27394014

Family Applications (8)

Application Number Title Priority Date Filing Date
CA002405912A Abandoned CA2405912A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405525A Abandoned CA2405525A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405550A Abandoned CA2405550A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405563A Abandoned CA2405563A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA2405557A Expired - Lifetime CA2405557C (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405709A Abandoned CA2405709A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA2747325A Abandoned CA2747325A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405701A Withdrawn CA2405701A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins

Family Applications After (7)

Application Number Title Priority Date Filing Date
CA002405525A Abandoned CA2405525A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405550A Abandoned CA2405550A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405563A Abandoned CA2405563A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA2405557A Expired - Lifetime CA2405557C (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405709A Abandoned CA2405709A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA2747325A Abandoned CA2747325A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
CA002405701A Withdrawn CA2405701A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins

Country Status (10)

Country Link
US (23) US6905688B2 (en)
EP (21) EP1278544A4 (en)
JP (9) JP2003530847A (en)
AU (7) AU2001259063A1 (en)
BE (1) BE2016C059I2 (en)
CA (8) CA2405912A1 (en)
DK (2) DK2236152T3 (en)
ES (2) ES2529300T3 (en)
FR (1) FR16C0043I2 (en)
WO (7) WO2001079480A1 (en)

Families Citing this family (639)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
WO2002018435A1 (en) * 2000-08-28 2002-03-07 Human Genome Sciences, Inc. 18 human secreted proteins
WO2001034627A1 (en) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 28 human secreted proteins
WO2001032910A2 (en) * 1999-10-29 2001-05-10 Human Genome Sciences, Inc. 27 human secreted proteins
WO2002024719A1 (en) * 2000-09-20 2002-03-28 Human Genome Sciences, Inc. 21 human secreted proteins
WO2001034769A2 (en) * 1999-11-05 2001-05-17 Human Genome Sciences, Inc. 24 human secreted proteins
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP0892047A3 (en) * 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Human and murine semaphorin L
US20030170794A1 (en) * 1997-09-18 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050181482A1 (en) * 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
US6548653B1 (en) * 1998-06-15 2003-04-15 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
US20040199099A1 (en) * 1998-07-10 2004-10-07 Matson James R Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
EP1121425B1 (en) 1998-10-13 2005-06-29 The University Of Georgia Research Foundation, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
EP1696038B1 (en) * 1999-05-05 2010-06-02 Phylogica Limited Isolating biological modulators from biodiverse gene fragment libraries
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US20020049312A1 (en) * 2000-05-23 2002-04-25 Turner C. Alexander Noel human thrombospondin-like proteins and polynucleotides encoding the same
AU1449001A (en) * 1999-11-05 2001-06-06 Human Genome Sciences, Inc. 28 human secreted proteins
ES2629683T3 (en) 1999-11-30 2017-08-14 Mayo Foundation For Medical Education And Research B7-H1, a new immunoregulatory molecule
CA2390691C (en) 1999-12-24 2016-05-10 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US7534417B2 (en) 2000-02-24 2009-05-19 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
US7291122B2 (en) * 2000-03-24 2007-11-06 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
CA2405912A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
EP1285066A1 (en) * 2000-05-12 2003-02-26 MERCK PATENT GmbH F-box containing protein
US6787040B2 (en) * 2000-05-16 2004-09-07 Immunocept, L.L.C. Method and system for colloid exchange therapy
ATE385504T1 (en) 2000-06-06 2008-02-15 Bristol Myers Squibb Co NUCLEIC ACIDS AND POLYPEPTIDES RELATED TO B7 AND THEIR USES FOR IMMUNE MODULATION
AU2001275401A1 (en) * 2000-06-08 2001-12-17 Incyte Genomics, Inc. Intracellular signaling proteins
EP1294871A1 (en) * 2000-06-21 2003-03-26 Amgen, Inc. Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof
CA2418680A1 (en) * 2000-08-18 2002-02-28 Human Genome Sciences, Inc. 11 human secreted proteins
CA2419306A1 (en) * 2000-08-18 2002-02-28 Human Genome Sciences, Inc. 23 human secreted proteins
AU2001229507A1 (en) * 2000-08-18 2002-03-04 Human Genome Sciences, Inc. 21 human secreted proteins
CA2421147A1 (en) * 2000-09-29 2002-04-11 Human Genome Sciences, Inc. 24 human secreted proteins
CA2425827A1 (en) * 2000-10-12 2002-04-18 Hyseq, Inc. Novel nucleic acids and polypeptides
US6531297B2 (en) * 2000-10-20 2003-03-11 Applera Corporation Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
US6949371B2 (en) 2000-10-20 2005-09-27 Applera Corporation Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
FR2815964A1 (en) * 2000-10-30 2002-05-03 Inst Nat Sante Rech Med RENIN AND / OR PRORENIN RECEPTOR PROTEIN, NUCLEIC ACID ENCODING THE RECEPTOR AND THEIR APPLICATIONS
EP1395657B1 (en) 2000-12-05 2007-04-18 Wisconsin Alumni Research Foundation Receptor for bacillus anthracis toxin
CA2434237C (en) 2000-12-07 2012-05-15 Eli Lilly And Company Glp-1 fusion proteins
US20030148920A1 (en) * 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
EP1354950A4 (en) * 2000-12-28 2005-01-12 Asahi Kasei Pharma Corp Nf-kb activating gene
CA2433469A1 (en) * 2001-02-23 2002-09-06 Human Genome Sciences, Inc. 83 human secreted proteins
EP1365801A4 (en) * 2001-03-08 2004-10-13 Nuvelo Inc Methods and materials relating to fibulin-like polypeptides and polynucleotides
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) * 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20030125521A1 (en) 2001-06-20 2003-07-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20040234537A1 (en) * 2001-07-06 2004-11-25 Lydie Bougueleret Carcinoma-related peptides
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
AU2002332041A1 (en) * 2001-10-05 2003-04-22 Human Genome Sciences, Inc. Albumin fusion proteins
DE10251673A1 (en) 2001-11-09 2003-07-10 Hoffmann La Roche Alström syndrome gene, gene variants, encoded protein and method for diagnosing Alström syndrome
KR100406760B1 (en) * 2001-11-16 2003-11-21 신코엠 주식회사 Semiconductor memory device
DE60231057D1 (en) 2001-12-17 2009-03-19 Serono Lab CHEMOKINE MUTANTS WORKING AS CHEMOKINE ANTAGONISTS
US20040082761A1 (en) * 2001-12-18 2004-04-29 Duggan Brendan M. Cell adhesion proteins
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
KR101271635B1 (en) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
WO2005003296A2 (en) * 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
ES2545090T3 (en) * 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Albumin and GCSF fusion proteins
US20060253913A1 (en) * 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
US7081446B2 (en) * 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
CA2485064A1 (en) * 2002-02-07 2003-08-14 Delta Biotechnology Limited Albumin-fused kunitz domain peptides
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
US20060241027A1 (en) * 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
DE10205520A1 (en) * 2002-02-08 2003-08-14 Aventis Behring Gmbh Inhibitory, monoclonal antibody against the clotting factor VII activating protease
WO2003072714A2 (en) * 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
EP1483580A4 (en) * 2002-03-05 2006-10-11 Merck & Co Inc Biomarker for efficacy of appetite suppressant drugs
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
CA2482856A1 (en) * 2002-04-15 2003-10-30 American National Red Cross Plasma protein-binding ligands
US20070015230A1 (en) * 2002-04-15 2007-01-18 Hammond David J Identification and characterization of analytes from whole blood
US7319138B2 (en) 2002-04-18 2008-01-15 The General Hospital Corporation Human DRG11-Responsive Axonal Guidance and Outgrowth of Neurite (DRAGON) proteins and variants thereof
US7141381B2 (en) 2002-04-25 2006-11-28 Bristol-Myers Squibb Company Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
GB0210464D0 (en) * 2002-05-08 2002-06-12 Svanborg Catharina Therapeutic treatment
ES2381265T3 (en) * 2002-06-07 2012-05-24 Zymogenetics, Inc. Use of IL-21 and monoclonal antibody to treat solid cancers
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK2298278T3 (en) 2002-06-07 2016-02-01 Dyax Corp Prevention and reduction of blood loss and inflammatory response
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
CN1241946C (en) * 2002-07-01 2006-02-15 美国福源集团 Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells
CN101172091B (en) * 2007-09-25 2011-04-27 北京美福源生物医药科技有限公司 Technique for preparing amalgamation protein skin-protection product containing albuminar and skin cell growth factor, and uses of the same
KR100711145B1 (en) * 2002-07-03 2007-04-24 (주)넥스젠 Fusion Polypeptide Comprising Epidermal Growth Factor and Human Serum Albumin
WO2004004649A2 (en) * 2002-07-08 2004-01-15 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004009626A1 (en) * 2002-07-22 2004-01-29 Yamanouchi Pharmaceutical Co., Ltd. Novel gene associated with rheumatoid arthritis
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
WO2004015113A2 (en) * 2002-08-07 2004-02-19 Delta Biotechnology Ltd. Albumin-fused ciliary neurotrophic factor
AU2003255276A1 (en) * 2002-08-13 2004-02-25 Arbios Systems, Inc. Selective plasma exchange therapy
CA2496789C (en) 2002-08-28 2013-12-17 Dyax Corp. Methods for preserving organs and tissues
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20040115194A1 (en) * 2002-09-06 2004-06-17 Yi Wang Method of treatment of asthma using antibodies to complement component C5
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
EP1539959A2 (en) * 2002-09-18 2005-06-15 Centre Hospitalier de l'Université de Montréal (CHUM) Ghrh analogues
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
AU2003292273A1 (en) * 2002-12-20 2004-07-14 Karolinska Institutet Innovations Ab Asthma susceptibility locus
KR20050085881A (en) * 2002-12-26 2005-08-29 다케다 야쿠힌 고교 가부시키가이샤 Novel proteins and use thereof
NZ603330A (en) * 2003-02-11 2015-02-27 Shire Human Genetic Therapies Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
AU2004220525B2 (en) * 2003-03-12 2011-03-31 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US20070041987A1 (en) * 2003-03-19 2007-02-22 Daniel Carter Fragments or polymers of albumin with tunable vascular residence time for use in therapeutic delivery and vaccine development
JP2007527206A (en) * 2003-04-04 2007-09-27 ユニバーシティ オブ ローザンヌ Peptabody for cancer treatment
KR20110094361A (en) 2003-04-11 2011-08-23 메디뮨 엘엘씨 Recombinant il-9 antibodies and uses thereof
WO2004094589A2 (en) * 2003-04-18 2004-11-04 Incyte Corporation Secreted proteins
WO2004101620A2 (en) * 2003-05-01 2004-11-25 Compound Therapeutics, Inc. Serum albumin scaffold-based proteins and uses thereof
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
EP1650302B1 (en) * 2003-06-30 2012-03-21 Nihon University Protein capable of deposition onto extracellular matrix
EP1644408A1 (en) 2003-07-15 2006-04-12 Barros Research Institute Eimeria tenella antigen for immunotherapy of coccidiosis
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
GB0320877D0 (en) * 2003-09-05 2003-10-08 Celltech R&D Ltd A protein involved in carcinoma
PL2149585T3 (en) 2003-11-04 2014-01-31 Novartis Vaccines & Diagnostics Inc Use of antagonistic anti-CD40 monoclonal antibodies
ES2380022T3 (en) * 2003-12-03 2012-05-07 Monika KRÖZ Interleukin-11 fusion proteins
CN100379762C (en) * 2003-12-08 2008-04-09 中国人民解放军军事医学科学院生物工程研究所 Interfusion protein between human serum albumin and interleukin, and encoding genes
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
WO2005058961A2 (en) 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
US9057061B2 (en) 2003-12-23 2015-06-16 Novozymes Biopharma Dk A/S Gene expression technique
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
CA2551546A1 (en) * 2003-12-24 2005-07-07 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
AU2005211725B2 (en) 2004-02-09 2010-07-15 Human Genome Sciences, Inc. Albumin fusion proteins
SE0400489D0 (en) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins
WO2005085472A2 (en) * 2004-03-03 2005-09-15 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases
CA2558439A1 (en) * 2004-03-11 2005-10-06 Kythera Biopharmaceuticals, Inc. Compositions and methods for preventing and treating skin and hair conditions
US20050201959A1 (en) * 2004-03-11 2005-09-15 Vvii Newco 2003, Inc. Methods and compositions for altering skin coloration
CN102718867A (en) 2004-03-12 2012-10-10 瓦斯基因治疗公司 Polypeptide compound for inhibiting angiogenesis and tumor growth
CA2604243C (en) 2004-04-14 2015-11-24 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
BRPI0510117A (en) * 2004-04-23 2007-09-25 Conjuchem Biotechnologies Inc method for purification of albumin conjugates
KR100599454B1 (en) * 2004-04-27 2006-07-12 재단법인서울대학교산학협력재단 3 Novel use of AIM3 acting as a tumor suppressor
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
WO2005121758A1 (en) * 2004-06-03 2005-12-22 Ciphergen Biosystems, Inc. Biomarkers for peripheral artery disease
CN101005828B (en) * 2004-06-17 2012-01-11 维尔恩公司 Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
EP1773375A1 (en) 2004-07-14 2007-04-18 University of Utah Research Foundation Netrin-related compositions and uses
CN102680686A (en) * 2004-08-13 2012-09-19 千年药品公司 Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2006034292A2 (en) 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20060204512A1 (en) * 2004-09-23 2006-09-14 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006039504A2 (en) * 2004-10-01 2006-04-13 Cell Ionix, Inc. Method and formulation for stem cells’ stimulation
CA2943949C (en) * 2004-10-06 2020-03-31 Mayo Foundation For Medical Education And Research B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
WO2006042197A2 (en) * 2004-10-11 2006-04-20 The Board Of Trustees Of The Leland Standford Junior University Use of del-1 in hair, bone and cartilage regeneration
WO2006046239A2 (en) * 2004-10-25 2006-05-04 Immune System Key Ltd A thymus-specific protein
KR100583350B1 (en) * 2004-11-03 2006-06-05 (주)넥스젠 -1 Method for Producing Epidermal Growth Factor Using Fusion Proteins Comprising Fas-1 Domain
CN101087805B (en) * 2004-11-09 2012-05-23 阿雷斯贸易股份有限公司 Method for purifying FSH
EP2446897A1 (en) 2005-01-06 2012-05-02 Novo Nordisk A/S Anti-KIR combination treatments and methods
US20060178301A1 (en) * 2005-02-04 2006-08-10 Mathias Jurs Albumin-fused ciliary neurotrophic factor
JP5651285B2 (en) 2005-02-15 2015-01-07 デューク ユニバーシティ Anti-CD19 antibodies and use in oncology
US20110230407A1 (en) * 2005-03-14 2011-09-22 Alexander Yuzhakov Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
AU2006226878A1 (en) * 2005-03-23 2006-09-28 Wyeth Detection of GDF-8 modulating agents
AU2006232914A1 (en) * 2005-03-23 2006-10-12 Wyeth Detection of an immune response to GDF-8 modulating agents
JP2008538290A (en) 2005-04-18 2008-10-23 ノボ ノルディスク アクティーゼルスカブ IL-21 mutant
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
JP5129122B2 (en) 2005-04-26 2013-01-23 トリオン ファーマ ゲーエムベーハー Combination of antibodies and glucocorticoids for cancer treatment
US8653028B2 (en) * 2005-04-29 2014-02-18 Rui Rong Yuan Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9585932B2 (en) 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
US9345745B2 (en) 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
AU2006244445B2 (en) 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
WO2007149067A2 (en) * 2005-05-12 2007-12-27 Zymogenetics, Inc. Methods of using phhla2 to co-stimulate t-cells
SI1907000T2 (en) 2005-06-08 2020-07-31 Dana-Farber Cancer Institute Methods and compositions for the treatment of persistent HIV infections by inhibiting the programmed cell death 1 (PD-1) pathway
WO2007014167A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions for and methods of treating epithelial diseases with growth factors
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
RS57549B1 (en) * 2005-08-26 2018-10-31 Ares Trading Sa Process for the preparation of glycosylated interferon beta
US7713715B2 (en) * 2005-09-06 2010-05-11 University Of Tennessee Research Foundation Method for diagnosing infections
AU2006294644A1 (en) * 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007040437A1 (en) * 2005-10-03 2007-04-12 Astrazeneca Ab Fusion proteins having a modulated half-life in plasma
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US8604175B2 (en) * 2005-12-09 2013-12-10 Ares Trading S.A. Method for purifying FSH or a FSH mutant
KR20080079301A (en) * 2005-12-09 2008-08-29 시애틀 지네틱스, 인크. Methods of using cd40 binding agents
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
JP2009520469A (en) * 2005-12-22 2009-05-28 コンジュクヘム ビオテクフノロギエス インコーポレイテッド Method for the production of preformed conjugates of albumin and therapeutic agents
US20090215084A1 (en) * 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
WO2007082144A2 (en) * 2006-01-05 2007-07-19 Mayo Foundation For Medical Education And Research B7-h1 and survivin in cancer
AU2007207544A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007097961A1 (en) * 2006-02-16 2007-08-30 Massachusetts Eye & Ear Infirmary Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
US8389688B2 (en) 2006-03-06 2013-03-05 Aeres Biomedical, Ltd. Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
KR20090005315A (en) * 2006-04-05 2009-01-13 애보트 바이오테크놀로지 리미티드 Antibody purification
DK2007885T3 (en) * 2006-04-11 2010-11-08 Csl Behring Gmbh Method for enhancing the in vivo recovery of therapeutic polypeptides
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
AU2013202566C1 (en) * 2006-06-14 2018-07-12 Csl Behring Gmbh Proteolytically cleavable fusion protein comprising a blood coagulation factor
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP1867660A1 (en) 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
AU2007260185B2 (en) 2006-06-14 2013-01-31 Csl Behring Gmbh Proteolytically cleavable fusion protein comprising a blood coagulation factor
CA2657277C (en) * 2006-07-13 2015-11-24 Upperton Limited Process for preparing particles of proteinaceous material
CA2658654A1 (en) 2006-07-24 2008-01-31 Biorexis Pharmaceutical Corporation Exendin fusion proteins
US20090208480A1 (en) * 2006-08-04 2009-08-20 Yue Huang Long half-life recombinant butyrylcholinesterase
CA2663047A1 (en) * 2006-09-06 2008-03-13 Phase Bioscience, Inc. Therapeutic elastin-like polypeptide (elp) fusion proteins
JP5840345B2 (en) 2006-09-08 2016-01-06 アンブルックス, インコーポレイテッドAmbrx, Inc. Modified human plasma polypeptides or modified human Fc scaffold proteins and uses thereof
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
AR063384A1 (en) * 2006-10-25 2009-01-28 Amgen Inc THERAPEUTIC AGENTS BASED ON PEPTIDES DERIVED FROM TOXINS
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
CN101636179B (en) 2006-11-07 2012-10-10 默沙东公司 Antagonists of pcsk9
JP5492563B2 (en) 2006-12-12 2014-05-14 バイオレクシス ファーマシューティカル コーポレーション Transferrin fusion protein library
WO2008074839A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
EP2097096B1 (en) * 2006-12-22 2017-05-31 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
EP1935430A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
WO2008094538A2 (en) 2007-01-30 2008-08-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
US8283319B2 (en) 2007-02-12 2012-10-09 Csl Behring Gmbh Therapeutic application of Kazal-type serine protease inhibitors
WO2008118386A2 (en) 2007-03-27 2008-10-02 Merck & Co., Inc. Method for detecting autoprocessed, secreted pcsk9
KR20100017514A (en) 2007-05-07 2010-02-16 메디뮨 엘엘씨 Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
NZ599278A (en) 2007-05-14 2013-12-20 Medimmune Llc Methods of reducing eosinophil levels
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2514762B1 (en) 2007-07-13 2015-04-08 The Johns Hopkins University B7-DC variants
AU2008275911A1 (en) * 2007-07-19 2009-01-22 Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University Self- anchoring MEMS intrafascicular neural electrode
EP2185701A4 (en) * 2007-08-15 2011-03-02 Amunix Operating Inc Compositions and methods for modifying properties of biologically active polypeptides
CN111909273B (en) 2007-08-29 2024-03-26 塞诺菲-安万特股份有限公司 humanized anti-CXCR 5 antibodies, derivatives thereof and uses thereof
JP2009055838A (en) * 2007-08-31 2009-03-19 Nipro Corp Fusion protein, gene related to the fusion protein, vector, transformant and anti-inflammatory medicinal composition
EP2853267B1 (en) * 2007-09-21 2016-12-07 The Regents of the University of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JP2011500757A (en) * 2007-10-22 2011-01-06 メルク セローノ ソシエテ アノニム Method for purifying Fc-containing protein
CA2702448A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying fc-fusion proteins
JP5490714B2 (en) 2007-11-28 2014-05-14 メディミューン，エルエルシー Protein preparation
EP3211010A1 (en) 2007-12-21 2017-08-30 Medimmune Limited Binding members for interleukin-4 receptor alpha (il-4r) - 173
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US20100311072A1 (en) * 2008-01-28 2010-12-09 Bristol-Myers Squibb Company Fluorescence polarization binding assay for characterizing glucokinase ligands
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
WO2009111315A2 (en) * 2008-02-29 2009-09-11 Mayo Foundation For Medical Education And Research Methods for reducing granulomatous inflammation
JP5020135B2 (en) * 2008-03-19 2012-09-05 ソニーモバイルコミュニケーションズ， エービー Portable terminal device and computer program
WO2009121884A1 (en) 2008-04-01 2009-10-08 Novo Nordisk A/S Insulin albumin conjugates
EP2260058A2 (en) 2008-04-07 2010-12-15 Ablynx N.V. Single variable domains against the notch pathways
ES2620285T3 (en) 2008-05-02 2017-06-28 Novartis Ag Binding molecules based on improved fibronectin and their uses
KR101648734B1 (en) * 2008-06-24 2016-08-18 체에스엘 베링 게엠베하 Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
AU2013202564B2 (en) * 2008-06-24 2015-09-17 Csl Behring Gmbh Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
JP2011526303A (en) 2008-06-27 2011-10-06 デューク ユニバーシティ A therapeutic agent containing an elastin-like peptide
WO2010005580A2 (en) * 2008-07-10 2010-01-14 Angion Biomedica Corp. Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
EP2313436B1 (en) 2008-07-22 2014-11-26 Ablynx N.V. Amino acid sequences directed against multitarget scavenger receptors and polypeptides
SG10201405377XA (en) 2008-08-05 2014-12-30 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
PE20110435A1 (en) 2008-08-25 2011-07-20 Amplimmune Inc ANTAGONIST COMPOSITIONS OF PD-1
AU2009288289B2 (en) * 2008-08-25 2012-11-08 Amplimmune, Inc. PD-1 antagonists and methods of use thereof
BRPI0823049A2 (en) 2008-09-07 2015-06-16 Glyconex Inc Anti-extended type 1 glycosphingolipid antibodies, derivatives thereof and use.
US20110293605A1 (en) 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
KR20110112301A (en) 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. Human serum albumin linkers and conjugates thereof
AU2009319701B2 (en) 2008-11-28 2014-10-09 Dana-Farber Cancer Institute, Inc. Methods for the treatment of infections and tumors
CN114835812A (en) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 anti-PD-L1 antibodies and their use for enhancing T cell function
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
SG172940A1 (en) 2009-01-16 2011-08-29 Teva Pharma New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CN102348715B (en) 2009-02-03 2017-12-08 阿穆尼克斯运营公司 Extension recombinant polypeptide and the composition for including the extension recombinant polypeptide
JP5936112B2 (en) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ Albumin variants and complexes
CA3018235C (en) 2009-03-20 2021-01-12 Amgen Inc. Carrier immunoglobulins and uses thereof
CN102549012B (en) 2009-05-07 2015-07-01 诺维信生物制药丹麦公司 Method for purifying albumin
US11512326B2 (en) * 2009-05-26 2022-11-29 University Of Florida Research Foundation, Incorporated Small angiotensin peptide expression system in mammalian cells
EP2258398A1 (en) * 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
CN101628346B (en) * 2009-07-25 2012-05-16 大连理工大学 Method for slowing down outlet speed of carbon fiber composite material hand-made hole and buffer device thereof
JP5883384B2 (en) 2009-08-13 2016-03-15 ザ ジョンズ ホプキンス ユニバーシティー How to regulate immune function
US20120148557A1 (en) 2009-08-20 2012-06-14 Ulrich Kronthaler Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US9044580B2 (en) 2009-08-24 2015-06-02 Arsenal Medical, Inc. In-situ forming foams with outer layer
US9173817B2 (en) 2009-08-24 2015-11-03 Arsenal Medical, Inc. In situ forming hemostatic foam implants
US10420862B2 (en) 2009-08-24 2019-09-24 Aresenal AAA, LLC. In-situ forming foams for treatment of aneurysms
US20110202016A1 (en) * 2009-08-24 2011-08-18 Arsenal Medical, Inc. Systems and methods relating to polymer foams
AU2010290077C1 (en) * 2009-08-24 2015-12-03 Bioverativ Therapeutics Inc. Coagulation factor IX compositions and methods of making and using same
US8451450B2 (en) * 2009-09-14 2013-05-28 Bio-Rad Laboratories, Inc. Near real time optical phase conjugation
UY32917A (en) 2009-10-02 2011-04-29 Boehringer Ingelheim Int DLL-4 BINDING MOLECULES
UY32920A (en) 2009-10-02 2011-04-29 Boehringer Ingelheim Int BISPECIFIC UNION MOLECULES FOR ANTI-ANGIOGENESIS THERAPY
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
JP5898082B2 (en) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド Fc region-containing polypeptide exhibiting improved effector function by changing the degree of fucosylation and use thereof
WO2011051278A1 (en) * 2009-10-26 2011-05-05 Externautics S.P.A. Lung tumor markers and methods of use thereof
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
EP2493507A4 (en) 2009-10-30 2013-11-20 Merck Sharp & Dohme Ax213 and ax132 pcsk9 antagonists and variants
GB2488077A (en) 2009-10-30 2012-08-15 Novozymes Biopharma Dk As Albumin variants
EP2493505A4 (en) 2009-10-30 2013-06-12 Merck Sharp & Dohme Ax1 and ax189 pcsk9 antagonists and variants
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
CA2817671A1 (en) * 2009-11-17 2011-05-26 Universite De Montreal Heteropeptides useful for reducing nonspecific adsorption
EA025416B1 (en) * 2009-12-06 2016-12-30 Байоджен Хемофилия Инк. Method for preventing or treating bleeding episodes using a long-acting factor viii chimeric polypeptide
EP2509616A4 (en) 2009-12-08 2013-05-29 Teva Pharma Bche albumin fusions for the treatment of cocaine abuse
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
WO2011084145A2 (en) 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
ES2688093T3 (en) 2010-01-06 2018-10-30 Dyax Corp. Plasma kallikrein binding proteins
AR079944A1 (en) 2010-01-20 2012-02-29 Boehringer Ingelheim Int NEUTRALIZING ANTIBODY OF THE ACTIVITY OF AN ANTICOAGULANT
CN102834109B (en) 2010-01-22 2016-01-20 诺沃—诺迪斯克保健股份有限公司 Stable growth hormone compound
JP5980689B2 (en) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Stable growth hormone compound
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011100460A2 (en) * 2010-02-11 2011-08-18 Ecole Polytechnique Federale De Lausanne Ccr7 ligand delivery and co-delivery in immunotherapy
JP5826194B2 (en) 2010-03-03 2015-12-02 アブリンクス ナームローゼ フェンノートシャップ Biparatopic A-beta binding polypeptide
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
CN106977608A (en) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 Albumin derivant and variant
ES2659406T3 (en) 2010-05-06 2018-03-15 Novartis Ag Compositions and methods of use for therapeutic antibodies against protein 6 related to low density lipoproteins (LRP6)
AU2011249782B2 (en) 2010-05-06 2014-10-02 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
NZ603570A (en) 2010-05-20 2014-12-24 Ablynx Nv Biological materials related to her3
WO2012006623A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
AU2011274414B2 (en) 2010-07-09 2016-10-06 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN103080134B (en) 2010-08-20 2015-11-25 诺华股份有限公司 The antibody of EGF-R ELISA 3 (HER3)
PE20140190A1 (en) 2010-08-27 2014-02-10 Stem Centrx Inc NOTUM PROTEIN MODULATORS AND METHODS OF USE
US9458231B2 (en) 2010-09-03 2016-10-04 Stemcentrx, Inc. Modulators and methods of use
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
EA201370076A1 (en) 2010-09-22 2013-08-30 Амген Инк. IMMUNE GLOBULIN TRANSFER AND THEIR APPLICATION
DK3241558T3 (en) 2010-09-28 2021-04-26 Aegerion Pharmaceuticals Inc HIGH RESOLUTION LEPTINES
CA2813466A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids that disrupt major groove binding partner interactions
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
US8853490B2 (en) * 2010-10-26 2014-10-07 Pioneer Hi Bred International Inc Antifungal proteins and methods of use
WO2012059486A1 (en) 2010-11-01 2012-05-10 Novozymes Biopharma Dk A/S Albumin variants
MX352929B (en) 2010-11-05 2017-12-13 Zymeworks Inc Stable heterodimeric antibody design with mutations in the fc domain.
TWI619811B (en) 2010-11-08 2018-04-01 諾華公司 Chemokine receptor binding polypeptides
US9095606B1 (en) 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US9066974B1 (en) 2010-11-13 2015-06-30 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
EP2648748A1 (en) 2010-12-08 2013-10-16 Stem Centrx, Inc. Novel modulators and methods of use
US10393757B2 (en) 2010-12-28 2019-08-27 Dainippon Sumitomo Pharma Co., Ltd. Diagnostic drug and diagnostic method for Alzheimer's disease
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
EP2661450A4 (en) 2011-01-06 2014-04-23 Dyax Corp Plasma kallikrein binding proteins
SA112330278B1 (en) 2011-02-18 2015-10-09 ستيم سينتركس، انك. Novel modulators and methods of use
CA2828405A1 (en) 2011-02-28 2012-09-07 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Apoptosis-inducing molecules and uses therefor
US9499605B2 (en) 2011-03-03 2016-11-22 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
EP2683397B1 (en) 2011-03-09 2017-08-09 CSL Behring GmbH Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
US20130344074A1 (en) 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
EP2686340A2 (en) 2011-03-16 2014-01-22 Amgen Inc. Potent and selective inhibitors of nav1.3 and nav1.7
US9340584B2 (en) 2011-03-29 2016-05-17 The General Hospital Corporation Engineered thioredoxin-like fold proteins
AP2013007046A0 (en) 2011-03-30 2013-08-31 Boehringer Ingelheim Int Anticoagulant antidotes
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20130078247A1 (en) 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
EP2697256A1 (en) 2011-04-15 2014-02-19 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP2515112B1 (en) * 2011-04-22 2015-08-12 Sysmex Corporation Method for electrochemically detecting analyte
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN110272484A (en) 2011-05-05 2019-09-24 阿尔布梅迪克斯医疗有限公司 Albumin variants
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR102231139B1 (en) 2011-06-28 2021-03-24 인히브릭스, 인크. Serpin fusion polypeptides and methods of use thereof
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
BR112014000042A2 (en) 2011-07-05 2017-02-21 Novozymes Biopharma Dk As composition, cell culture medium, use of a composition, and method for culturing cells
CA2840944A1 (en) 2011-07-08 2013-01-17 Bayer Intellectual Property Gmbh Fusion proteins releasing relaxin and uses thereof
US20140256621A1 (en) 2011-07-08 2014-09-11 Astrazeneca Pharmaceuticals Lp Engineered poypeptides having enhanced duration of action and reduced immunogenicity
CA2842323A1 (en) * 2011-07-18 2013-01-24 Arts Biologics A/S Long acting biologically active luteinizing hormone (lh) compound
KR102042982B1 (en) 2011-07-22 2019-11-11 체에스엘 베링 게엠베하 Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN110511939A (en) 2011-10-03 2019-11-29 现代泰克斯公司 Nucleosides, nucleotide and nucleic acid of modification and application thereof
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
CN104053671A (en) 2011-11-01 2014-09-17 生态学有限公司 Antibodies and methods of treating cancer
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
WO2013067055A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Methods of blocking cancer stem cell growth
US8993831B2 (en) * 2011-11-01 2015-03-31 Arsenal Medical, Inc. Foam and delivery system for treatment of postpartum hemorrhage
EP2773669B1 (en) 2011-11-04 2018-03-28 Novartis AG Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
DK2773671T3 (en) 2011-11-04 2021-11-15 Zymeworks Inc DESIGN OF STABLE HETERODIMED ANTIBODY WITH MUTATIONS IN THE FC DOMAIN
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
KR20140103135A (en) 2011-12-05 2014-08-25 노파르티스 아게 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
JP6243345B2 (en) 2011-12-05 2017-12-06 ノバルティス アーゲー Antibody to epidermal growth factor receptor 3 (HER3)
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
CN106831985A (en) 2011-12-21 2017-06-13 诺华股份有限公司 The composition and method of the P factors are targeted for antibody
WO2013093027A1 (en) 2011-12-22 2013-06-27 Csl Behring Gmbh Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
BR112014017165B1 (en) 2012-01-12 2023-05-02 Bioverativ Therapeutics Inc CHIMERIC PROTEIN COMPRISING A FACTOR VIII PROTEIN, PHARMACEUTICAL COMPOSITION, AND USES THEREOF
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
PL2814502T3 (en) * 2012-02-15 2018-02-28 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
NZ722352A (en) 2012-02-15 2022-05-27 Ecole Polytechnique Fed Lausanne Epfl Erythrocyte-binding therapeutics
WO2013122617A1 (en) 2012-02-15 2013-08-22 Amunix Operating Inc. Factor viii compositions and methods of making and using same
BR112014020826A8 (en) 2012-02-24 2017-09-19 Stem Centrx Inc ANTIBODY SPECIFICALLY BINDING TO AN Epitope, NUCLEIC ACID, VECTOR OR HOST CELL, DRUG CONJUGATE ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID ANTIBODY, USE THEREOF, KIT AND METHOD OF PREPARATION OF THE CONJUGATE
CN108610421B (en) 2012-02-27 2022-08-19 阿布林克斯有限公司 CX3CR1 binding polypeptides
CN104736559B (en) 2012-03-16 2022-04-08 阿尔布梅迪克斯医疗有限公司 Albumin variants
GB201204868D0 (en) * 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc Modified polynucleotides for the production of proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
IN2014MN02164A (en) * 2012-04-27 2015-08-28 Cytomx Therapeutics Inc
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US20130336973A1 (en) 2012-05-10 2013-12-19 Zymeworks Inc. Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc Domain
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
IN2014DN09358A (en) 2012-05-30 2015-07-17 Bayer Cropscience Ag
TR201816247T4 (en) 2012-05-30 2018-11-21 Bayer Cropscience Ag The composition comprising a fungicide selected from metalaxyl and metalaxyl-m and a biological control agent.
ES2666502T3 (en) 2012-05-30 2018-05-04 Bayer Cropscience Ag Compositions comprising a biological control agent and an insecticide
KR20150023299A (en) 2012-05-30 2015-03-05 바이엘 크롭사이언스 아게 Composition comprising a biological control agent and a fungicide selected from inhibitors of the ergosterol biosynthesis
PL2854549T3 (en) 2012-05-30 2019-02-28 Bayer Cropscience Ag Composition comprising a biological control agent and fluopicolide
EP3409120A1 (en) 2012-05-30 2018-12-05 Bayer CropScience Aktiengesellschaft Composition comprising a biological control agent and a fungicide
MX356530B (en) 2012-05-30 2018-06-01 Bayer Cropscience Ag Composition comprising a biological control agent and a fungicide selected from inhibitors of amino acid or protein biosynthesis, inhibitors of atp production and inhibitors of the cell wall synthesis.
AR091816A1 (en) 2012-05-30 2015-03-04 Bayer Cropscience Ag COMPOSITION THAT INCLUDES A BIOLOGICAL CONTROL AGENT AND AN INSECTICIDE
MX362859B (en) 2012-05-30 2019-02-20 Bayer Cropscience Ag Compositions comprising a biological control agent and an insecticide.
PT2854547T (en) 2012-05-30 2018-11-16 Bayer Cropscience Ag Composition comprising a biological control agent and trifloxystrobin
EP3205210A1 (en) 2012-05-30 2017-08-16 Bayer CropScience Aktiengesellschaft Composition comprising a biological control agent and a fungicide selected from inhibitors of the succinate dehydrogenase
ES2698951T3 (en) 2012-05-30 2019-02-06 Bayer Cropscience Ag Compositions comprising a biological control agent and an insecticide
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
JP2015521589A (en) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Procoagulant compounds
KR101380740B1 (en) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 Purification of iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
EP4269431A1 (en) 2012-07-11 2023-11-01 Bioverativ Therapeutics Inc. Factor viii complex with xten and von willebrand factor protein, and uses thereof
IN2015DN01115A (en) 2012-07-13 2015-06-26 Zymeworks Inc
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP2917233A1 (en) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Albumin variants
KR102381936B1 (en) 2012-11-13 2022-04-01 비온테크 에스이 Agents for treatment of claudin expressing cancer diseases
PT2922554T (en) 2012-11-26 2022-06-28 Modernatx Inc Terminally modified rna
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
CN104968678B (en) 2012-12-05 2018-12-11 诺华股份有限公司 Target the composition and method of the antibody of EPO
EP2935311B1 (en) 2012-12-20 2021-03-31 Amgen Inc. Apj receptor agonists and uses thereof
WO2014113359A1 (en) 2013-01-15 2014-07-24 Teva Pharmaceutical Industries Ltd. Formulations of albu-bche, preparation and uses thereof
KR101503907B1 (en) * 2013-01-17 2015-03-20 서울대학교산학협력단 Recombinant protein vaccine for preventing Actinobacillus pleuropneumoniae and Mycoplasma hyopneumoniae infection diseases
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
KR101993714B1 (en) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. Compositions and methods of use in treating metabolic disorders
EP2953469A1 (en) 2013-02-11 2015-12-16 Bayer Cropscience LP Compositions comprising a streptomyces-based biological control agent and another biological control agent
PL3889173T3 (en) 2013-02-15 2023-12-11 Bioverativ Therapeutics Inc. Optimized factor viii gene
EP3318124A3 (en) 2013-02-16 2018-05-30 Albumedix A/S Pharmacokinetic animal model
US10441631B2 (en) 2013-02-28 2019-10-15 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
USRE48805E1 (en) 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
US9255262B2 (en) * 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
EP2964255B1 (en) 2013-03-08 2020-11-04 CSL Behring GmbH Treatment and prevention of remote ischemia-reperfusion injury
WO2014164703A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
EP3473272A1 (en) 2013-03-29 2019-04-24 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
JP6464145B2 (en) * 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Growth hormone compound preparation
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
AR096601A1 (en) 2013-06-21 2016-01-20 Novartis Ag ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
US20160166660A1 (en) 2013-06-28 2016-06-16 Csl Behring Gmbh Combination therapy using a factor xii inhibitor and a c-1 inhibitor
CN104342420B (en) * 2013-07-30 2017-09-15 惠觅宙 A kind of recombinant long-acting people hyaluronidase, its encoding gene, production method and application
EP3033098B1 (en) 2013-08-14 2022-06-22 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US9579257B2 (en) 2013-08-20 2017-02-28 Anutra Medical, Inc. Haptic feedback and audible output syringe
EP3338793A1 (en) 2013-08-28 2018-06-27 AbbVie Stemcentrx LLC Novel sez6 modulators and methods of use
ES2871418T3 (en) 2013-08-28 2021-10-28 Abbvie Stemcentrx Llc Compositions and methods of conjugation of site-specific antibodies
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
CN103468662A (en) * 2013-09-29 2013-12-25 惠觅宙 Recombined human hyaluronidase, production and purification method and preparations thereof, use method and application
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015050663A1 (en) 2013-10-01 2015-04-09 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of bim
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057403A2 (en) * 2013-10-17 2015-04-23 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of inflammatory bowel disease
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
PL3063275T3 (en) 2013-10-31 2020-03-31 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods
WO2015063611A2 (en) 2013-11-01 2015-05-07 University Of Oslo Albumin variants and uses thereof
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
EP4101461A1 (en) 2014-01-09 2022-12-14 Hadasit Medical Research Services and Development Ltd. Improved cell compositions and methods for cancer therapy
BR112016015512B1 (en) 2014-01-10 2023-12-19 Bioverativ Therapeutics Inc CHIMERICAL PROTEIN, PHARMACEUTICAL COMPOSITION AND ITS USES
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
SG10202010936RA (en) 2014-02-21 2020-12-30 Ecole Polytecnique Fed De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
AU2015229381B2 (en) 2014-03-11 2019-11-07 University Of Florida Research Foundation, Inc. Use of AAV-expressed M013 protein as an anti-inflammatory therapeutic
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
WO2015160618A1 (en) 2014-04-16 2015-10-22 Bayer Cropscience Lp Compositions comprising ningnanmycin and a biological control agent
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
WO2015173633A2 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
CN105198999A (en) * 2014-05-27 2015-12-30 上海生物制品研究所有限责任公司 Fusion protein and its preparation method and use
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
WO2015191781A2 (en) 2014-06-10 2015-12-17 Amgen Inc. Apelin polypeptides
KR102513050B1 (en) 2014-06-18 2023-03-29 체에스엘 베링 게엠베하 Therapy using a factor xii inhibitor in a neurotraumatic disorder
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
AU2015279525A1 (en) 2014-06-24 2016-12-15 Novo Nordisk A/S MIC-1 fusion proteins and uses thereof
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
WO2016018931A1 (en) 2014-07-30 2016-02-04 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
JP6649358B2 (en) 2014-08-07 2020-02-19 ノバルティス アーゲー Angiopoietin-like 4 antibodies and methods of use
US9988443B2 (en) 2014-08-07 2018-06-05 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
RU2685869C1 (en) 2014-08-22 2019-04-23 Нэшенл Ченг Кунг Юниверсити Versions of disintegrin and their pharmaceutical application
RU2736827C2 (en) 2014-09-17 2020-11-20 Байер Кропсайенс Лп Compositions containing bacillus recombinant cells and another biological control agent
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CA2962486A1 (en) 2014-09-26 2016-03-31 Bayer Pharma Aktiengesellschaft Stabilized adrenomedullin derivatives and use thereof
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
JP6625627B2 (en) 2014-10-14 2019-12-25 ハロザイム インコーポレイテッド Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using the same
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
AP2017009828A0 (en) 2014-10-31 2017-03-31 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
UY36449A (en) 2014-12-19 2016-07-29 Novartis Ag COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6
WO2016102068A1 (en) * 2014-12-23 2016-06-30 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled container
CA2981312C (en) * 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
JP2016204292A (en) * 2015-04-21 2016-12-08 国立大学法人 熊本大学 Bmp7 mutant-albumin cointegrate, and renal disease therapeutic agent containing the same
PT3288965T (en) * 2015-04-29 2019-10-15 Mediolanum Farm S P A A soluble chimeric interleukin-10 receptor and therapeutic use thereof
WO2016195723A1 (en) * 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Methods of treatment for conditions mediated by substance p
AU2016273028B2 (en) 2015-06-05 2019-02-14 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
US11752242B2 (en) 2015-06-11 2023-09-12 Ath Therapeutics Inc. Medical devices, systems, and methods utilizing antithrombin-heparin composition
JOP20200312A1 (en) 2015-06-26 2017-06-16 Novartis Ag Factor xi antibodies and methods of use
US11020455B2 (en) * 2015-07-30 2021-06-01 Endor Technologies, S.L Colony stimulating factor for use in pancreatic or colon cancer treatment
CN108472337B (en) 2015-08-03 2022-11-25 比奥贝拉蒂治疗公司 Factor IX fusion proteins and methods of making and using same
US11236159B2 (en) 2015-08-03 2022-02-01 Novartis Ag Methods of treating FGF21-associated disorders
US20180230488A1 (en) * 2015-08-06 2018-08-16 The Trustees Of The University Of Pennsylvania Glp-1 and use thereof in compositions for treating metabolic diseases
EP3337816B1 (en) 2015-08-20 2024-02-14 Albumedix Ltd Albumin variants and conjugates
CA2996672C (en) 2015-09-08 2023-02-21 Jcr Pharmaceuticals Co., Ltd. Novel human serum albumin mutant
US10000561B2 (en) 2015-09-09 2018-06-19 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
CA2996635A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
KR20180049080A (en) * 2015-09-11 2018-05-10 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 Biologically related orthogonal cytokine / receptor pairs
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
ES2821099T3 (en) 2015-12-04 2021-04-23 Boehringer Ingelheim Int Gmbh & Co Kg Biparatopic polypeptides antagonists of WNT signaling in tumor cells
CA2994447A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
JP2019506844A (en) 2015-12-18 2019-03-14 ノバルティス アーゲー Antibodies targeting CD32b and methods of use thereof
EP3393494A1 (en) 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
IL260218B2 (en) 2016-01-11 2023-04-01 Novartis Ag Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
EP3851457A1 (en) 2016-01-21 2021-07-21 Novartis AG Multispecific molecules targeting cll-1
SG10201913278PA (en) 2016-02-01 2020-02-27 Bioverativ Therapeutics Inc Optimized factor viii genes
EP3431508A4 (en) 2016-03-14 2019-08-14 JCR Pharmaceuticals Co., Ltd. Serum albumin-20 k growth hormone fusion protein
CN108697799A (en) 2016-03-22 2018-10-23 生态学有限公司 The application of anti-LGR5 monoclonal antibodies
TWI815793B (en) 2016-03-31 2023-09-21 美商恩格姆生物製藥公司 Binding proteins and methods of use thereof
CA3019851A1 (en) 2016-04-06 2017-10-12 Csl Limited Method of treating atherosclerosis
CN109071647B (en) 2016-04-27 2022-11-22 诺华股份有限公司 Anti-growth differentiation factor 15 antibody and application thereof
PL3458478T3 (en) 2016-05-18 2021-06-28 Boehringer Ingelheim International Gmbh Anti pd-1 and anti-lag3 antibodies for cancer treatment
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
DK3481416T3 (en) * 2016-07-08 2020-12-14 CSL Behring Lengnau AG SUBCUTANEOUS ADMINISTRATION OF LONG-TERM FACTOR IX IN PEOPLE
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
EP3493832A1 (en) 2016-08-05 2019-06-12 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
JP2019534240A (en) 2016-08-23 2019-11-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Methods for preventing acute attacks of hereditary angioedema associated with C1 esterase inhibitor deficiency
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
JP2020500306A (en) 2016-11-04 2020-01-09 オーフス ウニベルシテット Identification and treatment of tumors characterized by neonatal Fc receptor overexpression
AU2017360043A1 (en) * 2016-11-18 2019-06-20 Hospital Clinic De Barcelona Combined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
BR112019011115A2 (en) 2016-12-02 2019-10-01 Bioverativ Therapeutics Inc methods for treating hemophilic arthropathy using chimeric clotting factors
KR20190091292A (en) 2016-12-02 2019-08-05 바이오버라티브 테라퓨틱스 인크. How to Induce Immune Resistance to Coagulation Factors
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20200031895A1 (en) 2016-12-16 2020-01-30 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
JP7110199B2 (en) 2016-12-23 2022-08-01 ノバルティス アーゲー Methods of treatment with anti-factor XI/XIa antibodies
CN110352242A (en) 2016-12-23 2019-10-18 哈佛大学的校长及成员们 The gene editing of PCSK9
JP7139332B2 (en) 2016-12-23 2022-09-20 ノバルティス アーゲー Factor XI Antibodies and Methods of Use
US20190382462A1 (en) 2017-01-13 2019-12-19 Pietro P. Sanna Methods and compositions for treating hpa hyperactivity
EP3576762A1 (en) 2017-01-31 2019-12-11 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
WO2018146594A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
MA50141A (en) 2017-04-20 2020-07-29 Novo Nordisk As ALBUMIN FUSION PROTEIN PURIFICATION PROCESSES
TWI710377B (en) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Mic-1 compounds and uses thereof
EP3630816B1 (en) 2017-05-31 2024-03-20 Boehringer Ingelheim International GmbH Polypeptides antagonizing wnt signaling in tumor cells
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
DK3645034T3 (en) 2017-06-29 2023-11-20 CSL Behring Lengnau AG THE 21-DAY DOSAGE REGIMEN OF FUSION PROTEINS INCLUDING DEFACTOR IX AND HUMAN ALBUMIN FOR THE PROPHYLAXIS TREATMENT OF HEMOPHILIA AND METHODS THEREOF
JP2020529986A (en) 2017-08-04 2020-10-15 アムジエン・インコーポレーテツド Cysteine-MAB conjugation method
EP3665289A1 (en) 2017-08-09 2020-06-17 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
WO2019036605A2 (en) 2017-08-17 2019-02-21 Massachusetts Institute Of Technology Multiple specificity binders of cxc chemokines and uses thereof
EP3681517A4 (en) 2017-09-15 2021-05-19 Cedars-Sinai Medical Center Methods for improving organ function in organ transplant patients
CA3072634A1 (en) * 2017-10-18 2019-04-25 Sabine Rauth Human serum albumin variants and uses thereof
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
BR112020011240A2 (en) 2017-12-15 2020-11-24 Csl Limited use of a fxiia inhibitor in the treatment of renal fibrosis and / or chronic kidney disease
WO2019129054A1 (en) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 Triabody, preparation method and use thereof
US11905327B2 (en) 2017-12-28 2024-02-20 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against TIGIT
US11246908B2 (en) * 2018-01-10 2022-02-15 The Johns Hopkins University Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
US11713353B2 (en) 2018-01-15 2023-08-01 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-1
MX2020008152A (en) 2018-02-01 2020-11-24 Bioverativ Therapeutics Inc Use of lentiviral vectors expressing factor viii.
US11660326B2 (en) * 2018-03-13 2023-05-30 Sepsia Therapeutics, S.L. Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes
HUE063489T2 (en) 2018-03-13 2024-01-28 Zymeworks Bc Inc Anti-her2 biparatopic antibody-drug conjugates and methods of use
PE20210313A1 (en) 2018-03-28 2021-02-12 Bristol Myers Squibb Co INTERLEUKIN-2 FUSION PROTEINS / INTERLEUKIN-2 ALPHA RECEPTOR AND METHODS OF USE
CA3093034A1 (en) 2018-03-30 2019-10-03 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against lag-3 and uses thereof
KR102119197B1 (en) * 2018-04-23 2020-06-05 주식회사 엘베이스 Composition for autophagy inhibiting in cell, And pharmaceutical composition for preventing or treating tumor disease, or inhibiting anti-cancer agents resistance containing the same
EP4242238A3 (en) 2018-05-14 2023-12-06 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
WO2019222294A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
EP3793588A1 (en) 2018-05-18 2021-03-24 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
UY38247A (en) 2018-05-30 2019-12-31 Novartis Ag ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
PE20210320A1 (en) 2018-06-01 2021-02-16 Novartis Ag BINDING MOLECULES AGAINST BCMA AND THE USES OF THEM
SG11202013240RA (en) 2018-07-03 2021-01-28 Bristol Myers Squibb Co Fgf21 formulations
CA3108799A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
MX2021002190A (en) 2018-08-31 2021-05-14 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies.
WO2020058759A1 (en) * 2018-09-17 2020-03-26 Kyoto University Administration of an anti-c5 agent for treatment of hepatic injury or failure
JP2022502088A (en) 2018-09-27 2022-01-11 エクシリオ デベロップメント， インコーポレイテッド Masked cytokine polypeptide
UY38407A (en) 2018-10-15 2020-05-29 Novartis Ag TREM2 STABILIZING ANTIBODIES
WO2020092448A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
EP3887393A1 (en) 2018-11-26 2021-10-06 Novartis AG Lpl-gpihbp1 fusion polypeptides
AU2019393880A1 (en) 2018-12-06 2021-07-15 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor IX
EP3941580A1 (en) 2019-03-22 2022-01-26 Reflexion Pharmaceuticals, Inc. D-peptidic compounds for vegf
EP3941581A2 (en) 2019-03-22 2022-01-26 Reflexion Pharmaceuticals, Inc. Multivalent d-peptidic compounds for target proteins
JP2022524215A (en) 2019-03-28 2022-04-28 ダニスコ・ユーエス・インク Modified antibody
CN114026085A (en) 2019-04-11 2022-02-08 安吉昂生物医药公司 (E) Solid forms of (E) -3- [2- (2-thienyl) vinyl ] -1H-pyrazole
BR112021022666A2 (en) 2019-05-14 2022-03-29 Werewolf Therapeutics Inc Separation fractions and their methods and use
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
US20230071196A1 (en) 2019-05-21 2023-03-09 Novartis Ag Variant cd58 domains and uses thereof
EP3976181A1 (en) 2019-05-24 2022-04-06 Sanofi Methods for treating systemic sclerosis
EP3986918A1 (en) 2019-06-18 2022-04-27 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
MX2022002637A (en) 2019-09-06 2022-03-25 Novartis Ag Therapeutic fusion proteins.
JP2022548881A (en) 2019-09-18 2022-11-22 ノバルティス アーゲー ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
TW202124446A (en) 2019-09-18 2021-07-01 瑞士商諾華公司 Combination therapies with entpd2 antibodies
EP4038182A1 (en) 2019-09-30 2022-08-10 Bioverativ Therapeutics Inc. Lentiviral vector formulations
WO2021075526A1 (en) 2019-10-17 2021-04-22 Ｊｃｒファーマ株式会社 Method for producing fusion protein of serum albumin and growth hormone
EP4059512A4 (en) 2019-10-30 2023-12-06 JCR Pharmaceuticals Co., Ltd. Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone
WO2021111143A1 (en) 2019-12-04 2021-06-10 Albumedix Limited Methods and compositions produced thereby
US11648296B2 (en) 2019-12-13 2023-05-16 Synthekine, Inc. IL-2 orthologs and methods of use
US20210181200A1 (en) * 2019-12-17 2021-06-17 Women's College Hospital Ovarian cancer biomarker and methods of using same
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
JP2023504675A (en) 2020-05-19 2023-02-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Binding molecules for cancer treatment
US20220119535A1 (en) 2020-10-21 2022-04-21 Boehringer Ingelheim International Gmbh Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
WO2022166720A1 (en) * 2021-02-05 2022-08-11 华南理工大学 Serum albumin-based fusion protein, and nano-assembly, preparation method therefor and application thereof
CN117321076A (en) 2021-02-19 2023-12-29 美国卫生及公众服务部代表 Single domain antibodies neutralizing SARS-CoV-2
TW202317625A (en) 2021-06-17 2023-05-01 德商百靈佳殷格翰國際股份有限公司 Novel tri-specific binding molecules
CN114133458B (en) * 2021-12-08 2023-11-14 福州大学 Method for fusing polypeptide in human serum albumin
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18
US20240052065A1 (en) 2022-07-15 2024-02-15 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies

Family Cites Families (517)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625041A (en) * 1990-09-12 1997-04-29 Delta Biotechnology Limited Purification of proteins
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2449885C3 (en) 1974-10-21 1980-04-30 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Process for the production of chemically modified, long-life hemoglobin preparations as well as the modified hemoglobin preparation produced by this process
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4440859A (en) * 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4363877B1 (en) 1977-09-23 1998-05-26 Univ California Recombinant dna transfer vectors
US4264731A (en) * 1977-05-27 1981-04-28 The Regents Of The University Of California DNA Joining method
US4283489A (en) 1977-09-23 1981-08-11 The Regents Of The University Of California Purification of nucleotide sequences suitable for expression in bacteria
US4407948A (en) 1977-09-23 1983-10-04 The Regents Of The University Of California Purification of nucleotide sequences suitable for expression in bacteria
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4652525A (en) * 1978-04-19 1987-03-24 The Regents Of The University Of California Recombinant bacterial plasmids containing the coding sequences of insulin genes
US4447538A (en) * 1978-04-19 1984-05-08 Regents Of The University Of California Microorganism containing gene for human chorionic somatomammotropin
US5326859A (en) 1979-10-30 1994-07-05 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
US5514567A (en) * 1979-01-30 1996-05-07 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
AU538665B2 (en) 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
GR73557B (en) 1980-01-08 1984-03-15 Biogen Inc
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
GR74498B (en) 1980-04-03 1984-06-28 Biogen Inc
DE3023787A1 (en) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim METHOD FOR INCREASING THE INCORPORATION AND EXPRESSION OF GENETIC MATERIAL IN THE CORE OF INTACT CELLS BY LIPOSOME
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
IL63916A0 (en) 1980-09-25 1981-12-31 Genentech Inc Microbial production of human fibroblast interferon
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
EP0070906B1 (en) 1981-02-04 1986-10-15 Juridical Foundation Japanese Foundation For Cancer Research Human interferon-beta gene
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
JPS57149228A (en) 1981-03-11 1982-09-14 Ajinomoto Co Inc Novel erythropoietin and its preparation
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4792602A (en) 1981-06-19 1988-12-20 Cornell Research Foundation, Inc. Adaptors, and synthesis and cloning of proinsulin genes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
IL66614A (en) 1981-08-28 1985-09-29 Genentech Inc Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
EP0079739A3 (en) 1981-11-12 1984-08-08 The Upjohn Company Albumin-based nucleotides, their replication and use, and plasmids for use therein
EP0091527A3 (en) 1981-12-14 1984-07-25 The President And Fellows Of Harvard College Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides
JPS58118008A (en) 1982-01-06 1983-07-13 Nec Corp Data processor
EP0098876A1 (en) 1982-01-19 1984-01-25 Cetus Corporation Multiclass hybrid interferons
EP0088046B1 (en) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipids in the aqueous phase
US4450103A (en) * 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US4670393A (en) * 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
US4778879A (en) 1982-04-20 1988-10-18 Sloan-Kettering Institute For Cancer Research Highly purified human interleukin 2 and method
US4925919A (en) * 1984-04-25 1990-05-15 Roland Mertelsmann Purified interleukin 2
US4499188A (en) * 1982-05-05 1985-02-12 Cetus Corporation Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE3218121A1 (en) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Pharmaceutical compositions for tumour treatment
EP0102324A3 (en) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipids and surfactants in an aqueous medium
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
IE56026B1 (en) 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
EP0116201B1 (en) 1983-01-12 1992-04-22 Chiron Corporation Secretory expression in eukaryotes
US4840934A (en) * 1983-01-25 1989-06-20 Eleanor Roosevelt Institute For Cancer Research, Inc. Therapeutic method using T cell growth factor
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4914026A (en) * 1983-04-07 1990-04-03 Chiron Corporation Alpha factor leader sequence directed secretion of insulin
US5015575A (en) * 1983-04-07 1991-05-14 Chiron Corporation Hybrid DNA synthesis of insulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
JPS60501140A (en) 1983-04-22 1985-07-25 アムジエン Secretion of exogenous polypeptides by yeast
US5010003A (en) * 1983-04-25 1991-04-23 Genentech, Inc. Use of yeast homologous signals to secrete heterologous proteins
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
CA1196863A (en) * 1983-06-08 1985-11-19 Mattheus F.A. Goosen Slow release injectable insulin composition
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4576813A (en) 1983-07-05 1986-03-18 Monsanto Company Heat recovery from concentrated sulfuric acid
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS6087792A (en) 1983-09-23 1985-05-17 ジェネックス・コーポレイション Variant control region
DE3486459D1 (en) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Means and product for the diagnosis and therapy of tumors and for the treatment of weaknesses in cellular and humoral immune defense
US4518564A (en) * 1983-10-03 1985-05-21 Jeneric Industries, Inc. Gallium and silver free, palladium based dental alloys for porcelain-fused-to-metal restorations
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
GB8334102D0 (en) 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
GB8334261D0 (en) 1983-12-22 1984-02-01 Bass Plc Fermentation processes
JPS60136596A (en) 1983-12-26 1985-07-20 Suntory Ltd Peptide and diuretic comprising it as active ingredient
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
CA1213537A (en) 1984-05-01 1986-11-04 Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee Polypeptide expression method
FR2564106B1 (en) * 1984-05-09 1988-04-22 Transgene Sa FACTOR IX EXPRESSION VECTORS, CELLS TRANSFORMED BY THESE VECTORS, AND PROCESS FOR THE PREPARATION OF FACTOR IX.
DK58285D0 (en) * 1984-05-30 1985-02-08 Novo Industri As PEPTIDES AND MANUFACTURING AND USING THEREOF
EP0172619A1 (en) 1984-06-20 1986-02-26 Takeda Chemical Industries, Ltd. Novel transformant and use thereof
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5908763A (en) 1984-07-06 1999-06-01 Novartis Corporation DNA encoding GM-CSF and a method of producing GM-CSF protein
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4716217A (en) 1984-08-31 1987-12-29 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
US4734491A (en) 1984-08-31 1988-03-29 University Patents, Inc. DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
GB8504099D0 (en) 1985-02-18 1985-03-20 Wellcome Found Physiologically active substances
FR2579224B1 (en) * 1985-03-25 1987-05-22 Genetica PROCESS FOR THE MICROBIOLOGICAL PREPARATION OF HUMAN SERUM-ALBUMIN
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
ATE63757T1 (en) 1985-03-28 1991-06-15 Chiron Corp EXPRESSION THROUGH USE OF FUSION GENES FOR PROTEIN PRODUCTION.
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GB8510219D0 (en) 1985-04-22 1985-05-30 Bass Plc Isolation of fermentation products
JPS6229985A (en) 1985-06-17 1987-02-07 ジエネツクス・コ−ポレ−シヨン Cloned prepro-human serum alubmin, human serum alubmin gene,plasmid containing said genes, bacteria receiving form conversion by plasmid and production of prepro-human serum alubmin using said bacteria
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS6296086A (en) 1985-10-21 1987-05-02 Agency Of Ind Science & Technol Composite plasmid
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
DE3689123T2 (en) 1985-11-01 1994-03-03 Xoma Corp MODULAR UNIT OF ANTIBODY GENES, ANTIBODIES MADE THEREOF AND USE.
CA1295566C (en) 1987-07-21 1992-02-11 Robert T. Garvin Characterization and structure of genes for protease a and protease b from streptomyces griseus
US5641663A (en) 1985-11-06 1997-06-24 Cangene Corporation Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
FR2594846B1 (en) * 1986-02-21 1989-10-20 Genetica PROCESS FOR THE PREPARATION OF MATURE HUMAN ALBUMIN SERUM
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
IT1203758B (en) 1986-03-27 1989-02-23 Univ Roma CLONING AND EXPRESSION VECTORS OF HETEROLOGICAL GENES IN YEASTS AND YEASES TRANSFORMED WITH SUCH CARRIERS
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK179286D0 (en) 1986-04-18 1986-04-18 Nordisk Gentofte INSULIN PREPARATION
US4765980A (en) 1986-04-28 1988-08-23 International Minerals & Chemical Corp. Stabilized porcine growth hormone
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
IT1204400B (en) * 1986-06-20 1989-03-01 Sclavo Spa PHARMACEUTICAL COMPOSITIONS CONTAINING A CALCITONIN
GB8615701D0 (en) 1986-06-27 1986-08-06 Delta Biotechnology Ltd Stable gene integration vector
IT1196484B (en) 1986-07-11 1988-11-16 Sclavo Spa YEAST EXPRESSION AND SECRETION VECTOR, USEFUL FOR THE PREPARATION OF HETEROLOGICAL PROTEINS
GR871067B (en) 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
US4857467A (en) 1986-07-23 1989-08-15 Phillips Petroleum Company Carbon and energy source markers for transformation of strains of the genes Pichia
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5002764A (en) * 1986-08-12 1991-03-26 Schering Corporation Treatment of actinic keratoses with alpha2 interferon
GB8620926D0 (en) * 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
JPH01502669A (en) 1987-03-13 1989-09-14 アムジエン・インコーポレーテツド Purified platelet-derived growth factor and its purification method
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
DE3888381T2 (en) * 1987-04-09 1994-07-28 Delta Biotechnology Ltd Yeast vector.
JPH0198489A (en) 1987-04-22 1989-04-17 Chiron Corp Recombinant production of platelet-derived growth factor a chain polypeptide
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1323850C (en) 1987-07-28 1993-11-02 Johannes A. Van Den Berg Kluyveromyces as a host strain
JP2627899B2 (en) 1987-08-19 1997-07-09 株式会社 ビタミン研究所 Production method of gene-encapsulated liposome
SE459586B (en) 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti THE STRUCTURES CODING FOR AUTHENTIC HUMAN SERUM ALBUMIN AND PROCEDURES FOR ITS PREPARATION
PT88641B (en) 1987-10-02 1993-04-30 Genentech Inc METHOD FOR PREPARING A VARIETY OF ADHESION
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
JPH0811074B2 (en) 1987-10-30 1996-02-07 財団法人化学及血清療法研究所 Recombinant plasmid incorporating a gene encoding prealbumin and method for producing prealbumin using the same
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JP2791418B2 (en) 1987-12-02 1998-08-27 株式会社ミドリ十字 Method for producing heterologous protein, recombinant DNA, transformant
ZA89430B (en) 1988-01-22 1989-10-25 Gen Hospital Corp Cloned genes encoding ig-cd4 fusion proteins and the use thereof
JPH01240191A (en) * 1988-02-16 1989-09-25 Green Cross Corp:The Novel signal peptide functioning by yeast and secretory manifestation of foreign protein using same
JPH01215289A (en) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk Production of normal human serum albumin a through gene recombination
US4999339A (en) * 1988-03-28 1991-03-12 Cetus Corporation Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5066489A (en) 1988-03-28 1991-11-19 Cetus Corporation Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5096707A (en) * 1988-04-15 1992-03-17 The United States Of America As Represented By The Department Of Health And Human Services Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers
US5061488A (en) 1988-04-15 1991-10-29 The United States Of America As Represented Department Of Health & Human Services Flavone-8-acetic acid and interleukin-2 for cancer therapy
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
IL89992A0 (en) 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of human serum albumin in methylotrophic yeasts
US5126129A (en) * 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
IL90730A0 (en) 1988-06-24 1990-01-18 Dow Chemical Co Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
PT90959B (en) 1988-06-24 1995-05-04 Dow Chemical Co PROCESS FOR THE PREPARATION OF BIFUNCTIONAL MACROCYCLIC CHELANTES, OF THEIR COMPLEXES AND THEIR CONJUGATES WITH ANTIBODIES
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
KR100195632B1 (en) 1988-07-23 1999-06-15 스티븐 조지 가랜드 New secretory leader sequences
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
FR2649991B2 (en) 1988-08-05 1994-03-04 Rhone Poulenc Sante USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES
FR2635115B1 (en) 1988-08-05 1992-04-03 Rhone Poulenc Sante PROCESS FOR THE PREPARATION OF HUMAN ALBUMIN SERUM FROM YEAST
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
IL91501A (en) 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5260202A (en) 1988-09-07 1993-11-09 Delta Biotechnology Limited Fermentation method
JPH02227079A (en) 1988-10-06 1990-09-10 Tonen Corp Human serum albumin fragment
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5298243A (en) 1988-10-20 1994-03-29 Denki Kagaku Kogyo Kabushiki Kaisha Colony stimulating factor-gelatin conjugate
US5759802A (en) 1988-10-26 1998-06-02 Tonen Corporation Production of human serum alubumin A
JPH02117384A (en) 1988-10-26 1990-05-01 Tonen Corp Production of human serum albumin a by yeast host
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
US5256410A (en) 1988-12-01 1993-10-26 Schering Corporation Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
US4975271A (en) 1988-12-19 1990-12-04 Vipont Pharmaceutical, Inc. Muscosal delivery systems for treatment of periodontal disease
JP2989002B2 (en) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
DK105489D0 (en) * 1989-03-03 1989-03-03 Novo Nordisk As POLYPEPTIDE
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
ATE277193T1 (en) 1989-03-21 2004-10-15 Vical Inc EXPRESSION OF EXOGENEOUS POLYNUCLEOTIDE SEQUENCES IN VERTEBRATES
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
ES2034790T3 (en) * 1989-04-11 1993-04-01 Boehringer Ingelheim International Gmbh USE OF AT LEAST ONE CITROQUINE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE SYSTEMATIC TREATMENT OF PRENEOPLASTIC INJURIES.
EP0395918A3 (en) 1989-04-13 1991-10-23 Vascular Laboratory, Inc. Plasminogen activator complex of pure pro-urokinase covalently bound by a disulfide bridge to human serum albumin
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
ATE92107T1 (en) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-TERMINAL FRAGMENTS OF HUMAN SERUM ALBUMIN-CONTAINING FUSION PROTEINS.
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
EP0399816B1 (en) 1989-05-24 1995-12-20 Merck & Co. Inc. Purification and characterization of a glioma-derived growth factor
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
EP0429586B1 (en) * 1989-06-09 1995-08-02 Gropep Pty. Ltd. Growth hormone fusion proteins
JPH0327320A (en) 1989-06-26 1991-02-05 Ajinomoto Co Inc Human b cell differentiation factor pharmaceutical composition
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
DE3924746A1 (en) * 1989-07-26 1991-01-31 Behringwerke Ag ERTHROPOIETIN (EPO) PEPTIDES AND ANTIBODIES THEREFOR
CU22222A1 (en) 1989-08-03 1995-01-31 Cigb PROCEDURE FOR THE EXPRESSION OF HETEROLOGICAL PROTEINS PRODUCED IN A FUSION FORM IN ESCHERICHIA COLI, ITS USE, EXPRESSION VECTORS AND RECOMBINANT STRAINS
FR2650598B1 (en) 1989-08-03 1994-06-03 Rhone Poulenc Sante DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
GB8927480D0 (en) 1989-12-05 1990-02-07 Delta Biotechnology Ltd Mutant fungal strain detection and new promoter
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6063373A (en) * 1989-09-19 2000-05-16 Maxim Pharmaceuticals, Inc. Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
FR2653020B1 (en) 1989-10-17 1993-03-26 Roussel Uclaf USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEUKEMIA.
GB8924021D0 (en) 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5173408A (en) 1989-11-13 1992-12-22 Lange Louis George Iii Mammalian pancreatic cholesterol esterase
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
JPH03201987A (en) * 1989-12-29 1991-09-03 Tonen Corp Human serum albumin fragment
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DE69117545T2 (en) * 1990-01-25 1996-10-31 Univ Washington Factor X-LACI hybrid protein
JPH04211375A (en) 1990-02-05 1992-08-03 Ajinomoto Co Inc Synthetic gene and production of human serum albumin using the synthetic gene
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5208018A (en) * 1990-03-19 1993-05-04 Brigham And Women's Hospital Treatment of cachexia with interleukin 2
FR2660863B1 (en) * 1990-04-17 1994-01-21 Roussel Uclaf USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PRIMITIVE CANCERS OF THE POWDER.
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
CA2084514A1 (en) 1990-07-10 1992-01-11 Guenther Adolf O-glycosylated ifn-alpha
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5225341A (en) 1990-07-19 1993-07-06 The Regents Of The University Of California Biologically safe plant transformation system using a ds transposon
US5202239A (en) * 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
US5071872A (en) 1990-08-14 1991-12-10 The Ohio State University Research Foundation Method for improving interleukin-2 activity using aci-reductone compounds
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5391183A (en) * 1990-09-21 1995-02-21 Datascope Investment Corp Device and method sealing puncture wounds
IT1242149B (en) 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche CODING NUCLEOTID SEQUENCE FOR A HUMAN PROTEIN WITH REGULATORY PROPERTIES OF ANGIOGENESIS
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JP3583420B2 (en) 1990-10-05 2004-11-04 メダレツクス・インコーポレーテツド Targeted immunization with bispecific reagents
JPH07108232B2 (en) 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 Method for producing peptide or protein
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
FR2668368B1 (en) 1990-10-30 1995-03-10 Roussel Uclaf USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MALIGNANT EPITHELIAL TUMORS.
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JPH0638771A (en) 1990-10-31 1994-02-15 Tonen Corp Expression of human protein disulfide isomerase gene and production of polypeptide by co-expression with the gene
US5353535A (en) 1990-11-05 1994-10-11 Plumly George W Floor type advertising apparatus
US5378823A (en) 1990-11-29 1995-01-03 Institut National De La Recherche Agronomique-I.N.R.A. Nucleic acids encoding type I interferon variants
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5272080A (en) * 1991-02-19 1993-12-21 Pharmavene, Inc. Production of butyrylcholinesterase
WO1994027631A1 (en) * 1993-05-21 1994-12-08 Zymogenetics, Inc. Modified factor vii
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5272070A (en) 1991-03-08 1993-12-21 Board Of Regents, The University Of Texas System Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
EP0503583A1 (en) 1991-03-12 1992-09-16 Takeda Chemical Industries, Ltd. Composition for sustained release of erythropoietin
US5817471A (en) 1991-03-14 1998-10-06 The United States Of America As Represented By The Department Of Health And Human Services Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
EP0506477B1 (en) 1991-03-28 1999-06-23 Merck & Co. Inc. Vascular endothelial cell growth factor C subunit
DK1471142T3 (en) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimeric receptor libraries using phagemids
US5374617A (en) 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
EP0509841A3 (en) 1991-04-18 1993-08-18 Tonen Corporation Co-expression system of protein disulfide isomerase gene and useful polypeptide gene and process for producing the polypeptide using its system
CA2058820C (en) 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
ES2093778T3 (en) 1991-04-26 1997-01-01 Surface Active Ltd NEW ANTIBODIES AND METHODS FOR USE.
US5330901A (en) 1991-04-26 1994-07-19 Research Corporation Technologies, Inc. Expression of human serum albumin in Pichia pastoris
FR2676070B1 (en) 1991-04-30 1994-09-30 Rhone Poulenc Rorer Sa YEAST PROMOTER AND ITS USE.
US5646012A (en) * 1991-04-30 1997-07-08 Rhone-Poulenc Rorer S.A. Yeast promoter and use thereof
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5304473A (en) * 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
JPH07503124A (en) 1991-06-14 1995-04-06 ゾーマ・コーポレーション Antibody fragments and their complexes produced by microorganisms
FR2677996B1 (en) 1991-06-21 1993-08-27 Rhone Poulenc Rorer Sa CLONING AND / OR EXPRESSION VECTORS PREPARATION AND USE.
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
JPH05292972A (en) 1991-07-29 1993-11-09 Tonen Corp Improved yeast expression system
US5723719A (en) 1991-08-08 1998-03-03 Health Research Inc. Transgenic mouse as model for diseases involving dopaminergic dysfunction
DE4126968A1 (en) 1991-08-14 1993-02-18 Detlev Prof Dr Med Ganten Transgenic rats that contain at least one human gene in their genome that is involved in blood pressure regulation
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
AU665599B2 (en) * 1991-11-08 1996-01-11 Hemosol Inc. Hemoglobins as drug delivery agents
US5786883A (en) * 1991-11-12 1998-07-28 Pilkington Barnes Hind, Inc. Annular mask contact lenses
ATE463573T1 (en) 1991-12-02 2010-04-15 Medimmune Ltd PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES
US5540923A (en) * 1991-12-06 1996-07-30 Landsforeningen Til Kraeftens Bekaemplse Interferon proteins
US6348327B1 (en) * 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
ES2204899T3 (en) 1992-01-07 2004-05-01 Elan Pharmaceuticals, Inc. MODELS OF TRANSGENIC ANIMALS FOR ALZHEIMER'S DISEASE.
GB9200417D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
FR2686620B1 (en) * 1992-01-27 1995-06-23 Rhone Poulenc Rorer Sa HUMAN SERUM-ALBUMIN, PREPARATION AND USE.
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686900B1 (en) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686901A1 (en) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa NOVEL ANTITHROMBOTIC POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DK0627940T3 (en) 1992-03-05 2003-09-01 Univ Texas Use of immunoconjugates for diagnosis and / or therapy of vascularized tumors
US5230886A (en) 1992-03-18 1993-07-27 Trustees Of Boston University Tumor cell suppression
DK36392D0 (en) * 1992-03-19 1992-03-19 Novo Nordisk As USE OF CHEMICAL COMPOUND
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5460954A (en) 1992-04-01 1995-10-24 Cheil Foods & Chemicals, Inc. Production of human proinsulin using a novel vector system
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
CA2102401A1 (en) 1992-06-09 1993-12-10 Friedrich Hoppe Latch and lockset system
US5686268A (en) * 1992-06-19 1997-11-11 Pfizer Inc. Fused proteins
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
JP3269504B2 (en) 1992-07-08 2002-03-25 三菱ウェルファーマ株式会社 Method for producing human serum albumin
FR2694294B1 (en) * 1992-07-30 1994-09-09 Rhone Poulenc Rorer Sa Yeast promoter and its user.
CA2139358C (en) 1992-07-31 2001-02-13 Barbara H. O'connor Human growth hormone aqueous formulation
US5602307A (en) 1992-08-12 1997-02-11 Baylor College Of Medicine Non-human animal having predefined allele of a cellular adhesion gene
DE4244915C2 (en) 1992-08-14 1998-12-03 Widmar Prof Dr Tanner Fungal cells contg. mutated DPM2 mannosyl transferase gene
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5731490A (en) 1992-09-29 1998-03-24 The Ontario Cancer Institute Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
FR2697752B1 (en) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Antitumor compositions containing taxane derivatives.
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5489743A (en) 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
FR2701953B1 (en) 1993-02-22 1995-05-24 Centre Nat Rech Scient Multi-VIP fusion protein and method for preparing recombinant VIP.
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
US5780021A (en) 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
US5869445A (en) 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5910488A (en) 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
DK82893D0 (en) * 1993-07-08 1993-07-08 Novo Nordisk As PEPTIDE
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5521086A (en) * 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5459031A (en) 1993-11-05 1995-10-17 Amgen Inc. Methods for controlling sialic acid derivatives in recombinant glycoproteins
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
ATE300610T1 (en) 1994-01-31 2005-08-15 Univ Boston LIBRARIES OF POLYCLONAL ANTIBODIES
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5932780A (en) 1994-02-28 1999-08-03 Yissum Research Development Company Of Hebrew University Of Jerusalem Transgenic non-human animal assay system for anti-cholinesterase substances
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5629286A (en) * 1994-03-31 1997-05-13 Brewitt; Barbara Homeopathic dilutions of growth factors
US5646113A (en) 1994-04-07 1997-07-08 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
FR2719593B1 (en) 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa New biologically active polypeptides, their preparation and pharmaceutical composition containing them.
GB9411356D0 (en) 1994-06-07 1994-07-27 Delta Biotechnology Ltd Yeast strains
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639642A (en) * 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
US5623054A (en) 1994-06-23 1997-04-22 The General Hospital Corporation Crucifer AFT proteins and uses thereof
JPH0851982A (en) 1994-08-11 1996-02-27 Asahi Glass Co Ltd Modified gene coding human serum albumen
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US6071923A (en) * 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
FR2726471B1 (en) 1994-11-07 1997-01-31 Pf Medicament PROCESS FOR IMPROVING THE IMMUNOGENICITY OF AN IMMUNOGENIC COMPOUND OR A HAPTENA AND APPLICATION TO THE PREPARATION OF VACCINES
FR2726576B1 (en) 1994-11-07 1997-01-31 Pf Medicament PRODUCTION OF HYDROPHOBIC PEPTIDE-LIKE PEPTIDES, RECOMBINANT PEPTIDE, CORRESPONDING DNA SEQUENCE
DE69434988T2 (en) 1994-11-07 2008-03-06 Human Genome Sciences, Inc. Tumor necrosis FACTOR GAMMA
AT403167B (en) 1994-11-14 1997-11-25 Immuno Ag SELECTION AND EXPRESSION OF FOREIGN PROTEINS BY MEANS OF A SELECTION-AMPLIFICATION SYSTEM
US5695750A (en) 1994-11-25 1997-12-09 The United States Of America As Represented By The Secretary Of The Army Compositions for use to deactivate organophosphates
WO1996018412A1 (en) * 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
US5652224A (en) 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5837281A (en) * 1995-03-17 1998-11-17 Takeda Chemical Industries, Ltd. Stabilized interface for iontophoresis
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
WO1996034095A1 (en) 1995-04-27 1996-10-31 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5480640A (en) 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
CN1125082C (en) 1995-05-05 2003-10-22 人类基因组科学公司 Human chemokine beta-8, chemokine beta-1 and macrophage inflammatory protein-4
US5728915A (en) 1995-05-08 1998-03-17 Children's Hospital, Inc. Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US6001625A (en) 1995-05-19 1999-12-14 The United States Of America As Represented By The Secretary Of The Army Site-directed mutagenesis of esterases
US5741815A (en) * 1995-06-02 1998-04-21 Lai; Ching-San Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
EP0858343B1 (en) 1995-11-02 2004-03-31 Schering Corporation Continuous low-dose cytokine infusion therapy
US6048964A (en) * 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US6110707A (en) 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6150337A (en) 1996-01-23 2000-11-21 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
JP2978435B2 (en) 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
US6045788A (en) * 1996-02-28 2000-04-04 Cornell Research Foundation, Inc. Method of stimulation of immune response with low doses of IL-2
DE19639601A1 (en) 1996-02-28 1997-09-04 Bayer Ag Parapox viruses that contain foreign DNA, their production and their use in vaccines
US5912229A (en) * 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
JP3794748B2 (en) * 1996-03-04 2006-07-12 第一アスビオファーマ株式会社 Method for culturing microorganisms with methanol metabolism
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
EP0904373A1 (en) 1996-03-14 1999-03-31 The Immune Response Corporation Targeted delivery of genes encoding interferon
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
CA2248136A1 (en) * 1996-03-21 1997-09-25 Human Genome Sciences, Inc. Human endometrial specific steroid-binding factor i, ii and iii
JP2000508522A (en) 1996-03-22 2000-07-11 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド Apoptosis-inducing molecule II
US6204022B1 (en) * 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
US6497878B1 (en) * 1996-04-23 2002-12-24 Chugai Seiyaku Kabushiki Kaisha Treatment of cerebral disorders by inhibition of IL-8 binding to receptor
ES2151277T3 (en) * 1996-05-22 2000-12-16 Protarga Inc COMPOSITIONS INCLUDING CONJUGATES OF CIS-DOCOSAHEXAENOIC ACID AND TAXOTERE.
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
WO1997047737A1 (en) * 1996-06-11 1997-12-18 Boehringer Mannheim Gmbh Recombinant blood-coagulation proteases
ES2242227T5 (en) 1996-07-15 2011-12-09 Chugai Seiyaku Kabushiki Kaisha NEW VEGF TYPE FACTOR.
DK0961831T3 (en) 1996-08-16 2009-01-12 Human Genome Sciences Inc Human alpha-endocrine
EP1947183B1 (en) 1996-08-16 2013-07-17 Merck Sharp & Dohme Corp. Mammalian cell surface antigens; related reagents
CA2263890C (en) 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
EP0961832A4 (en) * 1996-09-18 2003-02-26 Human Genome Sciences Inc Human tumor necrosis factor receptor-like genes
US6225290B1 (en) 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US5994112A (en) 1996-10-09 1999-11-30 Incyte Pharmaceuticals, Inc. Human protein tyrosine kinase
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5955508A (en) * 1996-10-15 1999-09-21 Loyola University Of Chicago Method for the enhancement of lymphocyte activity against opportunistic microbial pathogens
WO1998017281A1 (en) 1996-10-24 1998-04-30 Vion Pharmaceuticals, Inc. MONOPHOSPHATE PRODRUGS OF β-L-FD4C AND β-L-FddC AS POTENT ANTIVIRAL AGENTS
DK0939804T4 (en) 1996-10-25 2011-07-18 Human Genome Sciences Inc Neutrokine-alpha
JPH10134761A (en) 1996-10-30 1998-05-22 Ebara Corp Ion implantation device and method
US5908830A (en) * 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
UA65549C2 (en) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
GB9623205D0 (en) * 1996-11-07 1997-01-08 Eurand Int Novel pharmaceutical compositions
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US5833994A (en) 1997-01-08 1998-11-10 Paracelsian, Inc. Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
EP0990031B1 (en) 1997-01-14 2006-03-29 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
AU5549998A (en) * 1997-01-24 1998-08-18 Novo Nordisk A/S Synthetic leader peptide sequences
EP1862548A1 (en) 1997-01-28 2007-12-05 Human Genome Sciences, Inc. Death domain containing receptor 4 (DR4 : death receptor 4), member of the TNF-receptor superfamily and binding to trail (APO2-L)
ATE200030T1 (en) 1997-01-29 2001-04-15 Polymasc Pharmaceuticals Plc PEGYLATION PROCEDURE
GB2324529A (en) 1997-02-21 1998-10-28 Merck & Co Inc A combinatorial library based on a tetrapeptide substituted with aminomethylcoumarin for characterizing proteases
US7026447B2 (en) 1997-10-09 2006-04-11 Human Genome Sciences, Inc. 53 human secreted proteins
US6030961A (en) * 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
JP3876002B2 (en) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト Novel methods for producing anti-human antigen receptors and their use
AR012448A1 (en) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech COMPOSITION IN THE FORM OF MICROCAPSULES OR IMPLANTS COMPRISING A BIODEGRADABLE CONTAINER, POLYMER OR CO-POLYMER, OR A MIXTURE OF SUCH EXCIPIENTS, AND AN ACTIVE SUBSTANCE OR MIXTURE OF ACTIVE SUBSTANCES, PROCEDURE FOR THE PREPARATION OF A SUBSTANCE IN A SUBSTANCE
AU7273598A (en) 1997-05-05 1998-11-27 Regents Of The University Of California, The Naphthols useful in antiviral methods
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6214580B1 (en) 1997-05-30 2001-04-10 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr10
US6071743A (en) 1997-06-02 2000-06-06 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
JP2002503963A (en) 1997-06-11 2002-02-05 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド Human tumor necrosis factor receptor TR9
GB9713412D0 (en) 1997-06-26 1997-08-27 Delta Biotechnology Ltd Improved protein expression strains
US5858719A (en) 1997-07-17 1999-01-12 Incyte Pharmaceuticals, Inc. Polynucleotides encoding human ATP binding-cassette transport protein and methods of use
EP0903148B1 (en) 1997-09-21 2001-10-10 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
CA2305690A1 (en) * 1997-10-09 1999-04-22 Human Genome Sciences, Inc. 53 human secreted proteins
CA2309541C (en) 1997-11-03 2011-01-11 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
WO1999029314A1 (en) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Novel salts of metformin and method
CA2312188C (en) * 1997-12-08 2010-06-29 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US6221378B1 (en) * 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
DE19813802A1 (en) 1998-03-27 1999-11-11 Retro Tech Gmbh Anti-viral effects of propolis through inhibition of viral nucleic acid polymerases
GB9806631D0 (en) 1998-03-28 1998-05-27 Safeglass Europ Limited Safetyglass
US6251868B1 (en) 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
CN1230198C (en) * 1998-05-15 2005-12-07 先灵公司 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having G chronic hepatitis C infection
CN1119352C (en) 1998-05-15 2003-08-27 中国科学院上海生物化学研究所 Express and purification of human serum albumin in pichia
US5970300A (en) * 1998-06-01 1999-10-19 Xerox Corporation Apparatus for applying scents to paper in a printer/copier
US6548653B1 (en) * 1998-06-15 2003-04-15 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
CN1105727C (en) 1998-06-17 2003-04-16 上海海济医药生物工程有限公司 Process for preparing recombined human serum albumin
AU4716299A (en) 1998-06-24 2000-01-10 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
GB9817084D0 (en) 1998-08-06 1998-10-07 Wood Christopher B A method for promoting extra-heptic production of proteins for the correction of hypoalbuminaemia,anaemia,thrombocytopenia and/or coagulation disorders
US6346543B1 (en) * 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
US6193997B1 (en) * 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US20030190669A1 (en) * 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
US6348192B1 (en) * 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
CZ20014123A3 (en) 1999-05-19 2002-06-12 Lexigen Pharmaceuticals Corp. Expression and export of alpha interferons as Fc fusion proteins
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythopintin derivatives
US20020048571A1 (en) * 1999-07-19 2002-04-25 Jeno Gyuris Chimeric polypeptides of serum albumin and uses related thereto
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
CA2388432A1 (en) 1999-10-21 2001-04-26 Monsanto Company Post-translational modification of recombinant proteins produced in plants
US6569832B1 (en) * 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
CA2405912A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
HU230874B1 (en) * 2000-05-15 2018-11-29 F. Hoffmann-La Roche Ag Liquid pharmaceutical compositions stable at room temperature which comprising a pegylated human erythropoietin protein
US7101561B2 (en) * 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
CA2434237C (en) 2000-12-07 2012-05-15 Eli Lilly And Company Glp-1 fusion proteins
US7070973B2 (en) 2000-12-26 2006-07-04 Board Of Regents Of The University Of Nebraska Butyrylcholinesterase variants and methods of use
US20050244931A1 (en) 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20030143191A1 (en) * 2001-05-25 2003-07-31 Adam Bell Chemokine beta-1 fusion proteins
US7186797B2 (en) 2001-08-10 2007-03-06 Epix Pharmaceuticals, Inc. Polypeptide conjugates with extended circulating half-lives
AU2002332041A1 (en) 2001-10-05 2003-04-22 Human Genome Sciences, Inc. Albumin fusion proteins
CN101724075B (en) * 2001-10-10 2014-04-30 诺和诺德公司 Remodeling and glycoconjugation of peptides
AU2002364587A1 (en) * 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20080167238A1 (en) 2001-12-21 2008-07-10 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002353374A1 (en) 2001-12-21 2003-07-09 Nexia Biotechnologies, Inc. Production of butyrylcholinesterases in transgenic mammals
KR101271635B1 (en) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
ES2545090T3 (en) * 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Albumin and GCSF fusion proteins
MXPA04012496A (en) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Pegylated factor vii glycoforms.
CN1241946C (en) * 2002-07-01 2006-02-15 美国福源集团 Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells
US6913890B2 (en) * 2002-12-18 2005-07-05 Palo Alto Research Center Incorporated Process for preparing albumin protein conjugated oligonucleotide probes
DK2266630T3 (en) * 2003-02-27 2014-03-17 Baxter Int Device for calibration by a method for validating inactivation of pathogens in a biological fluid by irradiation
AU2005211725B2 (en) 2004-02-09 2010-07-15 Human Genome Sciences, Inc. Albumin fusion proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
US7436410B2 (en) * 2005-04-01 2008-10-14 Seiko Epson Corporation System and method for programming a controller
AU2006280312A1 (en) 2005-08-12 2007-02-22 Human Genome Sciences, Inc. Albumin fusion proteins
US7438904B1 (en) 2005-10-04 2008-10-21 University Of Kentucky Research Foundation High-activity mutants of butyrylcholinesterase for cocaine hydrolysis and method of generating the same
US8008257B2 (en) 2005-10-20 2011-08-30 University Of Ottawa Heart Institute ANF fusion proteins
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
US9486507B2 (en) * 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof

Also Published As

Publication number Publication date
WO2001079258A1 (en) 2001-10-25
US7482013B2 (en) 2009-01-27
AU2001266557A1 (en) 2001-10-23
US20050266533A1 (en) 2005-12-01
US10080785B2 (en) 2018-09-25
EP1983055A1 (en) 2008-10-22
EP2267026A1 (en) 2010-12-29
EP2213743A1 (en) 2010-08-04
EP2216409A1 (en) 2010-08-11
WO2001079443A3 (en) 2002-02-21
WO2001079480A9 (en) 2003-09-18
FR16C0043I1 (en) 2016-12-09
EP2275557A1 (en) 2011-01-19
CA2405557C (en) 2013-09-24
US20120141449A1 (en) 2012-06-07
EP2216409B1 (en) 2014-12-03
CA2405557A1 (en) 2001-10-25
WO2001077137A1 (en) 2001-10-18
EP2067488A1 (en) 2009-06-10
JP2014057589A (en) 2014-04-03
US20110280830A9 (en) 2011-11-17
EP1832599A3 (en) 2007-11-21
FR16C0043I2 (en) 2020-04-10
EP2311872A1 (en) 2011-04-20
EP1276849A2 (en) 2003-01-22
JP2003530852A (en) 2003-10-21
AU2001262942A1 (en) 2001-10-30
EP1276856A4 (en) 2004-06-09
US20080269127A1 (en) 2008-10-30
EP2295456A1 (en) 2011-03-16
EP1276756A4 (en) 2004-06-09
US20050266532A1 (en) 2005-12-01
DK2216409T3 (en) 2015-01-05
US9775888B2 (en) 2017-10-03
US20080261877A1 (en) 2008-10-23
DK2236152T3 (en) 2014-07-07
JP2003530846A (en) 2003-10-21
US20030125247A1 (en) 2003-07-03
US9849162B2 (en) 2017-12-26
US7507414B2 (en) 2009-03-24
EP1278544A2 (en) 2003-01-29
EP1278767A1 (en) 2003-01-29
EP2298355A3 (en) 2011-06-29
WO2001079442A2 (en) 2001-10-25
US8946156B2 (en) 2015-02-03
EP1274719A2 (en) 2003-01-15
EP1278544A4 (en) 2004-08-18
EP1832599A2 (en) 2007-09-12
ES2484966T3 (en) 2014-08-12
CA2405701A1 (en) 2001-10-25
US20080267962A1 (en) 2008-10-30
WO2001079258A9 (en) 2002-02-28
AU2001261024A1 (en) 2001-10-30
WO2001079443A2 (en) 2001-10-25
AU2001264563A1 (en) 2001-10-30
CA2405550A1 (en) 2001-10-25
AU2001274809A1 (en) 2001-10-30
US20120141415A1 (en) 2012-06-07
US9821039B2 (en) 2017-11-21
EP1803730A1 (en) 2007-07-04
BE2016C059I2 (en) 2020-08-20
US6926898B2 (en) 2005-08-09
EP1276849A4 (en) 2004-06-09
US20130266553A1 (en) 2013-10-10
US20040171123A1 (en) 2004-09-02
EP1274719A4 (en) 2004-05-19
AU2001259063A1 (en) 2001-10-30
EP2206720A1 (en) 2010-07-14
JP2004506407A (en) 2004-03-04
US20080269125A1 (en) 2008-10-30
WO2001079444A3 (en) 2002-05-23
US20040010134A1 (en) 2004-01-15
WO2001077137A9 (en) 2002-05-02
US20090285816A9 (en) 2009-11-19
EP2357008A1 (en) 2011-08-17
US20120252732A1 (en) 2012-10-04
WO2001079444A2 (en) 2001-10-25
WO2001079442A3 (en) 2002-06-06
ES2529300T3 (en) 2015-02-18
US20070287173A9 (en) 2007-12-13
US20030219875A1 (en) 2003-11-27
CA2747325A1 (en) 2001-10-25
JP2003530839A (en) 2003-10-21
US20140004095A1 (en) 2014-01-02
US6905688B2 (en) 2005-06-14
WO2001079271A1 (en) 2001-10-25
US20080269126A1 (en) 2008-10-30
CA2405709A1 (en) 2001-10-25
US20100189686A1 (en) 2010-07-29
EP1278767A4 (en) 2003-11-12
WO2001079480A1 (en) 2001-10-25
EP1274720A1 (en) 2003-01-15
JP2003530847A (en) 2003-10-21
EP1276856A1 (en) 2003-01-22
EP2236152B1 (en) 2014-06-04
JP2003531590A (en) 2003-10-28
US20080269128A1 (en) 2008-10-30
AU2001259066A1 (en) 2001-10-30
US20030199043A1 (en) 2003-10-23
US7785599B2 (en) 2010-08-31
EP2298355A2 (en) 2011-03-23
US20080131399A1 (en) 2008-06-05
CA2405525A1 (en) 2001-10-25
US20180200346A1 (en) 2018-07-19
JP2011217750A (en) 2011-11-04
US20140010798A1 (en) 2014-01-09
EP2236152A1 (en) 2010-10-06
US20030171267A1 (en) 2003-09-11
EP1274720A4 (en) 2004-08-18
EP1276756A1 (en) 2003-01-22
WO2001079271A9 (en) 2002-02-28
US6994857B2 (en) 2006-02-07
JP2003530838A (en) 2003-10-21
CA2405563A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
CA2405912A1 (en) Albumin fusion proteins
US11919931B2 (en) Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)
US20200377585A1 (en) Il-17a/f heterologous polypeptides and therapeutic uses thereof
RU2754058C2 (en) Antibody to human cd73
US10865250B2 (en) Anti-cancer fusion polypeptide
KR101561926B1 (en) - il-17a/f heterodimeric polypeptides and therapeutic uses thereof
DK2681245T3 (en) MULTIVALENT HEAT-MULTIMED SCAFFOLD DESIGN AND CONSTRUCTIONS
CN111182915A (en) Veterinary IgG Fc variants
CA2471363A1 (en) Albumin fusion proteins
EP1688430B1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20080057519A1 (en) Cell Surface Protein Associated with Human Chronic Lymphocytic Leukemia
US20070174922A1 (en) Nucleic acid encoding novel type-1 cytokine receptor glm-r
US7226591B2 (en) Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
JP2009219492A (en) New polypeptide having sequence similarity to gdnfr and nucleic acid encoding the same
WO2021247675A9 (en) Coronavirus-binding agents and uses thereof
US11072643B2 (en) Fusion protein
JP3660880B2 (en) Novel chimpanzee erythropoietin (CHEPO) polypeptide and nucleic acid encoding the same
US20220204606A1 (en) Il-17a/f heterologous polypeptides and therapeutic uses thereof
US20050037465A1 (en) Novel secreted polypeptide and methods of treatment of bone disorders

Legal Events

Date Code Title Description
FZDE Discontinued